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Abstract 
Herein is reported the synthesis of molecular probes for action of neuroactive steroids in vitro and 
in living organisms. In the first part, preparation f enantiomeric pregnane steroids is investigated, 
ultimately resulting into the total synthesis of ent-progesterone. The chirality of the target molecule is 
introduced by a highly effective organocatalytic asymmetric Robinson annulation. A new method for 
the sequential construction of five-membered carbocyclic ring is introduced as the key step. This is 
composed of substrate-controlled copper-catalyzed conjugate addition followed by radical 
oxygenation and subsequent thermal cyclization employing the persistent radical effect. The synthesis 
of truncated neurosteroid analogs is described and their biological activity at the NMDA receptor is 
compared with the native hormone.  
In the second part, methodology for specific deuteri m labeling of both angular methyls of the 
5β-pregnane steroid core is explored. Special attention was paid to the Barton-McCombie 
deoxygenation as the tool for introduction of the last deuterium atom into the methyl group. Both 
positions were labelled with total of three deuterium atoms in high isotopic purity. 
 
Souhrn 
V této práci je popsána syntéza molekulárních sond pro výzkum činnosti neuroaktivních steroidů 
in vitro a v živých organismech. V první části je zkoumána syntéza enantiomerních pregnanových 
steroidů, vedoucí k přípravě ent-progesteronu. Chiralita cílové molekuly je zavedena pomocí vysoce 
efektivní organokatalytické asymetrické Robinsonovy anelace. Jako klíčový krok je zde prozkoumána 
nová metoda postupné konstrukce 5-členného karbocyklu. Tato sestává ze substrátem řízené 
konjugované adice katalyzované mědí, následné radikálové oxygenace a termální cyklizace s využitím 
efektu perzistentního radikálu. Dále je v práci popsána příprava zkrácených analog neurosteroidů a 
jejich biologická aktivita na NMDA receptoru je srovnána s přirozeným hormonem. 
V druhé části je zkoumána metodologie specifického znače í obou angulárních methylů 5β-
pregnanového steroidního skeletu deuteriem. Zvláštní pozornost je zde věnována Barton-McCombie 
deoxygenaci jakožto nástroje pro zavedení posledního atomu deuteria do methylové skupiny. Obě 







AMPAR AMPA receptor 
ATD Amino terminal domain 
ATR Attenuated total reflectance 
9-BBN    9-Borabicyclo[3.3.1]nonane 
BINAM    1,1’-Binaphthyl-2,2’-diamine 
brsm    Based on recovered starting material 
CA     Conjugate addition 
CAN    Cerium(IV) ammonium nitrate 
CNS Central nervous system 
mCPBA    3-Chloroperbenzoic acid 
CSA Camphorsulfonic acid 
DIPEA N,N-Diisopropyl-ethylamine, Hünig’s base 
DMAP 4-Dimethylaminopyridine 
DMS    Dimethyl sulfide 
dba     (E,E)-1,5-Diphenyl-1,4-pentadien-3-one 
dppe    1,2-Bis(diphenylphosphino)ethane 
EC50 Half-maximal effective concentration 
FGI    Functional group interconversion 
FGA    Functional group addition 
GABAA Class A γ-aminobutyric acid receptor 
HPESW    Hajos-Parrish-Eder-Sauer-Wiechert 
IC50    Half-maximal inhibition concentration 
IBX 2-Iodoxybenzoic acid 
Josiphos (2R)-1-[(1R)-1-(Dicyclohexylphosphino)ethyl]-2-
diphenylphosphino)ferrocene 
LBD Ligand-binding domain 
(R)-MTPA (R)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoic acid, 
Mosher’s acid  
n/a Not available 
Nf     Nonaflyl or nonafluorobutanesulfonyl 
NHC N-Heterocyclic carbene 
NMDA N-Methyl-D-aspartic acid 
NMDAR NMDA receptor 
NOE    Nuclear Overhauser effect 
PG     Protecting group 
PIFA    (Bis(trifluoroacetoxy)iodo)benzene 
PMHS    Poly(methylhydrosiloxane) 
PNS Peripheral nervous system 
PPTS    Pyridinium p-toluenesulfonate 
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PRE    Persistent radical effect 
quant.    Quantitative 
ROESY    Rotating-frame nuclear Overhauser effect spectroscopy 
rt     Room temperature 
SET Single electron transfer 
TBAF Tetrabutylammonium fluoride 
TEMPO    (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl 
TFA    Trifluoroacetic acid 
TMD Transmembrane domain 
TMEDA    Tetramethylethylenediamine 
TMP    2,2,6,6-Tetramethylpiperidin-1-yl 
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1. INTRODUCTION  
1.1. NEUROACTIVE STEROIDS, HISTORY AND TERMINOLOGY  
The human brain, one of the most complex organic architectures in Nature, has always attracted 
the attention of scientists. How does it work? How can people move their body and perceive the 
surroundings? How are thoughts and memories formed, processed and forgotten? These are some 
ultimate questions with answers that are so far out of reach of our understanding. However, when 
divided into properly formulated simpler questions, we might be able to answer them.  
The nervous system is a subject of broad scientific d s ipline called neuroscience. The roots of 
neuroscience reach far into ancient Egypt and are int rtwined with the history of biology and 
medicine.2 On the verge of 19th century, pioneering works of G lgi and Ramón y Cajal (discovery of 
synaptic cleft, among many others, shared Nobel Prize 1906) and later Loewi (discovery of chemical 
transmission at synapses, Nobel Prize 1936)3 and Dale (identification of acetylcholine as 
neurotransmitter, Nobel Prize 1936)4,5 opened the field to chemical science.6,7 The second half of 20th 
century saw the birth of a new subdiscipline of neuroscience – neurochemistry – the specific study of 
molecules affecting the function of neurons. The natural progress in the field led to a boom in 
understanding of the elementary processes in the neural system, which was supported by development 
of new biochemical, genetic, imaging and data processing techniques. Most of the currently known 
neurotransmitters and neuromodulators were discovered in this era.  
Neuronal signal transduction is one of the methods how the brain controls bodily functions. 
Slower processes, mainly vegetative functions and homeostasis, are controlled through the endocrine 
system. The hypothalamus, a compartment of brain, releases tropic hormones into blood, triggering a 
tightly controlled signalling cascade going through several levels of endocrine glands. The cascade 
ends by the release of non-tropic hormones, which targe  multiple organs in the body and form a 
feedback loop. This complex system enables delicate and precise control of bodily functions through 
the action of chemical messengers.  
Steroid hormones form an important class of non-tropic hormones in vertebrates, insects and other 
organisms. They were amongst the first described and isolated hormones.8 Estrone was the first 
gonadal hormone to be isolated and characterized (1929 by Butenandt, Nobel Prize 1939),9,10 followed 
by testosterone (1934 by Butenandt),11,12 the progestational hormone progesterone (1934 by several 
groups),13–16 the adrenal hormones cortisone (1936 by Kendall and Reichstein, Nobel Prize 1950),17,18 
and aldosterone (1953 by Reichstein).19 These steroid hormones are typically biosynthesized n the 
respective endocrine glands from circulating steroidal precursors and are released into the blood 
stream. Being highly lipophilic, they easily penetrate cell membranes of target tissue and bind to 
nuclear receptors, which regulate expression of specific target genes.  
In contrast, a rapid inhibitory action of progesterone on the central nervous system was described 
in 1941 by Selye.20 This was the precedent for the direct steroid influence on signal transmission in the 
brain. Practical consequences of this discovery were the general anesthetics alfaxalone and alfadolone. 
Closer inspection of the phenomenon in the 1980’s showed a fundamentally different mechanism of 
action.21–23 Alfaxalone was shown by electrophysiological techniques to potentiate the inhibitory 
action of γ-aminobutyric acid (GABA) receptors, the major inhibitory ion channels of the central 
nervous system (CNS).24–26 Moreover, several steroids such as progesterone, dehydroepiandrosterone 
(DHEA), pregnenolone and their 5-reduced equivalents, were found to be biosynthesized in the brain, 
independently of gonadal and adrenal glands.27–29 Therefore, the term neurosteroids was coined for 
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steroids with neuromodulatory action, directly synthesized in brain, de facto paracrine and autocrine 
hormones. The broader term neuroactive steroids encompasses all steroidal compounds with 
neuromodulatory function, irrespective of their origin (e.g. synthetic or from systemic circulation).30  
Since then, neurosteroids have been found to influece a broad variety of receptors, such as 
GABAA, glutamate, glycine, σ1-opioid, nicotinic acetylcholine and serotonin receptors (5-HT3 
subtype), as well as T-type Ca2+ channels. In addition to these receptors in the CNS, neuroactive 
steroids also influence the peripheral nervous system (PNS). Both areas are well covered by several 
reviews.31–37  
1.2. NEUROACTIVE STEROIDS AT THE NMDA  RECEPTOR, STRUCTURE AND PHARMACOLOGY  
Some neurosteroids affect glutamate receptors. Glutamate mediates most of the fast excitatory 
neurotransmission in the CNS, and ca. 80-90% of the neurons in the brain are glutamatergic. 
Repolarization of membranes during glutamatergic activity may account for as much as 80% of the 
energy consumption of the brain. Glutamate is the principal neurotransmitter of sensory information, 
motor coordination, cognition, emotions and memory processes.38 
The family of glutamate receptors is composed of metabotropic glutamate receptors and ion 
channels, which form three further subclasses: N-methyl-D-aspartate receptors (NMDARs), α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and kainate receptors.  
NMDARs and AMPARs are the most abundant glutamate receptors in the CNS, usually 
colocalised at postsynaptic membranes. AMPARs are Na+ permeable ligand-gated ion channels, 
responsible for fast depolarization of glutamatergic postsynaptic neurons. The affinity of AMPARs for 
glutamate is lower (EC50 ≈ 400 µM), the duration of the AMPAR component of postsynaptic current is 
short (< 10 ms), but its amplitude is high. In contras , the more abundant ligand-gated NMDARs are 
permeable both for Ca2+ and Na+ and have a higher affinity for glutamate (EC50 ≈ 1 µM). Their 
component of postsynaptic current has a slower onset, lower amplitude and significantly longer decay 
(up to several hundred ms). In addition, they have  unique property, which distinguishes them from 
other types of ion channels – they are blocked by Mg2+ ions in a voltage-dependent manner. Thus at 
hyperpolarized membranes (< −50 mV), Mg2+ at physiological concentration works as an effectiv  
blocker of the channel, which is released as the membrane becomes depolarized through the action of 
other (e.g. AMPA) receptors.39 
From the structural point of view, NMDARs are hetero trameric transmembrane proteins, 
composed of a pair of GluN1 subunits and a pair of GluN2/GluN3 subunits, which largely differ in 
various areas of the CNS, as well as during ontogenesis. The structures of the extracellular and 
transmembrane domains of NMDAR were recently determined by X-ray crystallography 
independently by the groups of Furukawa and Gouaux (Figure 1).40,41 The main agonist glutamate is 
binding in the ligand binding domain (LBD) of the GluN2 subunit, while the co-agonist glycine has a 
binding pocket in the LBD of the GluN1 subunit. The binding of two molecules of both agonists is a 
necessary condition for opening of the channel, which is another speciality of NMDARs. The 
significance of glycine binding has remained so far uncertain, since the physiological concentration of 
glycine is well above its EC50. The pore of the ion channel is the binding site for the already 
mentioned Mg2+ and other voltage-dependent uncompetitive antagonists, such as a model compound 
MK-801, an anesthetic ketamine or an anti-Alzheimer drug memantine. The NMDAR selective non-
competitive antagonist ifenprodil has a binding pocket in the N-terminal domain (ATD) of the GluN2 
subunit. Moreover, NMDARs are subject to allosteric inhibition by Zn2+ and potentiation by 
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polyamines (e.g. spermine), both occuring in the ATD of the GluN2 subunit.39 For a more detailed 
description of other endo- and exogenous ligands of NMDARs see recent reviews.39,42 
 
Figure 1: X-ray crystal structure of the NMDAR showing the transmembrane domain (TMD), ligand-
binding domain (LBD) and N-terminal domain (ATD). The GluN1 subunit is shown in blue, GluN2B 
in orange. The right representation shows the structu e rotated by 120°. Reproduced without change 
from Gouaux et al.41 
Several naturally occurring neurosteroids have been shown to affect the activity of NMDARs 
(Figure 2). In contrast to GABA receptors, where uncharged pregnane steroids, for example 3α-
hydroxy-5α-pregnan-20-one, also known as allopregnanolone, show nanomolar activites, NMDARs 
are not effected by uncharged pregnane derivatives.35 However, sulfatation triggers a marked change 
of behavior of steroids towards these ion channels.  
Pregnenolone sulfate (1), a ubiquitous neurosteroid synthesized in the brain from cholesterol, is 
potentiating NMDA receptors, while inhibiting AMPA, kainate and GABAA receptors.
43,44 This 
potentiation is believed to be exerted through allosteric modulation at a binding site distinct from the 
agonists, noncompetitive antagonists and channel blockers.35 Experiments with receptors containing a 
chimeric GluN2 subunit and single point mutation exp riments helped to localize the probable binding 
site of 1 at an extracellular loop between the third and fourth α-helix of the TMD, together with the 
fourth α-helix of the TMD of GluN2.44,45  
 
Figure 2: Neuroactive steroids 
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Pregnanolone sulfate (2) is a typical member of neurosteroid family showing i hibition of the 
NMDA receptor.46 As other 5-reduced pregnane steroids, it is biosynthesized in the brain from 
progesterone (3), and acts similarly by allosteric modulation of the NMDA receptor. Its binding site is, 
however, different from known agonists, noncompetitive antagonists, channel blockers and also of 
1.47–49 Pregnanolone sulfate (2) is a use-dependent inhibitor, binding only after the channel is opened 
by agonists. Studies of the binding site suggest a loc tion at subunit GluN2 between the third and 
fourth α-helix of the TMD.50 However, the exact shape and position of the neuroster id binding sites 
are still unknown.51 
The NMDA receptor is an interesting pharmacological target because of its functional uniqueness. 
It is thought to be critical for memory formation ad modulation through regulation of synaptic 
plasticity. The NMDA receptor is directly involved in a phenomenon called long-term potentiation, 
where a high-frequency pulse triggers a long-lasting augmentation of signals in the connected neurons. 
The long-term potentiation is hypothesized to be onf the major cellular mechanisms for learning 
and memory.39 Overexpression of GluN2B subunits was shown to enhance learning and memory in 
model animals.52–54 Pregnenolone sulfate (1) has a remarkable ability to enhance mental performance 
of mice and rats.55–57  
In contrast, excessive stimulation of glutamate receptors leads to accumulation of intracellular 
Ca2+, which over time causes irreversible damage and lea s ultimately to apoptosis. This phenomenon 
is called excitotoxicity and is hypothesized to contribute to many neurodegenerative diseases and 
conditions like stroke, traumatic brain injury, Alzheimer’s disease, Parkinson’s disease, amyotrophic 
lateral sclerosis and others.38,39,42 Compounds inhibiting NMDARs may therefore have desirable 
impact on potential treatment of these conditions. Di sapointingly, most NMDA inhibitors failed in 
attempted clinical trials because of side effects, with the notable exception of memantine (3,5-
dimethyladamantan-1-amine). These failures were ascribed to psychotomimetic effects caused by 
overinhibition of NMDARs or insufficient ability to reach the target neurons.39,42 Synthetic 
neuroactive analogues of 2 were prepared in Chodounská’s group and tested for neu oprotective 
properties.58–62 Some of these compounds, e.g. pregnanolone glutamate (4), show promising in vitro 
and in vivo activities. Most importantly, their action appears to be free of psychotomimetic side effects 
in animal models.63–66 They are believed to share the same mechanism of action with the native 
neurosteroid 2, with improved pharmacological properties.35  
Steroids active at NMDAR’s share some common featurs. Most importantly, a charged 
substituent such as sulfate, carboxylic acid or quarternary ammonium salt at C-3 markedly increases 
their activity.47,48,51,58 5β-Reduced neuroactive steroids exert stronger inhibitory effect at NMDARs 
than 5α-reduced analogs.47,48 In contrast, the ∆5-double bond is typical for potentiating neurosteroids, 
such as 1. Substitution in positions C-7 and C-11 of 2 are not well tolerated,60 but substitution at ring 
D and steroid side chain can lead to more potent inhibition of NMDAR.62,67,68 
1.3. NOMENCLATURE OF STEROIDS 
Since the majority of this work will deal with steroids and their synthetic intermediates, it is useful 
to summarize briefly the nomenclature rules applying to this class of compounds. Steroids are 
compounds possessing the skeleton of cyclopenta[a]phenanthrene or a skeleton derived therefrom by 
one or more bond scissions, ring expansions or contractions.69 The systematic naming conventions are 
derived from the parent hydrocarbons, the two relevant for this thesis are depicted in Figure 3. The 
basic C19 skeleton 5 is called androstane, the C21 skeleton 6 pregnane. The rings are named A to D 
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from left to right and the carbon positions are numbered as shown in structure 6. The absolute 
stereochemistry is defined by the name of the parent structure for chiral centers at carbons 8, 9, 10, 13 
and 14 as shown in the structure of 5, and for the configuration of the side chain as shown in 6. Other 
stereocenters, including the one at C5, have to be declared both in a schematic structure and a name. 
The stereochemistry of the natural enantiomer can be stressed with the prefix nat-. When the rings of 
steroid are depicted as projections onto the plane of the paper as in 5 and nat-7a, substituents below 
the plane of paper are termed α, and above the plane as β. Unknown configurations are denoted with 
prefix ξ. Thus, pregnanolone (nat-7a) is systematically named 3α-hydroxy-5β-pregnane-20-one. 
Descriptors 8β, 9α, 10β, 13β, 14α and 17β can be omitted, since they constitute the natural 
configuration.  
 
Figure 3: Structure and atom numbering of steroids and theirenantiomers 
Unnatural enantiomers of steroids are designated by the prefix ent-. This implies that all 
stereocenters in the molecule are inverted, no matter whether they are cited separately, what is 
especially important for relative descriptors α and β, or are implied in the name. For example, the 
opposite enantiomer of nat-7a can be named as ent-3α-hydroxy-5β-pregnane-20-one (ent-7a), being 
the mirror image as can be seen in stereochemical structures nat-7b and ent-7b. Inversion of a single 
stereogenic center leads to a diastereomer – as in 3β-hydroxy-5β-pregnane-20-one (8).  
Since this thesis deals with the total synthesis of teroids and truncated analogs, it is necessary to 
define the nomenclature of steroids with an incomplete skeleton (Figure 4). Deletion of a methylene 
group from a steroid is indicated by the prefix nor-, which is preceded by the number of the deleted 
carbon atom. The remainder of the original steroid numbering is unchanged. The removal of a ring, 
with substitution at each junction with a hydrogen atom, is indicated by the prefix des-, followed by an 
italicized capital letter of the missing ring. Finally, fission of a ring, with addition of a hydrogen atom 
at each terminal group thus created, is indicated by the prefix seco-, with the original steroid 
numbering retained. Locants preceding the prefix specify the atoms of the deleted bond.69 The 
complete and detailed IUPAC nomenclature of steroids is available.70,71 
 
Figure 4: Nomenclature of truncated steroids  
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1.4. ENANTIOMERS OF NEUROACTIVE STEROIDS 
The cell membrane of neurons is a complex environment, composed of a phospholipid bilayer 
with increased proportion of cholesterol and abundant proteins, including the ion channels mentioned 
in Chapter 1.2. Steroids are lipophilic compounds and as such have a high affinity for the cell 
membrane. Questions arise whether the effects of neurosteroids are caused by tight binding with the 
protein structure, blocking of the channel, or are merely a perturbation of the membrane. Some studies 
suggested localization of the binding site for neurosteroids near to the surface of the cytoplasmic 
membrane.44,45 The membrane probably serves as a reservoir for neurosteroids, effectively increasing 
the concentration in close proximity of the ion channel.58,72  
The neurosteroid potentiating binding site for the GABAA receptor has been recently identified by 
photoaffinity labeling.73 The high affinity of neurosteroids for GABAA receptors in nanomolar range 
suggests the existence of a defined binding site. This is in contrast with neurosteroids active at the 
NMDA receptors, displaying activity in micromolar range.35 It is therefore of interest to distinguish 
the possible modes of neurosteroid action at the NMDA receptor. 
One of the methods to differentiate the specific protein binding from membrane effects is the 
application of opposite enantiomers of native neurosteroids (ent-steroids).74 It is assumed, that the 
unnatural enantiomer should exhibit much lower affinity in case of specific binding into a defined 
pocket in the protein. This process can be compared to fitting a right hand in a left-hand glove. In 
pharmacology, this concept is known as Pfeiffer’s rule: The greater the difference of pharmacological 
activity between both chiral antipodes, the greater th  specificity of the active isomer for the response 
of the tissue under test.75,76 In contrast, the environment of cell membranes is fluid and the overall 
diastereoselective interaction of the chiral substituted diacylglycerols with the substrate will be an 
average of interaction of all possible mutual orientations. Given that most phospholipids contain only 
one stereogenic center, the difference of interaction between both diastereomeric pairs will be very 
low. Therefore, the physicochemical properties and not the absolute configuration will be the main 
determinant of the behavior of steroids in the cytoplasmic membrane. The experimental support for 
this hypothesis in steroid-membrane interactions wa reviewed by Covey.74  
In agreement with Pfeiffer’s rule, the enantiomers of classical steroid hormones are devoid of 
activity at nuclear receptors.77 Racemic steroids usually exhibit 50% effect, which is consistent with 
the much lower activity of ent-steroids. The situation is more complex for the modulation of ligand-
gated ion channels by steroids. ent-3α-Hydroxy-5α-pregnane-20-one (ent-12), or ent-
allopregnanolone, is a significantly weaker potentiator of the GABAA receptor than nat-12.
78–80 In 
contrast, 3α-hydroxy-5β-pregnane-20-one (nat-7), or pregnanolone, shows a less pronounced 
difference, both in vitro and in vivo.81,82 Interestingly, ent-3α-hydroxy-5β-androstan-17-one (ent-13) 
shows higher potentiating GABAA activity than its natural counterpart. It is also w rth mentioning that 
the GABAA receptor does not discriminate between the enantiomers of inhibitory neurosteroid 
pregnenolone sulfate (1).83  
Studies of the influence of ent-steroids at the NMDA receptor are rarer in the litra ure. Only ent-
pregnenolone sulfate (ent-1) was tested so far and performed as well as its enantiomer nat-1.57 In 
accordance with these results, both enantiomers of 1 were shown to facilitate learning and memory of 
rats and mice.57,84 Interestingly, some steroids which are inert to GABAA or NMDA receptors showed 
in vivo neuroprotective activity. Progesterone (nat-3), for example, exerts neuroprotective action in a 
rodent model of traumatic brain injury.85 The enantiomer ent-3 proved to have identical 
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neuroprotective properties, but no activity at the progesterone nuclear receptor.86 The activities are 
summarized in Figure 5. 
 
Figure 5: Physiological activities of ent-steroids on GABAA and NMDA receptors 
1.5. TOTAL SYNTHESES OF PREGNANE STEROIDS  
ent-Steroids do not occur in the Nature because of conservative biosynthetic pathways. In 
mammals, cooperation of squalene monooxygenase and lanosterol synthase leads to the formation of 
single enantiomer of lanosterol, the precursor of all m mmalian steroids. Therefore the only method to 
obtain ent-steroids is total synthesis. In principle, this can be achieved either by preparation of racemic 
steroids followed by resolution or by enantioselective synthesis. Since the total synthesis of steroids is 
considered a classic in organic chemistry, many syntheses and successful attempts have been reported 
in the past 75 years. It is not a goal of this thesis to give detailed and exhausting summary of all pst 
syntheses. The employed strategies were reviewed in numerous monographs and reviews.77,87–91 
Therefore only total syntheses of pregnane steroids – progesterone 3, pregnenolone 14 and their 
reduced forms 7, 8, and 12 will be reviewed.  
The first syntheses of pregnane steroids are intertwined with the “steroid rush” of the 1950’s and 
the race for the first synthesis of cholesterol (17).92 Woodward’s famous synthesis of 17 published in 
1952 started from hydroquinone 15 and afforded a key intermediate methyl rac-3-oxo-
etioallocholanate (rac-16) in 25 steps. This intermediate was converted to rac-3 in 4 steps or to rac-17 
in 11 steps. Strategically, the CD rings were constructed first, followed by subsequent annelation of 
rings B and A; in short CD→BCD→ABCD.93 Robinson’s relay synthesis (1951) started from 1,6-
dihydroxynaphthalene 18 and reached pregnenolone rac-14 in 56 steps. This steroid can be either 
directly oxidized to rac-3, or continued to rac-17 in 6 steps. The order of ring construction 
corresponds to BC→ABC→ABCD.94,95 Both syntheses were linear, but were remarkable mil stones in 
organic synthesis, considering the unavailability of n wadays common structural analysis methods and 
the early stage of chromatographic techniques.  
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Scheme 1: Woodward’s and Robinson’s syntheses of rac-cholesterol (rac-17) and rac-progesterone 
(rac-3) 
Woodward’s strategic approach (CD→BCD→ABCD) was followed by Stork in the synthesis of 
rac-3 via rac-17-homotestosterone (rac-20).96 Starting from the Wieland-Miescher ketone rac-21 as a 
precursor for the CD ring system, the alkyl chain 22 was introduced to rac-23 by a thermodynamically 
controlled alkylation (Scheme 2). After two successive reductions, the substrate was prepared for the 
isoxazole annelation to give tricyclic rac-24. Importantly, the group found that reduction of the enone 
by lithium in ammonia followed by direct alkylation with MeI afforded a single diastereomer of rac-
25, which greatly facilitated this and some later syntheses. A deprotection and an intramolecular aldol 
reaction furnished the target rac-20 in 7 steps from rac-21. Conversion to rac-3 was possible in 8 
steps, although the yields were not stated.  
 
Scheme 2: Stork’s synthesis of rac-progesterone (rac-3) 
A truly remarkable biomimetic synthesis of rac-3 was published by Johnson et al. in 1968 and 
improved in 1971.97,98 The core of the synthesis was based on the concept of polyolefinic 
carbocationic cyclization, developed earlier in the same group. The synthesis itself is highly 
convergent and the order of ring construction can be summed up as A→ABCD (Scheme 3). Fragment 
26 is constructed from methacrolein (27) by addition of a Grignard reagent, followed by a Johnson-
Claisen rearrangement of the resulting alcohol 28 to ester 29, which underwent a two-step conversion 
to aldehyde 26. Wittig reagent 30 was prepared from 2-methylfuran (31) by ortho-lithiation and 
alkylation. An acid-catalyzed opening of the furan ing of 32 gave diketal 33, which was converted to 
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Scheme 3: Johnson’s synthesis of rac-progesterone (rac-3) 
The fragments 26 and 30 were coupled by Wittig reaction to afford selectively the E-alkene 34 
(97:3 E:Z, Scheme 4). Deprotection of 34 followed by an aldol condensation gave cyclopentenon  35, 
which was methylated to furnish an unstable tertiary alcohol rac-36. An acid-promoted cyclization 
gave rise to the tetracyclic ring system rac-37 in high yield, forming five new stereocenters in a single 
cascade reaction. Intermediate rac-37 was ozonolyzed and cyclized to rac-3 mixed with its 17-epimer, 
which was separated by crystallization. The longest linear sequence consisted of 11 steps and the 
overall yield of rac-3 was 5%. Modified procedures were later published by ifferent groups.99–101  
 
Scheme 4: Johnson’s total synthesis of rac-progesterone (rac-3) 
Multiple syntheses were based on the strategy CD→BCD→ABCD to synthesize androstane 
derivatives, which could be converted to the pregnane skeleton by introduction of the side chain. This 
approach was initially developed at Hoffmann-La Roche as an approach to 19-norsteroids.88,102,103 
Most importantly, one of their syntheses constituted he first synthesis of a steroid with catalytic 
asymmetric generation of stereocenters. The first chiral center was established by what is now known 
as Hajos-Parrish-Eder-Sauer-Wiechert (HPESW) reaction, the catalytic asymmetric variant of 
Robinson annulation (vide infra).104–106 This synthetic approach was later chosen by Ohloff’s and 
Rychnovsky’s group to target ent-steroids.107,108  
Triketone 38 was cyclized in the above mentioned HPESW reaction with subsequent acidic 
dehydration of the aldol to give Hajos-Parrish keton  ent-39 with 87% ee (Scheme 5). A selective 
borohydride reduction of the saturated ketone, followed by protection and reaction with the Stiles’ 
reagent afforded acid ent-40 in good overall yield. Hydrogenation established the trans-CD 
configuration and Mannich condensation with formaldehyde yielded enone nt-41. The Robinson 
annulation with 42 formed ring B in the tricyclic intermediate nt-43. Here, Rychnovsky’s group 
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diverted from the Hoffmann-La Roche synthesis and successfully applied Stork’s method for the 
introduction of the 19-methyl group (vide supra). The resulting ketone nt-44 was recrystallized to 
>97% ee and converted to ent-testosterone (ent-45) by treatment with methanolic HCl. The overall 
yield of ent-45 was 16% over 10 steps from triketone 38. The conversion to ent-cholesterol (ent-17) 

































































Scheme 5: Rychnovsky’s total synthesis of ent-testosterone (ent-45) and ent-cholesterol (ent-17) 
The synthesis of pregnane ent-steroids from a common precursor ent-45 was studied in detail by 
Covey’s group.109 Protection of the enone moiety of ent-45 gave rise to alcohol ent-46, which was 
oxidized and converted to ethylidene derivative ent-47 by a Wittig reaction. A hydroboration-
oxidation sequence with 9-BBN was regioselective for the side-chain double bond and installed the 
correct 17β-stereochemistry. Oxidation of the resulting alcohol followed by acidic deprotection 
afforded ent-progesterone (ent-3) in 7 steps and 21% overall yield from ent-45. ent-Testosterone (ent-
45) served as a precursor to other pregnane derivatives employing a similar methodology: ent-
Allopregnanolone (ent-12) was prepared in 6 steps and 10% yield, nt-pregnenolone (ent-14) in 8 
steps and 23% yield and ent-pregnanolone (ent-7) was elaborated in 9 steps with 12% overall yield 
from ent-45.83,110 
 
Scheme 6: Covey’s synthesis of ent-progesterone (ent-3)  
1.6. ASYMMETRIC ROBINSON ANNULATION  
Modern approaches to the total synthesis of optically active molecules preferably apply either 
starting materials from the chiral pool, or catalytic asymmetric methods. In such an arrangement, one 
molecule of the catalyst, which is derived from eith r the chiral pool or from resolution, gives rise to 
multiple chiral molecules of the product. In an ideal system, the catalyst should be readily available 
and cheap, the catalyst loading should be low, and the reaction should be scalable with minimal side 
products and waste.  
 18 
With respect to total syntheses of terpenoid natural products, the Robinson annulation is one of the 
well established and reliable methods to construct six-membered rings. The formation of bicyclic 
hydrindane 39 or decaline 21 systems is the cornerstone of several successful total syntheses of 
steroids (vide supra). The Wieland-Miescher ketone 21 is easily available from 2-methyl-cyclohexane-
1,3-dione (48) and methyl vinyl ketone (49), both bulk chemicals, by an asymmetric Robinson 
annulation (Scheme 7). It was in fact this reaction, which demonstrated he power of asymmetric 
organocatalysis. Nowadays, the reaction is named after its inventors Hajos, Parrish (both from 
Hoffmann-La Roche),104–106 and Eder, Sauer, Wiechert (all from Schering AG),111 who have 
discovered it independently. In the past 40 years, the reaction was optimized several times with respect 
to yield and enantiomeric excess.112,113 
 
Scheme 7: Hajos-Parrish-Eder-Sauer-Wiechert reaction 
The original catalyst L-proline (51) gave the Wieland-Miescher ketone (nat-21) from achiral 
triketone 50 in 81% yield and 70% optical purity (Figure 6).114 L-Proline (30 mol%) was also shown 
to catalyze the preceding Michael addition step to aff rd nat-21 in 49% yield and 76% ee in a one-pot 
sequence by Barbas.115  
Other proline-derived catalysts were studied with inferior results. The necessity of pyrrolidine and 
carboxylic acid functionality was postulated for an effective catalyst.115 Several amino acid catalysts 
were screened, but most of the substitutions brought no improvement over the original proline, with 
the notable exception of cispentacin 52.116 Diamines 53-55 were reported to be very efficient catalysts 
as salts of a strong acid.117–121  
One of the highest enantioselectivities for the synthesis of 21 was achieved with isophthalamide 
56.122 Amides of proline such as 57-60 constitute one of the most effective catalyst class employed in 
asymmetric Robinson annulations.123–125 Notably, BINAM derived amide 59 allows for very low 
catalyst loading under solvent-free conditions and fforded 21 in excellent yield and enantiomeric 
excess.126–129 Finally, chiral Brønsted acid 61 can also efficiently catalyze the formation of 21.130  
Importantly, 21 can be prepared in enantiopure form by fractional crystallization from Et2O at 
−20 °C with seeding by enantiopure material,114 or from Et2O/EtOAc at −70 °C by spontaneous 
resolution.131 Although asymmetric Robinson annulations can be conducted directly from substrates 48
and 49,115 the combined yield is better when the process is conducted stepwise.114,128 The triketone 50 
























































































64% (82% ee)  
Figure 6: Chiral catalysts for HPESW reaction with the respectiv  catalyst loading, yield of 21 and 
enantioselectivity achieved. 
1.7. COPPER-CATALYZED CONJUGATE ADDITION OF GRIGNARD REAGENTS TO ENONES 
Conjugate additions of carbon nucleophiles are among the most important C-C bond forming 
reactions. To promote the conjugate addition mode, soft nucleophiles are often used. In contrast, hard 
carbon nucleophiles, such as organolithium and organom gnesium compounds, often prefer 1,2-
addition. The conjugate addition of non-stabilized carbon nucleophiles is a domain of transition metal 
catalysis with copper being the most investigated elem nt in this respect,132 the others being 
rhodium,133–136 palladium,133,137,138 and nickel.139,140 
The history of organocopper chemistry can be backtred to preparation of phenylcopper by 
Reich,141 later expanded by preparation of ethylcopper by Gilman and Straley,142 who have 
demonstrated the applicability of organocopper reagents in organic chemistry. In 1941, Kharash and 
Tawney described the effect of catalytic copper(I) halides on the outcome of conjugate addition (CA) 
of Grignard reagents to enones.143 However, it was the introduction of organocuprates by Gilman,144 
followed by works of House145,146 and Corey,147 which spreaded the use of organocopper reagents in 
organic synthesis.  
Stoichiometric homoalkyl cuprates suffer from poor atom economy, with one of the alkyl group 
being lost in the unreactive monoalkylcopper. This issue was alleviated with the introduction of non-
transferable groups, such as thiolates, alkynyl or cyano residues.148,149 Another, perhaps more 
appealing option is catalysis by copper(I) species, which wastes only substoichiometric amounts of the 
potentially valuable organometallic reagent. Moreover, it opens a way to effective asymmetric variants 
of this transformation (Scheme 8).132,148,150–152 This introduction concentrates only on the aspect of 
diastereoselectivity of the copper-catalyzed CA. It is anticipated that the catalytic cycle doesn’t differ 
significantly for substrate- and reagent-controlled variants and it is based on the same mechanistic 
foundation as the stoichiometric addition of organocuprates. 
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Scheme 8: a) Catalytic cycle of copper(I) catalyzed CA, b) Casey’s experiment153 
The cycle begins with transmetallation of the dimeric complex A to generate the catalytically 
active species B. The dimer A with the Josiphos ligand was isolated and characterized by X-ray 
crystallography by Feringa et al. and the structure of B was supported by a detailed NMR study.154 
Coordination of the organometallic complex B to α,β-unsaturated carbonyl compound C is facilitated 
by the oxophilic magnesium ion, thus anchoring the copper complex at the C-C double bond through a 
halogen bridge. Similar bridging effects were described for sulfonamides in Cu-catalyzed CA of 
organozincs.155 Oxidative addition of CuI from the π-complex D results in the formation of CuIII  σ-
complex E. A rapid equilibrium occurs between these species, which is supported by cis-trans 
isomerisation of the double bond of (Z)-enones during the reaction course.154 Reductive elimination of 
CuIII  from σ-complex E leads to irreversible formation of magnesium enolate g and released CuI-
catalyst F. This step is rate-determining for the whole catalytic cycle.153 Thermodynamic stabilization 
of complex E in the equilibrium D/E can be achieved by using soft donor ligands (e.g. phosphines), 
while the kinetic lability in the reductive elimination step is mostly dependent on the geometry of E.154
A hypothetical SET pathway was originally proposed by House,156,157 but was later disproved in an 
elegant study by Casey,158 demonstrating stereospecificity in the vinylic cyclopropane ring-opening 
during the course of the reaction (Scheme 8b).153  
In principle, all organometallics in which the metal is less electronegative than copper and all 
organometallic species of similar electronegativity, but with weaker carbon-metal bonds, are potential 
candidates for transmetalation. Thus, besides organlithiums and Grignard reagents, reaction 
conditions have been found for transmetalation of organoboron, aluminum, zinc, tin, lead, tellurium, 
titanium, manganese, zirconium and samarium compounds.150 The central copper atom can 
accommodate for variety of ligands: Common are amines, phosphines, phosphoramidites and more 
recently also NHC ligands, which exhibit a significant accelerating effect and form the basis for 
asymmetric copper-catalyzed CA.132 However, no extra ligand is necessary for substrate-controlled 
CA in more polar solvents such as THF in contrast to Et2O, MTBE and CH2Cl2. LiCl has also been 
shown to be an efficient cocatalyst, forming a soluble Li2CuXCl2 complex in THF.
159 The 
 21 
regioselectivity of the addition seems to be dependent on the solubility of the active copper species 
rather than on the copper source.146,160  
A distinct advantage of the Cu-catalyzed CA is its generally predictable 
diastereoselectivity.150,161,162 The addition of organocuprates to a number of chiral cyclic enones 
proceeds with high level of stereoselectivity, owing to the existence of a single preferred reactive 
conformation (Scheme 9).150 Good to excellent trans-diastereoselectivity can be reached in 4-
substituted cyclopentenones 66 and 4- or 5-substituted cyclohexenones 69 or 72 respectively. In 
contrast, 6-substituted cyclohexenones 75 give cis-adduct 76.163–167 
 
Scheme 9: Diastereoselectivity of Cu-catalyzed CA in monocyclic enones 
In more complex fused carbocycles, the level of diastereoselectivity depends on the superposition 
of all substituent effects (Scheme 10). For example, cuprate attacks less hindered α-face in the 
catalyzed addition of MeMgI to octalone 78, avoiding a steric clash with the axial methyl group in 
80.168 A similar selectivity was observed en route to 7-substituted androstane analogues during 
alkylation of enone 81.169 On the other hand, the stereoselectivity was found to be surprisingly low for 
the cuprate addition to decahydrophenanthrenone 84 in the synthesis of (+)-2-deoxyphytocassane A.170  
















































Scheme 10: Diastereoselectivity of Cu-catalyzed CA in polycyclic enones 
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1.8. REDOX PROCESSES AT THE CARBONYL GROUP 
Organic synthesis relies upon reactive intermediates to achieve selective synthetic transformations. 
Frequently, these transformations include heterolytic processes, which operate with charged species – 
anions and cations. In contrast, homolytic cleavage of chemical bonds gives rise to radicals, with 
reactivity different from ions. Switching between these reactive intermediates in one process can lead 
to an advantageous reactivity pattern, which shares the better of both reactive species. 
Charged species and radicals can be interconverted by single electron transfer (SET).171 These 
transitions are illustrated for a general carbonyl group A (Scheme 11). Both neutral and charged 
species can undergo SET processes.  
Direct single electron reduction of A is common and leads to a radical anion B. Species B is a 
known intermediate in dissolving metal reductions (A→E), acyloin condensation and pinacol 
coupling, among others. In this process, alkali metals or SmI2 are usually used as reductants, because 
of the need for high reduction potential.172 Alkyl- or arylhalogen bonds are reducible to the respective 
carbanions by super-electron-donors such as tetrakis(dimethylamino)ethylene (not shown).173 
In contrast to reduction A→B, the carbonyl group itself is quite stable to oxidation. An enol form 
F undergoes more facile single electron oxidation to a radical cation G, which rapidly loses the acidic 
proton, leading to a neutral α-keto radical H. Ceric ammonium nitrate (CAN) is an archetypal reagent 
























































































Scheme 11: Redox interconversion of carbonyl compound-derived r active species and their 
transformations 
Deprotonation of the carbonyl compound A to enolate K  leads to an increase of the electron 
density of the system and therefore its nucleophilicity. Enolate K can participate in a multitude of 
polar reactions, here the Michael addition is depict d as an example (K→J). Anions can tranfer one 
electron to a suitable oxidizing agent and thus generate radicals (K→H), which can then undergo a 
typical radical reaction. An addition to a double bond (H→L ), followed by an elimination of radical or 
a recombination (L→M ) is shown as an example. Importantly, this constitutes a method to switch the 
reactivity of the intermediate, since the radicals and the anions can be viewed as orthogonal reactive 
species.  
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Enolates K  can be oxidized to α-carbonyl radicals H by a variety of reagents. SET oxidants can be 
divided according to Marcus theory to inner- and outer-sphere reagents. Inner-sphere reagents react 
through a bond formation with the substrate (e.g. K ), followed by a homolysis of the said bond. 
Among the more commonly used inner-sphere oxidants of enolates K  are transition metals in higher 
oxidation state: Cu(II) salts, Fe(III) salts, Ti(IV) and iodine compounds.171,174,177,182–185 In contrast to 
these stand the outer-sphere reagents, where the SET occurs through space (solvent). Anodic oxidation 
can be employed in this type of reaction.182 Ferrocenium salts can be used as distinct outer sphere SET 
oxidants of K .186–190 They are water-soluble intensively blue crystalline on-hygroscopic solids, 
whereas the reduced ferrocene is orange-colored, highly lipophilic compound soluble in organic 
solvents, which facilitates their separation from other organic material. Importantly, the redox 
properties of the ferrocene/ferrocenium couple can be fine-tuned by functionalization of the 
cyclopentadienyl ring.191,192  
The synthetic potential of ferrocenium salts has been xtensively studied by Jahn et al. Among the 
areas explored are tandem Michael addition-radical cyclizations,190,193–198 α-oxygenations of carbonyl 
functions,189,199 and oxidative homocoupling of enolates.200 Enantioselective oxidative homocoupling 
of titanium enolates was studied in the group of Schäfer.201 It is noteworthy that ferrocenium salts can 
be employed as a catalytic oxidant with stoichiometric amount of 2,2,6,6-tetramethyl-N-
oxopiperidinium salts, which generate in situ a persistent radical TEMPO.193  
The synthetic power of these transformations has been demonstrated in several syntheses of 
natural products (Figure 7). Jahn’s group has applied the methodology to the total synthesis of 
monoterpene (±)-dihydronepetalactone (87) and 15-F2t-isoprostane (88).
202–204 Theodorakis et al. have 
used TEMPO/Ferrocenium couple for the radical cyclization of the ring C of (−)-fusariasetin A (89).205 
The stereoselective oxidative dimerization of a keton  enolate mediated by ferrocenium salt was 
reported by Shair et al. in the total synthesis of lomaiviticin A aglycon precursor 90.206,207 Finally, the 
intramolecular cyclization of a seven-membered ringwas performed by the Li’s group in the synthesis 
of (+)-subincanadine F (91).208 Baran et al. have used a diastereoselective oxidative cyclization 



























































Figure 7: Applications of ferrocenium salts in total syntheses 
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1.9. THE PERSISTENT RADICAL EFFECT 
It has been noted throughout history that radical re ctions involving both transient and persistent 
species sometimes lead to unusually selective and high-yielding cross-coupling reaction of these 
radicals.210 The first to observe this phenomenon was probably Bachmann et al. in 1936,211 who 
noticed a remarkable effectivity in thermolysis-recombination of diphenylmethyl (transient) and 
triphenylmethyl (persistent) radicals. It was not until 1986, when Fischer and Ingold described the 
mechanistic rationale of the phenomenon and Finke coined the term persistent radical effect (PRE).212–
214 A simplified kinetic scheme of reactions is shown in Scheme 12.  
Typically, a homolytic cleavage gives rise to a transient radical R• and a persistent radical Y• (eq. 
1). The back-reaction should be faster for the PRE to be operative (k1<k−1), otherwise the rise in the 
concentration of R• would lead to a product R-R (eq. 2) and accumulation of Y•. This process occurs 
anyway to a small extent in the beginning of the reaction, resulting in a rapidly rising concentration f 
the persistent radical Y•, which does not deplete by dimerization (eq. 3). An excess of Y• effectively 
suppresses the R• dimerization (eq. 2) by accelerating the unproductive back-reaction (eq. 1). If radic l 
R• can undergo a rearrangement, intramolecular hydrogen abstraction, or perhaps a cyclization to 
radical R’• (eq. 4), the same rules apply for the latter, leading to the homo- or hetero-coupled products 
(eqs. 5, 6). If the rate of homolytic cleavage of RY exceeds that of R’Y (k1>k−6), the situation results 
in selective accumulation of the product R’Y in thereaction mixture. 
 
Scheme 12: The persistent radical effect 
Strikingly, this may also enable a productive channel for a thermodynamically less stable radical 
R’• if the kinetic conditions (k1>k−6) are favorable. The most significant applications were found in 
polymer chemistry in nitroxide mediated polymerization and atom transfer radical polymerization, 
where the PRE is used to achieve polymers with low molecular weight dispersity.210  
Besides being a mechanistic curiosity, the PRE has been used only sporadically in organic 
synthesis of low molecular weight targets. Notable exceptions are copper-catalyzed halogen transfer, 
radical reactions in the Barton nitrite reaction and reactions involving homolytic cleavage of weak 
organometallic bonds of transition metals.210 The thermolysis of nitroxide adducts is a powerful 
method in polymer chemistry, but remains underinvestigated in the field of organic synthesis. Studer 
et al. have explored its synthetic potential in connection with common radical cyclizations (Scheme 
13).213 To demonstrate the scope of this transformation, cyclopentenone 93 was transformed to 
tricyclic 94 in a domino reaction consisting of two consecutive 5-exo radical cyclizations.215 The same 
laboratory later demonstrated a possibility of CO incorporation during the sequence.216  
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Scheme 13: Radical cyclizations mediated by the PRE 
1.10. DEUTERIUM LABELING IN METABOLICALLY STABLE POSITIONS OF STEROIDS 
Considerable effort has been invested into synthetic modifications of native neurosteroids, leading 
to more effective ligands for membrane receptors. Some of them have shown interesting in vivo 
activity in animal models of diseases. For further d velopment of lead compounds toward possible 
clinical trials, it is necessary to study their pharm cokinetic properties and metabolism. For this 
purpose, mass spectrometry and especially the stable isotope dilution LC-MS/MS is the method of 
choice.217–219 It combines the extreme sensitivity of mass spectrometric detection with the selectivity of 
HPLC separation and the possibility of monitoring a specific fragmentation pattern in the MS/MS 
mode. The limitations of this method are the cost of instrumentation and the availability of isotopically 
labeled compounds. The tracers should differ from the native compound by 2-4 mass units and the 
isotope labeling should be introduced with high isotopic purity at metabolically and chemically stable 
sites.  
The most commonly employed nuclei for stable isotopic labeling are 2H and 13C. The 
incorporation of 13C nuclei into steroids has the advantage of very good chemical and metabolic 
stability, but is outweighed by the need for breaking and reforming of C-C bonds. Therefore, it is 
usually only feasible in the last steps of total synthesis.220,221 Deuterium reagents tend to be more 
accessible and economical, especially where simple acidobasic equilibrium can introduce deuterium 
from D2O. The condition of chemical and metabolic stability, however, excludes positions alpha to 
existing hydroxy or keto groups, which are the most accessible positions for deuterium exchange. 
However, these groups may serve as reactive handles at the steroid core and be removed after 
introduction of the stable isotope.222 Unfortunately, the parent oxo or hydroxy steroids are limited to a 
few available positions at the steroid core.  
From the point of metabolic stability, angular methyl groups are almost ideal targets for stable 
isotope labeling. Functionalization of the methyl group poses a challenging synthetic problem, which 
was nevertheless solved by utilization of remote functionalization strategies. An important precedent 
was set by Barton in the early 1960’s,223,224 which was successfully employed in the synthesis of 
aldosterone acetate (103).225 The free hydroxyl group of 98 was esterified with nitrosyl chloride and 
the resulting nitrite 99 was irradiated with mercury lamp to give oxime 100 (Scheme 14). The 
mechanism of the reaction is as follows: nitrite ester 104 is homolyzed by UV irradiation to give O-
centered radical 105 and a persistent radical – nitric oxide. Oxyl radicl 105 subsequently undergoes a 
1,5-hydrogen atom shift to afford thermodynamically more stable C-centered radical 106, which 
rapidly couples with nitric oxide. Tautomerization f nitrosoalcohol 107 to oxime 108 completes the 
transformation. The reactions perform well in rigid systems, where the O-centered radical 105 is 
conformationally locked in proximity of the hydrogen atom to be abstracted. The PRE (vide supra) is 
operative here and contributes to the high selectivity of the reaction.210  
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Many variants of this reaction were later introduced, where the nitrite ester was replaced by in situ 
generated labile oxygen-heteroatom bond. Lead tetraacet te and bis(acetoxy)iodobenzene are probably 
the most used reagents for this purpose. In addition, he C-centered radical 106 can undergo reaction 
with iodine, bromotrichloromethane or tetrachloromethane to afford the respective halogenides, or can 
even undergo a cascade cyclization to a suitably positioned double bond.226–228 These variations 
proceed under milder conditions and often give higher yields than the original procedure. 
 
Scheme 14: Barton reaction and the synthesis of aldosterone acetate (103). 
Most known methods for introduction of deuterium atoms into position C-19 are based on a 
variation of the Barton reaction (Scheme 15).229–231 The axial 6β-hydroxy group of halohydrin 109 
served as a directing group for this process and zic reduction reinstated the ∆5-double bond. 
Oxidation to carboxy derivative 110, followed by reduction with a deuterated reagent provided 
primary dideuteroalcohol 111, which was transformed into leaving group reducible y alkali metal 
deuterides. The most comprehensive study was performed by Kirk et al., who prepared [18-2H3]-
progesterone and [19-2H3]-progesterone by reduction of the corresponding dideutero tosylates of 111 
with LiEt3BD.
232 Černý et al. prepared [19-2H3]-pregnenolone by reduction of the mesylate of 111 
with Zn in presence of NaI and D2O.
233 A different approach was chosen by Kasuya et al., who 
introduced a perdeuterated C-19 methyl group by a regio- and stereoselective ring opening of 4,10-
epoxide 114 by trideuteromethylmagnesium iodide (Scheme 15).234,235 Finally, ent-[19-2H3]-
testosterone 116 was prepared by Covey et al. by total synthesis.236 None of the 18-d3 and 19-d3 
steroids were prepared in the 5β-series.  
 27 
 
Scheme 15: Preparation of 19-d3 steroids 112. 
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2. AIMS OF THE WORK 
Neuroactive steroids are an important class of isoprenoid compounds, affecting the function of 
mammalian CNS. Their action at NMDA receptors is thought to affect fundamental processes such as 
memory formation, cognitive functions and neuroprotection. The exact mechanism of action of 
neuroactive steroids at NMDA receptors is still unknown. Despite some attempts, the binding site of 
neurosteroids at NMDAR was never fully determined. Questions arise, if the defined binding site 
exists, or if the effects of neurosteroids are mediat  through a different mechanism. Membrane 
perturbation or blocking of the ion channel are viable alternatives.51  
Even less is known about the fate of neuroactive steroids in organisms. Modern analytical methods 
are capable of pharmacokinetic and metabolic studies with minute amounts of analyte. However, a 
necessary condition for these methods is the preparation of a tracer molecule. This is achievable only 
by organic synthesis.  
The main topic of this thesis will be to design and elaborate probes for distinguishing the 
mechanism of action of neurosteroids at the NMDA receptor. Unnatural enantiomers of native 
neurosteroids will be chosen as the synthetic tool capable of differentiating direct binding site-
mediated action from less specific mechanism. The desired pregnane nt-steroids will be prepared by 
total synthesis, which will also enable preparation of truncated mimics of neurosteroids in both 
enantiopure forms. These mimics will be exploited to identify minimum binding requirements for 
inhibition of the NMDA receptor. 
The last part of the thesis reports a study of incorporation of deuterium atoms into metabolically 
inaccessible positions of steroidal angular methyl groups to provide internal standards for 
pharmacokinetic measurements and tracing of metaboli es by HPLC-MS/MS analysis. 
 
Specific aims are: 
• To design and develop a modular total synthesis of pregnane ent-steroids. Strategically, this 
means assembling rings A and B first to allow for pssible modification/deletion of the side 
chain and rings D and C. ent-Pregnanolone (ent-7) will be chosen as the central intermediate for 
other pregnane derived ent-steroids. An original C-C bond forming methodology will be used 
for the annelation of the D-ring and its viability will be evaluated. 
 
  
• To synthesize truncated analogs of neurosteroids, lacking the steroid side chain and ring D or 
rings CD. These mimics will be prepared in both enantiomeric forms and converted to the 


























• To develop methods for incorporation of deuterium atoms into angular methyl groups of the 
steroid core in 5β-pregnane steroids. Special attention will be paid to radical methods and their 
applicability for this purpose. 
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3. RESULTS AND DISCUSSION 
3.1. TOTAL SYNTHESIS OF PREGNANE STEROIDS  
3.1.1 Retrosynthetic Analysis 
In the retrosynthetic planning, several points were taken into the consideration. First, Chodounská 
and Vyklický’s groups have found that binding of neuroactive steroids to the NMDA receptor can be 
enhanced by changes in the steroid side-chain (see Chapter 1.2). It was therefore desirable to design 
the retrosynthesis with the late construction of the rings C and D to enable the synthesis of biologically 
interesting truncated analogs 117 and 118. Second, since the bent shape of the cis-AB junction of the 
steroid core was responsible for the inhibitory action at the NMDA receptors (see Chapter 1.2), ent-
pregnanolone (ent-7) was chosen as the target molecule (Scheme 16). Third, the D-ring and the 
oxygen function in position C-20 seemed ideally positi ned for a radical 5-exo cyclization with 
oxygenative termination and offered an opportunity to extend the methodology of copper-catalyzed 
conjugate addition of organometallics with SET oxidat on of the resulting enolate (see Chapters 1.7-
1.8).  
A series of functional group interconversions (FGI’s) and a functional group addition (FGA) lead 
from ent-7 through ent-121 to the fully assembled carbon skeleton of ent-122. The C-18 methyl group 
is disconnected first to give nt-123, prepared for the key disconnection of the D-ring. The persistent 
radical TEMPO can be disconnected from ent-123 to give radical ent-124, enabling a radical 5-exo 
disconnection to an α-keto radical ent-125. This is in turn accessible from ent-126 by a SET process 
and a conjugate retro-addition of a carbon nucleophile 127. Different carbon nucleophiles 127 can be 






























































Scheme 16: Retrosynthetic analysis of ent-7 
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The double bond in ent-126 is on the other side of the C-ring than would be desirable and has to 
be repositioned by series of FGI’s. This in turn enables the Robinson disconnection of the C-ring of 
ent-128, leading to cis-decalin ent-129, which can be traced back to the known Wieland-Miesch r 
ketone ent-21 by a series of redox steps. The Hajos-Parrish-EderSauer-Wiechert (HPESW) 
disconnection leads to simple diketone 48 and enone 49 (See Chapter 1.6).  
3.1.2 Enantioselective Entry into the Synthesis 
The first step of the total synthesis was the HPESW reaction (Scheme 17). The described addition 
of diketone 48 to methyl vinyl ketone (49) catalyzed by triethylamine proceeded as reported with
quantitative yield to afford triketone 50.128 This reaction was scaled up to 100 g of 50 without a 
decrease in the yield.  
 
Scheme 17: Synthesis of the Wieland-Miescher ketone ent-21 
The catalyst for the asymmetric reaction was chosen on the basis of the highest yield and 
enantioselectivity published in the literature (see Chapter 1.6). None of the reported catalysts was 
commercially available, with the exception of the uns bstituted amino acids proline 51and cispentacin 
52, which offered only mediocre yields and enantioselectivity. The synthetic accessibility of the 
catalyst thus came into play. It was necessary to ensur  enough material of the organocatalyst to 
provide at least multigram amounts of cyclized product ent-21. Prolinanilides were selected as a first 
class of catalysts, since they met all the criteria and a small library could be rapidly assembled for 
screening.  
 
Scheme 18: Synthesis of the catalyst (R,Ra)-59 
Catalyst (R,Ra)-59 was prepared from a commercially available BINAM (Ra)-131 in 2 steps  by 
modification of the known procedure (Scheme 18).127,128 Instead of using N-protected proline, 
prolinoyl chloride hydrochloride (R)-130, was employed. It is a crystalline storable reagent, which was 
pioneered by Fischer237 and later utilized by Morán et al. in their synthesis of various prolinanilides.125 
This reagent was prepared by reaction of (R)-proline ((R)-51) with PCl5 in chloroform at −5 °C, 
typically in 70-80% yield. Tosylation of enantiopure (Ra)-131 afforded an inseparable mixture of 
mono- and ditosylate (Ra)-132 and (Ra)-133, respectively. Prolination with (R)-130 proceeded 
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smoothly, affording (R,Ra)-59 in 72% yield from (Ra)-131. No detectable racemization of the proline 
chiral center was observed by NMR spectroscopy.  
Because of the relatively high price of enantiopure (Ra)-131, it was decided to test Morán’s 
catalyst 60a, which was prepared according to the literature from (S)-130 or (R)-130 and commercially 
available aniline 134a in 77% yield (Scheme 19). Because the enantioselectivity and the rate of the 
HPESW reaction was postulated to be a function of the acidity of the amide hydrogen,125 a few related 
catalysts featuring electron withdrawing groups at the aniline ring were prepared. Thus, trinitroanilide 
60e was prepared according to the literature by nitration of 60b in 56% yield.238 Anilide 60b was 
synthesized in 81% yield from aniline (134b) and 130. Finally m- and p- substituted (pentafluoro-λ6-
sulfanyl)anilines 60c and 60d were prepared from the corresponding anilines 134c and 134d in 79% 
and 65% yield, respectively.  
Amides 60a and 60e were prepared in both enantiomeric forms. Their enantiomeric purity was 
confirmed by synthesis of both diastereomers of their Mosher’s amides. Comparison of 1H and 19F 
NMR spectra showed >99% ee. Compounds 60c and 60d were prepared only in the (S)-series and the 
NMR spectra of their respective amides with optically pure (R)-Mosher’s acid revealed single 
compounds.  
 
Scheme 19: Synthesis of prolineanilides 60a-e 
All catalysts were tested in the HPESW reaction with substrate 50 (Table 1). First, the catalysts 
were used under the reported conditions (Entries 1–3).125,126,128 Trinitroanilide 60e showed rather low 
enantioselectivity, therefore it was not further optimized (Entry 1). The use of (R,Ra)-59 afforded 
results comparable to those reported in the literature (Entry 3).126,128 In contrast, 60a gave 21 with 87% 
ee vs. The reported 96%.125 This might be caused by unintended deviation from the published 
procedure, since Morán et. al. performed the reaction as an NMR experiment without isolation of 
product. 
Viózquez et al. have shown that both the yield and the enantioselectivity of the cyclization with 59 
can be enhanced by: a) coapplication of a catalytic amount of benzoic acid, and b) running the reaction 
under solvent-free conditions.127 Gratifyingly, employing solvent-free conditions and 5 mol% of 60a 
gave the Wieland-Miescher ketone in 94% ee after 3 days, although the crude reaction mixture still 
contained ca. 25% of starting triketone 50 (Entry 4). Adding 1 mol% of benzoic acid acceleratd he 
reaction and afforded 21 in excellent yield and 96% ee (Entry 5). Lowering the catalyst amount to 
3 mol% did not affect the yield, but decreased slightly the enantioselectivity to 92% ee (Entry 6). 
Decreasing the temperature did not lead to an improvement (Entry 7). Catalysts 60c and 60d proved to 
be as effective as 60a under these optimized conditions (Entries 8–11). In both cases, addition of 
1 mol% of benzoic acid increased the rate of reaction and enantioselectivity (Entry 8 vs. 9, 10 vs. 11). 
The p-SF5 substituted catalyst 60c proved slightly inferior to the m-SF5 substituted catalyst 60d. The 
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latter gave almost identical results to 60a. A kinetic experiment for 5 mol% of 60a or 60d showed 
marked dependence of the reaction rate on the concentration of BzOH (see Appendix A). While it 
took ca. 20 h with 0.5 mol% of BzOH and 60a (5 mol%), to reach full conversion, cocatalysis with 
5 mol% of BzOH reduced the time to 3 h. The enantiomeric excess was slightly worse (93%) in all 
kinetic experiments (see Appendix A). These results are to our knowledge the best so far reported for 
the preparation of 21.  
Table 1: Screening of catalysts 59 and 60a-e for the asymmetric Robinson annulation 
 











b 10 – rt 7 92c 39 
2 60a CHCl3
b 10 – rt 7 70c 87 
3 59 – 2 0.5 rt 7 89c 92 
4 60a – 5 – rt 3 72d,e 94 
5 60a – 5 1 rt 3 98d 96 
6 60a – 3 0.5 rt 3 98d 92 
7 60a – 5 1 5  3 98d 94 
8 60c – 5 1 rt 3 95d 95 
9 60c – 5 – rt 5 93d 84 
10 60d – 5 1 rt 1 98d 96 
11 60d – 5 – rt 3 94d 95 
a Determined by HPLC at chiral stationary phase (seeAppendix A). b c[50] = 1 M. c Isolated yield at 5.0 mmol 
scale. d Isolated yield at 1.5 mmol scale.e ca. 75% conversion as indicated by 1H NMR spectroscopy. 
At preparative scale, the reaction of 8.23 g of 50 with 2 mol% of (R,Ra)-59 and 1 mol% of benzoic 
acid afforded 97% of 1 (95% ee) after 7 days. The reaction of 49.5 g 50 with 5 mol% of 60a and 
1 mol% of benzoic acid afforded quantitative yield of 21 (96% ee) after 24 h. A single crystallization 
from Et2O/EtOAc at −78 °C afforded 34.2 g (76% yield) of material with >99% ee. The mother 
liquors were utilized as a model substrate in further syntheses and optimizations. A racemic Robinson 
annulation catalyzed by pyrrolidine afforded rac-21 in 55% yield.239 This compound was used as a 
standard for chiral HPLC analysis. 
The observed behavior of catalysts 60a-e is consistent with the known Houk-List enamine 
mechanism,125,240,241 where the proline catalyst 51 is substituted by the respective prolinamide 59 or 60. 
The currently accepted mechanism is shown in Scheme 20. The anilide CONH group is a much 
weaker acid than proline COOH group (pKa = 1.99 in H2O).
242 For comparison, N-[2,4-
dinitrophenyl]anilides have pKa in the range 9.5-10.5.
243 The amide is too weakly acidic to completely 
protonate the amino group of proline (pKa = 10.6 in H2O)
242 and thus to inhibit the reaction, yet strong 
enough to be capable of forming zwitterions in equilibrium. The rate of the aldol reaction 
135A→135B has been shown to increase with more acidic prolinanilides.125 The same effect was 
observed for the dehydration step 135C→135D. The acceleration of the reaction in the absence of 
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solvent is, however, probably just a concentration effect. Small amounts of water, coformed during the 
condensation, have also been shown to accelerate the reaction by hydrolyzing proline-derived 
oxazolidinones 135E.127,244 Presumably, the same principle applies to imidazolidinones 135F, which 
have been observed during the reaction by Morán et. al.125,245 Running the reaction in neat conditions 















































Scheme 20: Mechanism of the HPESW reaction 
Benzoic acid catalyzes the formation of enamines 135A,C and their hydrolysis. Finally, the lowest 
rates of conversion and enantioselectivities were observed with catalysts 60c and 60e, which were the 
only crystalline compounds, suggesting solubility issues. In contrast, the dependence of the reaction 
rate or enantioselectivity on the electronic density of the aromatic ring seems to play a minor role. 
3.1.3 Stereoselective Reductions of the Decalin System 
Acetalization of the Wieland-Miescher ketone 21 afforded dioxolane 136a or 2,2-dimethyl-1,3-
dioxane 136b in moderate yield (Scheme 21). Hydrogenation over 5% Pd/CaCO3 at ambient pressure 
afforded smoothly the cis-diastereomers 137a,b in quantitative yield. The steric effect of 9-dioxolane 
is responsible for the high selectivity of hydrogenation of 21.246 Ketal-protected ketone 137a was 
reduced smoothly with NaBH4 to furnish the anticipated equatorial hydroxy derivative 138a in 91% 
yield.247 Isolation of the minor diastereomer 139a was not attempted. In contrast, reduction of ketal 
137 under identical conditions afforded 78% of equatoril alcohol 138b and 16% of axial alcohol 
139b. This difference in stereoselectivity can be attributed to a different composition of the cis-decalin 
conformers. Compound 138a showed broadened 1H and 13C NMR spectra of a single diastereomer, 
indicating slow ring inversion, which somewhat improved by measuring the sample at higher 
temperature (60 °C, CDCl3). The NMR spectra of alcohols 138b and 139b showed clearly the 
presence of two conformers, which coalesced into one set of signals at 60 °C in CDCl3. Hydrogenation 
of 21 afforded crude diketone 140 in a 14:1 cis:trans ratio of 140a:140b, as determined by 1H NMR, 
which yielded 92% of pure cis-decalindione 140a after column chromatography. The observed 
selectivity of hydrogenation compares favorably to known methods,246,248 since hydrogenation over 
5% Pd/CaCO3 in pyridine was reported to afford a 6:1 cis:trans mixture.
246 Similar results were 
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Scheme 21: Preparation and reduction of ketals 137a,b 
The subsequent regioselective reduction of 140a was possible under several conditions (Table 2). 
Unfortunately, the separation of stereoisomers was difficult, but it was at least possible to separate the 
fractions containing starting material, keto alcohols 141-143 and diols, respectively. This enabled to 
assess the regio- and stereoselectivity of several r agents by isolating the appropriate fraction and 
integrating the 1H NMR spectrum. NaBH4 at −40 °C afforded a very good 141:142 ratio, while the 
regioselectivity was mediocre (Entry 1). The best results were obtained under Luche reduction 
conditions (Entry 2), which afforded very good regio- and stereoselectivity. Surprisingly, bulky 
LiAlH(O tBu)3 provided the lowest regioselectivity, although the 141:142 ratio was the highest reached 
in the series (Entry 3). For the best isolated yields of alcohols 141-143, it was critical to quench the 
reaction mixture at low temperature with an excess of acetone, followed by acidification. Omitting 
acetone led to significant overreduction to diols. All reductions were attempted at the lowest possible 
temperature and were quenched when TLC showed disappearance of the starting material.  
Table 2: Regioselective reduction of 140a 
 













1 CH2Cl2/MeOH 1:1 NaBH4 (1.4) - −40 0.5 81 19:1:7 




- −40 1 95 20:1:10 
a Reactions were performed on 1 gram scale. Isolated yiel  of the monoalcohol fraction 141-143. b Determined 
from 1H NMR spectra. 
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On a larger scale, the crude mixture from reduction of 140a was benzoylated under standard 
conditions for the purpose of detection during HPLC separation (Scheme 22). The resulting mixture 
was even easily separable by flash column chromatogr phy affording the desired monobenzoate 144
as a pure compound in 73% yield over two steps. Saponification of 144 by NaOH in methanol 
afforded quantitatively the desired alcohol 141 as an analytically pure compound.  
 
Scheme 22: The preparation of 141 
3.1.4 Substrate-controlled Robinson Annulation 
With the three chiral centers successfully established, the Robinson annulation of ring C was 
explored. While it is possible to conduct the whole Robinson annulation in one flask by reaction with 
excess of methyl vinyl ketone (49) under basic conditions, the yields usually suffer, mainly by 
oligomerization of 49 and of the intermediates.249 It was therefore decided to split the reaction 
sequence into three separate steps: a Claisen condensation, a Michael addition and a Dieckmann 
condensation with a retro-Claisen condensation; an approach used in the syntheses of many terpenoid 
natural products.170,250–254 Activation of the ketone by α-formylation has been reported to facilitate the 
Michael addition and thus increase the overall yield of the transformation.250,254  
First, the hydroxy group at C-3 had to be protected with a base-stable protecting group to prevent 
side reactions. Thus, ketal-protected alcohol 138b was converted to benzyl ether 145 under standard 
conditions (Scheme 23). Crude 145 was directly hydrolyzed to the free ketone 146a by acid catalysis 
in acetone in 67% yield of desired 146a and 28% of recovered alcohol 141. The reduced yield was 
caused by incomplete conversion to benzyl ether 145. 
 
Scheme 23: Robinson annulation of 146a 
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Benzyl ether 146a was formylated by reaction with sodium methoxide in neat dry ethyl formate to 
afford β-dicarbonyl intermediate 147a in essentially quantitative yield. The crude material was 
subjected to a Michael addition with a slight excess of 49, catalyzed by 1% of Et3N in a manner 
analogous to the first step of the synthesis (Chapter 3.1.2, Scheme 17). A crude 3:1 mixture of 
diastereomers 148a at the newly formed stereocenter was obtained. However, this was irrelevant to the 
outcome of the Robinson annulation, since this stereocenter was epimerized in the last step of the 
sequence. The last step proved to be difficult both in terms of yield and stereoselectivity. By 
employing conditions reported in the literature,170 a complex reaction mixture was obtained. 
Chromatographic separation afforded tricyclic compound 150a in 21% overall yield for all three steps, 
along with 7% yield of the ∆8-double bond isomer 149a. Unfortunately, the desired diastereomer 151a 
was not observed.  
The stereochemistry of 150a was suggested by a missing NOE contact between CH3-19 and H-8 
(Figure 8). In addition, the benzyloxy substituent at C-3 was in an axial position, which was deducted 
from small coupling constants in 1H NMR spectrum (4J = 4.2 Hz, CH-3β). Clearly, conformer 150a’ 
predominates over the expected conformer 150a”. 
Since the deformylative condensation was performed under equilibrating conditions, a 
thermodynamically controlled product should be formed preferentially. Assuming that the desired 
151a is thermodynamically less stable than isolated 149a and 150a, it was attempted to enforce the 
desired 8β-configuration by employing a bulkier protecting group, which should prefer the equatorial 
position. This could twist cis-decalin 148 into a more favorable conformation, leading ultimately to 




Figure 8: a) Detail of the 1H NMR signal of CH-3β of 150a, measured at 400 MHz. b) Probable 
conformations of diastereomers 150a and 151a. The observed JH,H of crucial hydrogens H-3β and H-
8α are displayed below. 
Alcohol 141 was easily protected to afford either TBS ether 146b or trityl ether 146c in excellent 
yields (Scheme 24). Their Robinson annulation gave similar results. Again, the major products 150b,c 
had an undesired 8α-configuration, and the H-3β 1H NMR signal was a quintet as in 150a. No product 
with the desired stereochemistry was observed in either of the reactions. At this point, it was decided 
to abandon the Robinson annulation of cis-decalins 148. Nevertheless, the reaction should proceed 
with the desired stereoselectivity in case of a flat decalin system, either a trans-decalin or a decalin 
with a double bond at the ring-fusion.170,251,255  
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Scheme 24: Substrate-controlled Robinson annulation with 146a-c 
3.1.5. Second Generation 
The outcome of the substrate-controlled Robinson annul tion called for a change of the cis-decalin 
system to a more rigid trans-decalin. However, this would complicate the synthesis of 5β-steroids at 
late stages of the synthesis. It was therefore decided to accomplish the total synthesis with the ∆4-
double bond preserved in the molecule, leading to ent-progesterone ent-3 in the end – a known 
precursor to both 5α- and 5β-pregnanes. 
This approach required the chemoselective protection of the enone in the presence of the simple 
keto group in ent-21 (Scheme 25). Of the known robust protecting groups for ketones, a thioketal was 
ruled out on the basis of its reactivity with alkali metals in ammonia – a step planned later on in the 
synthesis (see Chapter 3.1.1). The regioselective protection of the 3-keto group f 21 as a dioxolane 
is possible with bis(trimethylsilyloxy)ethane and TMSOTf as an acid catalyst by employment of non-
equilibrating conditions at −78 °C.256 This method is on one hand highly selective and mild, 
proceeding with no shift of the conjugated double bond.256–258 On the other hand, the reaction time of a 
week for substrate 21 makes this method impractical. Another option for kinetic control is the 
application of bulky acid collidinium p-toluenesulfonate, which leads to a substantial deconjugation of 
the double bond.259,260 In contrast, classically employed methods provide s lectively 
thermodynamically more stable monoketal 136a (cf. Scheme 21).261 
A solution of the ketalization problem was found by serendipity during efforts to produce the 
thermodynamic ketal 136a. When the reaction was conducted with dry ethylene glycol in the presence 
of a slight excess of triethyl orthoformate and 10 mol% of pTsOH·H2O at 25 °C in benzene, the 
thermodynamic ketal 136a was formed in 67% yield (78% brsm). Lowering the temperature to −20 °C 
in toluene led to 72% yield of the kinetic ketal ent-152. These conditions were optimized to 86% yield 
in dry CH2Cl2 by using 2 mol% of TMSOTf as the catalyst (Scheme 25). Moreover, the unreacted 
starting material ent-21 could be easily recovered in 12% yield. Remarkably, these conditions 
completely prevented the migration of the double bond from the ∆4 to the ∆5-position. 
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Monoketal ent-152 was subjected to the Robinson annulation conditions. Ketone ent-152 was 
formylated in virtually quantitative yield, and the r sulting Michael donor ent-153 was coupled to 49, 
which proceeded smoothly to afford a crude mixture of diastereomers ent-154 in 2:1 ratio. At first 
attempt, the aldol condensation of this mixture with tBuOK/tBuOH at 25 °C afforded two separable 
double bond isomers: 40% of deconjugated enone ent-156 and 26% of desired ent-155. The ROESY 
spectrum of ent-155 clearly showed a NOE between CH3-19 and atoms H-1β, H-6β, H-8β and H-11, 
thus confirming the desired stereochemistry. The coupling constants were also consistent with an axial 
position of H-8β: J8β-7α = 12.3, J8β-14α = 10.1, J8β-7β = J8β-14β = 5.0, J8β-11 = 2.2 Hz. Please note that in 
ent-series the α-substituents are above the plane of drawing to maintain the relative stereochemistry 
(see Chapter 1.3). 
 Optimization of the reaction conditions for the last step of Robinson annulation seemed prudent. 
The main problem was identified as a follow-up reaction of ent-155 and ent-156 with oxygen, leading 
to formation of 8-hydroxy derivative nt-157. This oxygenation reaction was also observed with other 
bases such as aqueous K2CO3, KOH or methanolic NaOMe. For example, ent-157 was isolated in 30% 
yield after 4 h of reflux of ent-154 in 0.25 M nondegassed methanolic KOH. However, performing the 
reaction in degassed solvents with careful exclusion of air led to satisfactory yield 60% of ent-155 and 
23% of ent-156. Furthermore, the isolated deconjugated ketone e t-156 could be isomerized by 
refluxing with two equivalents of K2CO3 in degassed methanol to afford 46% of desired ent-155 and 
45% of recovered ent-156.  
 
Scheme 25: The substrate-controlled Robinson annulation 
Dissolving metal reduction of ent-155 in liquid ammonia smoothly afforded ketone ent-158 in 
very good yield (Scheme 26). The use of EtOH as a proton source and a temperatur  of −78 °C were 
crucial for good yield and chemoselectivity of the reduction. Some isomerization of the double bond 
was observed during the reaction leading to ca. 5% of ent-156, which was somewhat difficult to 
separate from ent-158. The correct stereochemistry was again confirmed by a ROESY spectrum. The 
CH3-19 group exhibited a NOE with H-1β, H-6β, H-8β and H-11β, but not with H-9, strongly 
suggesting a trans-BC ring junction. The trans-junction of the product is also consistent with the 
known course of the dissolving metal reduction of bicyclic enones.170,251,262  
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For introduction of the ∆13-double bond the Saegusa-Ito oxidation was chosen, because it offered 
the possibility of a catalytic reaction. Therefore the kinetic silyl enol ether ent-160 had to be 
selectively prepared. A number of bases were screened u der typical non-equilibrating conditions and 
consecutive addition of TMSCl. A mixture of isomeric TMS enol ethers ent-159 and ent-160 was 
isolated in virtually quantitative yield in each case. The ratios detected by 1H NMR of the crude 
reaction mixture are shown in Scheme 26. The steric effects are clearly reflected in the series 
LDA:LiHMDS:LiTMP (1:3.9 vs. 1:7.4 vs. 1:10 of ent-159:ent-160), while the role of counterion is 
visible in the series LiHMDS:NaHMDS:KHMDS (1:7.4 vs. 1:6.4 vs. 1:5.3 of ent-159:ent-160).  
 
Scheme 26: Dissolving metal reduction of ent-155 and a kinetic deprotonation of ent-158 
After finding satisfactory conditions for the preparation of ent-160, it was subjected to Saegusa-Ito 
oxidation (Table 3). The original conditions employing 0.5 equivalent of Pd(OAc)2 and benzoquinone 
as a sacrificial oxidant were attempted,263 but led to early precipitation of palladium black and 
incomplete conversion (Entry 1). Nevertheless, it afforded a sample of the desired enone e t-161. The 
major side reaction in all experiments was desilylat on, leading to saturated ketone ent-158. The 
Larock modification of the Saegusa-Ito reaction worked reasonably well,264 yet some loss of the ketal 
protecting group was observed during aq. workup (Entry 2). This was presumably caused by the acetic 
acid released by contact with water, since the allylic ketals are very sensitive to aq. acids, even more 
so than saturated ketals. This issue was solved by pouring the reaction mixture on ice-cold aq. 
NaHCO3 (Entries 3–5). Attempts to suppress the desilylative side reaction were also made. 
Employment of a catalytic amount of NaOAc as a mild acid scavenger led to an increased desilylation 
to ent-158 (Entry 4). The culprit was found to be fine particles of molecular sieves, suspended in the 
solvent during drying. Satisfactory yield was achieved by using distilled DMSO without contact with 
molecular sieves and by prolonging the reaction time (Entry 5). 
Finally, an effort was undertaken to decrease the catalyst loading. Tsuji et al. reported a procedure 
which makes use of a stoichiometric amount of allylic carbonate as the hydrogen acceptor.265 The 
catalytic species in this variant is Pd0 supported by dppe or dba ligands. The latter method was 
successfully applied by Shibasaki et al. in their synthesis of strychnine.266 The yields of enone nt-161 
obtained by these methods were inferior to the optimized Larock modification (Entries 7–10). The 
main problem of the former method was the precipitation of palladium black and loss of the catalytic 
activity. In some cases, this was accompanied by a significant desilylation of the starting material 
(Entries 6, 8, 9).  
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a Determined by 1H NMR. b Reactants 159 and 160 in a 1:4 ratio. c Dry, stored over 4Å molecular sieves. d Ca. 
40% deprotection of ketal e Reactants 159 and 160 in a 1:10 ratio. f Dry, stored without molecular sieves. g 
Isolated yield.  h Ketone ent-158 isolated in 13% yield. 
The enone ent-161 formed crystals suitable for X-ray analysis, which helped to confirm its 
structure unambiguously (Figure 9). The molecule is slightly bent with the C-19 methyl protruding 
from the convex face. Central ring B adopts chair a conformation and contains C-19, H-8 and H-9 in 
axial positions. Both the A and C rings are in half-chair conformation, where methyl C-19 and α-O of 
the ketal occupy pseudoaxial positions of the A-ring. Dioxolane ring is in a half-chair conformation, 
rather than an envelope.  
Entry 
Catalyst 









1b Pd(OAc)2 (50) MeCN 
Benzoquinone 
(0.5) 
rt 16 14 53 
2b Pd(OAc)2 (10) DMSO
c Air (excess) rt 16 7 63d 
3b Pd(OAc)2 (10) DMSO
c Air (excess) rt 11 8 59 




rt 1 0 24 
5e Pd(OAc)2 (10) DMSO
f Air (excess) rt 48 0 80g 
6e Pd(OAc)2 (2) MeCN 
Diallyl carbonate 
(1.4), dppe (0.02) 




























81 96 63g 19g,h 
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a)




Figure 9: a) X-ray crystal structure of ent-161. Thermal ellipsoids are drawn at the 30% probability 
level. b) Schematic representation, side-view 
3.1.6. The Tandem Conjugate Addition – Cyclization 
For practical reasons, a Grignard reagent was chosen a  the stoichiometric organometallic reagent 
in copper-catalyzed conjugate addition. The main factors in this decision were: a) Precedent of 
asymmetric copper-catalyzed CA of organomagnesium co pounds in the literature (See Chapter 
1.7), suggesting a larger synthetic potential b) Facile formation of Grignard reagents from the 
corresponding alkyl halides and magnesium metal. c) Stability during storage and existence of reliable 
titration procedures.267–269 d) The ability of magnesium enolates to undergo a single electron oxidation 





























E : Z 9:1
E : Z 6.5:1 E : Z 2:1
E : Z 8:1 to 2:1
166:167  
Scheme 27: Preparation of Grignard reagents 165 and 168 
Both Grignard reagents 165 and 168 were prepared in two steps from cyclopropyl methyl ketone 
(162) by reduction to an alcohol 163, followed by halogenation (Scheme 27).271,272 Alcohol 163 was 
substituted with bromide with concomittant opening of the cyclopropane ring affording 164. This 
procedure can be also performed as a one-pot operation. Chlorination of 163 with PCl5 proceeded 
predominantly with retention of the cyclopropyl ring to give secondary chloride 166 with a small 
amount of the linear 167. The cyclopropyl ring was opened in the reaction of 166 with magnesium to 
give pure 168 without detectable amount of the cyclic Grignard reagent. This is in accordance with the 
known shifted equilibrium between cyclic and linear fo ms of homoallylic Grignard reagents.273,274 
E/Z-isomerization of the double bond during the Grignard reagent formation was observed both in 165
and 168, which is consistent with the well-known SET mechanism of this reaction.275,276  
The screening of suitable conditions for a substrate-controlled copper-catalyzed CA was performed 
using cyclohexenone (169) (Table 4). LiCl was added to every reaction mixture to enhance the 
solubility of the copper salt.160 A control experiment in the absence of copper catalyst afforded a 
mixture of 1,2-adduct 171 and 1,4-adduct 170 in a 3:2 ratio (Entry 1). When the copper catalyst was 
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present, the regioselectivity was reversed (Entries 2–18). Surprisingly, the regioselectivity was only 
weakly dependent on copper source (Entries 2–6). Anhydrous CuCl2 was therefore chosen as a shelf-
stable convenient precatalyst in the following experim nts. Addition of ligands resulted in mild 
improvement of the regioselectivity (Entries 7–9). Interestingly, HMPA or TMEDA ligands led to 
deterioration of the E/Z ratio in the products. Slowing the rate of addition of 165 had a marked effect 
on the regioselectivity, allowing for a 99:1 ratio 170:171 (Entry 5 vs. 10, 11). More polar ethereal 
solvents THF and DME were more suitable than Et2O or MTBE (Entries 11–14). Lowering the 
catalyst loading below 10 mol% resulted in a significant decrease of regiselectivity (Entries 15, 16). 
Finally, CuCN gave worse regioselectivity even under slow addition conditions (Entry 17), whereas 
Cu(OTf)2 served as an equally good precatalyst as CuCl2 (Entry 19). The most practical reaction 
conditions are CuCl2 as the copper source in polar ethereal solvents such as THF or DME (Entries 11, 
14). 
Table 4: Optimization of the reaction conditions for the copper-catalyzed CA 
 











1 none LiCl (20) THF 5c 39 61 8.3 
2 CuCl (10) LiCl (20) THF 5c 82 18 7.6 
3 CuBr·DMS (10) LiCl (20) THF 5c 79 21 7.6 
4 CuI (10) LiCl (20) THF 5c 84 16 7.6 
5 CuCl2 (10) LiCl (20) THF 5
c 85 15 7.9 
6 CuCN (10) LiCl (20) THF 5c 87 13 7.6 
7 CuCl2 (10) 
LiCl (20), 
HMPA (200) 
THF 10c 94 6 1.7 
8 CuCl2 (10) 
LiCl (20), 
Ph3P (20) 
THF 7c 93 7 7.8 
9 CuCl2 (10) 
LiCl (20), 
TMEDA (20) 
THF 5c 91 9 1.9 
10 CuCl2 (10) LiCl (20) THF 30
c 97 3 7.5 
11 CuCl2 (10) LiCl (20) THF 60
d 99 1 7.3 
12 CuCl2 (10) LiCl (20) Et2O 60
d 77 23 7.6 
13 CuCl2 (10) LiCl (20) MTBE 60
d 71 29 7.9 
14 CuCl2 (10) LiCl (20) DME 60
d 99 1 7.5 
15 CuCl2 (1) LiCl (20) THF 60
d 60 40 7.5 
16 CuCl2 (5) LiCl (20) THF 60
d 86 14 7.8 
17 CuCN (10) LiCl (20) THF 60d 80 20 7.7 
18 Cu(OTf)2 (10) LiCl (20) THF 60
d 98 2 8.0 
a Grignard reagent 165 (1.3 equiv) was used b Ratios determined by GC. c Added manually. d Added with a 
syringe pump. 
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The most convenient reaction conditions found for 169 were applied to the steroid precursor ent-
161 (Scheme 28). To simplify the NMR analysis of the reaction mixture, but-3-enylmagnesium 
bromide, prepared from commercially available 4-bromobut-1-ene, was used instead of 165. 
 
Scheme 28: Copper-catalyzed conjugate addition of 3-butenylmagnesium bromide to ent-161 
Under the optimized conditions (Entry 11 of Table 4) at −78 °C the conversion was slow. The 
reaction was quenched after the addition of Grignard reagent and stirring for additional 30 min at the 
given temperature. The NMR of the crude reaction mixture showed 25% of the starting material ent-
161 and 75% of the expected products ent-172 and ent-173. When the temperature of the reaction was 
raised to −40 °C, the conversion reached completion in the same time. The products ent-172 and ent-
173 were hydrolyzed to the respective enones ent-175, ent-176 and isolated in 80% yield in a 4.5:1 
ratio. Neither of the diastereomeric pairs ent-172, ent-173 or ent-175, ent-176, respectively, was 
separable by chromatography. Nevertheless, the sterochemistry of the major isomer could be deduced 
from a J-resolved NMR spectrum measured in a 1:1 mixture of C6D6/CDCl3. The coupling constants 
of H-14 of the major component ent-175 were measured to be J8β-14α = 11.2 Hz, J13β-14α = 12.5 Hz, J13α-
14α = 4.1 Hz, showing clearly the axial position of H-14α. Please note that in ent-series the 
α-substituents are above the plane of drawing to maintain the relative stereochemistry (see Chapter 
1.3). The minor constituent ent-176 showed identical connectivity of atoms and was therefore assigned 
as the 14β-diastereomer. None of the 1,2-adducts ent-174 or ent-177 were detected in a measurable 
quantity.  
Hypothetical transition states of the reaction are depicted in Scheme 29. The cuprate reagent is 
coordinated through a metal halide bridge to the carbonyl group of enone 178. The structure of ent-
161 is conformationally locked by the trans-annelation of rings B and C, forming a bent shape (see 
Chapter 3.1.5., Figure 9). Coordination of the cuprate complex at the convex face (178A) leads to the 
major diastereomer ent-172, whereas coordination to the ∆13-double bond at the concave face (178B) 
results in minor distereomer ent-173. Oxidative addition of copper in 178B is accompanied by a 
double 1,3-diaxial interaction of the cuprate complex with H-7α and H-9α for the minor pathway. In 
the major pathway 178A, the largest contribution comes from steric interaction of cuprate with H-8β. 
Therefore, it seemed possible that an increase in the s eric bulk of the cuprate complex results in a 




Scheme 29: Proposed transition states for coordination of cuprate to ent-161 
Thus, Ph3P (20 mol%) or dppe (10 mol%) were added to the reaction mixture and the reaction was 
performed at −40 °C, followed by acidic hydrolysis. The 1,4-adducts ent-175 and ent-176 were 
isolated in 80% yield and the diastereomeric ratio improved to 9:1 or 10:1 respectively as estimated by 
13C NMR. The PPh3 ligand afforded a slightly worse diastereoselectivity and was harder to remove 
from the product. An attempt to reach better selectivity by lowering the temperature to −78 °C in the 
presence of 10 mol% dppe resulted in isolation of ent-175:ent-176:ent-177 in quantitative yield, but in 
13:2:5 ratio as estimated by 13C NMR. Presumably, the catalyzed reaction was too sl w at −78 °C and 
the uncatalyzed reaction took place upon warming, lowering both the regio- and the 
diastereoselectivity considerably. 
With the first step of the tandem reaction successfully established, the conditions for oxidation of 
the enolate were explored. Several SET oxidants were used in this study. Firstly, ferrocenium 
hexafluorophosphate (182) was used to generate the α-keto radical from the respective enolate (see 
Chapter 1.8). The resulting alkyl radical reacted with an added stable radical TEMPO (183). In 
another setup, 2,2,6,6-tetramethyl-1-oxopiperidinium tetrafluoroborate (180) was used as the terminal 
oxidant. The salt 180 has been shown to oxidize ferrocene (179) in situ to the corresponding 
ferrocenium salt 181 (Scheme 30).193 Conveniently, this process co-generates the trapping agent 183 
and enables catalytic turnover of 179. Low concentration of 183 in the reaction mixture increases the 
time-window for an intramolecular reaction of the radical generated from an enolate. It may be 
therefore advantageous to add or generate 183 slowly.193 The possibility of oxidative cyclization of the 















Scheme 30: SET oxidants employed in the tandem reaction 
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Table 5: Tandem copper-catalyzed CA–Oxidative cyclization 
 
a Unless mentioned otherwise, all reactions were performed at 0.5 mmol scale in THF (5 mL) with 10 mol% of 
Li 2CuCl4. RMgX (1.3 equiv) was added slowly over 1 h. 
b Inseparable mixture of 14α- and 14β-diastereomers 
184-188 a:b 4.5:1. c Temperature during the oxidation step. d Ratios determined by integration of the 1H NMR 
spectrum of the isolated mixture of 185-187. e Added slowly. f The magnesium enolate was trapped with TMSCl, 
the resulting silyl enol ether isolated in quantitative yield and redissolved in the respective solvent. The TMS 
group was transmetalated with MeLi (1.1 equiv) at rt. g Performed at 8 mmol scale. h Performed at 10 mmol 
scale, with 10 mol% of dppe ligand. Products obtained as inseparable mixture of 14α- and 14β-diastereomers 
184-188 a:b 6.2:1.   
Ferrocenium hexafluorophosphate (182) was ground to homogeneity with TEMPO 183 and this 
powder was slowly added to the generated enolate (Entry 1). This approach led to a low isolated yield 
of trans-alkoxyamines ent-184a and ent-184b. Although they were chromatographically inseparable, 
the former crystallized readily, in contrast to the latter. The second fraction contained cis-
alkoxyamines ent-185a,b, cyclized steroids ent-186 and a small amount of 13-bromo derivative ent-



















1 182 (1.0)e 183 (1.0)
e 165 THF 0 19 3 10 5 32 




165 THF 0 20 5 3 5 34 
3 180 (1.5)e 
179 (0.05), 
iPr2NH (1.0) 
165 THF 0 33 4 13 12 29 
4 182 (1.2)e 
183 (1.1), 
iPr2NH (1.0) 
165 THF 0 42 8 13 3 11 
5 182 (1.2)e 183 (1.15)
e 165 Et2O
f 0 35 10 trace 0 27 
6 180 (1.1)e 
179 (0.05), 
iPr2NH (0.5) 
165 DMEf 0 49 18 8 0 10 
7 182 (1.2)e 
183 (1.05),e 
iPr2NH (0.5) 
168 THF −40 51 14 16 3 5 
8 180 (1.2) iPr2NH (0.5) 168 THF −40  78 6 5 2 5 
9g 180 (1.2) iPr2NH (0.5) 168 THF −40 73 8 5 1 5 
10h 180 (1.5) iPr2NH (0.5) 168 THF −60 83 5 5 < 1 5 
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187a. Repeated chromatography in CH2Cl2/MTBE enabled separation of ent-185-187. The very last 
fraction consisted of simple 1,4-adducts ent-188. Addition of an excess of LiCl and HMPA before 
oxidation did not influence the composition of products significantly (Entry 2). Diisopropylamine was 
added to quench the excess of organometallic reagent (Entries 3,4,6–10). The applied catalytic 
oxidative conditions led to an increased proportion of halogenated byproducts ent-187a (Entry 3). 
Halogenation could be prevented to some extent by adding the TEMPO 183 to the reaction mixture in 
one portion, followed by a slow addition of the oxidant 182 (Entry 4). Next, the role of halides on the 
reaction was examined. With organomagnesium chloride 168, the formation of 187 was supressed in 
comparison with bromide 165 (Cf. entries 1–4 vs. 7–10). 
To examine the influence of enolate counterion and solvent on cyclization, the oxidation of 
lithium enolates was attempted in Et2O and DME, respectively (Entries 5, 6). The lithium enolates 
were prepared by the standard procedure, reported by Stork and Hudrlik,277,278 and subsequently 
oxidized by 182 in the presence of TEMPO 183 (Entry 5), or with 180 and a catalytic amount of 
ferrocene 179 (Entry 6). No halogenated product ent-187a was observed, yet the yield of cyclic 
isomers ent-186 remained very low.  
When performing the oxidation with a mixture of 182 and 183, slowly added to the enolate 
generated from 168, the cyclized product ent-186 was isolated in the highest observed yield (Entry 7). 
However, the direct TEMPO trapping products ent-184 and ent-185 were still the major components. 
Since the cyclization result could not be improved to a useful level, the yields of alkoxyamines nt-
184 and 185 were optimized instead. Therefore, the oxoammonium salt 180 was used without 
ferrocene 179 (Entry 8). This approach was rewarded with 78% yield of trans-adduct ent-184 and 6% 
of cis-adduct ent-185. The cyclized product ent-186 was isolated in mere 5% yield and the chloride 
ent-187b was detected only in minute amount. The reaction was scaled-up to a gram-scale synthesis 
without major change in yield or product ratios (Entry 9). Employing the dppe ligand for the CA step 
and lowering the temperature of oxidation to −60 °C improved the ratio of ent-184a:b to 6.2:1 and 
increased the yield (Entry 10). 
 
Scheme 31: Putative mechanism of formation of products ent-184-186 
A suggested mechanism of the oxidative part of the tandem reaction is depicted in Scheme 31. 
The first part of the tandem, the CA of the Grignard reagent, results in the enolate ent-189. In 
principle, the metal cation in ent-189 can be Li+, Cu+ or Mg2+, although the latter is present in excess 
and is therefore the most probable. The enolate ent-189 is oxidized by a SET oxidant, to afford a 
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transient α-carbonyl radical 190 (Pathway A). This can be mediated by an outer-sphere oxidant 182 or 
an inner-sphere oxidant Cu(II), through the formation and homolysis of Cu2+ enolate. Whether the 
oxoammonium salt 180 itself is capable of SET oxidation according to pathway A remains an open 
question, but polar addition of the enolate ent-189 to 180 seems to be a viable process (Pathway B). 
Copper(I) maybe oxidized to copper(II), either by the oxoammonium salt 180 or potentially by the 
ferrocenium salt 182.  
Pathway A1, which is predominant under all conditions, leads to direct trapping of 190 with 183. 
The upper face of intermediate 190B is less hindered, leading to the major product ent-184a. 1,3-
Diaxial interactions combined with steric hindrance by the β-alkyl substituent are supposedly the key 
factors for the observed diastereoselectivity.279 Similar interactions are governing the polar reaction 
according to pathway B, yet the face-selectivity is superior to pathway A1 (Entries 7 vs. 8). The α-
carbonyl radical 190 undergoes 5-exo cyclization to give radical 191 only to a minor extent (Pathway 
A2). Radical 191 is trapped by the present persistent radical TEMPO 183, affording the desired 
product ent-186 in low yield. 
Pathways A1 and A2 are directly competing and the distribution of products is determined by the 
respective rates of reaction. Combination of TEMPO radical with transient radicals occurs with k ≈ 108 
to 109 M−1s−1 at 80 °C, more polar solvents being at the slower end of the range.280,281 The 5-exo 
cyclization of the 2-(but-3-enyl)cyclohexyl radical has a rate constant k ≈ 4×105 s−1 at 65 °C.282 This 
explains the obtained results, however, since the cyclization is a unimolecular reaction, whereas the 
rate of combination reaction is dependent on the concentration of TEMPO 183, a larger amount of the 
cyclized material ent-186 can be isolated when 183 is added or generated slowly (Entries 3,4,7).  
Halogenated byproducts ent-187 are probably formed by the reaction of enolate 189 with 
copper(II) halide, generated by in situ oxidation of copper(I). Indeed, no ent-187 is formed in the 
absence of copper (Entries 5, 6, Table 5). Ligand transfer of halogen from copper(II) halide is a facile 
process, occurring with rate constants k ≈ 1–5×108 M−1s−1 for CuCl2 and about four times faster for 
CuBr2.
283 It is therefore not surprising that the use of alkyl magnesium chloride 168 instead of bromide 
165 led to a diminished amount of ent-187. Moreover, LiCl has been shown to accelerate the ligand 
transfer of X•.283 CuX2 is therefore directly competing with TEMPO (183) for the radical 190. This can 
be overcome by employing a higher concentration of 183 over the copper catalyst at the price of 
suppressing the 5-exo cyclization (Entry 4, Table 5).  
The structure of nat-184a was determined by single-crystal X-ray crystallography (Figure 10a). 
Both tetramethylpiperidinyloxy- (TMPO-) and pentenyl substituents occupy axial positions at the 
cyclohexane C-ring which exists in the boat conformation. This is consistent with the observed 
coupling constant J13β-14α= 1.6 Hz in CDCl3, corresponding to a dihedral angle of the respectiv  C-H 
bonds close to 90°. Supposedly, a steric clash between vicinal TMPO-, pentenyl and carbonyl groups 
forces the cyclohexanone ring into boat conformation. The axial pentenyl substituent also avoids the 
1,3-diaxial interaction with H-7α. An anomeric effect might be also contributing, in a  analogy to a 
reported α-halo ketone effect.284–286 
 For the minor isomer ent-184b, the signal of H-13α was obscured by the multiplet of the ketal 
OCH2 signals. However, deprotection in acetone with a cat lytic amount of acid afforded diketone ent-
192, which showed a coupling constant of J13β-14α= 3.5 Hz in d6-DMSO. The ROESY spectrum of ent-
192 confirmed the trans-configuration of the side chain and the TEMPO residue (Figure 10b). The 
constitution of the minor products ent-185 is identical to nat-184a based on their 2D NMR spectra. 
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Nevertheless, a conformational equilibrium of ring C caused broadening of the crucial 1H and 13C 




   
Figure 10: a) X-ray crystal structure of nat-184a. Thermal ellipsoids are drawn at the 30% probability 
level. b) Configuration and the probable conformation of ent-192. Arrows show important ROESY 
crosspeaks. 
To conclude, efficient reaction conditions were found for the high-yielding synthesis of acyclic 
products ent-184-185 with high 16:1 trans:cis ratio (Entry 10, Table 5). Competing halogenation side 
reactions can be suppressed by choosing proper substrates and reaction conditions, namely oxidant 
180 and alkyl magnesium chloride 168. The direct tandem cyclization is possible, although the 
maximum obtained yields of ent-186 remained low. 
3.1.7. Thermal Cyclization 
The potential of alkoxyamines ent-184-185 to undergo thermal cyclization employing the PRE 
effect was investigated (Scheme 32). tBuOH was used as the solvent to minimize radical side 
reactions. Since the applied temperature exceeded the boiling point, a microwave reactor was used. At 
100 °C, trans-alkoxyamine ent-184a cyclized in quantitative yield within 30 min. The diastereomeric 
ratio of the obtained steroids ent-186A,a was 5:5:2:1. The structure was elucidated after oxidative 
deprotection of TEMPO (vide infra). Addition of a small amount of triethylamine to the reaction 
mixture was necessary to suppress hydrolysis of the acid-sensitive ketal. The isolated cis-alkoxyamine 
ent-185a underwent the cyclization under identical conditions, affording exactly the same composition 
of diastereomers ent-186A,a. Importantly, this represented a proof of configuration of ent-185a. The 
H-14β isomer ent-184b did not cyclize at all at 100 °C, but required at least 130 °C to react. Even so, 
the reaction took approximately 4 h to completion and gave rise to a 4:4:1:1 mixture of diastereomers 
ent-186B,b. When a mixture of ent-184a and ent-184b was subjected to the reaction at 100 °C, ent-
184b was quantitatively recovered by column chromatography. The tetracyclic diastereomers ent-186 
were chromatographically inseparable from each other.  
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Scheme 32: Thermal cyclization to ring D 
To assign the stereochemistry at the newly formed st reocenters, the mixture of tetracyclic 
diastereomers ent-186A,a was fully deprotected by acidic hydrolysis of the ketal and subsequently by 
oxidative cleavage of the alkoxyamine (Scheme 33).287 Two diastereomeric triketones 193 and 194 
were obtained in a 3:1 ratio and excellent yield. The major compound 193 crystallized after HPLC 
separation and was characterized by X-ray crystallography (Figure 11).  
 
Scheme 33: Structure assignment of diastereomeric 18-norsteroids ent-186A,a  
The minor isomer ent-194 was inseparable from ent-193. Nevertheless, NMR assignment of the 
mixture was possible (Table 6). Control experiments were performed to confirm the determined 
stereochemistry. First, the 13-position was epimerized in an attempt to prepare all four diastereomers 
at C-13 and C-17 for complete comparison. Therefore, th  cyclized mixture ent-186A,a was 
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deprotonated with potassium hydride in THF and the potassium enolate was quenched with aqueous 
NH4Cl. The resulting mixture of diastereomers was deprotected to afford triketones ent-193 and ent-
195 in 5:2 ratio and 87% yield. Oxidative alkoxyamine d protection was in this case performed in a 
biphasic mixture CH2Cl2/H2O with phosphate buffer of pH 7.5 to prevent possible epimerization at 
C-17, but even so the expected minor diastereomer possessing H-13β,H-17β could not be found in the 
reaction mixture. Norsteroid ent-195 was crystalline and was unambiguously characterized by X-ray 
crystallography (Figure 11). 
  
Figure 11: X-ray crystal structure of ent-193 (left) and ent-195 (right). Thermal ellipsoids are drawn 
at 30% probability level.  
The stereochemistry of ent-195 corresponds to the all-trans isomer and the structure resembles 
that of native steroids. Rings B and C are in chair conformation and ring D is in envelope 
conformation with carbon C-14 in endo position. The acetyl side chain resides in pseudoequatorial 
position. In contrast, the structure of 193 is unexpectedly flat, because of a boat conformation of the 
C-ring. Rings A and B are in typical half-chair or chair conformation respectively, while the D-ring is 
again in a nearly perfect envelope conformation with carbon C-16 in endo position. The acetyl side 
chain occupies pseudoequatorial position. 
Table 6: D-ring coupling constants of triketones nt-193-195 and ent-200 
1H-1H Coupling constants (Hz) 
Triketone Stereochemistry J13-14 J13-17 J17-16a J17-16b 
ent-193 H-13α, H-14α, H-17β 7.4 11.1 7.7 7.7 
ent-194 H-13α, H-14α, H-17α 11.1 7.9 2.9 7.9 
ent-195 H-13β, H-14α, H-17α 10.0 11.2 10.0 6.5 
ent-200 H-13β, H-14β, H-17α 7.9 2.1 7.3 9.8 
The result of the epimerization experiment suggests that the diastereomer nt-195 shares a H-17α 
configuration with ent-194, if the 17-stereocenter did not isomerize during manipulation. To validate 
this, the potassium enolate of ent-186A,a was quenched with TMSCl and the mixture of TMS enol 
ethers ent-196 and 197 was isolated in quantitative yield (Scheme 33). The 13C NMR spectrum 
revealed the formation of four thermodynamic ∆12-enol ethers ent-196 and two kinetic ∆11-enol ethers 
ent-197 in ca. equimolar ratio (see Chapter 5.2). Therefore ent-193 and ent-194 must be epimeric at 
C-17, effectively leading to the proposal of a single possible configuration for ent-194, as shown in 
Scheme 33. 
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Based on this assignment, a likely mechanism of the thermal cyclization can be derived (Scheme 
34). Upon heating, the C-OTMP bond of ent-184a or ent-185a homolyze to radicals ent-198 and stable 
radical TEMPO.215 An identical stereochemical outcome of both cyclizations strongly suggests an 
identical intermediate nt-198 (vide supra). The thermal homolysis is facilitated by the releas  of steric 
strain in the boat-type C-ring. This is supported by the fact that both ent-184a and ent-185a homolyze 
at a by 30 °C lower temperature than ent-184b. In addition, the neighboring electron-withdrawing keto 
group is known to lower the homolytic C-OTMP bond dissociation energy.213  
The cyclization process is governed by the equilibrium established according to the persistent 
radical effect, which is responsible for the virtual absence of side reactions in the process (see 
Chapter 1.9). Radical ent-198 preferentially undergoes a 5-exo radical cyclization over a potential 6-
endo process, which is favored by the angle of attack of about 109°, the geometry of the system and 
the substitution pattern at the ∆17(20)-double bond.288 
The stereoselectivity of D-ring formation can be explained by the Beckwith-Houk model.289–291 
Two boat-like and two chair-like transition states ent-198 can be imagined. From the two possible cis-
transition states, the boat-like ent-198A display less interaction with the C-ring and is thus preferred 
over chair-like ent-198B. The resulting radicals 199 subsequently couple irreversibly with free radical 
TEMPO, since the C-OTMP bond dissociation energy of ent-186 is too high for homolysis at 
100 °C.213 The coupling is not stereoselective because of free rotation of the side chain in ent-199 
bearing the radical and unhindered coupling trajectories of TEMPO. The transition states nt-198C,D 



























































































Scheme 34: The suggested cyclization mechanism for the D-ring formation 
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The 14β-diastereomers ent-186B,b were also subjected to deprotection, affording trike one 
ent-200 in 85% yield (Scheme 35). The compound crystallized in long needles, which were not 
suitable for single crystal X-ray analysis. The struc ure was therefore assigned by its NMR spectrum 
on the basis of its characteristic coupling constant  (Table 6). Presumably, the major diastereomer 
ent-186B shares the same stereochemistry with ent-200. Unfortunately, the amount of the sample of 
triketones was too low to allow reliable detection a d analysis of the minor diastereomer. The 
configuration of ent-186b was therefore assigned by analogy with ent-186a. The hypothetical 
transition states ent-201A and ent-201B leading to both isomers ent-186B,b are shown in Scheme 35. 
The stereochemical preference of ent-201A vs. ent-201B is governed by minimalization of the allylic 
strain in the side chain. The trans-annelation of the D-ring is in case of H-14β-diastereomers ent-184b 
geometrically impossible, ruling out the 13α-configuration of ent-186B,b. 
 
Scheme 35: Structure assignment of diastereomeric 18-norsteroids ent-186B,b and favored transition 
states of the cyclization 
Finally, the mixture ent-186 and ent-185 obtained after the tandem CA-oxygenation reaction was
also deprotected (Scheme 36). Three compounds were obtained: tetracyclic diastereomers ent-193 and 
ent-194 in a 3:1 ratio and the bicyclic acid ent-202 in modest yield. The ratio of ent-193:194 
demonstrates a similar stereoselectivity of the tandem CA-oxidation and the stepwise thermal radical 
cyclizations. Formation of acid ent-202 is probably a consequence of oxidative cleavage of ent-185a. 
A suggested mechanism is drawn in Scheme 36. Alkoxyamine ent-203 is converted to its 
corresponding N-oxide ent-204A, which attacks C-12 carbonyl group to form tetrahedral intermediate 
ent-204B. Fragmentation of ent-204B leads to TMP ester ent-204C, which is oxidized under the 
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Scheme 36: Elucidation of the structure of 18-norsteroids ent-186 formed directly by the tandem 
conjugate addition – oxidative cyclization (top). A suggested mechanism of the oxidative cleavage of 
ent-203 (bottom)  
3.1.8. Completion of the Steroid Skeleton 
For the construction of the last C-C bond of the steroid skeleton (Scheme 37), the thermodynamic 
enolate from ent-186A,a was generated with a slight excess of KH in THF and subsequently 
methylated with an excess of methyl iodide. The resulting mixture of products ent-205 and ent-186 
was difficult to separate and so it was carried on to global deprotection. The expected steroid ent-207 
was isolated in low yield along with a minute amount of some remaining alkoxyamine ent-206. Non-
alkylated triketones ent-193 and ent-195 were isolated in moderate yield and a ca. 1:1 ratio. 
Importantly, both ent-206 and ent-207 crystallized in sufficient quality to allow a single-crystal 
diffraction analysis (Figure 12). The X-ray structure revealed a classical all-tr ns steroid skeleton, 
however with the side chain in pseudoaxial position f the D-ring. In ent-206, the 
tetramethylpiperidine ring resides over the D-ring, which illustrates the observed stereoselectivity in 
methylation of ent-186, provided that the solution conformation of the corresponding enolate is 
similar.  
 
Scheme 37 Introduction of the C-18 methyl group 
In an attempt to improve the synthesis of ent-205, other methods for generation of the 
thermodynamic enolate were explored. The use of TMSOTf with an excess of triethylamine or in situ 
 55 
generated TMSI failed to generate silyl enol ether ent-196 in good yield because of competing ring-
opening of the allylic ketal. Silyl enol ether nt-196 was therefore generated with KH and TMSCl and 
transmetalated with MeLi in DME (Cf. Scheme 33). The resulting lithium enolate proved to be too 
unreactive for alkylation with MeI, yielding only epimerized triketones ent-193 and 195 after global 
deprotection. The same negative result was obtained when the potassium enolate of ent-186A,a was 
treated first with anhydrous LiCl in THF and subsequ ntly with MeI. The use of NaH instead of KH at 
50 °C also did not lead to an appreciable extent of methylation. 
 
Figure 12: X-ray crystal structure of ent-206 (left) and ent-207 (right). Thermal ellipsoids are drawn 
at the 30% probability level.  
Once KH was identified as the most suitable base, th  reaction conditions were modified to 
improve the yield of alkylated product. The reaction time was prolonged to 2 h and an excess of 
hydride (3 equiv) was used. After deprotonation, the enolate was transferred to another flask and MeI 
was added. This approach led to significant overalkyl tion, resulting in a 4:3 ratio of 
monoalkylated:dialkylated product as determined by ESI+ mass spectrometry. This was presumably 
caused by fine KH particles present during the methyla ion. Therefore, a small amount of dry tBuOH 
(0.1 equiv) was added before MeI, which improved the ratio of monoalkylated:dialkylated steroids to 
5:1. The 1H NMR spectrum of the crude mixture of ent-205 also showed the presence of ca. 15% of O-
methylated products in both cases. Since no method to purify the mixture obtained after methylation 
was found, the next step was performed with the crude material. 
To access the enantiomers of neurosteroid ent-7, the C-12 carbonyl group had to be reduced to a 
methylene unit. A number of synthetic methods is avail ble for this operation, yet the two most 
popular could not be used. The classic Clemmensen reduction is incompatible with the ketal, while 
Wolff-Kishner reduction requires drastic thermal conditions, which would cause elimination of the 
alkoxyamine group in the side chain. The latter became apparent during the thermal cyclization of ent-
184 at temperatures above 130 °C. The Caglioti reaction was tried on model compound ent-152,292,293 
but tosylhydrazide reacted preferentially with the allylic ketal and the desired product ent-208 was not 
formed (Scheme 38). Instead, alcohol ent-209 was isolated as the major product. Addition of 
stoichiometric amount of triethylamine inhibited the tosylhydrazone formation completely. Myers 
modification of Wolff-Kishner reaction was also attempted at the substrate ent-205,294 but led only to 
intractable mixtures.  
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Scheme 38: Unsuccessful attempts for hydrazone formation  
The labile ketal in ent-205 was therefore exchanged for the more robust thioketal ent-210 in two 
steps and good overall yield (Scheme 39). More than one equivalent of pTsOH was necessary to start 
the reaction. Presumably, the first equivalent is unproductively consumed in salt formation with the 
nitrogen atom of the piperidine ring. The conversion t  tosylhydrazone nt-211, however, required 
harsh reaction conditions and the yield was very low. It should be nevertheless noted that the reaction 
was performed on a mixture of various alkylated products, since the mixtures ent-205 or ent-210 were 
inseparable. It can be envisaged that doubly alkylated products react more slowly, or even cannot be 
converted to a tosylhydrazone. 
The hydrazone ent-211 proved to be reducible, but only to the stage of ∆11-olefin. Only one 
diastereomer of ent-212 was isolated. These facts and the low yield of hydrazone formation can be 
explained by steric hindrance of C-12 in 13-methyl ketones ent-205 and ent-210. One of the isomers in 
position C-20 reacts either more slowly or not at all. LiAlH 4 apparently serves only as a base instead 
of a nucleophile in the reduction of ent-211, and the result is a Bamford-Stevens-Shapiro reaction 
giving alkene ent-212.295,296  
 
Scheme 39: Formation of hydrazone ent-211 and its reduction  
To improve the reduction of the C-12 carbonyl group, thioketal formation and its reduction was 
investigated (Scheme 40). For this study, model compounds hecogenin nat-213 and progesterone nat-
3 were employed to simplify interpretation of result and to save valuable synthetic material. 
Formation of thioketals nat-214 and nat-217 proceeded in neat 1,2-ethanedithiol with TMSCl as the 
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source of anhydrous HCl in excellent yields. Remarkably, the spiroketal unit of nat-213 remained 
untouched under these conditions. Desulfurization of the thioketal was successful, provided that fresh 
Raney nickel of W-2 quality was used. A mixture of tigogenin (nat-215) and ∆11-unsaturated steroid 















































Reagent (equiv) Solvent T t nat-217 nat-218 nat-3
Yield
IBX (1.5), AcOH (1.0) DMSO, DCM, H2O 50 °C 16 h - 44% -
PIFA (1.5) DCM, MeOH, H2O r.t. 2 h 0% 25% 75%
I2 (2.0), NaHCO3 (excess) DCM, MeCN, H2O 0 °C 2 h 0% 42% 42%  
Scheme 40: Thioketal formation, reduction and deprotection on model systems  
Next, selective deprotection of allylic thioketal in the presence of the alicyclic thioketal was 
investigated (Scheme 40). IBX gave the best yield of enone at-218, but the mass recovery was poor. 
In contrast, both bis(trifluoroacetoxy)iodobenzene (PIFA) or iodine gave clean conversions, although 
substantial amounts of globally deprotected progesterone nat-3 were isolated. Employing a lower 
amount of oxidant led in all three cases to incomplete conversion (not shown).  
In light of the low yields of selective thioketal deprotection and desulfurization, the strategy of 
carbonyl reduction was changed to conversion of the ketone to a sulfonyl enol ether, followed by 
catalytic reduction (Scheme 41).297–299 Hecogenin (nat-213) was protected as TBS ether nat-219 under 
standard conditions. Ketone nat-219 was deprotonated with a strong base and the enolat was trapped 
with N-phenylbis(trifluoromethanesulfonimide) or nonaflyl fluoride. The corresponding triflate nat-
220 or nonaflate nat-221 were isolated in 55% and 84% yields, respectively. Apart from the lower 
yield, the triflate nat-220 was contaminated with a small amount of the triflimide reagent and was 
therefore not further used in the synthesis. The nonaflate nat-221 was reduced to alkene nat-222 with 
tributylammonium formate in the presence of Pd0 catalyst in good yield. Hydrogenation of nat-222 
proceeded with a loss of TBS group to afford tigogenin (nat-215) in virtually quantitative yield. It is 
known that molecular hydrogen can be directly used as a reductant of enol sulfonates in the presence 
of heterogeneous Pd catalyst.299 Hydrogenation of nonaflate nat-221 over Pd/C in EtOH/EtOAc 
mixture in the presence of triethylamine gave directly the desired nat-215 in very good yield. When 
pyridine was employed as the solvent, the reduction of nat-221 stopped in the stage of ∆11-alkene nat-
222 and the TBS group was preserved.  
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Scheme 41: Formation and reduction of model compound nonaflate n -221  
3.1.9. Synthesis of ent-Progesterone 
The results of the model study were applied to the key substrate ent-205 (Table 7). The crude 
mixture of diastereomers ent-205 was deprotonated with strong base and NfF was added to form the 
respective nonaflate. Lithium diisopropylamide gave  modest yield of the desired nonaflate ent-223, 
which was inseparable from side product N,N-diisopropyl nonafluorobutanesulfonamide (Entry 1).300 
LiHMDS and KHMDS, sterically more hindered bases, led to low conversion (Entries 2, 3). 
Interestingly, only one diastereomer of 223 was isolated, suggesting a large difference in reactivity of 
the isomers at C-20, which were both present in the reaction mixture. tBuLi or iPrMgCl led to full 
recovery of the starting material (Entries 4, 5). Use of KH resulted in higher yields of the isolated 
nonaflates (Entries 6–9). Small amounts of protic additives were used to facilitate the deprotonation of 
the hindered ketone nt-205. The differences between these additives were neverthel ss quite small. 
The reaction of the respective potassium enolate wih NfF is relatively rapid, the composition of the 
reaction mixture did not change anymore after 30 min since NfF addition. Overall, KH with a 
sterically hindered additive proved to be the reagent of choice (Entries 6, 8). 
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ent-186: R = H












ent-223b: R = H
ent-223a: R = Me
 
     Yield (%) 




(°C) Timeb (h) 
Recovered 
ent-205 ent-223 
1 LDA (2.0) - −78 to 0 1 + 16  55 32c 
2 LiHMDS (2.0) - 0 2 + 16 84 13d 
3 KHMDS (2.4) - 0 to 25 2 + 16 55 17d 
4 iPrMgCl (1.1) - −78 to 0 3 + 16 100 0 
5 tBuLi (1.1) - −78 to 0 3 + 16 100 0 
6 KH (3.0) tBuOH (0.2) 25 2 + 1 16 56 
7 KH (3.0) iPrOH (1.0) 0 2 + 16 48 32 
8 KH (3.0) HMDS (1.0) 0 5 + 11 52 40d 
9 KH (1.5) iPrOH (1.0) 0 1.5 + 0.5 42 42 
All reactions were performed in THF with 2.0 equiv of NfF. a During deprotonation. b First number is the 
duration of deprotonation, the second is the reaction time after addition of NfF. c The product contained a large 
amount of inseparable sulfonamide iPr2NNf, 
300 the yield was calculated from integration of the 1H NMR 
spectrum. d Single diastereomer.  
The mixture of nonaflates ent-223 was subjected to reduction catalyzed by Pd(PPh3)4, but the 
reaction was much slower than for nat-221 (Scheme 42). After two days, the nonaflate was reduced 
and a mixture of olefins ent-224a and ent-224b was isolated in 50% yield. The mass spectrum of ent-
224 showed >80% of non-methylated product ent-224b. To facilitate interpretation of the NMR 
spectra, the ∆11-double bond was hydrogenated and the alkoxyamine sd chain oxidatively 
deprotected to afford a complex mixture of diketones ent-225b. Nevertheless, not a trace of desired 
ent-17-isoprogesterone or ent-progesterone (ent-3) was observed.  
 
Scheme 42: Attempted reduction of nonaflate ent-223 
The slow reduction of nonaflate ent-223 was thought to be caused by steric hindrance of a bulky 
side chain. This hypothesis was supported by the fact that unsubstituted nonaflates nt-223b were 
reduced preferentially, although slowly. To reduce th steric crowding next to C-12, alkoxyamines 
 60 
ent-223 were oxidized first to ketones ent-226 (Scheme 43). At slightly basic pH to preserve ketal and 
enol nonaflate, the oxidation smoothly afforded the expected ent-226a in 66% yield, diastereomer nt-
226b in 13% yield, and recovered ent-223a as a single diastereomer in 13% yield.  
 
Scheme 43: Chemoselective deprotection of nonaflate ent-223 
A selective reduction of ent-226a over heterogeneous palladium catalyst was explored (Table 8). 
Reduction over 10% Pd/C was relatively fast at 50 °C and also at room temperature, with the 12-
nonaflyl substituent disappearing in 1 day (Entries 1–4). The conversion was conveniently monitored 
by the ratio of CF3 signals in the 
19F NMR spectrum. An undesired reaction occurred at the ketal ent-
226, causing reduction of the ∆4-double bond. At the same time, the dioxolane ring was opened to 
afford alcohol ent-228.  
Table 8: Reduction of nonaflate nt-226a 
 











a : bb 
1 10% Pd/C (15) 10 50 1 100 0.6 : 1 5 : 1 
2 10% Pd/C (30) 10 25 1 100 
1.3 : 1 
 (33% : 31%)c 
9 : 1 
3 10% Pd/C (30) 1 25 1 100 1.7 : 1 6.6 : 1 
4 10% Pd/C (30) 1 25 2 100 
0.7 : 1 
(24% : 26%)c 
19 : 1 
5 5% Pd/CaCO3 (15)
d 1 25 1 to 6e 50 6.8 : 1 8.4 : 1 
6 5% Pd/CaCO3 (15) 1 25 2 to 6
e 66 6.6 : 1 5 : 1 
7 5% Pd/BaSO4 (26) 10 25 8 95 3.9 : 1 2.2 : 1 
8 5% Pd/Al2O3 (22) 1 25 8 85 4.3 : 1 2.1 : 1 
9 5% Pd/Al2O3 (22) 20 25 1
f 100 1.2 : 1 2.9 : 1 
The reaction was conducted at c = 14 mM in EtOH/EtOAc 1:1 and Et3N (5 equiv). 
a The conversion was 
determined by integration of the 19F NMR spectra. b The ratios were determined by integration of groups of 
characteristic signals in the 1H NMR spectra. c Isolated yield. d Lindlar catalyst, poisoned with lead e The 
conversion halted after the first day and the reaction mixture remained unchanged thereafter. f The reaction 
mixture from entry 8 was resubjected to the reaction under stated conditions. 
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To reach selective hydrogenation, other palladium catalysts were screened. The Lindlar catalyst or 
5% Pd/CaCO3 led to the best selectivity, but the reaction stalled once it reached 50% or 66% 
conversion, respectively (Entries 5, 6). A new portion of catalyst, an aqueous workup or changing the 
reaction solvent to ethanol with THF, MeCN or DMF instead of EtOAc did not lead to improvement. 
The use of 5% Pd/BaSO4 resulted in moderate selectivity with respect to ketal opening, but the 
hydrogenation of the ∆11-double bond was slow (Entry 7). Palladium on alumina proved comparable 
to Pd/BaSO4 (Entries 8, 9). Under all the investigated conditions, a reduction of ∆11-double bond was 
slower than that of the vinyl nonaflate. The ketal opening was found to be the slowest of the observed 
reactions. 
The reaction mixtures from entries 2 and 4 were separated by column chromatography to furnish 
33% and 24% of ent-227, respectively. Compounds ent-227a and ent-227b were inseparable by 
standard column chromatography. 
The obtained sample of ent-isoprogesterone (ent-227a) contaminated with ent-227b was subjected 
to the known isomerization of the side chain.301 The diastereomeric ratio of the obtained crude mixture 
was 3:1 ent-3:ent-227 as determined from 1H NMR spectrum. Column chromatography on silica gel 
impregnated with silver(I) nitrate enabled separation of the ∆11-double bond containing impurities, 
affording a mixture of diastereomers ent-3:ent-227 in a 3:1 ratio and 46% yield. These compounds are 
known to be separable by crystallization from EtOH.301 An enantiomeric sample obtained by 
isomerization of nat-3 was separable by preparative HPLC on silica gel in CHCl3/hexanes/MTBE 
6:3:1. Unfortunately, the amount of ent-3 so far obtained in the last step of the total synthesis did not 
allow for either of these methods. The identity of prepared ent-3 was confirmed by comparison of 1H 
and 13C NMR spectra with the natural enantiomer nat-3 (Appendix D). It should be noted that low 
yields in last two steps are in part result of working with less than 10 mg of material.  
 
Scheme 44: Isomerization of the steroid side chain to ent-3 
The summary of the total synthesis of ent-3 is depicted in Scheme 45. The first asymmetric center 
is introduced in the HPESW reaction, which was optimized to afford 98% yield of Wieland-Miescher 
ketone ent-21 with 96% ee. A single crystallization provided virtually enantiopure material, which was 
selectively protected and subjected to Robinson annul tion to furnish enone nt-155 in 52% overall 
yield for 4 steps. Deconjugated enone ent-156 was isolated in 20% yield, but could be easily 
equilibrated to ent-155. Consecutive Birch reduction and Saegusa oxidation installed the ∆13-double 
bond in 66% yield. The key tandem conjugate addition-oxygenation followed by a thermal radical 
cyclization afforded steroid ent-186A,a in 80% yield from ent-161. The C-18 methyl group was 
introduced by methylation of the thermodynamic enolate of ent-186A,a. Nonaflation and oxidation of 
the alkoxyamine in the side chain afforded ent-226a as a single diastereomer in 37% yield over three 
steps from ent-186A,a. Hydrogenation of nonaflate followed by acidic workup gave 24% yield of ent-
17-isoprogesterone (ent-227a). Epimerization of the side chain provided a sample of ent-progesterone 
(ent-3), which had identical spectral properties compared to native progesterone. The whole synthesis 
consisted of 15 steps in the longest linear sequence a d provided ent-3 in 2.4% overall yield. The 
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synthesis of larger amounts of ent-3 for the preparation of ent-pregnanolone (ent-7) and its sulfate as 
enantiomers of native neurosteroids is underway.  
 
Scheme 45: Summary of the total synthesis of ent-progesterone nt-3 and a formal synthesis of ent-
pregnenolone (ent-7) 
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3.2.  TRUNCATED STEROID ANALOGS 
3.2.1 Synthesis of the Bicyclic and Tricyclic Analogs 
To explore the minimum binding requirements of the NMDA receptor, bicyclic and tricyclic 
steroid analogs 117 and 118 were synthesized. The rings A and B were preserved together with the 
relative configuration of the native neurosteroid hormone nat-7. The potential B-ring and C-ring were 
left unsubstituted to exclude random polar interactions of the substrate with a surface of the receptor.  
The synthesis of 117 started from benzoate 144 (see Chapter 3.1.3). Both enantiomers of 144 
were subjected to the Huang-Minlon modification of the Wolff-Kishner reduction to afford the 
respective alcohol 229 in good yield (Scheme 46). Decalinol 229 was slightly volatile, which caused 
lower yield in case of ent-229, which was synthesized on a smaller scale. Sulfation of 229 with 
























> 99% ee  
Scheme 46: Preparation of bicyclic sulfates 117  
The tricyclic analogs 118 were prepared by taking another synthetic detour from the total 
synthesis. Ketone nat-158, which was accessed as shown in Chapter 3.1.5, was reduced in a manner 
analogous to benzoate 144 (Scheme 47). The corresponding ketal nat-231 was isolated in a modest 
yield, along with a small amount of doubly deoxygenated hydrocarbon at-230. Apparently, the harsh 
reaction conditions caused substitution of the ketal for hydrazone, which was then reduced. Partial 
migration of the ∆4-double bond to ∆3-position was observed in at-230. Nevertheless, sufficient 
amounts of material for further synthesis of nat-118 were obtained in this reaction. To reach a higher 
yield, ent-158 was reduced under Caglioti conditions by NaBH4 reduction of the respective 
tosylhydrazone. This variant worked better and the desired ent-231 was prepared in one-pot procedure 
and good yield. Interestingly, the allylic ketal remained untouched under the applied conditions (cf. 
Chapter 3.1.8). 
 
Scheme 47: Deoxygenation of carbonyl C-12  
The allylic ketal was deprotected and the ∆4-double bond was hydrogenated to afford 
preferentially 5β-isomer 233, which was inseparable from the minor 5α-isomer 232 (Scheme 48). 
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Luche reduction of the ketones gave the corresponding mixture of equatorial alcohols, from which 234 
was separated in pure form. The minor 3β,5α-isomer could not be purified even after repeated 
chromatography in various solvent systems (not shown). The sulfation of 234 proceeded uneventfully 












































Scheme 48: Preparation of tricyclic sulfates 118 
3.2.1 Biological Activity of the Truncated Analogs 
The in vitro activity of 117 and 118 at NMDA receptors was evaluated by Mgr. Barbora Krusová 
in the laboratory of Dr. Ladislav Vyklický, Jr. at the Institute of Physiology of Academy of Sciences 
of the Czech Republic. For comparison, data of native neurosteroid nat-2, measured under identical 
conditions, are displayed.58 For a more detailed description see Appendix B.  
The IC50 value of native neurosteroid nat-2 and synthetic analogs 117 and 118 is plotted in Figure 
13. The inhibitory activity of tricyclic analogs 118 approach that of native inhibitory ligand nat-2 of 
the NMDA receptor. The difference between both enantiomers of 118 is strikingly small, ca. 1.3-fold 
in favor of the natural enantiomer. In contrast, bicyclic sulfates 117 exhibit a markedly lower 






















Figure 13: Half-maximal inhibition concentration (IC50) of native neurosteroid nat-2 and truncated 
analogs 117 and 118 at the NMDA receptor. The values above columns show means, the error bars 
show the standard deviation. 
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These results suggest that the interaction of neuroster ids with the NMDA receptor tolerates the 
loss of D-ring and side chain, whereas cis-decalins 117 are already too short for a significant inhibition 
of the receptor. The small difference between both enantiomers of 118 points to a small binding 
specificity. This is also supported by the fact that a polar function in the side chain of nat-2 is not a 
neccessary condition for inhibitory activity. Since a charged polar group is indispensable for the 
activity at the NMDA receptor,35,58 it seems probable that this group will prefer an aqueous 
environment, while the hydrophobic steroid core fits in a lipophilic compartment. In other words, it is 
likely, that interaction with the membrane or lipophilic transmembrane domain is crucial for the action 
of steroids at the NMDA receptor. It is unlikely tha  a highly specific binding site for neurosteroids, 
known for example in nuclear receptors, exists in the NMDA receptor. It will be interesting to 
compare the activity of ent-2 with this data set. Currently, the synthesis of ent-2 is underway. 
3.3. SYNTHESIS OF DEUTERATED TRACERS OF NEUROACTIVE STEROIDS 
To gain insight into pharmacokinetics and metabolic fate of neuroactive steroids in vivo, methods 
of specific isotopic labeling were studied. Metabolical y non-exchangeable positions of the C-18 and 
C-19 methyl groups were chosen to provide reliable tracers for physiological testing. Although some 
methods for deuteration of steroid angular methyls were described (see Chapter 1.10), the preparation 
of specifically labeled 5β-pregnane steroids is unknown in the literature.  
From the synthetic point of view it is interesting that while radical chemistry is virtually the only 
method for functionalization of steroidal methyls, it is underused as a method for deuteration. In the 
third part of this thesis, a method of specific deuteri m labeling of angular methyls C-18 and C-19 
with focus on radical chemistry was developed. [18-2H3]  And [19-
2H3]-5β-pregnane-3,20-dione 119 
and 120 were chosen as target compounds, because they are readily convertible into a range of 
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Scheme 49: Functionalization of C-18 methyl group  
3.3.1. Synthesis of [18-2H3]-5β-pregnane-3,20-dione 
The synthesis of 119 started from commercially available nat-progesterone (nat-3), which was 
converted in two known steps to nat-pregnanolone (nat-7) (Scheme 49).222,303,304 The hydroxy group of 
nat-7 was protected as methoxymethoxy ether 235 and reduced with NaBH4 to afford selectively 20R-
alcohol 236, along with a small amount of separable 20S-alcohol 237. Pure 236 was subjected to a 
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Suárez reaction to afford a slightly unstable 18-iodo steroid 238 in acceptable yield.305,306 The major 
side products 239 and 240 were isolated in small amounts. Their formation ca be explained by 
β-fragmentation of the alkoxyl radical generated from 236 to acetaldehyde and secondary C-17 
radical, which reacts unselectively with iodine to form 239 and 240. Similar products were observed 
by others upon analogous oxidation with Pb(OAc)4 and iodine.
307,308  
To simplify later transformations, the hydroxy group of 238 was protected (Scheme 50). An 
attempt to introduce a methoxyethoxymethyl (MEM) protecting group failed, leading to cyclized ether 
241. In contrast, switching to more reactive methoxymethyl bromide smoothly afforded ether 242.  
 
Scheme 50: Protection of the side chain hydroxy group at C-20 
In the next step, the oxygenation of iodo derivative 242 was explored (Table 9). Simple 
nucleophilic substitution in the dipolar aprotic solvent HMPA led exclusively to cyclic ether 241 
without any trace of desired alcohol 243 (Entry 1). Reductive oxygenation with ABCN as an initiator, 
and Bu3SnH as the hydrogen donor afforded 243 in moderate yield (Entry 2).
309,310 A large amount of 
tributyltin oxide complicated the isolation and therefore a catalytic variant of the reaction was sought. 
Fu’s conditions were tried with little success (Entry 3).311,312 Changing the hydrogen donor for 
diphenylsilane led only to recovery of starting material (Entry 4), while tris(trimethylsilyl)silane gave 
the desired product in satisfactory yield (Entry 5). The addition of base proved beneficial for the 
stability of the protecting groups. Silyl ethers, which were coformed, were destroyed with a small 
excess of TBAF, facilitating purification and improving the yield.  
Table 9: Oxygenation of iodide 242 
 
     Yield (%) 
Entry Reagents (equiv) Solvent T (°C) Time 241 242 243 
1 KOH (5) HMPA 120 30 min 85 - 0 
2 O2,
a ABCN (0.2), Bu3SnH (3.0) PhMe 90 6 h - - 30 
3 
O2,
a ABCN (0.2), Bu3SnH 
(0.15), PMHS (5), nBuOH (5) 
PhMe 90 6 h - - 14 
4 O2,
a ABCN (0.2), Ph2SiH2 (3.0) PhMe 90 6 h - 99 0 
5 
O2,
a ABCN (0.2), TMS3SiH 
(1.5), DIPEA (1.5) 
PhMe 90 6 h - - 78b 
a Continuous stream of pure O2 used. 
b The crude reaction mixture was treated with TBAF (1.5 equiv).  
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The neopentylic alcohol 243 was oxidized by catalytic ruthenium tetroxide to the corresponding 
carboxylic acid, which was immediately esterified with diazomethane to furnish 244 (Scheme 51). 
Reduction with lithium aluminum deuteride to 245 introduced two deuterium atoms with more than 
99% isotopic purity, as shown by mass spectrometry. In preparation for the envisaged Barton-
McCombie deoxygenation, 245 was converted to xanthate 246 by a standard procedure in very good 
yield.  
 
Scheme 51: Introduction of two deuterium atoms to C-18 methyl group 
The Barton-McCombie deoxygenation of 246 under standard conditions with commercial 
tributyltin deuteride led only to recovery of starting material (Table 10, entry 1). The use of Et3B and 
O2 as the radical initiator with the Et3B-D2O couple as the deuterium donor led to a worse result (Entry 
2).313 A successful deoxygenation was achieved with tris(trimethylsilyl)silyl deuteride, which was 
prepared by a published procedure and showed >95% isotopic purity by MS (Entry 3).314 Both isolated 
products 248 and 249 contained the reduced methyl group C-18, but both cntained a hydrogen atom 
in position C-18, which was clearly observable by the presence of a broad singlet at δ 0.65 ppm in the 
1H NMR spectrum. MOM ether 248 was isolated as a mixture of 248a and 248b in 1:1 ratio differing 
by a deuterium atom at the terminal methoxy group. Similarly, the fragmented product 249 was 
isolated as a 1:1 mixture of 249a and 249b. This result prompted us to repeat the deoxygenatio  with 
Bu3SnD (Entry 4), this time using freshly prepared materi l, since commercial samples are sometimes 
of dubious quality. Thermally less stable AIBN allowed for the use benzene as a solvent, which has 
considerably less hydrogen-donating properties. Under these conditions the desired 18-d3 steroid 247 
was isolated in 35% yield. It should be nevertheless mentioned that an improvement of the Bu3SnD 
reduction may be possible by increasing the concentration. In the end the optimization was not 
attempted because the obtained amount of material was insufficient. 
The outcome of the Barton-McCombie reaction can be explained by the following mechanism 
(Scheme 52). The reaction is initiated by thermal decompositin of the azoalkane, which abstracts the 
deuterium atom from TMS3 iD or Bu3SnD. Thus generated TMS3 i or stannyl radicals rapidly add to 
xanthate 246, followed by a slower fragmentation to radical 250A, here shown in one sequence.315 The 
next step is deuterium abstraction from another molecule of TMS3SiD or Bu3SnD leading to 247. This 
pathway dominates when Bu3SnD is employed as deuterium source (Entry 4). However, TMS3SiH is 
about five-times slower hydrogen donor than Bu3SnH, with rates of approximately 6×10
6 M−1s−1 for 
primary alkyl radicals and Bu3SnH at 80 °C.
316 The deutero analogs are slower donors because of the 
primary kinetic isotope effect. For Bu3SnH/D and primary alkyl radicals the kH/kD is approximately 
2.317–319 Moreover, the bulkiness of TMS3 iD may contribute to lower rates with sterically hindered 
radicals such as neopentylic 250A. Therefore a time window exists for competitive processes.320  
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Table 10: Deuteration of xanthate 246 
 
      Yield (%) 




(°C) t (h) 246  247  248  249  
1 Bu3SnD
b (1.5), ABCN (0.2) PhMe 0.09 111 6 64 - - - 
2 Et3B
c (10), D2O (10), O2
c
 (0.8) C6H6 0.43 25 12 48 - - - 
3 TMS3SiD
d (1.2), ABCN (0.1) PhMe 0.21 111 5 - - 26e 72e 
4 Bu3SnD
d (1.5), AIBN (0.1) C6H6 0.33 80 2.5 - 35
f - - 
a Of the deuterium reagent. b Commercial.  c Added with syringe pump over 1 h. d Freshly prepared. e a : b in ca. 
1:1 ratio as determined by NMR and MS. f 88% isotopic purity by MS.  
Product 248 is probably formed via intermediate 250B by 1,8-hydrogen abstraction. Although 
rare, this process has been observed in carbohydrate chemistry.321 Deuterium abstraction from 
TMS3SiD or hydrogen abstraction from toluene completes the transformation to 248a or 248b, 
respectively. Double β-scission of species 250B can be envisaged to form two molecules of 
formaldehyde and radical 250D, which is transformed to the observed major products 249a and 249b.  
 
Scheme 52: Proposed mechanism for Barton-McCombie deoxygenatio w th (TMS)3SiD 
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An even more likely process is shown in the bottom of Scheme 52. Here 250A undergoes 1,6-
hydrogen atom transfer to generate 250C that fragments to methyl formate and 250D. Several 
arguments speak for the contribution of this second mechanism. First, the 1,6-hydrogen atom transfer 
is geometrically preferred over 1,8-hydrogen atom transfer.322 And second, the transition state leading 
to radical 250C is lower in energy than that leading to 250B by stabilization with one more alkoxy 
substituent. 
To provide a comparison for the Bu3SnD reduction of xanthate 246, alcohol 245 was converted to 
the corresponing tosylate 251 (Scheme 53). Reduction with LiAlD4 in n-heptane provided three 
compounds, which were isolated after acid mediated deprotection as the alcohols 252, 253 and 254 in 
modest yields. The yields obtained were inferior to th se reported for related pregn-5-ene derivatives, 
34% for an analog of 252 and 28% for an analog of 253.232 Presumably, the LiAlD4 quality was a 
factor. Nevertheless, the achieved 96% isotopic purity of 252 was higher than 88% in Bu3SnD 
reduction. The diol 252 was quantitatively converted to [18,18,18-2H3]-5β-pregnane-3,20-dione (119) 
by Jones oxidation.  
The synthesis of 119 from pregnanolone nat-7 was 12 steps long and gave 7.3% overall yield for 
the radical route or 3.7% overall yield for the reduction of tosylate 251, respectively. The former route 
afforded diketone 119 of slightly lower isotopic purity. Even so, the xanthate reduction compares 
favorably in terms of yield with the reduction of tsylate 251.  
  
Scheme 53: Alternative synthesis of 119 
3.3.2. Synthesis of [19-2H3]-5β-pregnane-3,20-dione 
The starting material 255 for synthesis of 120 was prepared in the Dr. Chodounská’s laboratory in 
8 steps and 26% overall yield from commercially avail ble pregnenolone acetate according to a 
published procedure.323 Oxidation by sodium periodate catalyzed by ruthenium dioxide, followed by 
methylation with trimethylsilyl diazomethane provided ester 256 in good yield (Scheme 54). 
Reduction of 256 by NaBH4/CeCl3 gave selectively the equatorial alcohol 257, which was hydrolyzed 
to diol 258. Global protection to base-stable MOM diether 259 and subsequent reduction with LiAlD4 
afforded d2-steroid 260 in very good yield and excellent isotopic purity. The alcohol was smoothly 
converted to xanthate 261 and deoxygenated under the previously optimized conditi s, with freshly 
prepared Bu3SnD. In contrast to reduction of xanthate 246, no issues were observed during C-19 
reduction and the product 262 was isolated in excellent yield and isotopic purity. Deprotection and 
Jones oxidation furnished the specifically labeled steroid 120 in almost quantitative yield. The final 
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isotopic purity was 95% as determined by mass spectrometry. The overall yield of 120 from 255 was 
37% over 10 steps. 
It should be noted that in case of 5β-pregnane steroids, reduction of the corresponding 19-tosylate 
with LiEt3BD
232 or NaI/Zn/D2O
233 failed to provide the respective 19-d3 steroid,
324 probably because of 
steric hindrance. This problem can nevertheless be circumvented by performing the deuteration with 
∆5-steroid and reducing the double bond later. The synthesis described here offers a high-yielding 
alternative and employs accessible reagent LiAlD4.  
 To compare the ease of deuteration of angular methyls C-18 and C-19 by Bu3SnD, the latter can 
be obtained in higher isotopic purity. When the whole synthesis from commercially starting material is 
taken into account, 119 is accessible in 14 steps and 3.1% overall yield from nat-progesterone (nat- 3). 
d3-Steroid 120 was synthesized in a total of 18 steps and 9.5% overall yield from commercially 
available pregnenolone acetate.  
 
Scheme 54: Preparation of 120 
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4. CONCLUSIONS 
A conceptually new synthetic approach to ent-progesterone (ent-3) was investigated. From the 
strategic point of view, the synthesis started by building chiral A,B-ring system of steroid core, 
followed by substrate-controlled annelation of ring C. Ring D was formed together with the side chain 
in a newly developed reaction sequence. 
The first chiral center of ent-3 originated in Hajos-Parrish-Eder-Sauer-Wiechert reaction, 
catalyzed by prolinanilide (R)-60a. Optimization of the reaction conditions allowed for an extremely 
effective synthesis of Wieland-Miescher ketone (ent-21) in high enantiomeric excess. Enantiopure 
synthetic material was achieved by a single crystallization. Reductions of 21 to the cis-decalin system 
146 were successfully investigated, leading to a good yield of potential precursor of 5β-saturated 
steroids. Their synthesis was hampered by unwanted conformation of the substituted cis-decalin, 
leading ultimately to an unnatural relative configuration of the steroid core. In a second generation 
synthesis, the troublesome cis-decalin intermediate was substituted for conformation lly stable octalin 
derivative. A developed chemoselective protection of enone ent-21, followed by substrate-controlled 
Robinson annulation enabled rapid high-yielding synthesis of the tricyclic system ent-155 with a 
correct configuration.  
The key step of the synthesis consisted of substrate-controlled copper-catalyzed conjugate addition 
followed by oxygenation with a TEMPO surrogate. In the investigated system, 10 mol% of Li2CuCl4 
with the dppe ligand emerged as the best catalyst for he conjugate addition of Grignard reagents. 
Excellent yields and high diastereoselectivity were achieved. An attempted single electron transfer 
induced radical cyclization did not lead to a significant extent of cyclization to the D-ring, yet enabled 
a high-yielding preparation of α-alkoxyamine derivatives ent-184a and 185a. The incorporation of the 
SET oxidant into the product renders the key step highly atom-economic. The α-alkoxyamine 
derivatives were found to cyclize quantitatively under thermal conditions in a radical process mediate 
by the persistent radical effect. The diastereoselectivity of the radical cyclization was thoroughly 
investigated and key intermediates were characterized unambiguously by single crystal X-ray 
diffraction.  
Methylation of the activated C-13 position completed he synthesis of steroid skeleton. However, 
deoxygenation of the advanced intermediate ent-205 proved difficult. Desulfurization or hydrazone 
reduction failed to provide the desired saturation of ring C. An acceptable solution was found in 
hydrogenolysis of a corresponding vinyl nonaflate ent-223a. Epimerization of the side chain provided 
ent-progesterone (ent-3) in 2.4% overall yield in the longest linear sequence of 15 steps. 
The total synthesis design toward ent-3 enabled the preparation of truncated neurosteroid 
congeners 117 and 118 in both enantiomeric forms. Bicyclic sulfates nat- and ent-117 were prepared 
in 7 steps and 20 or 42% overall yield, respectively. Tricyclic sulfates nat- and ent-118 were prepared 
in 12 steps and 11 or 18% overall yield, respectively. All four sulfates were tested for inhibitory 
activity at the NMDA receptor in collaboration with Dr. Vyklický’s group at the Institute of 
Physiology AS CR. While both enantiomers of tricyclic sulfates 118 exhibited activity comparable to 
native neurosteroid nat-2, bicyclic enantiomers 117 were significantly less active. This substrate 
tolerance suggests a lack of specifity of the steroid binding site at the NMDA receptor or possibly a 




To provide steroid tracers for pharmacokinetic and metabolic studies of neuroactive steroids, 
methods of specific perdeuteration of the C-18 and C-19 methyl groups were briefly investigated. The 
C-18 methyl group was functionalized by a Suárez reaction, followed by radical reductive oxygenation 
to provide 18-hydroxy steroid in moderate yield. Oxidation to acid, followed by reduction with LiAlD4 
was confirmed as an effective method for the introduction of two deuterium atoms into the molecule. 
Conversion to the corresponding xanthate enabled a study of radical deuterium donors. Bu3SnD 
emerged as an acceptable candidate, being fast enough t  outcompete undesirable intramolecular 
hydrogen transfer reactions. D3-diketone 119 of 88% isotopic purity was prepared in 14 steps and
3.1% yield from nat-progesterone. In comparison, an analogous approach f r t e deuteration of the C-
19 methyl group proved to be more successful becaus of fewer competing side reactions. The 
introduction of the third deuterium atom proceeded in almost quantitative yield and 95% isotopic 
purity. Thus d3-diketone 120 was prepared, albeit from advanced intermediate 255, in 37% overall 
yield and 10 steps. Both methods provide the first known access to [18-2H3]- and [19-
2H3]-labeled 5β-
pregnane steroids. 
Overall, the described total synthesis of ent-progesterone (ent-3) demonstrates the synthetic utility 
of tandem copper-catalyzed conjugate addition with oxygenation, followed by thermal cyclization of 
persistent radical adducts. Although the method itself leaves some space for improvement in terms of 
step-efficiency, it provides a practical solution for the synthesis of polycyclic natural compunds. 
Further mechanistic investigation and exploration of scope and limitations of this tandem reaction can 
be envisaged. Large potential can be seen especially in conjunction with the rapidly developing field 
of enantioselective copper-catalyzed conjugate additions. Improvement of the Wieland-Miescher 
ketone synthesis is also worth mentioning, since ent-21 is a common intermediate in numerous 
syntheses of terpenoids.  
The described synthesis of ent-3 also constitutes a formal synthesis of ent-pregnanolone (ent-7) 
and its sulfate ent-2. In light of the observed activity of neurosteroid congeners at the NMDA receptor, 
it will be interesting to see whether the enantiomers of neurosteroids posess the same activity. The 
synthesis of both ent-7 and ent-2 is in progress. It is noteworthy that the prepared enantiomers of 
pregnane steroids can be studied in relation to neurosteroid receptors other than NMDAR’s. 
 The tricyclic steroid congeners 118 are intriguing in relation to a known i  vivo activity of 
neuroactive steroids. While the neuroactive steroids are subject to an inherent metabolic regulation, he 
tricyclic congeners or their analogs might provide different pharmacokinetic properties. The topic was 
covered in a recent patent application from IOCB and Institute of Physiology AS CR.62 This synthetic 
study will be followed by structure-activity relationship studies of various tricyclic derivatives at 
NMDA receptors.  
Finally, the investigated method of specific d3-labeling of angular methyls of 5β-pregnane steroids 
presents a competitive deuteration strategy. The envisaged metabolic studies are expected in due 
course. 
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5. EXPERIMENTAL SECTION  
5.1. GENERAL EXPERIMENTAL CONDITIONS  
Reactions not involving aqueous conditions were performed in flame-dried glassware under a 
positive pressure of dinitrogen. Air- and moisture-sensitive liquids were transferred via syringe or 
stainless steel cannula.  
TLC analyses were performed on POLYGRAM SIL G/UV254 plates. TLC plates were visualized 
by exposure to ultraviolet light, then stained by chemical reagent. For this purpose, iodine vapors were 
used, followed by one of the following solutions: aq. phosphomolybdic acid with ceric sulfate, acidic 
methanolic anisaldehyde, basic aq. potassium permangan te or methanolic sulfuric acid. The TLC 
plate was then heated briefly to 200 °C. Chromatogrphic separations were carried out on silica gel 
(60 Å pore size, Fluka, 230-400 mesh) or Florisil (60-100 mesh) where specified. Preparative TLC 
(prep-TLC) was carried out on 200 mm × 200 mm plates coated with a 0.4 mm thick layer of silica gel 
with CaSO4 as the binder. 
Melting points were determined on a micro-melting point apparatus Hund/Wetzlar (Germany). 
Optical rotations were measured in chloroform using a  Autopol IV (Rudolf Research Analytical, 
Flanders, USA), [α]D values are given in ° (10-1 deg cm2 g-1). IR spectra of CHCl3 solutions were 
recorded on a Nicolet 6700 (Thermo Scientific) spectrometer and the characteristic absorptions are 
given in wavenumbers. Neat samples were measured on Bruker Alpha instrument by the attenuated 
total reflectance (ATR) method. 1H, 13C and 19F NMR spectra were recorded on a Bruker Avance 400 
or 600 spectrometers. Proton chemical shifts are expressed in ppm (δ scale) downfield from 
tetramethylsilane and are referenced to this standard. Carbon chemical shifts are expressed in ppm (δ 
scale) downfield from tetramethylsilane and are refr nced to carbon resonance of the NMR solvent 
(CDCl3 77.00, C6D6 128.06, d6-DMSO 39.52). Fluorine chemical shifts are expressed in ppm (δ scale) 
and referenced to internal standard PhCF3 (−63.72 ppm). Data are represented as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = 
broad signal), coupling constants (J) in Hz, integration, assignment. The connectivity was determined 
by 1H-1H COSY and 1H-13C HMBC experiments and 1H-13C assignments were obtained from HSQC 
measurements. The stereochemistry of critical intermediates of the total synthesis was assigned using 
1H-1H ROESY experiments. Numbering of the signals in NMR spectra of the steroids, their synthetic 
analogs and precursors follows the standard IUPAC recommendation for steroid compounds.69 Non-
discernable proton signals in the aliphatic region of steroids, which were not prepared by total 
synthesis, are omitted for clarity. Mass spectra were obtained with spectrometers Q-TOF micro 
(Waters), GC/TOF-MS GCT Premier (Waters). Elemental analyses were performed on 2400 Series II 
CHNS/O System (Perkin Elmer, USA). In case of deuterated analogs, calculated values of hydrogen 
content were corrected for the method of detection: xH = (nH + nD) × 1.00794 / Mw Where xH is weight 
ratio of hydrogen in sample, nH and nD are numbers of hydrogen or respectively deuterium atoms in 
molecular formula and Mw is molecular weight. Gas chromatography was performed on Agilent 6850 
Series GC System equipped with flame-ionization detector and nitrogen as a carrier gas, using Zebron 
ZB-1 column (L 30m × I.D. 0.32 mm × df 0.25 µm).  
X-Ray crystallographic analyses were performed by Dr. Ivana Císařová at the Department of 
Inorganic Chemistry, Faculty of Science, Charles University in Prague. X-Ray crystallographic data 
are described separately in Appendix C. Analytical HPLC was performed on Agilent 1200 Series 
instrument with diode array and light-scattering detectors. 
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Solvents and additives were dried prior to use according to standard procedures: THF, Et2O and 
DME were freshly distilled over Na or K with Ph2CO added. MeOH was dried with Mg, distilled and 
stored over 4Å molecular sieves. Toluene was freshly distilled with Na. Dry MTBE, pentane and 
EtOH were purchased. MeCN, ethyl formate, hexane and DMF were distilled (the latter under reduced 
pressure) from P2O5 and stored over 4Å molecular sieves. CH2 l2, Et3N, iPr2NH, HMDS, HMPA, 
TMEDA, TMSCl, pyridine and DMSO were distilled from CaH2 and kept over 4Å molecular sieves 
(except TMSCl, CH2Cl2, pyridine). Ethylene glycol, tBuOH and benzene were distilled with Na and 
stored over 4Å molecular sieves. 
(20R)-19-Hydroxy-3-oxo-5β-pregnan-20-yl acetate (255) was prepared from commercial 
pregnenolone according to the known procedure and its spectral and physical data matched those 
reported.323 3α-Hydroxy-5β-pregnan-20-one (nat-7) was prepared from commercially available 
progesterone (nat-3) according to the previously described procedure.222,303,304 TMS3SiD was prepared 
according to the literature,314 with D2O (>99% isotopic purity, Sigma-Aldrich) as a deuterium source. 
Diazomethane was prepared from N-nitroso-N-methylurea,325 by extraction into Et2O from conc. KOH 
solution. Tributyltin deuteride was freshly prepared from tributyltin chloride and LiAlD4 (>99% 
isotopic purity).326 Jones’ reagent,327 ferrocenium hexafluorophosphate (182)328 and 1-oxo-2,2,6,6-
tetramethyl-piperidinium tetrafluoroborate (180)329 were prepared according to the published 
procedures. Perfluorobutanesulfonyl fluoride (NfF) was purified by the described procedure.330 SF5 
anilines 134c and 134d were a generous gift from George Iacobson (IOCB AS CR). All other reagents 
were used as purchased. 
5.2. TOTAL SYNTHESIS OF PREGNANE STEROIDS  
General Procedure A: Prolinanilides 
The method is essentially identical to that of Moran nd Fischer.125,237 Phosphorus pentachloride 
(3.8 g, 18.2 mmol) was suspended in anhydrous chloroform (10 mL) under nitrogen in an ice–salt bath 
at −5 °C. Finely powdered D-Proline (2.0 g, 17.3 mmol) was added to the reaction mixture in small 
portions. The white suspension dissolved to a colorless solution. After ca. 30 min at −5 °C, prolinoyl 
chloride hydrochloride started to crystallize from the solution. The suspension was filtered under an 
inert atmosphere, the crystals were washed with anhydrous chloroform (2 × 10 mL) and dried in vacuo 
to yield 2.14 g (73%) of prolinoyl chloride hydrochloride (R)-130 as colorless crystals, which were 
immediately used in the next step.  
The appropriate amine (10.1 mmol) was dissolved in ry THF (25 mL) under a N2 atmosphere. D-
Prolinoyl chloride hydrochloride (R)-130 (2.14 g, 12.6 mmol) was added portionwise and the mixture 
was stirred for 15 min, when TLC showed full conversion of the starting material. The reaction was 
quenched with 5% aq. HCl (100 mL) and washed with Et2O (3 × 50 mL). The ethereal layer was 
discarded. The aqueous layer was made basic by addition of K2CO3 and the product was extracted 
with EtOAc (3 × 30 mL). The combined organic layers were dried over anhydrous Na2SO4 and the 
solvent was evaporated in vacuo. Column chromatography (silica gel, 5% to 10% MeOH/C 2Cl2) 




Prepared according to a modified procedure.331,127 (Ra)-BINAM ( Ra)-131 (1.02 g, 3.59 mmol) was 
dissolved in CH2Cl2 (27 mL) and pyridine (3.47 mL). A solution of tosyl chloride (1.026 g, 
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5.39 mmol) in CH2Cl2 (9 mL) was added dropwise over 10 min while stirring. 
After 4 h of stirring at rt, the reaction mixture was poured into 5% aq. HCl 
(100 mL) and extracted with CHCl3 (3 × 25 mL). The combined organic extracts 
were washed with brine, dried over Na2SO4 and evaporated in vacuo. The residue 
was subjected to chromatography on silica gel (30 g) in 15% EtOAc/hexane to 
afford 1.55 g of the inseparable mixture of monotosylamide (Ra)-132 and 
bistosylamide (Ra)-133, which was used for the next step according to the General procedure A for the 
preparation of prolinanilides. Chromatography on silica gel (50 g) in 50% EtOAc/hexanes removed 
the bistosylamide (Ra)-133. Switching to 10% MeOH/EtOAc eluted 1.38 g (72% overall) of (R,Ra)-59. 
[α]D20 +87.4 (c 0.183, CHCl3) for (R,Ra)-59; Lit. [α]D25 +93 (c 1.0, CHCl3) for (R,Ra)-59; 
Anal. Calcd for C32H29N3O3S: C, 71.75; H, 5.46; N, 7.84; S, 5.99; Found: C, 71.79; H, 5.59; N, 7.31; 
S, 5.41; for (R,Ra)-59. 
The 1H and 13C NMR spectra are in agreement with the literature.  
 
General Procedure B: Mosher’s amides 
Under inert conditions, oxalyl chloride (90 µL, 1 mmol) was added to a solution of (R)-MTPA (24 mg, 
0.1 mmol) and DMF (16 µL, 0.2 mmol) in hexane (5 mL) at room temperature. A white precipitate 
formed immediately. After stirring for 2 h, the reaction mixture was filtered through a glass wool plug 
in a syringe and the solvent was evaporated in vacuo to give a residue of chiral acyl chloride. Solid 
DMAP (24 mg, 0.2 mmol) was added to the reaction flask and it was evacuated and refilled with 
argon. A solution of the amine (0.04 mmol) in dichloromethane (2 mL) was transferred to the mixture, 
which was stirred overnight. The reaction was quench d with saturated aq. NH4Cl (5 mL) and the 
product was extracted into Et2O (20 mL). The organic layer was washed consecutively with saturated 
aq. NaHCO3 (5 mL) and brine (5 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure to give the desired Mosher’s amide in quantitative yield. The absence of the starting amine 
was checked by 1H NMR. The enantiomeric purity was determined according to the literature.332 
 
(R)-Pyrrolidine-2-carboxylic acid 3,5-bis(trifluoromethyl)phenylamide ((R)-60a) 
Prepared according to General procedure A in a yield of 1.61 g (77%).  
[α]D20 +42.5 (c 0.267, CHCl3); Lit. [α]D25 −37.52 (c 1.39, CHCl3) for the S-
enantiomer;125 
Anal. Calcd for C13H12F6N2O: C, 47.86; H, 3.71; F, 34.94; N, 8.59; Found: C, 
47.45; H, 3.68; F, 34.67; N, 8.30;  
The 1H and 13C NMR spectra are in agreement with the literature.125  
The enantiomeric purity was determined by preparing Mosher’s amide according to General procedure 
B. Comparison of the 1H and 19F NMR spectra of both diastereomers, separately and as a mixture, 
showed >99% ee. The signals used for quantitative analysis are underlined. 
1H NMR (400 MHz, CDCl3) δ 4.90 (dd, J = 8.2, 5.9 Hz, 1H, OCCHN)RR, 4.78 (dd, J = 7.8, 4.9 Hz, 
1H, OCCHN)SR, 3.95 (q, J = 1.5 Hz, 3H, OCH3)
RR, 3.69 (q, J = 1.5 Hz, 3H, OCH3)
SR, 3.63 (ddd, J = 
11.3, 8.1, 6.7 Hz, 1H, CHaHbN)
RR, 3.56 (dt, J = 11.5, 7.0 Hz, 1H, CHaHbN)
SR, 3.02 (ddd, J = 11.4, 7.5, 
4.8 Hz, 1H, CHaHbN)
RR, 2.87 (dt, J = 11.4, 6.9 Hz, 1H, CHa bN)
SR; 
19F NMR (376.3 MHz, CDCl3) δ −63.57 (s, 6F, Ar(CF3)2)SR, −63.70 (s, 6F, Ar(CF3)2)RR, −70.66 (br s, 
3F, CCF3)
















(S)-Pyrrolidine-2-carboxylic acid phenylamide ((S)-60b) and (R)-pyrrolidine-2-carboxylic acid 
phenylamide ((R)-60b) 
Prepared according to General procedure A in a yield of 1.55 g (81%). (Described 
for the opposite enantiomer).125 
(S)-60b: Mp 77-78 °C (hexane/CH2Cl2); Lit. Mp 79-80 °C (Et2O/hexane);
333 
[α]D20 −65.2 (c 0.282, CHCl3); Lit. [α]D22 −71.1 (c 0.9, CHCl3);333 
Anal. Calcd for C11H14N2O: C, 69.45; H, 7.42; N, 14.73; Found: C, 69.34; H, 7.36; N, 14.57; 
The 1H and 13C NMR spectra are in agreement with the literature.  
 
(S)-Pyrrolidine-2-carboxylic acid 4-(pentafluoro-λ6-sulfanyl)phenylamide ((S)-60c) 
Prepared according to General procedure A in a yield of 250 mg (79%).  
[α]D20 −35.2 (c 0.270, CHCl3);  
IR (CHCl3); ν[cm-1]: 581, 597 (p-Ar), 822, 852 (SF), 1102 (Ar), 1317 (Ar), 
1405 (CH2), 1498 (Ar), 1518 (CON), 1595 (Ar), 1691 (CON), 2876 (CH2), 
2979, 3254 (NH).  
1H NMR (400 MHz, CDCl3) δ 9.99 (s, 1H, NHCO), 7.70 (s, 4H, CH-2’, CH-3’), 3.88 (dd, J = 9.3, 5.2 
Hz, 1H, CH-2), 3.10 (dt, J = 10.3, 6.8 Hz, 1H, CH-5a), 2.98 (dt, J = 10.3, 6.3 Hz, 1H, CH-5b), 2.23 
(ddt, J = 13.0, 9.2, 7.5 Hz, 1H, CH-3a), 2.04 (dtd, J = 13.0, 6.8, 5.3 Hz, 1H, CH-3b), 2.04 (br s, 1H, 
CHNHCH2), 1.80-1.73 (m, 2H, CH2-4). 
19F NMR (377 MHz, CDCl3) δ 85.78-84.18 (m, 1F), 63.05 (d, J = 150.0 Hz, 4F). 
13C NMR (101 MHz, CDCl3) δ 173.9 (C, C-1), ~148.8 (m, C, C-4’), 140.4 (C, C-1’), 26.9 (CH, quint, 
JCF = 4.6 Hz, C-3’), 118.5 (CH, C-2’), 61.0 (CH, C-2), 47.4 (CH2, C-5), 30.7 (CH2, C-3), 26.3 (CH2, 
C-4). 
MS (CI+) m/z, (%): 297 (100, [M+H−HF]+), 317 (51, [M+H]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C11H14F5N2OS 317.0747; Found 317.0751;  
Anal. Calcd for C11H13F5N2OS: C, 41.77; H, 4.14; F, 30.03; N, 8.86; S, 10.14; Found: C, 41.62; H, 
4.02; F, 30.28; N, 8.60; S, 10.69; 
The enantiomeric purity was determined by preparing Mosher’s amide according to General procedure 
B. Comparison of the 1H and 19F NMR spectra showed >99% ee. The signals used for quantitative 
analysis are underlined. The (R,R)-diastereomer was not observed in either of the spectra. 
1H NMR (400 MHz, CDCl3) δ 4.82 (dd, J = 7.6, 3.1 Hz, 1H, OCCHN)SR, 3.68 (d, J = 1.5 Hz, 3H, 
OCH3)
SR, 3.53 (dt, J = 11.6, 7.5 Hz, 1H, CHaHbN)
SR, 2.73 (ddd, J = 11.7, 7.2, 5.1 Hz, 1H, CHa bN)
SR. 
19F NMR (376.3 MHz, CDCl3) δ −70.92 (br s, 3F, CCF3)SR. 
 
(S)-Pyrrolidine-2-carboxylic acid 3-(pentafluoro-λ6-sulfanyl)phenylamide ((S)-60d) 
Prepared according to General procedure A in a yield of 206 mg (65%).  
[α]D20 −38.7 (c 0.527, CHCl3); 
IR (CHCl3); ν[cm-1]: 575, 597, 647, 685 (m-Ar), 820, 855 (SF), 1098 (Ar), 1420, 1431 (Ar), 1522 
(CON), 1587, 1606 (Ar), 1684 (CON), 2876 (CH2), 2979, 3256 (NH).  
1H NMR (400 MHz, CDCl3) δ 9.97 (s, 1H, NHCO), 8.01 (t, J = 2.1 Hz, 1H, CH-
2’), 7.84 (d, J = 8.1 Hz, 1H, CH-6’), 7.47 (ddd, J = 8.3, 2.1, 1.1 Hz, 1H, CH-4’), 
7.40 (t, J = 8.1 Hz, 1H, CH-5’), 3.88 (dd, J = 9.3, 5.1 Hz, 1H, CH-2), 3.11 (dt, J 







































13.0, 9.3, 7.5 Hz, 1H, CH-3a), 2.18 (br s, 1H, CHNHCH2), 2.05 (dtd, J = 13.1, 6.7, 5.2 Hz, 1H, CH-
3b), 1.83-1.72 (m, 2H, CH2-4). 
19F NMR (377 MHz, CDCl3) δ 84.62-83.02 (m, 1F), 62.16 (d, J = 150.0 Hz, 4F). 
13C NMR (101 MHz, CDCl3) δ 173.8 (C, C-1), 154.2 (m, C, C-3’), 138.3 (C, C-1’), 29.1 (CH, C-5’), 
122.1 (CH, C-6’), 121.1 (CH, quint, JCF = 4.7 Hz, C-4’), 116.8 (CH, quint, JCF = 4.9 Hz, C-2’), 61.0 
(CH, C-2), 47.4 (CH2, C-5), 30.7 (CH2, C-3), 26.3 (CH2, C-4). 
MS (CI+) m/z, (%): 297 (85, [M+H−HF]+), 317 (100, [M+H]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C11H14F5N2OS 317.0747; Found 317.0748;  
Anal. Calcd for C11H13F5N2OS: C, 41.77; H, 4.14; F, 30.03; N, 8.86; S, 10.14; Found: C, 41.72; H, 
4.08; F, 29.51; N, 8.56; S, 9.87;  
The enantiomeric purity was determined by preparing Mosher’s amide according to General procedure 
B. Comparison of the 1H and 19F NMR spectra showed >99% ee. The signals used for quantitative 
analysis are underlined. The (R,R)-diastereomer was not observed in either of the spectra. 
1H NMR (400 MHz, CDCl3) δ 4.80 (dd, J = 7.5, 3.3 Hz, 1H, OCCHN)SR, 3.69 (d, J = 1.5 Hz, 3H, 
OCH3)
SR, 3.54 (dt, J = 11.6, 7.3 Hz, 1H, CHaHbN)
SR, 2.76 (ddd, J = 11.8, 7.2, 5.2 Hz, 1H, CHa bN)
SR. 
19F NMR (376.3 MHz, CDCl3) δ −70.95 (br s, 3F, CCF3)SR. 
 
(R)-Pyrrolidine-2-carboxylic acid 2,4,6-trinitrophenylamide ((R)-60e) and (S)-pyrrolidine-2-
carboxylic acid 2,4,6-trinitrophenylamide ((S)-60e) 
The (S)-enantiomer was prepared according to the literature238 from 2.156 g (11.3 mmol) of 
prolinanilide (S)-60b. Crystallization from MeCN gave 2.07 g (56%) of bright yellow crystals of 
trinitroanilide (S)-60e.  
(S)-60e: Mp 175-180 °C decomp. (MeCN); Lit. Mp 174-178 °C (MeCN);238 
[α]D20 −138.5 (c 0.395, DMSO); Lit. [α]D18 −155. 2 (c 1.00, DMSO);238 
Anal. Calcd for C11H11N5O7: C, 40.62; H, 3.41; N, 21.53; Found: C, 40.40; H, 
3.42; N, 21.41. 
 
(R)-60e: Mp 176-180 °C decomp. (MeCN); 
[α]D20 +141.7 (c 0.261, DMSO);  
Anal. Calcd for C11H11N5O7: C, 40.62; H, 3.41; N, 21.53; Found: C, 40.49; H, 
3.38; N, 21.24; 
The 1H and 13C NMR spectra are in agreement with the literature.238  
 
The enantiomeric purity was determined by preparing Mosher’s amide according to General procedure 
B. Comparison of the 1H and 19F NMR spectra of both diastereomers, separately and as a mixture, 
showed >99% ee. The signals used for quantitative analysis are underlined. 
1H NMR (400 MHz, CDCl3) δ 4.88 (dd, J = 7.6, 4.7 Hz, 1H, OCCHN)RR, 4.84 (dd, J = 8.2, 3.1 Hz, 
1H, OCCHN)SR, 3.72 (q, J = 1.7 Hz, 3H, OCH3)
RR, 3.67 (q, J = 1.7 Hz, 3H, OCH3)
SR, 3.49 (dt, J = 
11.6, 6.7 Hz, 1H, CHaHbN)
RR, 3.46 (dt, J = 11.3, 7.7 Hz, 1H, CHaHbN)
SR, 2.73 (dt, J = 11.3, 6.2 Hz, 
1H, CHaHbN)
SR, 2.83 (dt, J = 11.5, 6.8 Hz, 1H, CHa bN)
RR. 19F NMR (376.3 MHz, CDCl3) δ −70.06 
(s, 3F, CF3)
MTPA, −70.80 (br s, 3F, CF3)



















Prepared according to the literature. The crude product was purified by 
chromatography on silica gel (500 g) in 10% to 50% EtOAc/hexanes to afford 101.6 g 
(99%) 50 as a colorless liquid.128,126 
Anal. Calcd for C11H16O3: C, 67.32; H, 8.22; Found: C, 67.23; H, 8.23; 
The 1H and 13C NMR spectra are in agreement with the literature.  
 
(R)-8a-Methyl-3,4,8,8a-tetrahydro-1,6-(2H,7H)-naphthalenedione or ent-Wieland-Miescher 
ketone (ent-21) 
A mixture of triketone 50 (49.50 g, 252.2 mmol), (R)-prolinanilide 60a (4.115 g, 
12.61 mmol, 5 mol%) and benzoic acid (308 mg, 2.52 mmol) together with a big 
magnetic strirring bar to ensure efficient stirring was degassed and refilled with 
nitrogen. The thick oil was stirred at rt for 24 h. A sample taken from the reaction mixture showed full 
conversion by 1H NMR. The reaction mixture was dried by azeotropic distillation with toluene under 
reduced pressure. The residue was purified by column chromatography on silica gel (600 g) in 20% to 
40% EtOAc/hexanes to afford 44.83 g (100%, 96% ee) ent-21 as a brownish oil, which was dissolved 
in a mixture of Et2O (480 mL) and EtOAc (48 mL) and cooled to −78 °C for 6 h. The resulting crystals 
were filtered under nitrogen, warmed to rt and dried in vacuo. The yield of ent-Wieland-Miescher 
ketone ent-21 was 34.23 g (76%), with an enantiomeric purity 99.7% ee as determined by HPLC on 
chiral stationary phase.  
Mp 45-47 °C; Lit.128 mp 49-50 °C. 
[α]D20 −94.1 (c 0.324, benzene) for ent-21; Lit.126 [α]D20 +96 (c 1.1, benzene) for nat-21; 
Anal. Calcd for C11H14O2: C, 74.13; H, 7.92; Found: C, 73.76; H, 7.77. 
HPLC was performed with an Eurocel 01 column (Knauer, 250 × 4.6 mm, 5µm particle size, isocratic 
heptane/iPrOH 95:5, 1.0 mL·min-1, detection at 254 nm) and gave retention times tS = 32.2 min, tR = 
34.4 min. 
The spectral properties are in agreement with the li erature126,128. 
 
(±)-8a-Methyl-3,4,8,8a-tetrahydronaphthalene-1,6(2H,7H)-dione (rac-21) 
Prepared according to the literature from triketone 50 in 55% yield.239  
The spectral and physical properties of the product are in agreement with the literature 
and identical to ent-21. 
Mp 47-50 °C; 
Anal. Calcd for C11H14O2: C, 74.13; H, 7.92; Found: C, 73.77; H, 7.95. 
 
(±)-5-(Ethylenedioxy)-4a-methyl-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (136a) 
Diketone 21 (4.73 g, 26.5 mmol), triethyl orthoformate (4.12 mL, 24.8 mmol) and 
ethylene glycol (1.65 mL, 29.6 mmol) were dissolved in benzene (29 mL) and 
pTsOH·H2O (507 mg, 2.66 mmol) was added with stirring at rt The mixture was 
stirred for 4 h and quenched with Et3N (740 µL, 5.3 mmol). The solvent was 
evaporated in vacuo and the residue was purified by chromatography on silica gel (140 g) in 5% to 
10% EtOAc/hexanes to afford 3.96 g (67%) of monoketal 136a as a yellow oil, followed by 658 mg 
(14%) of recovered starting material. 











Anal. Calcd for C13H18O3: C, 70.24; H, 8.16; Found: C, 70.27; H, 8.24.  
 
(±)-(4aS*,8aR*)-5-(Ethylenedioxy)-4a-methyloctahydronaphthalen-2(1H)-one (137a) 
Ketal 136a (3.120 g, 14.04 mmol) was dissolved in EtOH (20 mL) and 5% palladium 
on CaCO3 (135 mg) was added to the reaction mixture. The mixture was hydrogenated 
under a slight overpressure of hydrogen for 16 h. The catalyst was filtered off and the 
solvent evaporated in vacuo to afford 3.117 g (99%) of saturated ketone 137a as a 
colorless oil, which solidified on standing. 
The 1H and 13C NMR spectra are in agreement with the literature.247,246 
 
(±)-(2R*,4aS*,8aR*)-5-(Ethylenedioxy)-4a-methyldecahydronaphthalen-2-ol (138a)  
Ketone 137a (2.976 g, 13.27 mmol) was dissolved in CH2 l2 (15 mL) and MeOH 
(15 mL), the reaction flask was immersed in −45 °C bath and NaBH4 (784 mg, 
20.72 mmol) was added portionwise. The mixture was stirred at −45 °C for 30 min 
and subsequently warmed slowly to rt The reaction was quenched with 5% aq. citric 
acid (50 mL), the organic layer separated and the aqueous extracted with CHCl3 (2 × 25 mL). The 
combined extracts were washed with saturated aq. NaHCO3 (50 mL), dried with MgSO4 and 
evaporated in vacuo. The residue was purified by chromatography on silica gel (60 g) in 20% 
EtOAc/hexanes + 0.2% Et3N to afford 2.741 g (91%) of alcohol 138a as a colorless oil. 
Anal. Calcd for C11H14O2: C, 68.99; H, 9.80; Found: C, 69.03; H, 9.87. 
The IR, MS, 1H NMR and 13C NMR spectra are in agreement with the literature.247 
 
(±)-5-(2’ ,2’ -Dimethylpropylenedioxy)-4a-methyl-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one 
(136b) 
Diketone 21 (2.386 g, 13.39 mmol), neopentyl glycol (1.528 g, 14.67 mmol) and 
trimethyl orthoformate (1.46 mL, 14.18 mmol) were dissolved in Et2O (33 mL) and 
BF3·Et2O (0.168 mL, 1.36 mmol) was added dropwise to the reaction mixture with 
stirring. The content of the flask was stirred for 48 h, quenched with saturated aq. 
NaHCO3 (50 mL) and extracted with Et2O (3 × 20 mL). The combined organic 
extracts were dried with MgSO4 and concentrated in vacuo. The residue was purified by 
chromatography on silica gel (60 g) in 15% EtOAc/hexanes to afford 2.438 g (69%) of monoketal 
136b as an off-white solid, which was crystallized from Et2O.  
Mp 97-99 °C; Lit.335 mp 96 °C, for (−)-136b. 
IR (CHCl3); ν[cm-1]: 873, 913 (COCOC), 1013 (CH3), 1037, 1049, 1111, 1153, 1233, 1282 (COCOC), 
1375, 1396, 1443, 1463, 1472, 1481 (CH3), 1620 (C=C), 1661 (C=O), 2871 (CH3), 2959 (CH2); 
1H NMR (400 MHz, CDCl3) δ 5.79 (d, J = 2.0 Hz, 1H, CH-4), 3.73 (d, J = 11.5 Hz, 1H, CH-1’a), 3.58 
(d, J = 11.5 Hz, 1H, CH-3’a), 3.34 (dd, J = 11.5, 2.5 Hz, 1H, CH-1’b), 3.33 (dd, J = 11.5, 2.5 Hz, 1H, 
CH-3’b), 2.76 (td, J = 13.8, 5.1 Hz, 1H, CH-1a), 2.68 (ddd, J = 10.6, 2.5, 1.5 Hz, 1H, CH-8a), 2.47 
(dddd, J = 16.7, 5.2, 3.6, 0.8 Hz, 1H, CH-2a), 2.76-2.68 (m, 1H, CH-2b), 2.38 (ddd, J = 16.8, 14.1, 5.3 
Hz, 1H, CH-6a), 2.31-2.22 (m, 1H, 6b), 1.86 (ddd, J = 13.7, 5.3, 3.7 Hz, 1H, CH-1b), 1.76-1.68 (m, 





























13C NMR (101 MHz, CDCl3) δ 199.6 (C, C-3), 168.0 (C, C-5), 125.7 (CH, C-4), 100.7 (C, C-9), 70.1 
(CH2, C-1’), 69.9 (CH2, C-3’), 45.6 (C, C-10), 34.3 (CH2, C-2), 31.5 (CH2, C-6), 29.7 (C, C-2’), 26.6 
(CH2, C-1), 23.4 (CH3, C-4’), 22.2 (CH3, C-5’), 21.2 (CH2, C-8), 20.7 (CH2, C-7), 19.6 (CH3, C-19).
 
MS (ESI+) m/z, (%): 265 (10, [M+H]+), 287 (100, [M+Na]+), 551 (33, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C16H25O3 265.1798; Found 265.1799;  
Anal. Calcd for C16H24O3: C, 72.69; H, 9.15; Found: C, 72.66; H, 9.15. 
 
(±)-(4aS*,8aR*)-5-(2’ ,2’ -Dimethylpropylenedioxy)-4a-methyloctahydronaphthalen-2(1H)-one 
(137b) 
Enone 136b (4.413 g, 16.69 mmol) was dissolved in EtOH (25 mL) and 5% 
palladium on CaCO3 (100 mg) was added to the reaction mixture. The mixture was 
hydrogenated under a slight overpressure of hydrogen for 14 h. The catalyst was 
filtered off and the solvent evaporated in vacuo to afford 4.44 g (100%) of 
saturated ketone 137b, crystallizing from hexane. 
Mp 87-88 °C; 
IR (CHCl3); ν[cm-1]: 876, 911 (COCOC), 1013 (CH3), 1026, 1041, 1103, 1146, 1236, 1282 (COCOC), 
1375, 1395, 1444, 1464, 1472, 1481 (CH3), 1704 (C=O), 2868 (CH3), 2931 (CH2), 2959 (CH3); 
1H NMR (400 MHz, CDCl3) δ 3.69 (d, J = 11.1 Hz, 1H, CH-1’a), 3.64 (d, J = 11.1 Hz, 1H, CH-3’a), 
3.33 (dd, J = 11.1, 2.7 Hz, 1H, CH-1’b), 3.29 (dd, J = 11.1, 2.7 Hz, 1H, CH-3’b), 2.63 (dd, J = 14.8, 
5.8 Hz, 1H, CH-4a), 2.46 (ddd, J = 15.2, 7.2, 0.8 Hz, 1H, CH-2a), 2.42 (ddd, J = 15.3, 7.1, 0.8 Hz, 1H, 
CH-8a), 2.32 (ddt, J = 15.2, 5.1, 2.7 Hz, 1H, CH-2b), 2.15-2.06 (m, 3H, CH-1a, CH-4b, CH-5), 1.77 
(dddd, J = 13.8, 7.1, 2.8, 1.7 Hz, 1H, CH-1b), 1.62-1.53 (m, 1H, CH-7a), 1.51-1.43 (m, 1H, CH-6a), 
1.43-1.32 (m, 2H, CH-7b, CH-8b), 1.39 (s, 3H, CH3-19), 1.29-1.17 (m, 1H, CH-6b), 1.22 (s, 3H, CH3-
4’), 0.73 (s, 3H, CH3-5’);
 
13C NMR (101 MHz, CDCl3) δ 212.9 (C, C-3), 100.7 (C, C-9), 69.7 (CH2, C-1’), 69.4 (CH2, C-3’), 
44.3 (CH2, C-4), 41.7 (C, C-10), 41.3 (CH, C-5), 37.9 (CH2, C-2), 29.8 (C, C-2’), 28.5 (CH2, C-6), 
28.3 (CH2, C-1), 23.6 (CH3, C-4’), 22.4 (CH3, C-5’), 21.0 (CH2, C-7/8), 20.9 (CH2, C-7/8), 17.5 (CH3, 
C-19); 
MS (ESI+) m/z, (%): 267 (1, [M+H]+), 289 (100, [M+Na]+), 555 (9, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C16H26NaO3 289.1774; Found 289.1775;  
Anal. Calcd for C16H26O3: C, 72.14; H, 9.84; Found: C, 72.02; H, 9.77. 
The NMR and IR spectral data differ from those repoted for the (±)-(4aS*,8aS*) isomer.336 
 
(±)-(2R*,4aS*,8aR*)-5-(2’ ,2’ -Dimethylpropylenedioxy)-4a-methyldecahydronaphthalen-2-ol 
(138b) and (±)-(2S*,4aS*,8aR*)-5-(2’ ,2’ -Dimethylpropylenedioxy)-4a-
methyldecahydronaphthalen-2-ol (139b) 
Ketone 137b (4.553 g, 17.09 mmol) was dissolved in CH2 l2 (25 mL) and MeOH (25 mL), the 
reaction flask was immersed in −40 °C bath and NaBH4 (775 mg, 20.51 mmol) was added 
portionwise. The mixture was stirred for 2 h at −40 °C and warmed slowly to rt The reaction was 
quenched with 5% aq. citric acid (50 mL), the organic layer was separated and the aqueous extracted 
with CH2Cl2 (2 × 25 mL). The combined extracts were washed with saturated aq. NaHCO3 (50 mL), 
dried with MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel 






















Equatorial alcohol 138b: colorless oil 
IR (CHCl3); ν[cm-1]: 876, 908 (COCOC), 999 (OH), 1013 (CH3), 1036, 1105, 
1237 (COCOC), 1363, 1380, 1395 (CH3), 1448, 1472, 1481 (CH3), 2868 (CH3), 
2931 (CH2), 2957 (CH3), 3455 (OH), 3609 (OH); 
1H NMR (500 MHz, CDCl3 at 60 °C) δ 3.73 (tt, J = 8.6, 4.3 Hz, 1H, CH-3), 3.66 
(d, J = 11.2 Hz, 1H, CH-1’a), 3.62 (d, J = 11.2 Hz, 1H, CH-3’a), 3.30 (dd, J = 
11.2, 2.7 Hz, 1H, CH-3’b), 3.26 (dd, J = 11.2, 2.7 Hz, 1H, CH-1’b), 2.29 (dt, J = 14.2, 5.4 Hz, 1H, 
CH-1a), 2.20-2.10 (br m, 1H, CH-8a), 1.88 (dddd, J = 12.9, 10.1, 8.4, 4.7 Hz, 1H, CH-2a), 1.85-1.79 
(m, 1H, CH-4a), 1.78-1.71 (m, 1H, CH-2b), 1.75-1.66 (m, 1H, CH-6a), 1.64-1.55 (m, 1H, CH-8b), 
1.61-1.49 (m, 5H, CH-4b, CH-6b, CH-5, CH-7a, OH), 1.43-1.36 (m, 1H, CH-7b), 1.19 (s, 3H, CH3-
4’), 1.07 (ddd, J = 14.2, 10.2, 5.0 Hz, 1H, CH-1b), 1.03 (s, 3H, CH3-19), 0.69 (s, 3H, CH3-5’);
 
13C NMR (126 MHz, CDCl3 at 60 °C) δ 102.0 (C, C-9), 70.3 (CH, C-3), 69.5 (CH2, C-1’), 69.3 (CH2, 
C-3’), 40.9 (CH, C-5), 37.0 (CH2, C-4), 32.6 (CH2, C-2), 31.6 (C, C-2’), 29.7 (CH2 + C, CH2-1, C-10), 
28.6 (CH2, C-6), 23.5 (2 × CH3, C-4’, C-19), 22.4 (CH3, C-5’), 22.2 (CH2, C-8), 19.8 (CH2, C-7). 
MS (ESI+) m/z, (%): 291 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C16H28NaO3 291.1931; Found 291.1931;  
Anal. Calcd for C16H28O3: C, 71.60; H, 10.52; Found: C, 72.02; H, 10.68. 
 
Axial alcohol 139b: Mp 110-113 °C (Et2O/hexane); 
IR (CHCl3); ν[cm-1]: 892, 907 (COCOC), 1015 (CH3), 1037 (COCOC), 1054 
(OH), 1104, 1236, 1288 (COCOC), 1364, 1378, 1395 (CH3), 1443, 1473, 1481 
(CH3), 2865 (CH3), 2932 (CH2), 2956 (CH3), 3463 (OH), 3607 (OH); 
1H NMR (400 MHz, CDCl3) δ 3.89 (tt, J = 10.8, 5.4 Hz, 1H, CH-3), 3.69 (d, J = 
11.6 Hz, 1H, CH-1’a), 3.61 (d, J = 11.6 Hz, 1H, CH-3’a), 3.29 (dd, J = 11.6, 2.7 
Hz, 1H, CH-3’b), 3.26 (dd, J = 11.6, 2.7 Hz, 1H, CH-1’b), 2.49 (br d, J = 12.0 Hz, 1H, CH-8a), 1.90-
1.82 (m, 1H, CH-2a), 1.90-1.79 (m, 1H, CH-5), 1.77-1.66 (m, 1H, CH-1a, CH-6a), 1.69-1.60 (m, 2H, 
CH2-4), 1.60-1.50 (m, 5H, CH-7a, CH-6b, CH-2b, CH-1b, OH), 1.36-1.26 (m, 1H, CH-7b), 1.32-1.26 
(m, 1H, CH-8b), 1.22 (s, 3H, CH3-19), 1.19 (s, 3H, CH3-4’), 0.71 (s, 3H, CH3-5’). 
13C NMR (101 MHz, CDCl3) δ 100.9 (C, C-9), 69.7 (CH2, C-1’), 69.3 (CH2, C-3’), 66.9 (CH, C-3), 
41.8 (C, C-10), 38.9 (CH, C-5), 36.6 (CH2, C-4), 31.5 (CH2, C-2), 29.8 (C, C-2’), 27.9 (CH2, C-6), 
25.9 (CH2, C-1), 23.6 (CH3, C-4’), 22.4 (CH3, C-5’), 21.4 (CH2, C-7), 20.9 (CH2, C-8), 17.2 (CH3, C-
19); 
MS (ESI+) m/z, (%): 269 (51, [M+H]+), 291 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C16H29O3 269.2111; Found 269.2112; [M+Na]
+ Calcd for 
C16H28NaO3 291.1931; Found 291.1932; 
Anal. Calcd for C16H28O3: C, 71.60; H, 10.52; Found: C, 71.36; H, 10.53. 
 
(−)-(4aR,8aS)-8a-Methylhexahydronaphthalene-1,6(2H,7H)-dione (ent-140a)  
Prepared from 3.60 g (20.2 mmol) enone ent-21 by the method published in the 
literature yielding a 14:1 5β:5α mixture of ent-140a and ent-140b in quantitative 
yield.248 This mixture was purified by chromatography on silica gel (100 g) in 5% to 
10% EtOAc/hexanes to yield 3.36 g (92%) of ent-140a as colorless crystals. 
Mp 50-52 °C; Lit.337 mp 52-54 °C; 











































Anal. Calcd for C11H16O2: C, 73.30; H, 8.95; Found: C, 73.21; H, 8.93. ent-140a; 
The 1H and 13C NMR spectra are in agreement with the literature.338,246 
 
(−)-(2R,4aS,8aR)-4a-Methyl-5-oxodecahydronaphthalen-2-yl benzoate (nat-144) and 
(+)-(2S,4aR,8aS)-4a-Methyl-5-oxodecahydronaphthalen-2-yl benzoate (ent-144) 
Diketone 140a (5.88 g, 32.6 mmol) was dissolved in CH2Cl2 (40 mL) and dry 
MeOH (40 mL) and the solution was cooled to −78 °C. NaBH4 (1.48 g, 
39.1 mmol) was added portionwise with stirring and the mixture was warmed to 
−40 °C. After 30 min at −40 °C, TLC showed full consumption of the starting 
material. Acetone (5 mL) was added slowly to the cooled solution and the reaction 
was quenched with 5% HCl (150 mL). The organic layer was separated and the aqueous was extracted 
with chloroform (3 × 50 mL). The combined organic extracts were washed with saturated aq. NaHCO3 
(100 mL), dried over MgSO4 and evaporated in vacuo. The residue was redissolved in dry pyridine 
(40 mL) and the solution was cooled to 0 °C. Benzoyl chloride (7.64 mL, 65.8 mmol) was added 
slowly at 0 °C, the mixture was warmed to rt and stirred for 30 min. The reaction mixture was poured 
on ice (150 mL) and acidified with 35% aq. HCl to pH < 2. The resulting emulsion was extracted with 
EtOAc (3 × 50 mL) and the combined organic layers were subsequently washed with water (150 mL), 
saturated aq. NaHCO3 (150 mL) and brine. The organic layer was dried over MgSO4 and the solvent 
was evaporated. Chromatography of the residue on silica gel (150 g) in 10% EtOAc/hexanes afforded 
6.11 g (73%) of the benzoate 144 as a low-melting solid. 
[α]D20 +2.4 (c 0.246, CHCl3) for ent-144; 
[α]D20 −8.3 (c 0.204, CHCl3) for nat-144; 
IR (CHCl3); ν[cm-1]: 713 (C=O), 998, 1026, 1071 (=CH), 1119, 1279 (COC), 1315, 1322, 1382 (CH3), 
1451 (=CH), 1466 (CH3), 1603 (ring), 1705 (C=O), 2879 (CH3), 2948 (CH3); 
1H NMR (400 MHz, CDCl3) δ 8.03-7.99 (m, 2H, CH-3’), 7.57-7.52 (m, 1H, CH-5’), 7.45-7.40 (m, 2H, 
CH-4’), 4.97 (tt, J = 11.2, 4.3 Hz, 1H, CH-3), 2.64-2.54 (m, 1H, CH-8a), 2.37 (dt, J = 13.9, 3.7 Hz, 
1H, CH-1a), 2.32-2.26 (m, 1H, CH-8b), 2.31-2.19 (m,1H, CH-6a), 2.06-2.00 (m, 1H, CH-5), 1.99-
1.90 (m, 3H, CH2-7, CH-2a), 1.87 (dtd, J = 12.7, 3.8, 2.4 Hz, 1H, CH-4a), 1.67 (dddd, J = 13.4, 12.6, 
11.3, 4.0 Hz, 1H, CH-2b), 1.57-1.49 (m, 1H, CH-6b), 1.51 (td, J = 12.8, 11.0 Hz, 1H, CH-4b), 1.26 (s, 
3H, CH3-19), 1.08 (td, J = 13.7, 4.0 Hz, 1H, CH-1b). 
13C NMR (101 MHz, CDCl3) δ 214.7 (C, C-9), 166.0 (C, C-1’), 132.7 (CH, C-5’), 130.7 (C, C-2’), 
129.5 (CH, C-3’), 128.2 (CH, C-4’), 73.7 (CH, C-3), 48.5 (C, C-10), 43.4 (CH, C-5), 37.8 (CH2, C-8), 
34.4 (CH2, C-4), 32.6 (CH2, C-1), 28.6 (CH2, C-2), 26.4 (CH3, C-19), 26.2 (CH2, C-6), 22.1 (CH2, C-
7); 
MS (ESI+) m/z, (%): 309 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C18H22NaO3 309.1461; Found 309.1460;  
Anal. Calcd for C18H22O3: C, 75.50; H, 7.74; Found: C, 75.48; H, 7.73 for ent-144. 
Anal. Calcd for C18H22O3: C, 75.50; H, 7.74; Found: C, 74.90; H, 7.82 for nat-144. 
 
(±)-(4aR*,6R*,8aS*)-6-Hydroxy-8a-methyloctahydronaphthalen-1(2H)-one (141) 
Benzoate (±)-144 (2.865 g, 10.0 mmol) was dissolved in MeOH (150 mL) and solid 
KOH (5.6 g, 100 mmol) was added while stirring. The reaction mixture was warmed 
to 50 °C during 1 h and concentrated in vacuo to one third of the volume. The solution 


















extracts were washed with saturated aq. NaHCO3 (100 mL) and with brine (100 mL). The organic 
layers were dried over MgSO4 and evaporated in vacuo to afford 1.80 g (99%) of alcohol 141 as a 
low-melting solid.  
The 1H NMR and 13C NMR spectra are in agreement with the literature.339  
 
(±)-(4aR*,6R*,8aS*)-6-(Benzyloxy)-8a-methyloctahydronaphthalen-1(2H)-one (146a) and (±)- 
(4aR*,6R*,8aS*)-6-hydroxy-8a-methyloctahydronaphthalen-1(2H)-one (141)  
Alcohol 138a (2.648 g, 11.7 mmol) was dissolved in THF (30 mL) and NaH (1.123 g of 50% 
suspension in paraffin, 23.4 mmol) was added portionw se, followed by tetrabutylammonium iodide 
(432 mg, 1.16 mmol) and benzyl bromide (4.18 mL, 35.1 mmol). The reaction mixture was refluxed 
for 3 days, quenched with water (0.5 mL) and concentrated in vacuo. The 1H NMR spectrum of the 
crude reaction mixture showed ca. 2/3 conversion. The residue was redissolved in acetone (25 mL), 
water (5 mL) and concentrated aq. HCl (1.0 mL, 35% w/v) and stirred at rt overnight. The reaction 
mixture was poured into saturated aq. NaHCO3 (150 mL), extracted with EtOAc (3 × 50 mL) and the
combined organic extracts were washed with brine, dri d over MgSO4 and concentrated in vacuo. The 
residue was purified by chromatography on silica gel (100 g) in 5% to 30% EtOAc/hexanes to afford 
2.144 g (67%) of benzyl ether 146a, followed by 603 mg (28%) of free alcohol 141. 
146a: colorless oil 
IR (CHCl3); ν[cm-1]: 699, 921, 1029, 1070 (Ph), 1090 (COC), 1314 (Ph), 1363 
(PhCH2), 1380 (CH3), 1423 (COCH2), 1454, 1496, 1702 (C=O), 2872 (CH3), 2945 
(CH2), 3011; 
1H NMR (400 MHz, CDCl3) δ 7.35-7.30 (m, 4H, Ph), 7.29-7.23 (m, 1H, p-Ph), 
4.54 (AB system, J = 11.9 Hz, 2H, PhCH2), 3.36 (tt, J = 10.8, 4.0 Hz, 1H, CH-3), 2.54 (ddd, J = 15.3, 
12.7, 7.9 Hz, 1H, CH-8a), 2.32 (dt, J = 13.8, 3.7 Hz, 1H, CH-1a), 2.28-2.19 (m, 1H, CH-8b), 2.27-2.14 
(m, 1H, CH-7a), 2.00-1.84 (m, 2H, CH2-6), 1.98-1.89 (m, 1H, CH-2a), 1.90-1.80 (m, 1H, CH-5), 1.85-
1.75 (m, 1H, CH-4a), 1.54-1.47 (dqt, J = 14.1, 2.6, 1.5 Hz, 1H, CH-7b), 1.46-1.36 (m, 1H, CH-2b), 
1.36 (td, J = 12.9, 10.7 Hz, 1H, CH-4b), 1.20 (s, 3H, CH3-19), 0.89 (td, J = 13.6, 3.9 Hz, 1H, CH-1b). 
13C NMR (101 MHz, CDCl3) δ 214.8 (C, C-9), 139.0 (C, Ph), 128.3 (CH, Ph), 127.5 (CH, Ph), 127.4 
(CH, p-Ph), 77.4 (CH2, C-3), 69.7 (CH2, PhCH2), 48.8 (C, C-10), 43.5 (CH, C-5), 37.8 (CH2, C-8), 
35.3 (CH2, C-4), 32.8 (CH2, C-1), 29.1 (CH2, C-2), 26.5 (CH3, C-19), 26.4 (CH2, C-7), 22.0 (CH2, C-
6); 
MS (ESI+) m/z, (%): 295 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C18H24NaO2 295.1669; Found 295.1670;  




Alcohol 141 (505 mg, 2.77 mmol) and imidazole (226 mg, 3.32 mmol) were 
dissolved in DMF (2 mL), cooled to 0 °C and a soluti n of TBSCl (460 mg, 
3.05 mmol) in DMF (1 mL) was added dropwise while stirring. The conversion 
was complete after 90 min and the mixture was poured into water (25 mL) and 
extracted with hexane (3 × 15 mL). The combined organic extracts were dried 
over MgSO4 and the solvents were evaporated in vacuo. The residue was purified by chromatography 




























IR (CHCl3); ν[cm-1]: 837, 864 (Si-CH3), 1066, 1071, 1095 (C-O), 1257 (Si-CH3), 1361 (tBu), 1374 
(CH3), 1422 (COCH2), 1463, 1472 (tBu), 1703 (C=O), 2858 (CH3), 2883 (tBu), 2903 (SiCH3), 2930, 
2949 (tBu); 
1H NMR (400 MHz, CDCl3) δ 3.57 (tt, J = 10.6, 4.2 Hz, 1H, CH-3), 2.52 (ddd, J = 15.3, 12.9, 7.5 Hz, 
1H, CH-8a), 2.32-2.18 (m, 1H, CH-1a), 2.29-2.18 (m,1H, CH-8b), 2.25-2.12 (m, 1H, CH-6a), 1.95 
(qt, J = 13.3, 4.6 Hz, 1H, CH-7a), 1.93-1.79 (m, 1H, CH-7b), 1.91-1.81 (m, 1H, CH-5), 1.72-1.63 (m, 
1H, CH-2a), 1.56 (dtd, J = 12.9, 3.8, 2.4 Hz, 1H, CH-4a), 1.49 (br d, J = 13.8 Hz, 1H, CH-6b), 1.45-
1.31 (m, 1H, CH-2b), 1.37-1.25 (m, 1H, CH-4b), 1.18 (s, 3H, CH3-19), 0.96-0.85 (m, 1H, CH-1b), 
0.87 (s, 9H, tBu), 0.03 (m, 6H, 2 × SiCH3). 
13C NMR (101 MHz, CDCl3) δ 214.8 (C, C-9), 71.5 (CH, C-3), 48.5 (C, C-10), 43.6 (CH, C-5), 38.8 
(CH2, C-4), 37.8 (CH2, C-8), 32.9 (2 × CH2, C-1, C-2), 26.5 (CH2, C-6), 26.4 (CH3, C-19), 25.9 (CH3, 
tBu), 22.0 (CH2, C-7), 18.1 (C, tBu), −4.6 (CH3, SiCH3), −4.7 (CH3, SiCH3).
 
MS (ESI+) m/z, (%): 319 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C17H32NaO2Si 319.2064; Found 319.2064;  
Anal. Calcd for C17H32O2Si: C, 68.86; H, 10.88; Found: C, 68.78; H, 10.83; 
 
(±)-(4aR*,6R*,8aS*)-6-(Trityloxy)-8a-methyloctahydronaphthalen-1(2H)-one (146c) 
Alcohol 141 (443 mg, 2.43 mmol), DMAP (60 mg, 0.49 mmol) and 
trityl chloride (1.23 g, 4.40 mmol) were dissolved in CH2Cl2 (10 mL) 
and triethylamine (1.35 mL, 9.69 mmol) and the mixture was refluxed 
for 16 h. After cooling to rt, the raction mixture was poured into 5% 
aq. solution of citric acid (50 mL) and extracted with CH2Cl2 (3 × 
15 mL). The combined organic extracts were washed subsequently with 5% aq. citric acid (50 mL), 
saturated aq. NaHCO3 (50 mL), brine (50 mL) and dried over Na2SO4. The solvent was evaporated in 
vacuo and some trityl alcohol was crystallized off from hot hexane. The mother liquors were subjected 
to chromatography on silica gel (20 g) in 10% EtOAc/hexanes to afford 934 mg (91%) of trityl ether 
146c as a colorless oil. 
IR (CHCl3); ν[cm-1]: 630, 703, 709, 1032 (Ph), 1054, 1083 (C-O), 1152 (Ph), 1371, 1384 (CH3), 1423 
(COCH2), 1449, 1491 (Ph), 1597 (Ph), 1703 (C=O), 2872, 2881 (CH3), 2946 (CH2), 3033, 3061 (C-
H); 
1H NMR (400 MHz, CDCl3) δ 7.55-7.50 (m, 6H, CH-3’), 7.37-7.17 (m, 9H, CH-4’, CH-5’), 3.42 (tt, J 
= 10.5, 3.8 Hz, 1H, CH-3), 2.49 (ddd, J = 15.2, 12.7, 7.9 Hz, 1H, CH-8a), 2.24-2.18 (m, 1HC -8b), 
2.49 (dt, J = 13.7, 3.5 Hz, 1H, CH-1a), 2.08-2.01 (m, 1H, CH-6a), 1.93-1.78 (m, 2H, CH2-7), 1.54 (dq, 
J = 13.3, 3.3 Hz, 1H, CH-5), 1.40 (tdd, J = 13.4, 10.8, 3.7 Hz, 1H, CH-2a), 1.32-1.17 (m, 1HC -4a), 
1.29-1.22 (m, 1H, CH-2b), 1.27-1.14 (m, 1H, CH-6b), 1.08 (s, 3H, CH3-19), 0.88 (dq, J = 12.6, 3.1 
Hz, 1H, CH-4b), 0.64 (td, J = 13.7, 4.0 Hz, 1H, CH-1b). 
13C NMR (101 MHz, CDCl3) δ 215.0 (C, C-9), 145.4 (C, C-2’), 128.9 (CH, C-3’/C-4’), 127.6 (CH, C-
3’/C-4’), 126.8 (CH, C-5’), 86.6 (C, C-1’), 73.2 (CH, C-3), 48.5 (C, C-10), 43.7 (CH, C-5), 37.8 (CH2, 
C-8), 36.8 (CH2, C-4), 33.2 (CH2, C-1), 31.0 (CH2, C-2), 26.44 (CH3, C-19), 26.38 (CH2, C-6), 22.0 
(CH2, C-7). 
MS (ESI+) m/z, (%): 447 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C30H32NaO2 447.2295; Found 447.2295;  






















General procedure C: Substrate-controlled Robinson a nulation 
Ketone 146a-c (1.686 mmol) was dissolved in dry ethyl formate (5 mL) at 0 °C and sodium hydride 
(270 mg, 6.75 mmol, 60% suspension in oil) was added portionwise. MeOH (82 µL, 2.03 mmol) was 
added dropwise while stirring vigorously. The reaction mixture turned into a thick slurry after a few 
minutes. After 30 min, the reaction was quenched with saturated aq. NH4Cl (50 mL) and extracted 
with EtOAc (3 × 10 mL). The combined organic extracs were dried over Na2SO4 and concentrated in
vacuo to give the crystalline formyl derivative in essentially quantitative yield. To this neat compound, 
methyl vinyl ketone (186 µL, 2.23 mmol) is added, followed by triethylamine (2.5 µL, 18 µmol) and 
the mixture was stirred overnight. The excess of methyl vinyl ketone was evaporated in vacuo and the 
crude mixture was dissolved in tBuOH (8 mL). tBuOK (378 mg, 3.37 mmol) was added in one portion 
and the mixture was stirred at rt for 45 min. The reaction was quenched with saturated aq. NH4Cl 
(50 mL) and extracted with EtOAc (3 × 15 mL). The combined organic extracts were washed with 
brine, dried over MgSO4 and evaporated in vacuo.  
 
rac-3α-(Benzyloxy)-des-D-18-nor-5β,8α-androst-9(11)-en-12-one (150a) and rac-3α-(benzyloxy)-
des-D-18-nor-5β-androst-8-en-12-one (149a) 
Prepared according to General procedure C. The crude mixture was purified by column 
chromatography on silica gel (90 g) in 5% EtOAc/hexanes to afford 180 mg (7%) of ketone 149a, 
followed by 575 mg (21%) of conjugated enone 150a as a colorless oil. 
Conjugated enone 150a: 
IR (CHCl3); ν[cm-1]: 698 (Ph), 1028 (Ph), 1068 (Ph), 1090 (COC), 1268 (CH3), 
1330 (CH2), 1353 (CH2), 1454 (Ph), 1467 (CH2), 1496 (Ph), 1598 (C=C), 1660 
(C=O), 2865 (CH2), 2936 (CH2); 
1H NMR (400 MHz, CDCl3) δ 7.37-7.31 (m, 4H, CH-3’, CH-4’), 7.31-7.24 (m, 
1H, CH-5’), 6.07 (d, J = 1.9 Hz, 1H, CH-11), 4.54 (d, J = 12.1 Hz, 1H, 
PhCHaHbO), 4.49 (d, J = 12.0 Hz, 1H, PhCHaHbO), 3.57 (quint, J = 4.2 Hz, 1H, CH-3), 2.57 (ddtd, J = 
12.0, 9.6, 4.7, 2.0 Hz, 1H, CH-8), 2.42 (dt, J = 16.4, 4.1 Hz, 1H, CH-13a), 2.29 (ddd, J = 16.5, 14.0, 
5.0 Hz, 1H, CH-13b), 2.24-2.13 (m, 2H, CH-1a, CH-6a), 2.10-2.00 (m, 1H, CH-14a), 1.99-1.88 (m, 
1H, CH-4a), 1.89-1.79 (m, 1H, CH-7a), 1.82-1.65 (m,2H, CH2-2), 1.80-1.70 (m, 1H, CH-6b), 1.77-
1.66 (m, 1H, CH-4b), 1.65-1.50 (m, 1H, CH-14b), 1.60-1.49 (m, 1H, CH-5), 1.27-1.11 (m, 1H, CH-
7b), 1.23 (s, 3H, CH3-19), 1.05-0.94 (m, 1H, CH-1b). 
13C NMR (101 MHz, CDCl3) δ 200.9 (C, C-12), 174.9 (C, C-9), 139.0 (C, C-2’), 128.3 (CH, C-4’), 
127.3 (CH, C-5’), 127.2 (CH, C-3’), 123.4 (CH, C-11), 73.7 (CH, C-3), 69.9 (CH2, PhCH2O), 40.3 (C, 
C-10), 39.8 (CH, C-5), 36.7 (CH2, C-13), 35.1 (CH, C-8), 33.4 (CH2, C-4), 31.9 (CH2, C-7), 31.3 
(CH2, C-1), 30.3 (CH2, C-14), 28.0 (CH2, C-6), 26.8 (CH2, C-2), 24.7 (CH3, C-19). 
MS (ESI+) m/z, (%): 325 (27, [M+H]+), 347 (100, [M+Na]+), 649 (4, [2M+H]+), 671 (36, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C22H28NaO2 347.1982; Found 347.1982;  
Anal. Calcd for C22H28O2: C, 81.44; H, 8.70; Found: C, 80.99; H, 8.75; 
 
Deconjugated enone 149a: 
IR (CHCl3); ν[cm-1]: 699 (Ph), 1028 (Ph), 1066, 1076 (Ph), 1089 (COC), 








































1H NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 4H, C-3’, C-4’), 7.30-7.23 (m, 1H, C-5’), 4.57 (d, J = 
11.8 Hz, 1H, CH-1’a), 4.53 (d, J = 11.8 Hz, 1H, CH-1’b), 3.43-3.35 (m, 1H, CH-3), 2.8  (br d, J = 
20.1 Hz, 1H, CH-11a), 2.70 (br d, J = 20.1 Hz, 1H, CH-11b), 2.48 (dddd, J = 14.2, 9.3, 7.2, 0.6 Hz, 
1H, CH-13a), 2.39 (dddd, J = 14.2, 6.2, 5.1, 1.1 Hz, 1H, CH-13b), 2.36-2.20 (m, 2H, CH2-14), 2.19-
2.01 (m, 1H, CH-7a), 2.06-1.91 (m, 1H, CH-6a), 1.97-1.89 (m, 1H, CH-2a), 1.95-1.82 (m, 1H, CH-
7b), 1.85-1.73 (m, 1H, CH-1a), 1.84-1.75 (m, 1H, CH-4a), 1.59-1.51 (m, 1H, CH-5), 1.56-1.41 (m, 
1H, CH-4b), 1.46-1.38 (m, 1H, CH-6b), 1.12-0.98 (m,1H, CH-2b), 1.09-1.00 (m, 1H, CH-1b), 0.99 (s, 
3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 211.6 (C, C-12), 138.9 (C, C-2’), 129.4 (C, C-9), 129.1 (C, C-8), 128.3 
(CH, C-3’/C-4’), 127.5 (CH, C-3’/C-4’), 127.4 (CH, C-5’), 77.4 (CH, C-3), 71.0 (CH2, C-1’), 39.5 
(CH, C-5), 38.7 (CH2, C-11), 38.4 (CH2, C-13), 36.7 (C, C-10), 34.1 (CH2, C-1), 33.4 (CH2, C-4), 30.9 
(CH2, C-14), 29.3 (CH2, C-2), 28.4 (CH3, C-19), 26.6 (CH2, C-7), 23.6 (CH2, C-6). 
MS (ESI+) m/z, (%): 325 (16, [M+H]+), 347 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C22H28NaO2 347.1982; Found 347.1982;  
 
rac-3α-(tert-Butyldimethylsilyloxy)-des-D-18-nor-5β,8α-androst-9(11)-en-12-one (150b) 
Prepared according to General procedure C. The crude mixture was purified by 
column chromatography on silica gel (30 g) in 5% EtOAc/hexanes to afford 
236 mg (40%) of conjugated enone 150b as a colorless oil.  
IR (CHCl3); ν[cm-1]: 837 (SiCH3), 854, 1006 (OTBDMS), 1036, 1062 (C-O), 
1256 (CH3), 1330, 1374 (CH3), 1455, 1463 (CH2), 1471 (tBu) 1597 (C=C), 
1659 (C=O), 2858 (CH3), 2930 (CH2), 2954 (CH3); 
1H NMR (400 MHz, CDCl3) δ 6.06 (d, J = 2.1 Hz, 1H, CH-11), 3.87 (quint, J = 4.0 Hz, 1H, CH-3), 
2.56 (ddtd, J = 12.3, 9.8, 4.8, 2.2 Hz, 1H, CH-8), 2.42 (dt, J = 16.5, 4.1 Hz, 1H, CH-13a), 2.30 (ddd, J 
= 16.5, 14.0, 5.0 Hz, 1H, CH-13b), 2.27-2.17 (m, 1HCH-6a), 2.18 (ddd, J = 14.8, 13.3, 3.7 Hz, 1H, 
CH-1a), 2.06 (dtd, J = 13.3, 4.7, 3.8 Hz, 1H, CH-14a), 1.94-1.84 (m, 1HC -4a), 1.88-1.79 (m, 1H, 
CH-7a), 1.77-1.66 (m, 1H, CH-2a), 1.73-1.63 (m, 1H,C -6b), 1.64-1.51 (m, 1H, CH-14b), 1.57-1.47 
(m, 1H, CH-5), 1.51-1.43 (m, 1H, CH-2b), 1.49-1.39 (m, 1H, CH-4b), 1.20 (s, 3H, CH3-19), 1.16 (qd, 
J = 12.9, 5.1 Hz, 1H, CH-7b), 1.00-0.90 (m, 1H, CH-1b), 0.90 (s, 9H, tBu), –0.04 (s, 3H, SiCH3), –
0.05 (s, 3H, SiCH3); 
13C NMR (101 MHz, CDCl3) δ 200.9 (C, C-12), 175.3 (C, C-9), 123.3 (CH, C-11), 67.2 (CH, C-3), 
40.3 (C, C-10), 40.0 (CH, C-5), 37.2 (CH2, C-4), 36.8 (CH2, C-13), 35.3 (CH, C-8), 32.2 (CH2, C-7), 
30.9 (CH2, C-1), 30.4 (CH2, C-2), 30.3 (CH2, C-14), 28.7 (CH2, C-6), 25.9 (CH3, tBu), 24.6 (CH3, C-
19), 18.1 (C, tBu), −4.86 (CH3, SiCH3), –4.89 (CH3, SiCH3). 
MS (ESI+) m/z, (%): 349 (16, [M+H]+), 371 (100, [M+Na]+), 697 (4, [2M+H]+), 719 (26, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H36NaO2Si 371.2377; Found 371.2377;  
Anal. Calcd for C21H36O2Si: C, 72.35; H, 10.41; Found: C, 72.04; H, 10.71; 
 
rac-3α-(Trityloxy)-des-D-18-nor-5β,8α-androst-9(11)-en-12-one (150c) 
Prepared according to General procedure C. The crude mixture was purified by column 
chromatography on silica gel (30 g) in 5% EtOAc/hexanes to afford 306 mg (32%) of pure conjugated 
enone 150c as a colorless oil. 
IR (CHCl3); ν[cm-1]: 631, 707, 1029 (Ph), 1053 (C-O), 1151 (Ph), 1372 (CH3), 1449, 1490 (Ph), 1597 





















1H NMR (400 MHz, CDCl3) δ 7.54-7.45 (m, 3H, CH-5’), 7.32-7.18 
(m, 12H, CH-3’, CH-4’), 6.01 (d, J = 2.1 Hz, 1H, CH-11), 3.71 
(quint, J = 4.8 Hz, 1H, CH-3), 2.62 (ddtd, J = 12.3, 9.9, 4.8, 2.2 Hz, 
1H, CH-8), 2.43 (dt, J = 16.5, 4.0 Hz, 1H, CH-13a), 2.33 (ddd, J = 
16.5, 14.0, 4.9 Hz, 1H, CH-13b), 2.22-2.09 (m, 1H, CH-6a), 2.19-
2.09 (m, 1H, CH-1a), 2.12-2.03 (m, 1H, CH-14a), 1.87-1.81 (m, 1H, 
CH-7a), 1.70-1.60 (m, 1H, CH-6b), 1.65-1.51 (m, 1H,CH-14b), 1.43 
(dt, J = 14.1, 4.2 Hz, 1H, CH-4a), 1.38-1.32 (m, 1H, CH-5), 1.28-1.20 (m, 1H, CH-2a), 1.23-1.07 (m, 
1H, CH-7b), 1.15-1.07 (m, 1H, CH-4b), 1.10-1.00 (m, 1H, CH-2b), 1.08 (s, 1H, CH3-19), 0.90-0.80 
(m, 1H, CH-1b); 
13C NMR (101 MHz, CDCl3) δ 200.9 (C, C-12), 175.1 (C, C-9), 145.3 (C, C-2’), 129.0 (CH, C-3’), 
127.7 (CH, C-4’), 126.9 (CH, C-5’), 123.6 (CH, C-11), 87.5 (C, C-1’), 69.2 (CH, C-3), 39.94 (C, C-
10), 39.86 (CH, C-5), 36.9 (CH2, C-13), 35.6 (CH2, C-4), 35.3 (CH, C-8), 32.3 (CH2, C-1), 31.4 (CH2, 
C-7), 30.5 (CH2, C-14), 28.4 (CH2, C-2), 28.1 (CH2, C-6), 25.2 (CH3, C-19). 
MS (ESI+) m/z, (%): 499 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C34H36NaO2 499.2608; Found 499.2608;  
Anal. Calcd for C34H36O2: C, 85.67; H, 7.61; Found: C, 85.37; H, 7.65; 
 
(S)-6-(Ethylenedioxy)-8a-methyl-3,4,6,7,8,8a-hexahydronaphthalen-1(2H)-one (nat-152) and (R)-
6-(ethylenedioxy)-8a-methyl-3,4,6,7,8,8a-hexahydronaphthalen-1(2H)-one (ent-152) 
Diketone 21 (7.36 g, 41.3 mmol), triethyl orthoformate (7.58 mL, 45.6 mmol) and 
ethylene glycol (12.7 mL, 228 mmol) were dissolved in CH2Cl2 (50 mL) and the 
reaction flask was immersed in salt-ice bath kept at −10 °C. TMSOTf (150 µL, 
830 µmol) was added with stirring and the temperature was kept at −10 °C for 1 h. 
Et3N (200 µL, 1.43 mmol) was added to the reaction mixture, which was subsequently poured into 
saturated aq. NaHCO3 (200 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
extracts were dried with MgSO4 and concentrated in vacuo. The residue was purified by 
chromatography on silica gel (150 g) in 20% EtOAc/hexanes + 0.5% Et3N to afford 7.88 g (86%) of 
pure monoketal 152 as an off-white solid, followed by 1.04 g of mixture consisting of ketal 136a and 
starting material 21. This mixture was dissolved in a solution of aceton  (5 mL), water (0.7 mL) and 
conc. HCl (0.4 mL) and stirred overnight at rt. The reaction mixture was diluted with water (25 mL) 
and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with saturated aq. 
NaHCO3 (25 mL), dried over MgSO4 and concentrated in vacuo. Distillation of the residue in 
Kugelrohr at 150 °C and 0.1 mbar afforded 0.88 g (12%) of 21, showing identical properties with the 
starting material, including enantiomeric excess. 
152:Mp 48-51 °C; 
[α]D20 +97.7 (c 0.267, CHCl3) for nat-152; 
[α]D20 −82.7 (c 0.202, CHCl3) for ent-152; 
IR (CHCl3); ν[cm-1]: 946, 959, 1003, 1072, 1096 (ring), 1148, 1161, 1234 (COCOC), 1340, 1361, 
1378 (CH3) 1442, 1447, 1461 (CH2), 1661 (C=C), 1711 (C=O), 2885 (CH3), 2953 (CH2), 2975 (CH3); 
1H NMR (400 MHz, CDCl3) δ 5.41 (dd, J = 1.8, 0.9 Hz, 1H, CH-4), 4.02-3.87 (m, 4H, OCH2 2O), 
2.64 (ddd, J = 15.2, 13.4, 6.3 Hz, 1H, CH-8a), 2.56 (dddd, J = 14.0, 13.5, 5.0, 1.9 Hz, 1H, CH-6a), 







































2.16-2.08 (m, 1H, CH-1a), 2.07-1.99 (m, 1H, CH-7a), 1.86-1.77 (m, 2H, CH2-2), 1.77-1.69 (m, 1H, 
CH-1b), 1.65 (qt, J = 13.3, 4.6 Hz, 1H, CH-7b), 1.32 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 212.5 (C, C-9), 146.6 (C, C-5), 123.4 (CH, C-4), 105.4 (C, C-3), 64.6 
(CH2, OCH2CH2O), 64.3 (CH2, OCH2CH2O), 50.2 (C, C-10), 37.8 (CH2, C-8), 30.8 (CH2, C-6), 29.8 
(CH2, C-2), 28.6 (CH2, C-1), 24.3 (CH2, C-7), 23.8 (CH3, C-19). 
MS (ESI+) m/z, (%): 223 (40, [M+H]+), 245 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C13H18NaO3 245.1148; Found 245.1148;  
Anal. Calcd for C13H18O3: C, 70.24; H, 8.16; Found: C, 69.86; H, 8.19. for nat-152; 
Anal. Calcd for C13H18O3: C, 70.24; H, 8.16; Found: C, 70.25; H, 8.14. for ent-152; 
 
3-(Ethylenedioxy)-des-D-18-norandrosta-4,9(11)-dien-12-one (nat-155), 3-(ethylenedioxy)-des-D-
18-norandrosta-4,8-dien-12-one (nat-156) and ent-3-(ethylenedioxy)-des-D-18-norandrosta-
4,9(11)-dien-12-one (ent-155), ent-3-(ethylenedioxy)-des-D-18-norandrosta-4,8-dien-12-one (ent-
156) 
Ketone 152 (20.87 g, 93.89 mmol) was dissolved in dry ethyl formate (250 mL) at 0 °C and sodium 
hydride (9.39 g, 235 mmol, 60% suspension in oil, washed with THF - 3 × 25 mL) suspended in THF 
(10 mL) was added portionwise. MeOH (3.80 mL, 93.9 mmol) was added dropwise at 0 °C over 
15 min. The reaction mixture turned into a thick slurry after a few minutes. After 30 min, the reaction 
mixture was warmed to rt and after another 30 min quenched with saturated aq. NH4Cl (400 mL) and 
extracted with EtOAc (3 × 100 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo to give the crystalline formyl derivative 153 in essentially quantitative yield. 
1H NMR (400 MHz, CDCl3) δ 14.67 (br s, 1H, OH), 8.54 (s, 1H, CHOH), 5.39 (t, J = 1.1 Hz, 1H, CH-
4), 4.05-3.84 (m, 4H, OCH2CH2O), 2.57-2.30 (m, 2H, CH2-7), 2.43-2.22 (m, 2H, 
CH2-6), 2.13-1.82 (m, 4H, CH2-1, CH2-2), 1.37 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 190.2 (C, C-9), 185.8 (CH, CHOH), 145.0 (C, C-
5), 122.5 (CH, C-4), 106.8 (C, C-8), 105.3 (C, C-3), 64.7 (CH2, OCH2CH2O), 
64.3 (CH2, OCH2CH2O), 42.0 (C, C-10), 30.3 (CH2, C-1), 29.9 (CH2, C-2), 29.1 (CH2, C-6), 24.3 
(CH2, C-7), 23.8 (CH3, C-19). 
To the neat compound, methyl vinyl ketone (8.77 mL,105 mmol) was added, followed by 
triethylamine (245 µL, 1.75 mmol) and the mixture was stirred overnight. The excess of methyl vinyl 
ketone was evaporated in vacuo, the crude mixture was dissolved in MeOH (320 mL) and degassed by 
sonication under vacuum, followed by flushing with argon (3 cycles). KOH (15.26 g, 272 mmol) was 
dissolved in degassed H2O, the methanolic solution was added via cannula and the mixture was 
refluxed under N2 for 30 min. The solution was cooled to rt, quenched with saturated aq. NH4Cl 
(400 mL) and extracted with EtOAc (3 × 330 mL). The organic extracts were washed with brine 
(400 mL), dried over Na2SO4 and evaporated in vacuo. The residue was purified by chromatography 
on silica gel (350 g) in 20% EtOAc/hexanes + 0.5% Et3N to 50% EtOAc/hexanes + 0.5% Et3N to yield 
5.49 g (23%) of 156 and 14.53 g (60%) of 155.  
 
155: Colorless solid, 
[α]D20 +149.8 (c 0.259, CHCl3) for nat-155; Mp 105-108 °C; 















IR (CHCl3); ν[cm-1]: 883, 946, 1078, 1091 (ring), 1132, 1168, 1361 (CH2), 1379 
(CH3) 1451, 1454 (CH2), 1604 (C=C), 1664 (C=O), 2865 (CH2), 2887 (CH3), 
2941 (CH2), 2978 (CH3); 
1H NMR (400 MHz, CDCl3) δ 5.97 (d, J = 2.1 Hz, 1H, CH-11), 5.36 (d, J = 1.3 
Hz, 1H, CH-4), 4.06-3.86 (m, 4H, OCH2CH2O), 2.68 (ddtd, J = 12.3, 10.1, 5.0, 
2.2 Hz, 1H, CH-8), 2.47 (tdd, J = 14.0, 4.4, 1.9 Hz, 1H, CH-6a), 2.45-2.39 (m, 1H, CH-13a), 2.30 
(ddd, J = 16.5, 14.1, 5.0 Hz, 1H, CH-13b), 2.21 (ddd, J = 14.0, 3.9, 2.8 Hz, 1H, CH-6b), 2.14-2.05 (m, 
1H, CH-14a), 2.10-2.00 (m, 1H, CH-1a), 2.00-1.93 (m, 1H, CH-7a), 1.94-1.85 (m, 2H, CH2-2), 1.91-
1.82 (m, 1H, CH-1b), 1.61 (tdd, J = 13.8, 10.2, 4.6 Hz, 1H, CH-14b), 1.32 (dtd, J = 14.1, 12.8, 4.1 Hz, 
1H, CH-7b), 1.31 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 200.3 (C, C-12), 172.4 (C, C-9), 147.2 (C, C-5), 122.7 (CH, C-11), 
122.3 (CH, C-4), 105.4 (C, C-3), 64.7 (CH2, OCH2CH2O), 64.3 (CH2, OCH2CH2O), 41.4 (C, C-10), 
36.4 (CH2, C-13), 35.2 (CH, C-8), 34.1 (CH2, C-7), 32.1 (CH2, C-1), 31.4 (CH2, C-6), 30.0 (CH2, C-2), 
29.5 (CH2, C-14), 27.2 (CH3, C-19). 
MS (ESI+) m/z, (%): 275 (57, [M+H]+), 297 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C17H23O3 275.1642; Found 275.1644;  
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 74.29; H, 7.98. for nat-155 
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 74.56; H, 7.86. for ent-155. 
 
156: Oily liquid, 
[α]D20 +217.7 (c 0.215, CHCl3) for nat-156;  
[α]D20 –245.5 (c 0.283, CHCl3) for ent-156; 
IR (CHCl3); ν[cm-1]: 946, 961, 1086 (ring), 1137, 1363 (CH2), 1380 (CH3), 1443, 
1450 (CH2), 1674 (C=C), 1713 (C=O), 2855 (CH2), 2927, 2954 (CH2); 
1H NMR (400 MHz, CDCl3) δ 5.33 (t, J = 1.6 Hz, 1H, CH-4), 4.08-3.81 (m, 4H, 
OCH2CH2O), 2.89 (br d, J = 20.1 Hz, 1H, CH-11a), 2.76 (br d, J = 20.1 Hz, 1H, CH-11b), 2.46-2.33 
(m, 2H, CH2-13), 2.44-2.34 (m, 1H, CH-2a), 2.36-2.29 (m, 2H, CH2-14), 2.30-2.19 (m, 1H, CH-1a), 
2.23-2.12 (m, 1H, CH-2b), 2.17-2.05 (m, 1H, CH-1b), 1.98-1.74 (m, 2H, CH2-6), 1.78-1.60 (m, 2H, 
CH2-7), 1.18 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 211.2 (C, C-12), 148.4 (C, C-5), 132.4 (C, C-9), 128.6 (C, C-8), 120.2 
(CH, C-4), 105.6 (C, C-3), 64.7 (CH, OCH2CH2O), 64.2 (CH, OCH2CH2O), 38.5 (CH2, C-11), 38.0 
(CH2, C-13), 37.6 (C, C-10), 32.4 (CH2, C-7), 32.3 (CH2, C-1), 30.2 (CH2, C-6/C-14), 30.1 (CH2, C-
6/C-14), 29.1 (CH2, C-2), 23.0 (CH3, C-19). 
MS (ESI+) m/z, (%): 275 (100, [M+H]+), 297 (42, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C17H23O3 275.1642; Found 275.1643;  
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 74.80; H, 8.82. for nat-156; 
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 73.36; H, 8.05. for ent-156; 
 
ent-3-(Ethylenedioxy)-8β-hydroxy-des-D-18-norandrosta-4,9(11)-dien-12-one (ent-157) 
The crude triketone nt-154 (105 mg, 383 µmol) was dissolved in nondegassed methanol (4 mL). An 
aq. KOH solution (2 M, 610 µL, 1.22 mmol) was added to the methanolic soution and the mixture was 
refluxed for 4 h under air. The solution was cooled to rt, quenched with saturated aq. NH4Cl (25 mL) 
and extracted with CH2Cl2 (3 × 10 mL). The combined extracts were washed with saturated aq. 







































purified by chromatography on silica gel (3 g) in 30% EtOAc/hexanes + 1.0% 
Et3N to 50% EtOAc/hexanes + 1.0% Et3N to yield 33 mg (30%) of ent-157.  
IR (ATR); ν[cm-1]: 513, 907, 935, 973, 1017, 1081, 1089 (ring), 1110, 120, 
1198, 1218, 1280, 1328, 1361, 1364 (CH2), 1382 (CH3), 1441 (CH2), 1610 (C=C), 
1653 (C=O), 2877 (CH2), 2947 (CH2), 2965 (CH3), 3405 (OH); 
1H NMR (400 MHz, CDCl3) δ 5.94 (s, 1H, CH-11), 5.37 (br s, 1H, CH-4), 4.06-3.84 (m, 4H, 
OCH2CH2O), 2.84 (dddd, J = 14.0, 13.7, 4.1, 1.8 Hz, 1H, CH-6a), 2.81-2.72 (m, 1H, CH-13a), 2.38 
(br dt, J = 17.4, 3.0 Hz, 1H, CH-13b), 2.20 (br s, 1H, OH), 2.08 (ddd, J = 13.7, 3.7, 3.0 Hz, 1H, CH-
6b), 2.02-1.95 (m, 3H, CH-7a, CH2-14), 1.95-1.87 (m, 4H, CH2-1, CH2-2), 1.67 (td, J = 14.2, 4.0 Hz, 
1H, 7b), 1.47 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 200.0 (C, C-12), 168.9 (C, C-9), 147.2 (C, C-5), 124.9 (CH, C-11), 
121.9 (CH, C-4), 105.2 (C, C-3), 68.7 (C, C-8), 64.6 (CH2, OCH2CH2O), 64.2 (CH2, OCH2CH2O), 
40.6 (C, C-10), 40.2 (CH2, C-7), 37.9 (CH2, C-14), 33.0 (CH2, C-1), 32.4 (CH2, C-13), 29.8 (CH2, C-
2), 28.0 (CH3, C-19), 27.4 (CH2, C-6). 
MS (ESI+) m/z, (%): 291 (69, [M1+H]
+), 307 (7, [M2+H]
+), 313 (100, [M1+Na]
+), 329 (13, [M2+Na]
+), 
603 (48, [2M1+Na]
+), 619 (16, [M1+M2+Na]
+); Where M1 is the title compound, M2 is the analogous 
hydroperoxide. 
HRMS (ESI+) m/z: [M1+H]
+ Calcd for C17H23O4 291.1591; Found 291.1593; [M1+Na]
+ Calcd for 
C17H22NaO4 314.1410; Found 314.1410; 
 
3-(Ethylenedioxy)-des-D-18-norandrost-4-en-12-one (nat-158) and ent-3-(ethylenedioxy)-des-D-
18-norandrost-4-en-12-one (ent-158) 
Liquid ammonia (ca. 200 mL) was dried with lithium pellets (ca. 0.5 g) and a 
catalytic amount of FeCl3 (20 mg) at reflux temperature. After the deep blue 
solution turned colorless, the ammonia was distilled to a three-necked round 
bottom flask (500 mL) with a stirring bar, nitrogen inlet and a dry-ice cooled 
condenser. The flask was cooled to −78 °C and a solution of enone 155 (9.074 g, 
33.07 mmol) in THF (90 mL) was added, followed by abs. EtOH (4.96 mL, 84.9 mmol). Crushed 
lithium pellets (2.66 g, 383 mmol) were added portionwise with vigorous stirring at −78 °C. A 
persistent blue coloration was indicative of a complete reduction. The reaction was quenched with 
solid NH4Cl and the excess of ammonia was carefully evaporated. The residue was poured into 
saturated aq. NaHCO3 (300 mL) and extracted with EtOAc (3 × 100 mL). The combined organic 
extracts were washed with brine, dried over MgSO4 and evaporated in vacuo. The residue was purified 
by chromatography on silica gel (150 g) in 30% EtOAc/hexanes + 0.5% Et3N to give 7.625 g (83%) of 
158 as a colorless oil, containing ca 5% of inseparable enone 156. 
[α]D20 +144.7 (c 0.409, CHCl3) for nat-158; 
[α]D20 −138.3 (c 0.248, CHCl3) for ent-158; 
IR (CHCl3); ν[cm-1]: 947, 964, 1009 (ring), 1089, 1113, 1169, 1182, 133 (COCOC), 1366, 1381 
(CH3), 1440 (CH2), 1664 (C=C), 1711 (C=O), 2864, 2888 (CH3), 2938 (CH2), 2969 (CH3); 
1H NMR (400 MHz, CDCl3) δ 5.31 (t, J = 1.2 Hz, 1H, CH-4), 4.07-3.82 (m, 4H, OCH2CH2O), 2.44-
2.33 (m, 1H, CH-11a), 2.38-2.28 (m, 2H, CH2-13), 2.32-2.24 (m, 1H, CH-6a), 2.17-2.09 (m, 1H, C-
11b), 2.14-2.07 (m, 1H, CH-6b), 2.04-1.97 (m, 1H, C-14a), 1.89-1.81 (m, 1H, CH-7a), 1.85-1.75 (m, 
1H, CH-8), 1.82-1.72 (m, 2H, CH2-2), 1.69-1.64 (m, 1H, CH-1a), 1.61-1.51 (m, 1H, CH-1b), 1.47-









































13C NMR (101 MHz, CDCl3) δ 211.8 (C, C-12), 149.2 (C, C-5), 121.1 (CH, C-4), 105.8 (C, C-3), 64.6 
(CH2, OCH2CH2O), 64.3 (CH2, OCH2CH2O), 53.0 (CH, C-9), 41.1 (CH2, C-11), 40.9 (CH2, C-13), 
37.7 (C, C-10), 35.9 (CH, C-8), 34.1 (CH2, C-1), 33.6 (CH2, C-7), 33.3 (CH2, C-14), 31.6 (CH2, C-6), 
29.7 (CH2, C-2), 17.6 (CH3, C-19). 
MS (ESI+) m/z, (%): 277 (23, [M+H]+), 299 (100, [M+Na]+), 575 (21, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C17H25O3 277.1798; Found 277.1799; [M+Na]
+ Calcd for 
C17H24NaO3 299.16177; Found 299.16181; 
Anal. Calcd for C17H24O3: C, 73.88; H, 8.75; Found: C, 74.01; H, 8.69. for nat-158. 
Anal. Calcd for C17H24O3: C, 73.88; H, 8.75; Found: C, 73.80; H, 8.82. for ent-158. 
 
3-(Ethylenedioxy)-des-D-18-norandrosta-4,13-dien-12-one (nat-161) 
2,2,6,6-Tetramethylpiperidine (4.03 mL, 23.88 mmol) was dissolved in THF (30 mL) and the solution 
was cooled in an ice bath. nBuLi (2.25 M in hexane, 10.6 mL, 23.88 mmol) was added dropwise at 
0 °C, the homogeneous solution was stirred for 30 min and cooled to −78 °C. A solution of ketone 158 
(4.405 g, 15.93 mmol) in THF (50 mL) was added dropwise with stirring and the reaction mixture was 
kept at −78 °C for 1 h. TMSCl (2.83 mL, 22.3 mmol) diluted with THF (2 mL) was added dropwise 
and after 30 min of stirring at −78 °C, the reaction mixture was warmed to 0 °C. The content of the 
reaction flask was poured onto a 1:1 mixture of ice and saturated aq. NaHCO3 (400 mL in total) and 
extracted with hexane (3 × 150 mL). The combined organic extracts were washed with brine, dried 
over MgSO4 and evaporated in vacuo to afford 6.02 g of crude silyl enol ether 159/160. 
1H NMR (400 MHz, CDCl3) δ 5.26 (s, 1H, CH-4), 4.81 (t, J = 1.9 Hz, 1H, CH-
11)*, 4.78 (br d, J = 5.6 Hz, 1H, CH-13), 4.05-3.83 (m, 4H, OCH2CH2O), 2.24 
(tdd, J = 13.9, 4.8, 1.7 Hz, 1H, CH-6a), 2.13-2.02 (m, 1H,C -14a), 2.09-2.00 (m, 
1H, CH-6b), 1.97-1.91 (m, 2H, CH2-11), 1.90-1.80 (m, 1H, CH-7a), 1.82-1.73 
(m, 2H, CH2-2), 1.77-1.59 (m, 2H, CH2-1), 1.70-1.59 (m, 1H, CH-14b), 1.64-1.49 
(m, 1H, CH-8), 1.40-1.30 (m, 1H, CH-9), 1.18-1.04 (m, 1H, CH-7b), 1.03 (s, 3H, CH3-19), 0.95 (s, 
3H, CH3-19)*, 0.19 (s, 9H, TMS)*, 0.18 (s, 9H, TMS). * Denotes the minor ∆11 silyl enol ether 159 
signals where possible. The ratio of ∆11 :∆12 159:160 was found to be 1:10. 
13C NMR (101 MHz, CDCl3) δ 151.2 (C, C-5), 149.5 (C, C-12), 119.7 (CH, C-4), 106.1 (C, C-3), 
102.3 (CH, C-13), 64.5 (CH2, OCH2CH2O), 64.2 (CH2, OCH2CH2O), 48.5 (CH, C-9), 37.2 (C, C-10), 
34.45 (CH2, C-1/C-7), 34.42 (CH2, C-1/C-7), 32.2 (CH, C-8), 32.0 (CH2, C-14), 31.6 (CH2, C-6), 29.8 
(CH2, C-2), 29.5 (CH2, C-11), 18.2 (CH3, C-19), 0.3 (CH3, SiCH3).  
The crude silyl enol ether 159/160 was dissolved in DMSO (130 mL, fractionally distilled under 
vacuum) and transferred to a gas washing bottle equipped with a frit and a stirring bar. A gentle flow 
of air, predried by passing through a plug of KOH pellets, was passed through the solution with 
stirring. Palladium(II) acetate (360 mg, 1.60 mmol) was added to the solution, resulting in an orange-
brown solution. Bubbling and stirring was maintained for 48 h, during which the color remained 
unchanged. The reaction mixture was poured onto a 1:1 mixture of ice and saturated aq. NaHCO3 
(400 mL in total) and extracted with Et2O (3 × 150 mL). The combined organic extracts were washed 
with brine (400 mL), dried over MgSO4 and evaporated in vacuo to afford solid crude enone 161. 
Crystallization from hexane:Et2O afforded 2.436 g (56%) of pure 161 as off-white crystals. The 
mother liquors were evaporated in vacuo and the residue was purified by chromatography 
on silica gel (70 g) in 30% EtOAc/hexanes + 0.5% Et3N to afford another 1.05 g (24%) of enone 161 






















Mp 114-117 °C; 
[α]D20 +204.5 (c 0.243, CHCl3) for nat-161; 
[α]D20 −243.8 (c 0.244, CHCl3) for ent-161; 
IR (CHCl3); ν[cm-1]: 946, 961, 1002 (ring), 1091, 1157, 1233 (COCOC), 1368, 
1383, 1389 (CH3), 1440, 1449 (CH2), 1618 (C=C), 1676 (C=O), 2863, 2887 
(CH3), 2941 (CH2), 2972 (CH3); 
1H NMR (400 MHz, CDCl3) δ 6.71 (dd, J = 10.0, 1.8 Hz, 1H, CH-14), 5.96 (ddd, J = 10.0, 2.8, 1.0 Hz, 
1H, CH-13), 5.33 (s, 1H, CH-4), 4.06-3.83 (m, 4H, OCH2CH2O), 2.55-2.47 (m, 1H, CH-8), 2.48 (dd, J 
= 16.0, 3.4 Hz, 1H, CH-11a), 2.39 (tdd, J = 13.9, 5.0, 1.9 Hz, 1H, CH-6a), 2.20 (ddd, J = 14.0, 4.3, 2.4 
Hz, 1H, CH-6b), 2.19 (dd, J = 16.1, 14.3 Hz, 1H, CH-11b), 2.01 (dddd, J = 12.5, 5.0, 3.9, 2.4 Hz, 1H, 
CH-7a), 1.82-1.78 (m, 2H, CH2-2), 1.78-1.67 (m, 1H, CH-1a), 1.74-1.60 (m, 1H, CH-9), 1.61-1.53 (m, 
1H, CH-1b), 1.31 (qd, J = 13.1, 4.4 Hz, 1H, CH-7b), 1.08 (s, 3H, CH3-19); 
13C NMR (101 MHz, CDCl3) δ 200.0 (C, C-12), 154.8 (CH, C-14), 148.2 (C, C-5), 128.6 (CH, C-13), 
121.9 (CH, C-4), 105.7 (C, C-3), 64.7 (CH2, OCH2CH2O), 64.3 (CH2, OCH2CH2O), 51.1 (CH, C-9), 
38.0 (CH2, C-11), 37.2 (C, C-10), 36.9 (CH, C-8), 33.8 (CH2, C-1), 32.4 (CH2, C-7), 31.9 (CH2, C-6), 
29.6 (CH2, C-2), 17.6 (CH3, C-19); 
MS (ESI+) m/z, (%): 275 (23, [M+H]+), 297 (100, [M+Na]+), 572 (7, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C17H22NaO3 297.1461; Found 297.1457;  
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 73.74; H, 8.12. for nat-161. 
Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; Found: C, 74.35; H, 8.27. for ent-161. 
X-ray data are available in Appendix C. 
 
(±)-1-Cyclopropylethanol (163) 
Prepared according to literature.271 
Bp 121-122 °C (Lit.272 bp 121-122 °C); 
1H NMR (400 MHz, CDCl3) δ 3.08 (dq, J = 8.0, 6.2 Hz, 1H, CH-2), 1.96 (s, 1H, OH), 1.28 
(d, J = 6.2 Hz, 3H, CH3-1), 0.91 (qt, J = 8.1, 5.0 Hz, 1H, CH-3), 0.54-0.45 (m, 2H, CH-4cis, CH-5cis), 
0.33-0.23 (m, 1H, CH-4trans), 0.23-0.13 (m, 1H, CH-5trans); 




Prepared according to the literature as a 9:1 mixture of E:Z isomers.271 
Bp 127-128 °C (Lit.271 bp 125-126 °C) 
1H NMR (400 MHz, CDCl3) δ 5.66-5.56 (m, 1H, CH-2)*, 5.56 (dqt, J = 15.2, 6.3, 1.2 Hz, 1H, CH-2), 
5.44-5.35 (m, 1H, CH-3)*, 5.41 (dtq, J = 15.2, 6.6, 1.6 Hz, 1H, CH-3), 3.38 (t, J = 7.2 Hz, 2H, CH2-
5)*, 3.36 (t, J = 7.1 Hz, 2H, CH2-5), 2.63 (qqd, J = 7.2, 1.6, 0.8 Hz, 2H, CH2-4)*, 2.54 (qquint, J = 7.0, 
1.2 Hz, 2H, CH2-4), 1.68 (dq, J = 6.3, 1.2 Hz, 3H, CH3-1), 1.64 (ddt, J = 6.8, 1.8, 0.9 Hz, 3H, CH3-
1)*. 
13C NMR (101 MHz, CDCl3) δ 128.3 (CH, C-2/C-3), 127.7 (CH, C-2/C-3), 127.0 (CH, C-2/C-3)*, 
126.8 (CH, C-2/C-3)*, 36.0 (CH2, C-4), 32.8 (CH2, C-5), 32.4 (CH2, C-5)*, 30.5 (CH2, C-4)*, 17.9 
(CH3, C-1), 12.9 (CH3, C-1)*. 




































Prepared according to literature.272 The product contained ca. 5% of 5-chloropent-2-ene 
(167). 
Bp 99-104 °C (Lit.272 bp 100-102 °C); 
1H NMR (400 MHz, CDCl3) δ 3.41 (dq, J = 9.1, 6.6 Hz, 1H, CH-2), 1.60 (d, J = 6.6 Hz, 3H, CH3-1), 
1.17 (dtt, J = 9.1, 8.1, 4.8 Hz, 1H, CH-3), 0.70-0.62 (m, 2H, CH-4cis, CH-5cis), 0.46-0.37 (m, 1H, 
CH-4trans), 0.37-0.28 (m, 1H, CH-5trans); 
13C NMR (101 MHz, CDCl3) δ 64.2 (CH, C-2), 25.1 (CH3, C-1), 20.6 (CH, C-3), 5.9 (CH2, C-4/C-5), 
5.4 (CH2, C-4/C-5). 
 
General procedure D: Grignard reagent preparation ad titration 
Magnesium powder (2.40 g, 98.9 mmol) was flame-dried in Schlenk flask under vacuum. The flask 
was refilled with argon and cooled to rt. The powder was stirred dry under argon for 1 h and 
suspended in THF (22 mL). Neat 164 or 166/167 (7.50 mmol) was added dropwise and the mixture 
was stirred until the exothermic reaction started. In the case of bromide 164, a drop of dibromoethane 
was used to start the reaction if necessary. When t mixture ceased to reflux, the rest of 164 or 
166/167 (22.5 mmol) was added dropwise and the mixture was refluxed for 1 hr. The solution was 
cooled to rt and diluted with THF (13 mL). The reagnt was stored in the reaction flask under argon at 
rt without the loss of titre for several weeks. Yields varied between 80% and 95%.  
Titration was performed with salicylaldehyde phenylhydrazone according to the known protocol.269 
 
(±)-3-(Pent-3-en-1-yl)cyclohexanone (170) and (±)-3-(pent-3-en-1-yl)cyclohex-2-en-1-ol (171) 
Cyclohexenone (387 µL, 4 mmol) and CuBr·Me2S (40 mg, 0.20 mmol) were dissolved in THF and the 
mixture was cooled to −78 °C. A freshly prepared soluti n of Grignard reagent 165 (0.70 M in THF, 
6.25 mL, 4.4 mmol) was added dropwise over 10 min and the mixture was stirred at −78 °C for 
30 min. The reaction was quenched with a few drops of aturated aq. NH4Cl and filtered through a 
short pad of silica gel. The solvent was evaporated in vacuo to ca. 600 mg of liquid, which was 
purified by flash column chromatography on silica gel (30 g) in 5% EtOAc/hexanes to furnish 78 mg 
(12%) of ketone 170, followed by 212 mg (32%) of alcohol 171. 
170: IR (CHCl3); ν[cm-1]: 968 (CH=), 1057, 1314, 1348, 1379 (CH3), 1426, 1439, 1452 (CH2), 1650 
(C=C), 1707 (C=O), 2853 (CH2), 2885 (CH3), 2934 (CH2); 
1H NMR (400 MHz, CDCl3) δ 5.48-5.41 (m, 1H, CH-10)*, 5.43-5.36 (m, 2H, 
CH-9, CH-10), 5.40-5.32 (m, 1H, CH-9)*, 2.45-2.40 (m, 1H, CH-2a), 2.39-
2.32 (m, 1H, CH-6a), 2.25 (dddd, J = 14.1, 12.3, 6.1, 1.2 Hz, 1H, CH-6b), 2.09-1.97 (m, 1H, CH-5a), 
2.05-1.95 (m, 3H, CH2-8, CH-2b), 1.94-1.86 (m, 1H, CH-4a), 1.84-1.73 (m,1H, CH-3), 1.70-1.59 (m, 
1H, CH-5b), 1.64 (br d, J = 5.9 Hz, 3H, CH3-11), 1.46-1.29 (m, 2H, CH2-7), 1.38-1.26 (m, 1H, CH-
4b). 
13C NMR (101 MHz, CDCl3) δ 211.9 (C, C-1), 130.7 (CH, C-9), 129.9 (CH, C-9)*, 125.2 (CH, C-10), 
124.2 (CH, C-10)*, 48.08 (CH2, C-2)*, 48.03 (CH2, C-2), 41.47 (CH2, C-6), 41.46 (CH2, C-6)*, 38.6 
(CH, C-3)*, 38.4 (CH, C-3), 36.4 (CH2, C-7), 36.3 (CH2, C-7)*, 31.22 (CH2, C-4)*, 31.19 (CH2, C-4), 
29.6 (CH2, C-8), 25.22 (CH2, C-5), 25.21 (CH2, C-5)*, 24.0 (CH2, C-8)*, 17.9 (CH3, C-11), 12.7 (CH3, 
C-11)*. Detectable signals of the minor Z-isomer are denoted by an *. 
MS (ESI+) m/z, (%): 167 (1, [M+H]+), 189 (53, [M+Na]+), 355 (100, [2M+Na]+); 



















GC (Temperature program: 60 °C for 2 min, followed by linear gradient 10 °C·min−1 for 14 min) 
showed 2 peaks in 89:11 ratio (tE = 12.94 min, tZ = 13.01 min). Under identical conditions, 
cyclohexenone elutes at t = 4.96 min. 
171 : IR (CHCl3); ν[cm−1]: 967 (CH=), 1059, 1076 (C-O), 1163, 1231, 1314, 1348, 1379 (CH3), 1439 
(CH2), 1452 (CH2), 1646 (C=C), 2856 (CH2), 2885 (CH3), 2938 (CH2), 3467, 
3603 (OH); 
1H NMR (400 MHz, CDCl3) δ 5.80 (ddd, J = 10.0, 4.5, 3.1 Hz, 1H, CH-3), 5.62 
(br d, J = 10.0 Hz, 1H, CH-2), 5.47-5.33 (m, 2H, CH-9, CH-10), 2.12-2.04 (m, 2H, CH2-8), 2.09-1.98 
(m, 1H, CH-4a), 1.98-1.88 (m, 1H, CH-4b), 1.80-1.65 (m, 7H, CH2-5, CH2-6, CH3-11), 1.65-1.55 (m, 
2H, CH2-7).  
13C NMR (101 MHz, CDCl3) δ 132.58 (CH, C-2), 132.57 (CH, C-2)*, 131.4 (CH, C-9), 130.6 (CH, C-
9)*, 129.80 (CH, C-3)*, 129.78 (CH, C-3), 124.8 (CH, C-10), 123.9 (CH, C-10)*, 69.7 (C, C-1), 42.0 
(CH2, C-7), 41.9 (CH2, C-7)*, 35.49 (CH2, C-6), 35.45 (CH2, C-6)*, 26.7 (CH2, C-8), 25.22 (2 × CH2, 
C-4, C-4*), 21.17 (CH2, C-8)*, 19.0 (2 × CH2, C-5, C-5*), 17.9 (CH3, C-11), 14.2 (CH3, C-11)*. 
Detectable signals of minor Z-isomer are denoted by an *. 
MS (ESI+) m/z, (%): 189 (11, [M+Na]+), 355 (100, [2M+Na]+); 
Anal. Calcd for C11H18O: C, 79.46; H, 10.91; Found: C, 79.14; H, 10.95;  
GC (Temperature program: 60 °C for 2 min, followed by linear gradient 10 °C·min−1 for 14 min) 
showed a single peak at t = 10.7.  
 
ent-17-Methylene-18-nor-13,17-secoandrost-4-ene-3,12-dione (ent-175) and ent-17-methylene-18-
nor-13,17-seco-14β-androst-4-ene-3,12-dione (ent-176) 
Anhydrous copper(II) chloride (2.5 mg, 18.2 µmol) and lithium chloride 
(1.5 mg, 36.4 µmol) were flame-dried under vacuum in Schlenk flask with 
stirring bar. Enone nt-161 (50 mg, 182 µmol) was added as a solution in 
THF (1.5 mL) and the brown homogeneous solution was cooled to −40 °C, 
resulting in a yellow homogeneous solution. But-3-enylmagnesium 
chloride solution (0.48 mL, 237 µmol, 0.49 M in Et2O) was added at −40 °C via syringe pump over 
1 h. The mixture was stirred at −40 °C for 30 min and quenched with saturated aq. NH4Cl (0.5 mL), 
followed by saturated aq. NaHCO3 (2 mL) and extracted with hexane (3 × 2 mL). The combined 
organic layers were dried with MgSO4 and the solvents were evaporated in vacuo. The residue was 
redissolved in acetone (1 mL) and 5 drops of 1 M HCl were added. After 5 min, the reaction mixture 
was quenched with saturated aq. NaHCO3 (2 mL), extracted with hexane (3 × 2 mL) and the combined 
organic layers were dried with MgSO4 and evaporated in vacuo. The residue was purified by 
chromatography on silica gel (3 g) in 40% EtOAc/hexanes to afford 41.9 mg (80%) of a 4.5:1 mixture 
of inseparable diastereomers ent-175 and ent-176 as a colorless oil. 
[α]D20 −70.2 (c 0.225, CHCl3); 
IR (CHCl3); ν[cm-1]: 918, 995 (=CH), 1238, 1356 (CH2), 1380 (CH3), 1435, 1450 (CH2), 1620 (C=C), 
1642 (C=CH2) 1668 (C=O conjug.), 1709 (C=O), 2868, 2921 (CH3), 2946 (CH2), 2971, 3013 (=CH), 
3080 (=CH2). 
1H NMR (600 MHz, C6D6:CDCl3 1:1) δ 5.69 (ddt, J = 17.0, 10.4, 6.6 Hz, 1H, CH-17), 5.68 (br d, J =
1.9 Hz, 1H, CH-4), 5.00 (br d, J = 17.0 Hz, 1H, CH-20Z), 4.96 (br d, J = 10.4 Hz, 1H, CH-20E), 2.31 
(ddd, J = 13.6, 4.1, 2.2 Hz, 1H, CH-13α), 2.17 (ddd, J = 13.5, 4.9, 2.2 Hz, 1H, CH-11α), 2.16 (m, 2H, 




























6α), 1.97 (m, 1H, CH-16a), 1.88 (dddd, J = 13.2, 5.2, 3.5, 2.8 Hz, 1H, CH-7β), 1.83 (td, J = 13.5, 1.1 
Hz, 1H, CH-11β), 1.80 (m, 1H, CH-16b), 1.77 (ddd, J = 13.6, 12.5, 1.1 Hz, 1H, CH-13β), 1.57 (ddd, J 
= 13.4, 5.0, 3.4 Hz, 1H, CH-1β), 1.52 (m, 1H, CH-15a), 1.34 (br td, J = 13.7, 13.4, 5.6 Hz, 1H, CH-
1α), 1.23 (m, 1H, CH-8), 1.17 (m, 1H, CH-14), 1.11 (m, 1H, CH-15b), 1.09 (m, 1H, CH-9), 0.83 (br s, 
3H, CH3-19), 0.70 (dddd, J = 13.6, 13.2, 11.5, 4.7 Hz, 1H, CH-7α). 
13C NMR (150.9 MHz, C6D6:CDCl3 1:1) δ 210.4 (C, C-12)*, 209.9 (C, C-12), 198.5 (C, C-3)*, 198.4 
(C, C-3), 168.3 (C, C-5), 168.1 (C, C-5)*, 138.2 (CH, C-17), 138.1 (CH, C-17)*, 124.6 (CH, C-4)*, 
124.4 (CH, C-4), 115.4 (CH2, C-20)*, 115.2 (CH2, C-20), 52.5 (CH, C-9), 47.3 (CH, C-9)*, 45.7 (CH2, 
C-13), 45.2 (CH2, C-13)*, 42.3 (CH, C-14), 40.9 (CH2, C-11), 40.7 (CH2, C-11)*, 39.8 (2 × CH, C-
14*, C-8), 39.2 (CH, C-8)*, 38.7 (2 × C, C-10, C-10*), 35.2 (2 × CH2, C-1, C-1*), 33.84 (CH2, C-2), 
33.82 (CH2, C-2)*, 32.6 (CH2, C-16*), 32.4 (CH2, C-15), 32.2 (CH2, C-6), 31.7 (CH2, C-6)*, 30.4 
(CH2, C-7), 30.1 (CH2, C-16), 30.0 (CH2, C-15)*, 26.1 (CH2, C-7)*, 17.4 (CH3, C-19)*, 17.1 (CH3, C-
19). Signals of minor 14β-isomer are denoted with an *. 
MS (CI+) m/z, (%): 287 (100, [M+H]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C19H27O2 287.2011; Found 287.2012;  
 
Tandem copper-catalyzed conjugate addition – oxygenation 
Variant A: 
Anhydrous copper(II) chloride (7.4 mg, 54.7 µmol) and lithium chloride (4.6 mg, 109 µmol) were 
flame-dried under vacuum in a Schlenk flask with a stirring bar. Enone 161 (150 mg, 547 µmol) was 
added as a solution in THF (6 mL) and the brown homogeneous solution was cooled to −40 °C, 
resulting in a yellow homogeneous solution. Pent-3-enylmagnesium chloride solution (168) 
(0.925 mL, 712 µmol, 0.77 M in THF) was added at −40 °C via syringe pump over 1 h. During the 
addition the color changed through red to yellow. The mixture was stirred for 30 min and 
diisopropylamine (38.5 µL, 275 µmol) was added. 2,2,6,6-Tetramethyl-1-oxopiperidinium 
tetrafluoroborate (180) (160 mg, 657 µmol) was added portionwise at −40 °C during 3 min with 
vigorous stirring, until the solution attained an orange-brown color. The reaction mixture was warmed 
to rt, turning the color to green, and the reaction was quenched with few drops of saturated aq. NH4Cl. 
The suspension was diluted with Et2O (20 mL), passed through a plug of silica gel (3 cm), washed 
with Et2O (20 mL) and evaporated. The residue was purified by chromatography on silica gel (10 g) in 
10% EtOAc/hexanes + 0.5% Et3N to afford 214 mg (78%) of trans-alkoxyamines 184a and 184b in 
4.5:1 ratio, followed by 37.0 mg (13%) of inseparable cis-alkoxyamines 185, cyclized 186 and 187 in 
6:5:2 ratio, and finally 9.4 mg (5%) of 188. Analytically pure 184a was obtained by crystallization 
from hexane as a 9:2 mixture of ∆17(20)-E and ∆17(20)-Z isomers. 
 
Variant B: Transmetallation to Lithium enolate 
Anhydrous copper(II) chloride (7.4 mg, 54.7 µmol) and lithium chloride (4.6 mg, 109 µmol) were 
flame-dried under vacuum in Schlenk flask with stirring bar. Enone 161 (150 mg, 547 µmol) was 
added as a solution in THF (6 mL) and the brown homogeneous solution was cooled to −40 °C, 
resulting in a yellow homogeneous solution. Pent-3-enylmagnesium bromide solution (165) (1.8 mL, 
657 µmol, 0.37 M in THF) was added at −40 °C via syringe pump over 1 h. During the addition the 
color changed through red to yellow. The mixture was stirred for 30 min, cooled to −78 °C and 
TMSCl (104 µL, 0.82 mmol) was added dropwise, followed by anhydrous Et3N (114 µL, 0.82 mmol). 
The reaction mixture was warmed to rt, stirred for 30 min and diluted with hexane (5 mL). The content 
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of the reaction flask was poured onto a 1:1 mixture of ice and saturated aq. NaHCO3 (40 mL in total) 
and extracted with hexane (3 × 10 mL). The combined organic extracts were washed with brine, dried 
over MgSO4 and evaporated in vacuo to afford 227 mg (99%) of crude silyl enol ether, which was 
dissolved in anhydrous DME at rt. MeLi (0.41 mL, 656 µmol, 1.60 M in Et2O) was added dropwise 
and the mixture was stirred for 15 min, followed byaddition of diisopropylamine (38 µL) and 
ferrocene (5 mg, 27.3 µmol). The mixture was cooled in an ice bath and 180 (146 mg, 601 µmol) was 
added slowly over 1 h. After another 1 h of stirring at 0 °C, the reaction was quenched with few drops 
of saturated aq. NH4Cl. The suspension was diluted with Et2O (20 mL), passed through a plug of silica 
gel (3 cm), washed with Et2O (20 mL) and evaporated. The residue was purified by chromatography 
on silica gel (10 g) in 10% EtOAc/hexanes + 0.5% Et3N o afford 133 mg (49%) of trans-
alkoxyamines 184a and 184b in 4.5:1 ratio, followed by 70.6 mg (26%) of inseparable cis-
alkoxyamines 185 and cyclized 186 in 18:8 ratio, and finally 18.2 mg (10%) of 188. All corresponding 
∆17(20)-E and ∆17(20)-Z isomers were in 3:1 ratio according to 1H NMR spectra. 
 
Variant C: With dppe ligand 
Anhydrous copper(II) chloride (139 mg, 1.03 mmol) and lithium chloride (87.6 mg, 2.06 mmol) were 
flame-dried under vacuum in 250 mL Schlenk flask with stirring bar. Bis(diphenylphosphino)ethane 
(411 mg, 1.03 mmol) was added and the catalyst was dissolved in THF (105 mL). Enone 161 (2.84 g, 
10.3 mmol) was added neat, dissolved at rt and the nearly colorless homogeneous solution was cooled 
to −40 °C. Pent-3-enylmagnesium chloride solution (168) (14.8 mL, 12.39 mmol, 0.835 M in THF) 
diluted with THF (15 mL) was added at −40 °C via syringe pump over 1 h. During the addition the 
color changed to yellow. The mixture was stirred for 30 min, diisopropylamine (0.723 mL, 
5.16 mmol) was added and after 15 min of stirring at −40 °C, the reaction mixture was cooled to 
−60 °C. Solid 180 (3.76 g, 15.5 mmol) was added in four portions during 5 min at −60 °C, turning the 
mixture to grayish green color, and the mixture was stirred for 2 h after which it was warmed to 0 °C. 
The reaction was poured into a mixture of saturated q. NH4Cl (50 mL) and saturated aq. NaHCO3 
(250 mL) and extracted with EtOAc (3 × 75 mL). The combined organic layers were washed with 
brine, dried over Na2SO4 and evaporated in vacuo. The residue was purified by chromatography on 
silica gel (150 g) in 10% EtOAc/hexanes + 0.5% Et3N to afford 4.32 g (83%) of trans-alkoxyamines 
184a and 184b in 6.2:1 ratio as determined from 1H NMR spectrum, followed by 559 mg (10%) of 
inseparable cis-alkoxyamines 185 and cyclized 186 in 1:1 ratio, and finally 123 mg (5%) of 188. All 
corresponding ∆17(20)-E and ∆17(20)-Z isomers were in 2:3 ratio according to 1H NMR spectra. 
 
3-(Ethylenedioxy)-13α-(2,2,6,6-tetramethylpiperidin-1-yloxy)-18-nor-13,17-secopregna-4,17(20)-
dien-12-one (nat-184a) and ent-3-(ethylenedioxy)-13α-(2,2,6,6-tetramethylpiperidin-1-yloxy)-18-
nor-13,17-secopregna-4,17(20)-dien-12-one (nt-184a) 
[α]D20 +89.6 (c 0.260, CHCl3) for nat-184a; Mp 144-147 °C; 
[α]D20 −101.5 (c 0.261, CHCl3) for ent-184a; Mp 141-143°C; 
IR (CHCl3); ν[cm-1]: 947, 1092, 1133, 1162 (COCOC), 1364, 1376, 
1381 (CH3), 1662 (C=C), 1711 (C=O), 2856, 2886 (CH3), 2936 (CH2), 
2975 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.47-5.29 (m, 2H, CH-17, CH-20), 5.28 
(s, 1H, CH-4), 4.06-3.85 (m, 4H, OCH2CH2O), 3.79 (d, J = 1.7 Hz, 1H, 






















12.9, 12.2, 5.3 Hz, 1H, CH-9), 2.23 (tdd, J = 13.8, 4.7, 1.8 Hz, 1H, CH-6a), 2.11 (ddd, J = 14.1, 4.1, 
2.4 Hz, 1H, CH-6b), 2.08-1.98 (m, 1H, CH-16a), 2.02-1.92 (m, 1H, CH-16b), 2.00-1.90 (m, 1H, CH-
7a), 1.96 (dd, J = 18.5, 12.9 Hz, 1H, CH-11b), 1.95-1.85 (m, 1H, CH-14), 1.82-1.79 (m, 2H, CH2-2), 
1.71-1.61 (m, 1H, CH-1a), 1.62 (dd, J = 5.9, 1.1 Hz, 3H, CH3-21), 1.66-1.56 (m, 1H, CH-1b), 1.60-
1.56 (m, 3H, CH3-21)*, 1.50-1.36 (m, 4H, CH2-3’, CH2-5’), 1.49-1.40 (m, 1H, CH-4’a), 1.41-1.26 (m, 
1H, CH-7b), 1.37-1.26 (m, 1H, CH-4’b), 1.33-1.18 (m, 2H, CH2-15), 1.26-1.14 (m, 1H, CH-8), 1.14 
(br s, 3H, CH3-7’), 1.08 (br s, 3H, CH3-10’), 1.07 (br s, 3H, CH3-8’), 0.982 (s, 3H, CH3-19)*, 0.977 (s, 
3H, CH3-19), 0.94 (br s, 3H, CH3-9’).  
13C NMR (101 MHz, CDCl3) δ 211.6 (C, C-12), 149.9 (C, C-5), 130.5 (CH, C-20), 129.7 (CH, C-20)*, 
125.5 (CH, C-17), 124.6 (CH, C-17)*, 120.5 (CH, C-4), 106.0 (C, C-3), 91.5 (CH, C-13), 64.6 (CH2, 
OCH2CH2O), 64.3 (CH2, OCH2CH2O), 60.3 (C, C-2’), 59.1 (C, C-6’), 46.1 (CH, C-14)*, 45.9 (CH, C-
14), 45.2 (CH, C-9), 40.0 (2 × CH2, C-3’, C-5’), 39.1 (CH, C-8), 37.9 (CH2, C-11), 37.4 (C, C-10), 
35.7 (CH2, C-7), 34.5 (CH2, C-1/C-15), 34.4 (CH2, C-1/C-15), 34.2 (CH3, C-7’/C-9’), 33.7 (CH3, C-
7’/C-9’), 32.3 (CH2, C-6), 30.2 (CH2, C-16), 29.8 (CH2, C-2), 24.6 (CH2, C-16)*, 20.9 (CH3, C-8’/C-
10’), 20.1 (CH3, C-8’/C-10’), 17.9 (CH3, C-21), 17.5 (2 × CH3, C-19, C-19*), 17.1 (CH2, C-4’), 12.9 
(CH3, C-21)*; Signals of minor Z-isomer are denoted with an *. 
MS (ESI+) m/z, (%): 500 (100, [M+H]+), 522 (6, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C31H50NO4 500.3734; Found 500.3727;  
Anal. Calcd for C31H49NO4: C, 74.51; H, 9.88; N, 2.80; Found: C, 74.41; H, 9.86; N, 2.75; for nat- 
184a; 
Anal. Calcd for C31H49NO4: C, 74.51; H, 9.88; N, 2.80; Found: C, 74.74; H, 10.05; N, 2.69; for ent- 
184a; 
X-ray data are available in Appendix C.  
 
ent-3-(Ethylenedioxy)-13β-(2,2,6,6-tetramethylpiperidin-1-yloxy)-18-nor-13,17-secopregna-
4,17(20)-dien-12-one (ent-185a) and ent-13β-bromo-3-(ethylenedioxy)-18-nor-13,17-secopregna-
4,17(20)-dien-12-one (nat-187a) 
Isolated from combined chromatographic fractions of cyclized 186 and 185, 187 from the tandem 
conjugate addition-oxygenation experiments with pentenylmagnesium bromide 165. Flash 
chromatography in 10% MTBE/CH2Cl2 afforded 35.2 mg of 187, followed by 78.8 mg of 185 and 
90.0 mg of 186.  
1H NMR (600 MHz, C6D6) δ 5.51 (m, 2H, CH-17, CH-20), 5.52 (br s, 
1H, CH-4), 4.84 (br d, J = 5.3 Hz, 1H, CH-13), 3.77-3.60 (m, 4H, 
OCH2CH2O), 2.32 (m, 1H, CH-11a), 2.17 (m, 1H, CH-2a), 2.11 (m, 1H, 
CH-6a), 2.08 (m, 1H, CH-2b), 2.06 (m, 1H, CH-8), 1.98 (m, 1H, CH-
6b), 1.90 (m, 2H, CH-1a, CH-16a), 1.88 (m, 1H, CH-14), 1.85 (m, 1H, 
CH-9), 1.83 (m, 2H, CH-1b, CH-16b), 1.74 (m, 1H, CH-7a), 1.68 (m, 
3H, CH3-21), 1.63 (m, 1H, CH-15a), 1.60 (m, 1H, CH-11b), 1.47 (m, 
4H, CH2-3’, CH2-5’), 1.43 (br s, 13H, CH3-7’, CH3-8’, CH3-9’, CH3-10’, CH-4‘a), 1.36 (m, 2H, CH-
7b, CH-15b), 1.15 (m, 1H, CH-4’b), 0.69 (s, 3H, CH3-19); 
13C NMR (150.9 MHz, C6D6) δ 208.2 (C, C-12), 147.3 (C, C-5), 131.0 (CH, C-20), 124.9 (CH, C-17), 
121.7 (CH, C-4), 105.7 (C, C-3), 88.2 (CH, C-13), 64.2 (CH2, OCH2CH2O), 63.7 (CH2, OCH2CH2O), 
60.4 (C, C-2’), 58.7 (C, C-6’), 40.0 (2 × CH2, C-3’, C-5’), 38.6 (CH2, C-11), 37.1 (C, C-10), 36.5 (CH, 

















C-8), 30.2 (CH2, C-2), 29.9 (CH + 2 × CH2, C-1, C-16, C-9), 20.6 (CH3, C-8’/C-10’), 20.5 (CH3, C-
8’/C-10’), 17.6 (CH3, C-21), 17.0 (CH2, C-4’), 16.2 (CH3, C-19);  
MS (ESI+) m/z, (%): 500 (100, [M+H]+), 522 (23, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C31H50NO4 500.3734; Found 500.3733;  
 
ent-187a: Colorless oil, 
1H NMR (400 MHz, C6D6) δ 5.53-5.37 (m, 1H, CH-20)*, 5.46-5.37 
(m, 1H, CH-17)*, 5.41-5.23 (m, 1H, CH-20), 5.39 (br s, 2H, CH-4, 
CH-4*), 5.36-5.18 (m, 1H, CH-17), 4.34 (dd, J = 2.8, 1.3 Hz, 1H, CH-
13)*, 4.30 (dd, J = 2.8, 1.3 Hz, 1H, CH-13), 3.65-3.47 (m, 8H, 
OCH2CH2O, OCH2CH2O*), 2.85 (t, J = 13.8 Hz, 1H, CH-11a), 2.17 
(ddd, J = 13.8, 3.8, 1.4 Hz, 1H, CH-11b), 1.99-1.85 (m, 1H, CH-16a), 
1.96-1.79 (m, 2H, CH2-6), 1.82-1.66 (m, 2H, CH2-2), 1.71-1.55 (m, 1H, CH-8), 1.68-1.55 (m, 1H, CH-
16b), 1.64-1.49 (m, 1H, CH-7a), 1.59 (br d, J = 6.0 Hz, 3H, CH3-21), 1.57-1.42 (m, 1H, CH-1a), 1.55 
(br d, J = 6.8 Hz, 3H, CH3-21)*, 1.49-1.37 (m, 1H, CH-15a), 1.37-1.23 (m, 1H, CH-1b), 1.35-1.21 (m, 
1H, CH-15b), 1.05-0.91 (m, 1H, CH-9), 0.90-0.78 (m, 1H, CH-14), 0.71 (s, 6H, CH3-19, CH3-19*), 
0.48 (qd, J = 12.5, 5.3 Hz, 1H, CH-7b). 
13C NMR (101 MHz, C6D6) δ 203.1 (C, C-12), 147.7 (C, C-5), 130.5 (CH, C-17/C-20), 129.5 (CH, C-
17/C-20)*, 125.9 (CH, C-17/C-20), 125.0 (CH, C-17/C-20)*, 122.12 (CH, C-4)*, 122.11 (CH, C-4), 
106.0 (C, C-3), 64.7 (CH2, OCH2CH2O), 64.2 (CH2, OCH2CH2O), 57.88 (CH, C-13)*, 57.86 (CH, C-
13), 52.46 (CH, C-9)*, 52.42 (CH, C-9), 45.8 (CH, C-14)*, 45.5 (CH, C-14), 37.8 (C, C-10), 35.60 
(CH, C-8), 35.59 (CH, C-8)*, 35.4 (CH2, C-11), 34.48 (CH2, C-1)*, 34.45 (CH2, C-1), 31.6 (CH2, C-
6), 30.4 (CH2, C-7), 30.3 (CH2, C-2), 29.7 (CH2, C-15), 29.6 (CH2, C-15)*, 29.2 (CH2, C-16), 23.6 
(CH2, C-16)*, 18.1 (CH3, C-21), 17.2 (CH3, C-19, C-19*), 12.6 (CH3, C-21)*. Signals of minor Z-
isomer are denoted with an *. 
MS (ESI+) m/z, (%): 343 (3, [M−HBr+H]+), 365 (12, [M−HBr+Na]+), 423/425 (88, [M+H]+), 445/447 
(100, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C22H32




 trans-Alkoxyamine ent-184 (325 mg, 650 µmol, mixture of ent-
184a/ent-184b isomers 9:2) and a crystal of TEMPO (ca. 0.1 mg) was 
dissolved in dry tBuOH (5 mL) with heating and triethylamine (9 µL, 
65 µmol) was added to the reaction mixture. The solution was degassed 
by purging with nitrogen at 30 °C for 30 min. The reaction mixture was 
heated to 100 °C in a closed vessel in a microwave reactor for 2 h. The 
solution was concentrated in vacuo. Flash chromatography of the residue 
on silica gel (10 g) in 10% EtOAc/hexanes + 0.5% Et3N afforded 51.6 mg (16%) of ent-184b as a 
reddish foam, followed by 273 mg (84%) of the mixture of cyclized isomers ent-186A,a as a white 
foam.  
[α]D20 −104.1 (c 0.243, CHCl3); 
IR (CHCl3); ν[cm-1]: 946, 1012, 1091 (ketal), 1133, 1156 (COCOC), 1363, 1376, 1381 (CH3), 1662 



























1H NMR (400 MHz, CDCl3) δ 5.47-5.33 (m, 2H, CH-20, CH-20*), 5.28 (s, 2H, CH-4, CH-4*), 5.33-
5.32 (m, 2H, CH-17, CH-17*), 4.07-3.83 (m, 8H, OCH2 2O, OCH2CH2O*), 3.93-3.83 (m, 2H, CH-
13, CH-13*), 2.77 (t, J = 12.4 Hz, 1H, CH-11a), 2.42-2.29 (m, 1H, CH-8), 2.37-2.26 (m, 1H, CH-6a), 
2.32-2.21 (m, 1H, CH-14), 2.22-2.12 (m, 1H, CH-11b), 2.18-2.07 (m, 1H, CH-6b), 2.08-1.99 (m, 1H, 
CH-16a), 1.87-1.78 (m, 1H, CH-16b), 1.78-1.74 (m, 2H CH2-2), 1.69-1.59 (m, 1H, CH-1a), 1.62-1.52 
(m, 1H, CH-7a), 1.60 (dq, J = 6.0, 1.1 Hz, 3H, CH3-21), 1.60-1.55 (m, 3H, CH3-21)*, 1.59-1.49 (m, 
1H, CH-1b), 1.57-1.43 (m, 1H, CH-9), 1.50-1.40 (m, 5H, CH2-3‘, CH2-5‘, CH-4‘a), 1.42-1.31 (m, 1H, 
CH-7b), 1.39-1.28 (m, 1H, CH-15a), 1.38-1.25 (m, 1H, CH-4‘b), 1.17-1.08 (m, 9H, CH3-7‘, CH3-8‘, 
CH3-9‘), 1.12 (s, 3H, CH3-19), 0.96 (br s, 3H, CH3-10‘), 0.91-0.75 (m, 1H, CH-15b). 
13C NMR (101 MHz, CDCl3) δ 212.7 (C, C-12), 149.3 (C, C-5), 130.4 (CH, C-17), 129.6 (CH, C-17)*, 
125.5 (CH, C-20), 124.5 (CH, C-20)*, 120.7 (CH, C-4), 105.7 (C, C-3), 90.7 (CH, C-13), 64.5 (CH2, 
OCH2CH2O), 64.2 (CH2, OCH2CH2O), 60.2 (C, C-2‘, C-2‘*), 59.2 (C, C-6‘, C-6‘*), 48.1 (CH, C-9), 
45.8 (CH, C-14)*, 45.5 (CH, C-14), 40.0 (CH2, C-3‘, C-5‘), 38.3 (CH2, C-11), 37.9 (C, C-10), 34.2 
(CH2 + CH3, C-1, C-7‘, C-9‘, C-7‘*, C-9‘*), 33.7 (CH, C-8), 31.9 (CH2, C-6), 30.4 (CH2, C-16), 30.0 
(CH2, C-7), 29.6 (CH2, C-2), 24.8 (CH2, C-16)*, 23.76 (CH2, C-15), 23.76 (CH2, C-15)*, 20.1 (2 × 
CH3, C-8‘, C-10‘), 17.71 (CH3, C-19/C-21), 17.69 (CH3, C-19/C-21), 16.9 (CH2, C-4‘), 12.7 (CH3, C-
21)*. 
MS (ESI+) m/z, (%): 500 (100, [M+H]+), 522 (44, [M+Na]+), 1022 (7, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C31H50NO4 500.3734; Found 500.3735; [M+Na]
+ Calcd for 
C31H49NNaO4 522.3554; Found 522.3554;  






(325 mg, 650 µmol, mixture of 
Z/E isomers 2:9) and 1 crystal 
of TEMPO (ca. 0.1 mg) was 
dissolved in dry tBuOH 
(5 mL) at 40 °C and triethylamine (9 µL, 65 µmol) was added to the reaction mixture. The solution 
was degassed by purging with nitrogen at 30 °C for 30 min. The reaction mixture was heated to 
100 °C in a closed vessel in a microwave reactor for 30 min. The solution was concentrated in vacuo 
to afford 325 mg (99%) of an inseparable mixture of cyclized isomers ent-186A,a as a white foam.  
The mixture composed of 17α20R : 17α20S : 17β20ξ: 17β20ξ isomers in 5:5:2:1 ratio. NMR signals of 
the respective 17α-isomers are denoted with A, a, while 17β-isomers are marked with B, b. 
HPLC (SUPELCOSIL™ LC-Si Column, 5 µm particle size, L × I.D. 15 cm × 4.6 mm, t = 25 °C,
isocratic hexane/CH2Cl2/Et3N = 60:40:0.2 during 20 min, followed by gradient to hexane/CH2Cl2/Et3N 
= 50:50:0.25 during 10 min, 1.0 mL·min-1; detection at Light Scattering Detector) showed 4 peaks in 
9:40:34:17 ratio (t1 = 14.7 min, t2 = 17.5 min, t3 = 19.5 min, t4 = 25.2 min) of the crude product. Under 
identical conditions, starting material ent-184a elutes at trans = 4.5 min. 
IR (CHCl3); ν[cm-1]: 946, 1089 (ketal), 1133, 1174 (COCOC), 1367, 1375 (CH3), 1440, 1451 (CH3), 















1H NMR (400 MHz, C6D6) δ 5.45 (s, 4H, CH-4)AaBb, 4.92 (quint, J = 6.5 Hz, 1H, CH-20)B, 4.71 (dq, J 
= 10.1, 6.2 Hz, 1H, CH-20)b, 4.17 (qd, J = 6.4, 4.0 Hz, 1H, CH-20)A, 4.01 (quint, J = 6.3 Hz, 1H, CH-
20)a, 3.69-3.48 (m, 16H, OCH2CH2O)
AaBb, 2.93 (t, J = 8.2 Hz, 1H, CH-13)b, 2.73 (t, J = 8.8 Hz, 1H, 
CH-13)A, 2.55-2.47 (m, 1H, CH-17)a, 2.52-2.44 (m, 2H, CH-13)aB, 2.39-2.31 (m, 1H, CH-17)A, 2.30-
1.10 (m, aliphatic region), 1.93-1.83 (m, 1H, CH-17)b, 1.87-1.78 (m, 1H, CH-17)B, 1.35 (d, J = 6.5 Hz, 
3H, CH3-21)
B, 1.32 (d, J = 6.2 Hz, 3H, CH3-21)
b, 1.31 (d, J = 6.5 Hz, 3H, CH3-21)
A, 1.28 (d, J = 6.3 
Hz, 3H, CH3-21)
a, 0.76 (s, 3H, CH3-19)
b, 0.742 (s, 3H, CH3-19)
 A/a, 0.739 (s, 3H, CH3-19)
B, 0.73 (s, 
3H, CH3-19)
A/a. 
13C NMR (101 MHz, C6D6) δ 211.81 (C, C-12)A/a, 211.53 (C, C-12)B, 211.27 (C, C-12)b, 211.22 (C, C-
12)A/a, 148.57 (C, C-5)B, 148.54 (C, C-5)b, 148.39 (C, C-5)A/a, 148.33 (C, C-5)A/a, 122.17 (CH, C-4)A/a, 
122.12 (CH, C-4)A/a, 121.91 (CH, C-4)B, 121.87 (CH, C-4) b, 106.33 (C, C-3)Bb, 106.24 (C, C-3)Aa, 
80.88 (CH, C-20)a, 78.55 (CH, C-20)b, 78.31 (CH, C-20)A, 77.02 (CH, C-20)B, 64.65 (CH2, 
OCH2CH2O)
AaBb, 64.28 (CH2, OCH2CH2O)
b, 64.25 (CH2, OCH2CH2O)
A/a, 64.24 (CH2, 
OCH2CH2O)
A/a, 61.14 (C, C-2’/C-6’)A/a, 60.94 (C, C-2’/C-6’)B/b, 60.81 (C, C-2’/C-6’)A/a, 60.63 (C, C-
2’/C-6’)B/b, 59.19 (C, C-2’/C-6’)A/a, 59.17 (C, C-2’/C-6’)A/a, 58.81 (C, C-2’/C-6’)Bb, 56.47 (CH, C-13)a, 
54.47 (CH, C-13)A, 52.25 (CH, C-9)A/a, 51.83 (CH, C-13)b, 51.62 (CH, C-13)B, 51.50 (CH, C-9)A/a, 
50.56 (CH, C-17)B, 50.11 (CH, C-14)A/a, 50.03 (CH)b, 49.90 (CH)b, 49.66 (CH, C-14)A/a, 49.12 (CH)b, 
48.72 (CH, C-9)B, 48.09 (CH, C-17)A, 47.87 (CH, C-14)B, 47.45 (CH, C-17)a, 41.87 (CH2, C-11)
b, 
41.48 (CH2, C-11)
B, 41.14 (CH2, C-3’/C-5’), 41.04 (CH2, C-3’/C-5’), 40.99 (CH2, C-3’/C-5’), 40.86 
(CH2, C-3’/C-5’), 40.75 (CH2, C-3’/C-5’), 40.65 (CH2, C-3’/C-5’), 40.54 (CH2, C-3’/C-5’), 39.78 
(CH, C-8)B, 39.11 (CH, C-8)b, 38.68 (CH2, C-11)
A/a, 38.63 (CH2, C-11)
A/a, 38.14 (CH, C-8)A/a, 37.92 
(C, C-10)A/a, 37.80 (C, C-10)A/a, 37.72 (CH, C-8)A/a, 34.91 (2 × CH3, C-7‘, C-9‘)
Bb, 34.81 (CH2)
B, 
34.69 (2 × CH3, C-7‘, C-9‘)
Aa, 34.58 (CH2)





A/a, 33.02 (CH2, C-7)
A/a, 31.97 (CH2, C-6)















A/a, 21.19 (2 × CH3, C-8‘, C-10‘)
b, 21.13 (2 × 
CH3, C-8‘, C-10‘)
A/a, 20.99 (2 × CH3, C-8‘, C-10‘)
A/a, 20.87 (2 × CH3, C-8‘, C-10‘)
B, 19.66 (CH3, C-
21)B, 19.06 (CH3, C-21)
b, 18.42 (CH3, C-21)
A/a, 18.16 (CH3, C-19)
b, 18.01 (CH3, C-19)
B, 17.82 (CH2, 
C-4’)b/B, 17.78 (CH2, C-4’)
b/B, 17.77 (CH2, C-4’)
A/a, 17.76 (CH2, C-4’)
A/a, 17.70 (CH3, C-19)
A/a, 17.62 
(CH3, C-19)
A/a, 17.18 (CH3, C-21)
A/a. 
MS (ESI+) m/z, (%): 500 (100, [M+H]+), 522 (3, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C31H50NO4 500.3734; Found 500.3732; 




trans-Alkoxyamines ent-184b (61.5 mg, 123 µmol) and 1 crystal of TEMPO (ca. 0.1 mg) was 
dissolved in dry tBuOH (3 mL) and triethylamine (3 µL, 21.5 µmol) was dded. The solution was 


























closed vessel in a microwave reactor for 4 h. The solution was concentrated in vacuo to afford 61 mg 
(99%) of an inseparable mixture of cyclized isomers ent-186B,b as a white foam.  
The mixture composed of 17β20R : 17β20S : 17α20R : 17α20S isomers in 4:4:1:1 ratio. NMR signals 
of the respective 17β-isomers are denoted with A, a, while 17α-isomers are marked with B, b. 
HPLC (SUPELCOSIL™ LC-Si Column, 5 µm particle size, L × I.D. 15 cm × 4.6 mm, t = 25 °C,
isocratic hexane/CH2Cl2/Et3N = 60:40:0.2 during 20 min, followed by gradient to hexane/CH2Cl2/Et3N 
= 50:50:0.25 during 10 min, 1.0 mL·min-1; detection at Light Scattering Detector) showed 3 peaks in 
7:5:88 ratio (t1 = 9.1 min, t2 = 12.1 min, t3 = 14.7 min) of the crude product. Under identical 
conditions, starting material ent-184b elutes at cis = 6.3 min.  
IR (CHCl3); ν[cm-1]: 946, 1089 (ketal), 1133, 1174 (COCOC), 1367, 1375 (CH3), 1440, 1451 (CH3), 
1663 (C=C), 1697 (C=O), 2887 (CH3), 2937 (CH2), 2973 (CH3). 
1H NMR (400 MHz, C6D6) δ 5.43 (s, 4H, CH-4)AaBb, 5.23 (dq, J = 9.4, 6.1 Hz, 1H, CH-20)B, 5.17 (dq, 
J = 9.6, 6.3 Hz, 1H, CH-20)b, 4.06 (quint, J = 6.2 Hz, 1H, CH-20)A, 3.94 (quint, J = 6.1 Hz, 1H, CH-
20)a, 3.67-3.47 (m, 16H, OCH2CH2O)
AaBb, 3.21-3.11 (m, 2H, CH-17)Aa, 2.93 (t, J = 5.5 Hz, 1H, CH-
13)b, 2.79 (dd, J = 7.8, 2.1 Hz, 1H, CH-13)a, 2.56 (dd, J = 7.1, 2.5 Hz, 1H, CH-13)A, 2.33-2.25 (m, 1H, 
CH-13)B, 2.30-0.80 (m, aliphatic region), 1.74-1.61 (m, 1H, CH-17)B, 1.69-1.54 (m, 1H, CH-17)b, 1.40 
(d, J = 6.1 Hz, 3H, CH3-21)
B, 1.33 (d, J = 6.3 Hz, 3H, CH3-21)
b, 1.31 (d, J = 6.1 Hz, 3H, CH3-21)
a, 
1.28 (d, J = 6.2 Hz, 3H, CH3-21)
A, 0.76 (s, 3H, CH3-19)
 B/b, 0.734 (s, 3H, CH3-19)
A/a, 0.730 (s, 3H, 
CH3-19)
 B/b, 0.70 (s, 3H, CH3-19)
A/a. 
13C NMR (101 MHz, C6D6) δ 211.35 (C, C-12)B/b, 210.54 (C, C-12)B/b, 209.83 (C, C-12)A/a, 209.80 (C, 
C-12)A/a, 148.00 (C, C-5)A/a, 147.97 (C, C-5)A/a, 147.76 (C, C-5)B/b, 147.70 (C, C-5)B/b, 122.68 (CH, C-
4)B/b, 122.65 (CH, C-4)B/b, 122.47 (CH, C-4)A/a, 122.46 (CH, C-4)A/a, 106.19 (2 × C, C-3)Aa, 106.16 (2 
× C, C-3)Bb, 80.43 (CH, C-20)A, 80.21 (CH, C-20)a, 78.69 (CH, C-20)B, 77.60 (CH, C-20)b, 64.67 
(CH2, OCH2CH2O)
AaBb, 64.23 (CH2, OCH2CH2O)
AaBb, 60.94 (C, C-2’/C-6’)A/a, 60.92 (C, C-2’/C-6’)A/a, 
60.87 (C, C-2’/C-6’)B/b, 60.63 (C, C-2’/C-6’)B/b, 59.20 (C, C-2’/C-6’)A/a, 59.12 (C, C-2’/C-6’)A/a, 58.76 
(C, C-2’/C-6’)B/b, 58.65 (C, C-2’/C-6’)B/b, 56.09 (CH, C-13)A, 55.30 (CH, C-13)B, 53.96 (CH, C-13)a, 
53.80 (CH, C-13)b, 50.02 (CH)B/b, 49.90 (CH)B/b, 49.69 (CH)B/b, 49.47 (CH)B/b, 48.94 (CH)B/b, 48.85 
(CH)B/b, 48.45 (CH, C-14)A/a, 48.14 (CH, C-14)A/a, 47.77 (CH, C-9)A/a, 47.69 (CH, C-9)A/a, 42.61 (CH, 
C-17)A/a, 42.56 (CH, C-17)A/a, 42.30 (CH2, C-11)
B/b, 41.68 (CH2, C-11)
A/a, 41.56 (CH2, C-11)
A/a, 41.03 
(CH2, C-11)
B/b, 41.00 (CH2, C-3‘/C-5‘)
B/b, 40.89 (2 × CH2, C-3‘/C-5‘)
A/a, 40.58 (CH2, C-3‘/C-5‘)
A/a, 
40.48 (CH2, C-3‘/C-5‘)
A/a, 40.37 (CH2, C-3‘/C-5‘)
B/b, 37.90 (C, C-10)B/b, 37.77 (C, C-10)B/b, 37.70 (C, 
C-10)Aa, 37.17 (CH, C-8)B/b, 36.98 (CH, C-8)B/b, 36.93 (2 × CH, C-8)Aa, 35.22 (CH3, C-7‘/C-9‘)
A/a, 
34.94 (CH3, C-7‘/C-9‘)
A/a, 34.86 (CH2, C-1)
B/b, 34.83 (CH2, C-1)
B/b, 34.72 (CH2, C-1)
A/a, 34.71 (CH2, 
C-1)A/a, 34.67 (CH3, C-7‘/C-9‘)
B/b, 34.64 (CH3, C-7‘/C-9‘)
B/b, 34.56 (CH3, C-7‘/C-9‘)




B/b, 30.40 (CH2, C-2)
aA, 27.07 (CH2, C-16)
a, 26.24 
(CH2)
B/b, 26.01 (CH2, C-15)
a, 25.89 (CH2, C-15)





B/b, 21.09 (CH3, C-8‘/C-10‘)
A/a, 21.03 (CH3, C-8‘/C-10‘)
A/a, 20.97 (CH3, C-8‘/C-10‘)
A/a, 
20.89 (CH3, C-8‘/C-10‘)
A/a, 20.77 (CH3, C-8‘/C-10‘)
B/b, 19.82 (CH3, C-21)
B/b, 19.26 (CH3, C-21)
B/b, 
18.47 (CH3, C-21)
A/a, 18.35 (CH3, C-21)
A/a, 17.89 (CH2, C-4’)
B/b, 17.85 (CH2, C-4’)
B/b, 17.74 (CH2, C-
4’)Aa, 17.61 (CH3, C-19)
A/a, 17.59 (CH3, C-19)
A/a, 17.56 (CH3, C-19)
B/b, 17.54 (CH3, C-19)
B/b. 
MS (ESI+) m/z, (%): 500 (100, [M+H]+), 522 (3, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C31H50NO4 500.3734; Found 500.3732; 





cis-Alkoxyamine ent-184b (68 mg, 136 µmol, mixture of E/Z isomers 
3:2) was dissolved in acetone (5 mL) and water (500 µL) and 1 M aq. 
HCl (250 µL, 250 µmol) was added to the reaction mixture. After 
5 min, the reaction was quenched with saturated aq. N HCO3 (25 mL) 
and extracted with Et2O (3 × 10 mL). The combined extracts were dried 
over Na2SO4 and the solution was concentrated in vacuo. Flash 
chromatography of the residue on silica gel (1 g) in 10% EtOAc/hexanes afforded 59 mg (95%) of ent-
192 as a white foam.  
Mixture of ∆17(20)-E and ∆17(20)-Z isomers in 3:2 ratio. NMR signals of minor Z-isomer are denoted 
with an *. 
[α]D20 −119.3 (c 0.609, CHCl3); 
IR (CHCl3); ν[cm-1]: 973 (=C-H), 1011, 1134, 1362, 1376 (CH3), 1454, 1462 (CH2), 1618 (C=C), 
1667 (C=O), 1715 (C=O), 2871 (CH3), 2935 (CH2), 2974 (CH3). 
1H NMR (600 MHz, d6-DMSO) δ 5.67 (d, J = 1.8 Hz, 2H, CH-4, CH-4*), 5.40 (m, 1H, CH-20), 5.37 
(m, 1H, CH-20)*, 5.30 (m, 1H, CH-17)*, 5.27 (m, 1H, CH-17), 3.795 (dd, J = 3.5, 1.2 Hz, 1H, CH-
13α), 3.76 (dd, J = 3.5, 1.2 Hz, 1H, CH-13α)*, 2.750 (t, J = 12.5 Hz, 1H, CH-11β), 2.745 (t, J = 12.5 
Hz, 1H, CH-11β)*, 2.50 (m, 2H, CH-6β, CH-6β*), 2.40 (tdd, J = 12.4, 4.2, 3.1 Hz, 2H, CH-8β, CH-
8β*), 2.376 (ddd, J = 16.7, 14.5, 5.1 Hz, 2H, CH-2β, CH-2β*), 2.31 (m, 2H, CH-6α, CH-6α*), 2.30 
(dddd, J = 8.7, 6.7, 3.5, 3.1 Hz, 1H, CH-14β), 2.29 (dddd, J = 8.7, 6.7, 3.5, 3.1 Hz, 1H, CH-14β)*, 
2.16 (ddd, J = 16.7, 4.4, 3.3 Hz, 2H, CH-2α, CH-2α*), 2.12 (ddd, J = 12.5, 4.5, 1.2 Hz, 2H, CH-11α, 
CH-11α*), 2.03 (m, 1H, CH-16a), 1.96 (m, 1H, CH-16a)*, 1.92 (ddd, J = 13.4, 5.1, 3.3 Hz, 2H, CH-
1β, CH-1β*), 1.84 (m, 1H, CH-16b), 1.80 (m, 1H, CH-16b)*, 1.65 (m, 2H, CH-7β, CH-7β*), 1.64 
(ddd, J = 14.5, 13.4, 4.4 Hz, 2H, CH-1α, CH-1α*), 1.57 (m, 3H, CH3-21), 1.56 (td, J = 12.5, 4.5 Hz, 
2H, CH-9α, CH-9α*), 1.54 (m, 3H, CH3-21)*, 1.52 (m, 2H, CH-4’a, CH-4’a*), 1.47 (m, 4H, CH-3’a, 
CH-5’a, CH-3’a*, CH-5’a*), 1.365 (m, 6H, CH-7α, CH-3’b, CH-5’b, CH-7α*, CH-3’b*, CH-5’b*), 
1.36 (m, 2H, CH-15a, CH-15a*), 1.27 (m, 2H, CH-4’b, CH-4’b*), 1.205 (s, 3H, CH3-19), 1.203 (s, 
3H, CH3-19)*, 1.14 (s, 12H, CH3-7‘, CH3-9‘, CH3-7‘*, CH3-9‘*), 1.10 (s, 6H, CH3-10‘, CH3-10‘*), 
0.90 (s, 6H, CH3-8‘, CH3-8‘*), 0.76 (m, 2H, CH-15b, CH-15b*).  
13C NMR (150.9 MHz, d6-DMSO) δ 211.42 (C, C-12)*, 211.41 (C, C-12), 198.09 (C, C-3)*, 198.08 
(C, C-3), 168.93 (C, C-5)*, 168.90 (C, C-5), 130.6 (CH, C-17)*, 129.8 (CH, C-17), 125.49 (CH, C-
20), 125.47 (CH, C-20)*, 123.84 (CH, C-4), 123.83 (CH, C-4)*, 90.36 (CH, C-13), 90.34 (CH, C-
13)*, 59.8 (C, C-2‘, C-2‘*), 59.0 (C, C-6‘, C-6‘*), 47.6 (CH, C-9, C-9*), 45.2 (CH, C-14), 44.8 (CH, 
C-14)*, 40.0 (CH2, C-3‘, C-5‘, C-3‘*, C-5‘*), 38.8 (C, C-10, C-10*), 37.7 (CH2, C-11, C-11*), 34.5 
(CH2, C-1, C-1*), 33.7 (CH3, C-8‘, C-8‘*), 33.6 (CH2, C-2, C-2*), 33.3 (CH3, C-7‘, C-7‘*), 33.2 (CH, 
C-8, C-8*), 32.19 (CH2, C-6)*, 32.18 (CH2, C-6), 30.0 (CH2, C-16)*, 29.2 (CH2, C-7)*, 29.1 (CH2, C-
7), 24.4 (CH2, C-16), 23.33 (CH2, C-15), 23.32 (CH2, C-15)*, 20.1 (CH3, C-9‘, C-9‘*), 20.0 (CH3, C-
10‘, C-10‘*), 17.9 (CH3, C-21), 17.0 (CH3, C-19, C-19*), 16.7 (CH2, C-4‘, C-4‘*), 12.8 (CH3, C-21)*. 
MS (ESI+) m/z, (%): 456 (100, [M+H]+), 478 (21, [M+Na]+), 934 (33, [2M+Na]+), 1389 (12, 
[3M+Na]+); 























Stereoselectivity of cyclization – control experiments: 
Deprotection of 14α cyclized alkoxyamines 186A,a 
The cyclization product ent-186A,a (50 mg, 100 µmol) was dissolved in acetone (1 mL) and 5% aq. 
HCl (100 µL) was added to the stirred solution. After 10 min at rt, the reaction mixture was quenched 
with sat. aq. NaHCO3 (10 mL) and the products were extracted into EtOAc (3 × 3 mL). The combined 
organic fraction was dried over Na2SO4 and evaporated in vacuo to afford 45 mg of the crude 
diketone, which was dissolved in CH2Cl2 (2 mL) and cooled to 0 °C. m-CPBA (30 mg, 174 µmol) was 
added to the stirred solution. The reaction was stirred at 0 °C for 30 min and quenched with 15% aq. 
ascorbic acid (10 mL). The biphasic mixture was diluted with hexane (10 mL) and the organic layer 
was separated. The aqueous layer was extracted with EtOAc (2 × 5 mL). The organic extracts were 
washed with saturated aq. NaHCO3 (2 × 15 mL). The combined organic layers were dried over MgSO4 
and evaporated in vacuo to afford 29.1 mg (92%) of a crude 3:1 mixture ent-193 : ent-194. 
 
ent-18-Nor-13α,17α-pregn-4-ene-3,12,20-trione (ent-193) 
Colorless prisms, Mp 90-92 °C. 
IR (ATR); ν[cm-1]: 867 (=C-H), 1151, 1188, 1246, 1272, 1360, 1425 
(CH2), 1625 (C=C), 1676 (enone), 1694 (C=O), 1714 (acetyl), 2857 (CH2), 
2869 (CH3), 2942 (CH2), 2961 (CH3). 
 1H NMR (600 MHz, CDCl3) δ 5.79 (br d, J = 2.1 Hz, 1H, CH-4), 3.37 (m, 
1H, CH-17), 3.18 (dd, J = 11.0, 7.4 Hz, 1H, CH-13), 2.52 (m, 1H, CH-11a), 2.40 (m, 1H, CH-6a), 2.39 
(m, 2H, CH2-2), 2.31 (m, 1H, CH-6b), 2.24 (m, 1H, CH-11b), 2.22 (s, 3H, CH3-21), 2.17 (m, 1H, CH-
14), 2.14 (m, 1H, CH-7a), 2.08 (m, 1H, CH-16a), 2.06 (m, 1H, CH-15a), 1.95 (m, 1H, CH-1a), 1.89 
(m, 1H, CH-9), 1.76 (m, 1H, CH-1b), 1.60 (m, 1H, CH-16b), 1.32 (m, 1H, CH-15b), 1.31 (m, 1H, CH-
8), 1.22 (m, 1H, CH-7b), 1.16 (s, 3H, CH3-19); 
13C NMR (150.9 MHz, CDCl3) δ 212.0 (C, C-20), 209.0 (C, C-12), 198.9 (C, C-3), 168.8 (C, C-5), 
124.2 (CH, C-4), 52.2 (CH, C-17), 52.1 (CH, C-13), 49.0 (CH, C-9), 47.7 (CH, C-14), 38.69 (C, C-
10), 38.68 (CH+CH2, C-8, C-11), 35.1 (CH2, C-1), 33.5 (CH2, C-2), 32.74 (CH2, C-7), 32.70 (CH2, C-
15), 31.9 (CH2, C-6), 29.16 (CH3, C-21), 29.15 (CH2, C-16), 17.7 (CH3, C-19). 
MS (ESI+) m/z, (%): 315 (44, [M+H]+), 337 (100, [M+Na]+), 629 (1, [2M+H]+), 651 (84, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C20H27O3 315.1955; Found 337.1957; [M+Na]
+ Calcd for 
C20H26NaO3 337.1774; Found 337.1774; 
X-ray data are available in Appendix C. 
 
ent-18-Nor-13α-pregn-4-ene-3,12,20-trione (ent-194) 
1H NMR (600 MHz, CDCl3) δ 5.78 (br s, 1H, CH-4), 3.60 (td, J = 7.9, 2.9 
Hz, 1H, CH-17), 2.79 (br dd, J = 11.1, 7.9 Hz, 1H, CH-13), 2.44 (m, 2H, 
CH-6a, CH-11a), 2.39 (m, 3H, CH2-2, CH-11b), 2.34 (m, 1H, CH-6b), 2.17 











































CH-1a), 1.91 (m, 1H, CH-16a), 1.81 (m, 1H, CH-16b), 1.73 (m, 1H, CH-1b), 1.64 (m, 1H, CH-9), 
1.45 (m, 1H, CH-15b), 1.23 (s, 3H, CH3-19); Hydrogen atoms CH2-7 and CH-8 could not be assigned.
 
13C NMR (150.9 MHz, CDCl3) δ 213.4 (C, C-12), 210.0 (C, C-20), 199.0 (C, C-3), 169.8 (C, C-5), 
123.8 (CH, C-4), 56.5 (CH, C-17), 52.05 (CH, C-13), 48.6 (CH, C-9), 44.6 (CH, C-14), 39.4 (CH2, C-
11), 38.6 (C+CH, C-10, C-8), 35.2 (CH2, C-1), 33.6 (CH2, C-2), 32.9 (CH2, C-7), 32.1 (CH2, C-6), 
31.0 (CH2, C-15), 29.1 (CH3, C-21), 28.4 (CH2, C-16), 17.9 (CH3, C-19). 
Data taken from a mixture with ent-193. 
 
Isomerization of 14α cyclised alkoxyamines 186A,a and deprotection 
A suspension of KH (ca. 35% w/v in mineral oil, 60 mg of pure KH; 1.50 mmol) was transferred to a 
pre-dried Schlenk flask and washed with dry pentane (3 × 2 mL). The remaining solvent was 
evaporated in vacuo and the flask was back-filled with nitrogen. A solution of ketone ent-186A,a 
(63 mg, 126 µmol) in THF (7 mL) was added dropwise at rt, which caused immediate foaming of the 
mixture. The suspension was stirred at rt for 2 h, quenched with saturated aq. NH4Cl (15 mL) and the 
products were extracted into EtOAc (3 × 5 mL). The combined organic layers were washed with 
saturated aq. NaHCO3 (15 mL), dried over MgSO4 and evaporated in vacuo. The residue was 
dissolved in acetone (1 mL) and 5% aq. HCl (300 µL) was added to the stirred solution. After 15 min 
at rt, the reaction mixture was diluted with CH2Cl2 (3 mL) and aq. phosphate buffer (pH 7.5, 0.5 M, 
3 mL) and the biphasic mixture was cooled to 0 °C. m-CPBA (33 mg, 189 µmol) was added 
portionwise to the stirred solution. The reaction was stirred at 0 °C for 45 min and was quenched with
10% aq. Na2S2O3 (5 mL). The mixture was extracted with CH2Cl2 (3 × 5 mL), the combined organic 
layers were washed with NaHCO3 (2 × 5 mL), dried over MgSO4 and evaporated in vacuo. The 
residue was purified by column chromatography on silica gel (0.9 g) in 30% EtOAc/hexanes to afford 
34.5 mg (87%) of a 5:2 mixture of ent-193:ent-195. Further chromatography on silica gel (0.9 g) in 
30% MTBE/hexanes afforded 12 mg of an enriched sample of ent-195, which was crystallized from 
Et2O/hexane to furnish 6 mg of pure ent-195. 
 
ent-18-Norpregn-4-ene-3,12,20-trione (ent-195) 
Colorless prisms, Mp 173-175 °C (Et2O/hexane).  
IR (CHCl3); ν[cm-1]: 1176, 1233, 1357, 1377 (CH3), 1619 (C=C), 1669, 1709 (C=O), 2917, 2943 
(CH2), 2970 (CH3). 
1H NMR (600 MHz, CDCl3) δ 5.78 (br d, J = 2.1 Hz, 1H, CH-4), 3.23 (ddd, 
J = 11.2, 10.0, 6.5 Hz, 1H, CH-17), 2.78 (ddd, J = 11.2, 10.0, 1.3 Hz, 1H, 
CH-13), 2.47 (m, 1H, CH-6a), 2.42 (m, 1H, CH-11a), 2.41 (m, 1H, CH-2a), 
2.38 (m, 1H, CH-2b), 2.35 (m, 1H, CH-6b), 2.31 (m, 1H, CH-11b), 2.23 (s, 
3H, CH3-21), 2.06 (m, 1H, CH-7a), 1.99 (m, 2H, CH-16a, CH-15a), 1.94 
(m, 1H, CH-1a), 1.82 (m, 2H, CH-8, CH-16b), 1.72 (m, 1H, CH-1b), 1.50 (m, 1H, CH-9), 1.43 (m, 





































13C NMR (150.9 MHz, CDCl3) δ 209.9 (C, C-20), 208.0 (C, C-12), 198.7 (C, C-3), 168.4 (C, C-5), 
124.7 (CH, C-4), 58.3 (CH, C-13), 54.9 (CH, C-9), 53.0 (CH, C-14), 48.3 (CH, C-17), 41.3 (CH, C-8), 
41.0 (CH2, C-11), 38.9 (C, C-10), 35.4 (CH2, C-1), 33.7 (CH2, C-2), 32.2 (CH2, C-6), 31.1 (CH2, C-7), 
29.9 (CH3, C-21), 29.7 (CH2, C-15), 26.6 (CH2, C-16), 17.1 (CH3, C-19). 
MS (CI+) m/z, (%): 315 (100, [M+H]+), 343 (19, [M+C2H5]
+); 
HRMS (CI+) m/z: [M+H] + Calcd for C20H27O3 315.1955; Found 315.1961; 
X-ray data are available in Appendix C.  
 
ent-3-(Ethylenedioxy)-20ξ-(2,2,6,6-tetramethylpiperidin-1-yloxy)-12-(trimethylsilyloxy)-18-nor-
17ξ-pregna-4,12-diene (ent-196) and ent-3-(Ethylenedioxy)-20ξ-(2,2,6,6-tetramethylpiperidin-1-
yloxy)-12-(trimethylsilyloxy)-18-nor-17ξ,13α-pregna-4,11-diene (ent-197) 
A suspension of KH (ca. 35% w/v in mineral oil, 60 mg of pure KH; 
1.50 mmol) was transferred to a pre-dried Schlenk flask and washed 
with dry pentane (3 × 2 mL). The remaining solvent was evaporated in 
vacuo and the flask was back-filled with nitrogen. A solution of 
ketone ent-186A,a (50 mg, 100 µmol) in THF (3 mL) was added 
dropwise at rt, which caused immediate foaming of the mixture. The 
suspension was stirred at rt for 2 h, neat TMSCl (25 µL, 200 µmol) was added and the solution was 
stirred for 30 min. The reaction mixture was diluted with dry pentane (7 mL) and transferred by a 
syringe to a mixture of saturated aq. NaHCO3 (25 mL) with ice (25 mL). The mixture was 
subsequently extracted with pentane (3 × 10 mL), the combined organic extracts were dried over 
MgSO4, filtered and evaporated in vacuo to afford 62.2 mg (108%) of a 2:1 mixture of ent-196:ent-
197 as a colorless oil, contaminated with hexamethyldisiloxane.  
1H NMR (400 MHz, CDCl3) δ [5.29, 5.26 (br s, CH-4)], [4.75, 4.59, 4.34, 4.27 (m, CH-20)], [4.68, 
4.67 (m, 2H, CH-11)]K, 4.09-3.82 (m, OCH2CH2O), [3.26, 3.19, 2.75, 2.66, 2.58 (m, aliphatic)]
TK, 
2.34-0.79 (m, aliphatic), [0.21, 0.19, 0.18, 0.15, 0.14, 0.11 (SiMe3)]. 
13C NMR (101 MHz, CDCl3) δ [155.8, 154.6 (C, C-12)]K, [151.13, 151.11, 150.78, 150.72, 150.19, 
150.18 (C, C-5)], [140.5, 140.4, 139.8, 139.5 (C, C-12)]T, [122.2, 121.9, 121.6, 121.3 (C, C-13)]T, 
[120.14, 120.13, 119.27, 119.24, 2 × 119.06 (CH, C-4)], [105.86, 105.83, 105.81, 2 × 105.79, 105.75 
(C, C-3)]TK, [101.3, 100.4 (CH, C-11)]K, [79.8, 78.7, 78.3, 77.6, 76.6, 75.9 (C, C-20)], [64.26, 64.25, 
64.23, 64.22, 64.21, 64.19 (CH2, OCH2CH2O)], [63.92, 2 × 63.88, 63.87, 2 × 63.86 (C, OCH2 2O)], 
[60.4, 60.1, 59.8, 58.53, 58.46, 58.3 (C, C-2’, C-6’)], [51.35, 51.31, 49.8, 49.6, 49.4, 48.9, 48.8, 4.45, 
48.43, 48.2, 47.8, 47.0, 45.7, 45.6, 45.0, 44.51, 44.47, 43.5, 43.0 (CH)], [40.6, 40.5, 40.4, 40.2, 40.0 , 
39.98 (CH2, C-3’, C-5’)], [38.9, 38.7, 38.5, 38.1, 34.8, 33.2 (CH)], [37.39, 37.34, 37.2, 37.03, 36.96, 
36.9 (C, C-10)], [34.36, 34.35, 34.33, 34.25, 34.04, 34.02 (CH2, C-1)], [34.6, 34.0, 33.8, 33.7 (CH3, C-
7’, C-9’)], [32.4, 32.3, 32.2, 32.1, 31.9, 31.74, 31.67, 31.5, 31.08, 31.05, 30.95, 30.5, 30.3, 30.01, 
29.97, 29.8, 29.52, 29.47, 29.44, 29.42, 29.41, 28.4, 28.2, 25.53, 25.52, 25.3, 24.2, 24.1, 23.7, 22.5 
(CH2)], [21.0, 20.44, 20.39, 20.30, 20.26, 20.2 (CH3, C-8’, C-10’)], [19.4, 19.0, 18.4, 17.8, 17.7, 
17.19, 17.16, 17.09, 16.8, 15.3, 14.2, 13.3 (CH3, C-19, C-21)], [17.11, 17.07, 17.01, 17.00, 16.98 
(CH2, C-4’)], [0.84, 0.76, 0.72, 0.6, 0.2, 0.1 (CH3, SiMe3)]. 
Signals of ent-196 are labeled with T and are in ca. 1:1:1:1 ratio, while those of 197 are labeled K and 











Deprotection of 14β cyclic alkoxyamines ent-186B,b 
The cyclization product ent-
186B,b (27 mg, 54 µmol) was 
dissolved in acetone (1 mL) and 
5% aq. HCl (100 µL) was added. 
After 10 min of stirring at rt, the 
reaction mixture was quenched 
with sat. aq. NaHCO3 (10 mL) and the products were extracted into EtOAc (3 × 3 mL). The combined 
organic fractions were dried over Na2SO4 and evaporated in vacuo to afford 21.2 mg of crude 
diketone, which was dissolved in CH2Cl2 (1.5 mL). The solution was cooled to 0 °C and m-CPBA 
(14 mg, 81 µmol) was added to the stirred solution. The reaction was stirred at 0 °C for 30 min and 
quenched with 15% aq. ascorbic acid (10 mL). The biphasic mixture was diluted with hexane (10 mL) 
and the organic layer was separated. The aqueous layer was extracted with EtOAc (2 × 5 mL). The 
organic extracts were washed with sat. aq. NaHCO3 (2 × 15 mL). The combined organic layers were 




Colorless needles, Mp 104-107 °C (Hexane). 
[α]D20 −120.8 (c 0.187, CHCl3); 
IR (CHCl3); ν[cm-1]: 869 (=C-H), 1172, 1186, 1245, 1356, 1380 (CH3), 
1619 (C=C), 1667, 1702 (C=O), 2874 (CH3), 2935 (CH2), 2969 (CH3). 
1H NMR (600 MHz, CDCl3) δ 5.78 (d, J = 2.0 Hz, 1H, CH-4), 3.75 (ddd, J 
= 9.8, 7.3, 2.1 Hz, 1H, CH-17), 3.13 (br d, J = 7.9 Hz, 1H, CH-13), 2.47 
(dddd, J = 14.4, 14.0, 5.1, 2.0 Hz, 1H, CH-6a), 2.44 (m, 1HC -11a), 2.42 
(m, 1H, CH-2a), 2.41 (m, 1H, CH-14), 2.38 (m, 1H, CH-2b), 2.34 (ddd, J = 14.4, 4.2, 2.5, 1H, CH-6b), 
2.32 (m, 1H, CH-8), 2.27 (m, 1H, CH-11b), 2.17 (s, 3H, CH3-21), 2.07 (m, 1H, CH-16a), 2.00 (m, 1H, 
CH-1a), 1.87 (dddd, J = 13.1, 5.1, 3.5, 2.5 Hz, 1H, CH-7a), 1.73 (m, 1H,CH-1b), 1.63 (m, 1H, CH-
15a), 1.60 (m, 1H, CH-9), 1.57 (m, 1H, CH-16b), 1.31 (dddd, J = 14.4, 13.1, 12.5, 4.2 Hz, 1H, CH-
7b), 1.23 (s, 3H, CH3-19), 1.04 (m, 1H, CH-15b). 
13C NMR (150.9 MHz, CDCl3) δ 210.3 (C, C-12), 209.4 (C, C-20), 198.8 (C, C-3), 168.2 (C, C-5), 
124.7 (CH, C-4), 53.4 (CH, C-13), 49.1 (CH, C-17), 47.7 (CH, C-9), 47.4 (CH, C-14), 41.0 (CH2, C-
11), 38.6 (C, C-10), 36.0 (CH, C-8), 35.3 (CH2, C-1), 33.6 (CH2, C-2), 32.8 (CH2, C-6), 31.1 (CH2, C-
7), 28.4 (CH3, C-21), 26.1 (CH2, C-16), 25.4 (CH2, C-15), 17.4 (CH3, C-19). 
MS (CI+) m/z, (%): 315 (100, [M+H]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C20H27O3 315.1960; Found 315.1962; 
Anal. Calcd for C20H26O3: C, 76.40; H, 8.34; Found: C, 76.63; H, 8.37;  
 
(R)-2-((1R,2S,8aS)-1-(2-(2,2,6,6-Tetramethylpiperidin-1-yloxy)-2-oxoethyl)-8a-methyl-6-oxo-
1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)hept-5-enoic acid (ent-202) 
The cyclized fraction ent-186A,a and ent-185a (120 mg, 239 µmol) was dissolved in acetone (3 mL)
and 5% aq. HCl (100 µL) was added to the stirred solution. After 30 min of stirring at rt, the reaction 
mixture was quenched with saturated aq. NaHCO3 (10 mL) and the aq. layer was extracted with 






























to afford 109 mg of the intermediate, which was redissolved in CH2Cl2 
(2 mL) and the solution was cooled to 0 °C. m-CPBA (56 mg, 325 µmol) 
was added portionwise to the stirred cooled solution. The reaction was 
stirred at 0 °C for 45 min and quenched with 15% aq. ascorbic acid (5 mL). 
The mixture was extracted with hexane (10 mL) and with EtOAc (2 × 5 mL), 
the combined organic layers were washed twice with NaHCO3 (2 × 5 mL), 
dried over MgSO4 and evaporated in vacuo. The residue was purified by 
flash chromatography on silica gel (3 g) in 10% to 40% EtOAc/hexanes to 
afford 26 mg (35%) of 18-nor steroids ent-193 and ent-194 in 3:1 ratio, followed by 30 mg (26%) of 
the title compound ent-202, crystallizing as colorless threads from CH2 l2/hexane:  
ent-202: Colorless needles, Mp 179-182 °C. 
[α]D20 −67.1 (c 0.198, CHCl3); 
IR (CHCl3); ν[cm-1]: 1131 (C-O), 1277 (COH), 1365, 1380 (CH3), 1420 (CH2) 1437, 1454, 1462 
(piperidin), 1620 (C=C), 1669 (enone), 1705 (COOH dimer), 1761 (COOH, COOR), 2873 (CH3), 
2943 (CH2), 2967, 2976 (CH3), 3510 (OH). 
1H NMR (400 MHz, CDCl3) δ 5.77 (d, J = 1.5 Hz, 2H, CH-4, CH-4*), 5.45-5.35 (m, 2H, CH-20, CH-
20*), 5.36-5.27 (m, 2H, CH-17, CH-17*), 2.60-2.49 (m, 1H, CH-14), 2.58-2.49 (m, 2H, CH2-7), 2.44-
2.35 (m, 2H, CH2-2), 2.33-2.24 (m, 2H, CH2-6), 2.21-2.09 (m, 1H, CH-8), 2.15-2.03 (m, 1H, CH-9), 
2.14-2.03 (m, 1H, CH-16a), 2.04-1.95 (m, 1H, CH-16a)*, 2.01-1.88 (m, 1H, CH-16b), 1.95-1.83 (m, 
1H, CH-16b)*, 1.98-1.85 (m, 1H, CH-1a), 1.97-1.87 (m, 1H, CH-11a), 1.72-1.48 (m, 8H, CH2-3’, 
CH2-5’, CH2-3’*, CH2-5’*), 1.70-1.61 (m, 1H, CH-15a), 1.58 (br d, J = 5.0 Hz, 3H, CH3-21)*, 1.56-
1.45 (m, 1H, CH-15b), 1.55 (dd, J = 6.6, 1.8 Hz, 3H, CH3-21), 1.50-1..40 (m, 4H, CH2-4’, CH2-4’*), 
1.46-1.33 (m, 1H, CH-11b), 1.21 (s, 3H, CH3-19), 1.20 (s, 3H, CH3-19)*, 1.17 (br s, 12H, CH3-7’, 
CH3-8’, CH3-7’*, CH3-8’*), 1.07 (br s, 6H, CH3-9’, CH3-9’*), 1.07-1.01 (m, 1H, CH-1b), 1.04 (br s, 
6H, CH3-10’, CH3-10’*). 
13C NMR (101 MHz, CDCl3) δ 199.1 (C, C-3, C-3*), 180.5 (C, C-12)*, 180.4 (C, -12), 172.8 (C, C-
13, C-13*), 168.9 (C, C-5, C-5*), 130.5 (CH, C-17)*, 129.6 (CH, C-17), 125.4 (CH, C-20)*, 124.6 
(CH, C-20), 123.98 (CH, C-4)*, 123.96 (CH, C-4), 60.2 (C, C-2’/C-6’), 60.1 (C, C-2’/C-6’), 46.0 (CH, 
C-14)*, 45.8 (CH, C-14), 44.67 (CH, C-9), 44.64 (CH, C-9)*, 40.8 (CH, C-8)*, 40.5 (CH, C-8), 39.91 
(C, C-10), 39.89 (C, C-10)*, 39.0 (CH2, C-3’, C-5’), 35.19 (CH2, C-1), 35.16 (CH2, C-1)*, 33.5 (CH2, 
C-2, C-2*), 32.3 (CH2, C-6, C-6*), 32.2 (CH3, C-9’, C-10’)*, 31.9 (CH3, C-9’, C-10’), 31.3 (CH2, C-
16)*, 31.1 (CH2, C-7)*, 30.9 (CH2, C-7), 27.5 (CH2, C-11), 27.4 (CH2, C-11)*, 25.5 (CH2, C-16), 24.4 
(CH2, C-15)*, 24.1 (CH2, C-15), 20.60 (CH3, C-7’, C-8’)*, 20.55 (CH3, C-7’, C-8’), 18.20 (CH3, C-19, 
C-19*), 18.15 (CH3, C-21)*, 16.9 (CH2, C-4’, C-4’*), 12.7 (CH3, C-21). 
Mixture of ∆17(20)-E and ∆17(20)-Z isomers in 3:2 ratio. Signals of the minor Z-isomer are marked by an * 
where observable. 
MS (ESI−) m/z, (%): 347 (40, [M−TMP]−), 486 (100, [M−H]−), 974 (21, [2M−H]−), 996 (3, 
[2M+Na−2H]−); 
MS (ESI+) m/z, (%): 488 (100, [M+H]+), 510 (10, [M+Na]+), 998 (11, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C29H46NO5 488.3371; Found 488.3371;  





































A suspension of KH (20 mg of pure KH, 0.50 mmol, ca. 35% w/v in mineral oil) was transferred to a 
pre-dried Schlenk flask and washed with dry pentane (3 × 2 mL). The remaining solvent was 
evaporated in vacuo and the flask was back-filled with nitrogen. A solution of ketone ent-186A,a 
(170 mg, 336 µmol) in THF (3 mL) was added dropwise at rt, which caused immediate foaming of the 
mixture. The suspension was stirred at rt for 45 min, neat methyl iodide (63 µL, 1.01 mmol) was 
added and the solution became cloudy. The reaction mixture was stirred for 1 h and quenched 
carefully with saturated aq. NH4Cl (5 mL). The mixture was extracted with CH2Cl2 (3 × 3 mL) and the 
combined organic fractions were evaporated in vacuo. The oily residue was redissolved in acetone 
(3 mL) and 5% aq. HCl (100 µL) was added to the stirred solution. After stirring at rt for 10 min, the 
reaction mixture was quenched with saturated aq. NaHCO3 (10 mL) and the products were extracted 
into CH2Cl2 (3 × 3 mL). The combined organic fractions were drie  over MgSO4 and evaporated in 
vacuo to afford the crude diketone. After dissolution in CH2Cl2 (5 mL), the solution was cooled to 
0 °C and mCPBA (86 mg, 0.50 mmol) was added portionwise. The reaction mixture was stirred at 
0 °C for 45 min and was quenched with 10% aq. Na2S2O3 (5 mL). The mixture was extracted with 
CH2Cl2 (3 × 5 mL), the combined organic layers were washed with NaHCO3 (2 × 5 mL), dried over 
MgSO4 and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (7 g) 
in 30% hexane/MTBE to afford 8.6 mg (4%) of alkoxyamine ent-206, followed by 21.2 mg (19%) of 




IR (ATR); ν[cm-1]: 738, 765, 1131 (C-O), 1235, 1273, 1366, 1380 (CH3), 1427 (CH2), 1457, 1471 
(piperidin), 1623 (C=C), 1674 (enone), 1706 (C=O), 2861 (CH3), 2934 
(CH2). 
1H NMR (600 MHz, CDCl3) δ 5.78 (br d, J = 1.9 Hz, 1H, CH-4), 4.95 
(qd, J = 6.5, 1.8 Hz, 1H, CH-20), 2.48 (tdd, J = 14.4, 5.2, 1.9 Hz, 1H, 
CH-6a), 2.45 (dd, J = 16.6, 13.2 Hz, 1H, CH-11a), 2.45 (m, 1H, CH-14), 
2.42 (m, 1H, CH-2a), 2.35 (m, 2H, CH-2b, CH-6b), 2.34 (dd, J = 16.6, 5.4 Hz, 1H, CH-11b), 2.02 (m, 
1H, CH-7a), 1.98 (m, 1H, CH-16a), 1.95 (m, 1H, CH-17), 1.93 (ddd, J = 13.2, 5.0, 3.1 Hz, 1H, CH-
1a), 1.83 (m, 1H, CH-15a), 1.80 (m, 1H, CH-8), 1.75 (m, 1H, CH-16b), 1.65 (m, 1H, CH-1b), 1.49 
(ddd, J = 13.2, 11.1, 5.4 Hz, 1H, CH-9), 1.45 (m, 1H, CH-5’), 1.40 (m, 3H, CH-15b, CH2-3’), 1.36 (m, 
1H, CH-5’), 1.26 (m, 2H, CH2-4’), 1.24 (s, 3H, CH3-19), 1.16 (d, J = 6.5 Hz, 3H, CH3-21), 1.15 (s, 
3H, CH3-7’), 1.11 (m, 1H, 7b), 1.08 (s, 3H, CH3-9’), 1.06 (s, 3H, CH3-18), 0.97 (s, 3H, CH3-10’), 0.96 
(s, 3H, CH3-8’). 
13C NMR (150.9 MHz, CDCl3) δ 212.8 (C, C-12), 198.6 (C, C-3), 169.1 (C, C-5), 124.0 (CH, C-4), 
74.2 (CH, C-20), 59.8 (C, C-2‘), 58.4 (C, C-6‘), 55.0 (C, C-13), 52.5 (CH, C-9), 51.0 (CH, C-17), 48.2 
(CH, C-14), 40.6 (CH2, C-5‘), 40.0 (CH2, C-3‘), 38.0 (C, C-10), 37.7 (CH2, C-11), 35.0 (CH2, C-1), 
34.0 (CH, C-8), 33.4 (CH3, C-9‘), 33.3 (CH2, C-2), 32.3 (CH3, C-7‘), 32.2 (CH2, C-6), 31.4 (CH2, C-
7), 23.8 (CH2, C-15), 21.4 (CH3, C-18), 20.9 (CH3, C-8‘), 20.5 (CH3, C-10‘), 19.7 (CH2, C-16), 17.1 
(CH3, C-21), 16.8 (CH2, C-4‘), 16.4 (CH3, C-19). 
MS (ESI+) m/z, (%): 313 (6, [M−TEMPOH+H]+), 470 (100, [M+H]+), 492 (26, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C30H48NO3 470.3629; Found 470.3628; [M+Na]
+ Calcd for 











X-ray data are available in Appendix C.  
 
ent-17α-Pregn-4-ene-3,12,20-trione (ent-207) 
The NMR spectra differ significantly from known 17α-pregn-4-ene-3,12,20-trione.340 
Mp 224-225 °C (sublimes above 200 °C). 
IR (CHCl3); ν[cm-1]: 1175, 1234, 1361, 1377 (CH3), 1619 (C=C), 1670, 1711 (C=O), 2920, 2943 
(CH2), 2969 (CH3). 
1H NMR (600 MHz, CDCl3) δ 5.78 (br d, J = 2.1 Hz, 1H, CH-4), 2.93 (dd, J 
= 9.3, 2.6 Hz, 1H, CH-17), 2.46 (dddd, J = 14.8, 13.8, 5.4, 2.1 Hz, 1H, CH-
6a), 2.41 (dd, J = 15.5, 13.2 Hz, 1H, CH-11a), 2.38 (m, 2H, CH2-2), 2.36 
(br ddd, J = 14.8, 4.4, 2.4 Hz, 1H, CH-6b), 2.33 (ddd, J = 12.3, 11.1, 7.1 
Hz, 1H, CH-14), 2.29 (s, 3H, CH3-21), 2.28 (dd, J = 15.5, 5.3 Hz, 1H, CH-11b), 2.01 (dddd, J = 14.0, 
10.6, 9.3, 2.5 Hz, 1H, CH-16a), 1.97 (dddd, J = 12.8, 4.4, 3.6, 2.4 Hz, 1H, CH-7a), 1.94 (dddd, J = 
12.1, 9.1, 7.1, 2.5 Hz, 1H, CH-15a), 1.89 (ddd, J = 13.4, 4.8, 3.3 Hz, 1H, CH-1a), 1.87 (dtd, J = 11.5, 
11.1, 3.6 Hz, 1H, CH-8), 1.70 (dddd, J = 13.6, 13.4, 5.7, 0.6 Hz, 1H, CH-1b), 1.64 (dddd, J = 14.0, 
9.1, 7.5, 2.6 Hz, 1H, CH-16b), 1.54 (ddd, J = 13.2, 11.1, 5.3 Hz, 1H, CH-9), 1.53 (dddd, J = 12.3, 
12.1, 10.6, 7.5 Hz, 1H, CH-15b), 1.24 (d, J = 0.6 Hz, 3H, CH3-19), 1.23 (dddd, J = 13.8, 12.8, 11.5, 
4.4 Hz, 1H, CH-7b), 1.12 (s, 3H, CH3-18). 
13C NMR (150.9 MHz, CDCl3) δ 212.9 (C, C-20), 211.5 (C, C-12), 198.8 (C, C-3), 168.7 (C, C-5), 
124.6 (CH, C-4), 60.6 (C, C-13), 54.8 (CH, C-17), 53.3 (CH, C-9), 49.4 (CH, C-14), 38.5 (C, C-10), 
37.2 (CH2, C-11), 35.2 (CH2, C-1), 34.5 (CH, C-8), 33.7 (CH2, C-2), 32.7 (CH3, C-21), 32.5 (CH2, C-
6), 31.3 (CH2, C-7), 25.5 (CH2, C-16), 24.8 (CH2, C-15), 19.8 (CH3, C-18), 16.8 (CH3, C-19). 
MS (CI+) m/z, (%): 329 (100, [M+H]+), 357 (20, [M+C2H5]
+); 
HRMS (CI+) m/z: [M+H] + Calcd for C21H29O3 329.2111; Found 329.2118; 




Ketone ent-152 (222 mg, 1 mmol) was dissolved anhydrous MeOH 
(5 mL) and Et3N (14 µL, 0.10 mmol). p-Toluenesulfonyl hydrazide 
(279 mg, 1.50 mmol) was added and the mixture was stirred at rt 
overnight, causing complete consumption of starting material. NaBH4 
(756 mg, 20 mmol) was added portionwise and the mixture was 
refluxed for 14 h. The reaction was carefully quenched by 5% aq. citric acid (25 mL) and extracted 
with CHCl3 (3 × 5 mL). The combined organic fractions were washed with saturated aq. NaHCO3 
(25 mL), dried over MgSO4 and evaporated in vacuo. Crystallization from benzene/hexane afforded 
240 mg (69%) of ent-209 in 3:1 E/Z ratio as colorless crystals. 
Mp 127-129 °C. 
[α]D20 −169.3 (c 0.310, CHCl3); 
IR (CHCl3); ν[cm-1]: 814, 903, 929, 1035, 1047, 1094 (Ph), 1161 (SO2), 1308, 1325, 1420 (CH2), 1603 
(Ph), 1633 (C=C), 2840 (CH2), 2878 (CH3), 2952 (CH2), 3080 (NH), 3468 (OH). 
1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 8.2 Hz, 4H, CH-2’, CH-2’*), 7.56 (br s, NH), 7.31 (d, J = 
8.2 Hz, 4H, CH-3’, CH-3’*), 6.11 (s, 1H, CH-4*), 5.89 (s, 1H, CH-4), 3.32 (dd, J = 11.7, 4.0 Hz, 1H, 





























5’*), 2.35-2.29 (m, 1H, CH-6a*), 2.26-2.17 (m, 1H, CH-6a), 2.19-2.12 (m, 2H, CH-6b, CH-6b*), 
2.14-2.08 (m, 1H, CH-2b), 2.10-2.03 (m, 2H, CH-1a, CH-2a*), 2.06-1.99 (m, 1H, CH-1a*), 1.88-1.75 
(m, 2H, CH-7a, CH-7a*), 1.84-1.73 (m, 2H, CH-8a, CH-8a*), 1.70-1.57 (m, 2H, CH-8b, CH-8b*), 
1.59-1.53 (m, 2H, CH-1b, CH-1b*), 1.37-1.27 (m, 3H, CH-7b, CH-7b*, CH-2b*), 1.09 (s, 3H, CH3-
19*), 1.03 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) ~154.8 (C, C-5), 144.0 (C, C-4’), 135.4 (C, C-1’), 129.6 (CH, C-3’, C-
3’*), 128.13 (CH, C-2’*), 128.08 (CH, C-2’), 122.2 (br CH, C-4), 112.64 (br CH, C-4*), 78.5 (CH, C-
9), 78.1 (CH, C-9’), ~42.1 (C, C-10*), 40.8 (C, C-10), 34.2 (CH2, C-1*), 33.1 (CH2, C-1), 32.6 (CH2, 
C-6*), 31.5 (CH2, C-6), 30.5 (CH2, C-8), 30.3 (CH2, C-8*), 27.10 (CH2, C-2*), 23.7 (CH2, C-7*), 23.6 
(CH2, C-7), 21.6 (CH3, C-5’, C-5’*), 20.5 (CH2, C-2*), 16.1 (CH3, C-19*), 15.3 (CH3, C-19). Signals 
of the minor Z-diastereomer are marked by an *. Carbons C-3, C-3*, C-5*, C-1’* and C-4’* were lost 
in signal noise. 
MS (ESI+) m/z, (%): 349 (57, [M+H]+), 371 (49, [M+Na]+), 697 (12, [2M+H]+), 719 (100, [2M+Na]+), 
1067 (27, [3M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C18H25N2O3S 349.1580; Found 349.1582; [M+Na]
+ Calcd for 
C18H25N2NaO3S 371.1400; Found 349.1401; 
Anal. Calcd for C78H102N8O12S4 (with 1/4 equiv of benzene): C, 63.65; H, 6.98; N, 7.61; Found: C, 




A suspension of KH (cca 35% w/v in mineral oil, 205 mg of KH; 
5.13 mmol) was transferred to a pre-dried Schlenk flask and washed 
with dry pentane (3 × 2 mL). The remaining solvent was evaporated at 
low pressure and the flask was back-filled with nitrogen. A solution of 
ketone ent-186A,a (500 mg, 1.0 mmol) in THF (10 mL) was added 
dropwise at rt, which caused immediate foaming of the mixture. The suspension was stirred at rt for 
90 min and the supernatant was transferred via cannul  to another pre-dried Schlenk flask. Neat 
methyl iodide (188 µL, 3.02 mmol) was added at once to this solution, turning the solution cloudy. 
The reaction mixture was stirred for another 30 minand quenched carefully with saturated aq. NH4Cl 
(25 mL). The mixture was extracted with EtOAc (3 × 25 mL), the combined organic fractions were 
dried over Na2SO4 and evaporated in vacuo. The solution was concentrated in vacuo to afford 474 mg 
(92%) of an inseparable mixture of alkylated products ent-205 as a white foam. The crude mixture was 
dissolved in acetone (15 mL), 5% aq. HCl (0.5 mL) was added and the mixture was stirred at rt for 
10 min. The reaction was quenched with saturated aq. N HCO3 (50 mL) and extracted with CHCl3 (3 
× 15 mL). The organic extracts were dried over Na2SO4 and evaporated to afford 437 mg of a pale 
yellow oil, which was dissolved in glacial AcOH (1.42 mL). Ethane-1,2-dithiol (82 µL, 970 µmol) and 
dried pTsOH (191 mg, 1.11 mmol) were added, the mixture was stirred at rt for 1 h and poured 
carefully into 10% aq. Na2CO3 (150 mL). The emulsion was extracted with EtOAc (3 × 25 mL), the 
organic extracts were washed with saturated aq. NaHCO3 (2 × 50 mL), dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by flash chromatography on silica gel (15 g) in 5% to 
20% EtOAc/hexanes to afford 352.7 mg (64%) of a first f action of thioketals ent-210a, followed by 









ent-210a: IR (CHCl3); ν[cm-1]: 1132, 1364, 1375 (CH3), 1440, 1457 (CH2), 1645 (C=C), 1696 (C=O), 
2872 (CH3), 2934 (CH2), 2973 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.53 (m, 1H, CH-4), 4.94 (m, CH-20), 4.67 (m, CH-20), 4.09 (m, CH-
20), 4.09 (m, CH-20), 3.98 (m, CH-20), 3.92 (m, CH-20), 3.41-3.31 (m, 3H, SCH2CH2S), 3.28-3.18 
(m, 1H, SCH2CH2S), 2.50-0.80 (m, aliphatic). 
MS (ESI+) m/z, (%): 546 (100, [M+H]+), 560 (87, [M2+H]+); Where M2 is doubly alkylated product. 
HRMS (ESI+) m/z: [M+H] + Calcd for C32H52NO2S2 546.3434; Found 546.3436; 
The complex mixture ent-210a consisted of at least six compounds, as is apparent from number of 
signals of CH-20. In all compounds, a thioketal at C-3 was present, while C-12 was carbonyl.  
 
ent-210b: 1H NMR (400 MHz, CDCl3) δ 5.55 (br s, 1H, CH-4), 5.54 (br s, 1H, CH-4), 4.31 (qd, J = 
6.6, 4.3 Hz, 1H, CH-20), 4.31 (quint, J = 6.1 Hz, 1H, CH-20), 3.41-3.31 (m, 6H, SCH2CH2S), 3.28-
3.18 (m, 2H, SCH2CH2S), 2.50-0.80 (m, aliphatic), 1.17 (d, J = 6.1 Hz, 3H, CH3-21), 1.11 (br s, CH3-
7’, CH3-8’, CH3-9’, CH3-10’), 1.09 (s, 3H, CH3-18), 1.05 (s, 3H, CH3-19), 1.04 (s, 3H, CH3-19), 0.95 
(d, J = 6.6 Hz, 3H, CH3-21).  
13C NMR (101 MHz, CDCl3) δ 214.0 (C, C-12), 213.1 (C, C-12), 144.6 (C, C-5), 144.5 (C, C-5), 
125.05 (CH, C-4), 125.03 (CH, C-4), 80.4 (CH, C-20), 76.3 (CH, C-20), 65.3 (2 × C, C-3), 60.4 (br C, 
C-2’), 58.7 (br C, C-6’), 56.9 (CH, C-13), 55.8 (C, -13), 53.4 (CH, C-9) 53.0 (CH, C-9), 50.4 (CH), 
50.0 (CH), 48.8 (CH, CH-17), 47.6 (CH, CH-17), 40.3 (2 × CH2, C-3’, C-5’), 40.05 (CH2), 39.99 
(CH2), 39.97 (CH2), 39.52 (CH2), 39.47 (CH2), 38.4 (CH2), 37.62 (CH2), 37.59 (CH), 37.0 (C, C-10), 
36.60 (CH2), 36.53 (C, C-10), 36.48 (CH2), 34.8 (CH), 34.2 (2 × CH3, C-7’, C-9’), 32.7 (CH2), 32.2 
(CH2), 31.61 (CH2), 31.57 (CH2), 29.87 (CH2), 26.8 (CH2), 24.5 (CH2), 22.5 (CH2), 21.0 (CH2), 20.6 
(2 × CH3, C-8’, C-10’), 18.5 (CH3, C-19), 17.8 (CH3, C-19), 17.23 (CH2, C-4’), 17.19 (CH2, C-4’), 
16.9 (CH3, C-21), 16.5 (CH3, C-21). 
The mixture ent-210b consisted of two major compounds, one with 18-Me, one without (1:1, forming 
ca 80% of the mixture, based on integration of 1H NMR spectra). 
MS (ESI+) m/z, (%): 532 (47, [M0+H]+), 546 (100, [M+H]+); M0 is 18-norsteroid ent-186. 




Ketone ent-210a (100 mg, 183 µmol) was dissolved in glacial acetic 
acid (1.0 mL), dry pTsOH (33 mg, 192 µmol) and p-toluenesulfonyl 
hydrazide (41 mg, 220 µmol) were added and the solution was 
warmed to 70 °C overnight. The reaction mixture was slowly poured 
into 1 M aq. Na2CO3 (25 mL), diluted with saturated aq. NaHCO3 to 
50 mL and the suspension was extracted with EtOAc (3 × 25 mL). 
The combined organic fractions were dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by flash chromatography on silica gel (3 g) in 6% to 
10% EtOAc/hexanes to afford 49.4 mg (49%) of recovered starting material ent-210a, followed by 
24.1 mg (18%) of 2:1 mixture of diastereomers nt-211 as a colorless oil. 
IR (CHCl3); ν[cm-1]: 1093 (Ph), 1165 (SO2), 1363, 1379 (CH3), 1440, 1458 (CH2), 1599 (Ph), 2855 


















1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.2 Hz, 4H, CH-2”, CH-2”*), 7.28 (d, J = 8.2 Hz, 4H, CH-
3”, CH-3”*), 7.27 (br s, 2H, NH), 5.50 (br s, 1H, CH-4), 5.46 (br s, 1H, CH-4)*, 4.66 (q, J = 6.4 Hz, 
1H, CH-20), 3.68 (quint, J = 6.3 Hz, 1H, CH-20)*, 3.40-3.31 (m, 6H, SCH2CH2S, SCH2CH2S*), 3.27-
3.18 (m, 2H, SCH2CH2S, SCH2CH2S*), 2.49 (dd, J = 16.8, 5.9 Hz, 1H, CH-11a), 2.43 (s, 6H, CH3-5”, 
CH3-5”*), 2.35-0.80 (m, aliphatic), 1.29 (d, J = 6.3 Hz, 3H, CH3-21)*, 1.16 (s, 3H, CH3-18)*, 1.09 (d, 
J = 6.5 Hz, 3H, CH3-21), 1.05 (s, 3H, CH3-7’), 1.02 (s, 3H, CH3-19)*, 1.01 (s, 3H, CH3-19), 0.94 (s, 
3H, CH3-8’/CH3-10’), 0.92 (s, 3H, CH3-8’/CH3-10’), 0.82 (s, 3H, CH3-18), 0.60 (s, 3H, CH3-9’). 
13C NMR (101 MHz, CDCl3) δ ~167.8 (C, C-12)*, 164.0 (C, C-12), 145.2 (C, C-5)*, 145.1 (C, C-5), 
143.7 (2 × C, C-1”, C-1”*), 135.3 (2 × C, C-4”, C-4”*), 129.2 (2 × CH, C-2”, C-2”*), 128.3 (2 × CH, 
C-3”, C-3”*), 124.7 (CH, C-4), 123.9 (CH, C-4)*, 79.4 (CH, C-20)*, 74.5 (CH, C-20), 65.6 (C, C-3)*, 
65.3 (C, C-3), 60.0 (CH, C-17)*, 59.8 (2 × C, C-2’, C-2’*), 58.6 (2 × C, C-6’, C-6’*), 56.8 (C, C-13)*, 
52.3 (CH, C-17), 52.1 (CH, C-9), 50.7 (CH, C-14)*, 50.4 (C, C-13), 47.8 (CH, C-14), 40.6 (2 × CH2, 
C-3’, C-3’*), 40.3 (2 × CH2, C-5’, C-5’*), 40.0 (CH2, SCH2CH2S), 39.9 (CH2, SCH2CH2S)*, 39.48 
(CH2, SCH2CH2S)*, 39.43 (CH2, SCH2CH2S), 38.0 (CH)*, 37.8 (CH2, C-1)*, 37.6 (CH2, C-1), 37.07 
(CH)*, 37.02 (CH2), 36.54 (C, C-10), 36.46 (C, C-10)*, 34.4 (CH, C-8), 33.9 (2 × CH3, C-7’, C-7’*), 
33.8 (2 × CH3, C-9’, C-9’*), 33.4 (CH2)*, 32.5 (CH2), 32.4 (CH2), 31.8 (CH2, C-6)*, 31.6 (CH2, C-6), 
31.3 (CH3, C-21)*, 30.3 (CH2)*, 27.3 (CH2)*, 24.4 (CH2), 24.0 (CH3, C-18), 23.9 (CH3, C-18)*, 23.3 
(CH2, C-11), 22.6 (CH2)*, 21.5 (2 × CH3, C-5”, C-5”*), 21.20 (2 × CH3, C-8’/C-10’, C-8’/C-10’*), 
21.14 (CH3, C-8’/C-10’*), 21.07 (CH3, C-8’/C-10’), 20.1 (CH2), 18.92 (CH3, C-21), 18.88 (CH3, C-
19)*, 17.9 (CH3, C-19), 17.2 (2 × CH2, C-4’, C-4’*). 
Signals of the minor diastereomer are marked by an *.
MS (ESI+) m/z, (%): 557 (36, [M−TEMPOH+H]+), 714 (100, [M+H]+);  




Hydrazone ent-211 (23 mg, 32.2 µmol) was dissolved in THF (1.0 mL), a solution of LiAlH4 (1.8 M in 
THF, 36 µL, 64.8 µmol) was added and the reaction mixture was stirred at rt overnight. The reaction 
mixture was quenched with a few drops of saturated q. Na2SO4, diluted with Et2O (5 mL), dried over 
Na2SO4 and filtered through a pad of celite, which was washed with Et2O (3 × 2 mL). The solvent was 
evaporated in vacuo and the residue was purified by flash 
chromatography on silica gel (1.5 g) in 5% EtOAc/hexanes to afford 
8.9 mg (52%) of a single diastereomer ent-212 as a colorless oil. 
IR (ATR); ν[cm-1]: 968, 1085, 1135, 1190, 1367, 1380 (CH3), 1463 
(CH2), 2862 (CH3), 2931 (CH2). 
1H NMR (400 MHz, CDCl3) δ 6.05 (dd, J = 10.2, 2.7 Hz, 1H, CH-12), 5.53 (s, 1H, CH-4), 5.45 (dd, J 
= 10.3, 1.6 Hz, 1H, CH-11), 4.06 (br q, J = 6.4 Hz, 1H, CH-20), 3.41-3.33 (m, 3H, SCH2CH2S), 3.27-
3.19 (m, 1H, SCH2CH2S), 2.28-2.22 (m, 1H, CH-6a), 2.24-2.14 (m, 2H, CH2-2), 2.14-2.08 (m, 2H, 
CH-6b, CH-14), 1.92-1.85 (m, 2H, CH-1a, CH-16a), 1.79-1.71 (m, 2H, CH-7a, CH-17), 1.75-1.65 (m, 
1H, CH-8), 1.69-1.61 (m, 3H, CH-9, CH-15a, CH-16b), 1.64-1.54 (m, 1H, CH-1b), 1.57-1.48 (m, 1H, 
CH-4’a), 1.49-1.29 (m, 4H, CH2-3’, CH2-5’), 1.32-1.22 (m, 1H, CH-4’b), 1.29-1.16 (m, 1H, CH-15b), 
1.18-1.02 (m, 1H, CH-7b), 1.16 (d, J = 6.5 Hz, 3H, CH3-21), 1.11 (s, 3H, CH3-7’), 1.08 (s, 3H, CH3-








13C NMR (101 MHz, CDCl3) δ 145.8 (C, C-5), 137.8 (CH, C-12), 125.2 (CH, C-4), 124.5 (CH, C-11), 
78.2 (CH, C-20), 65.9 (C, C-3), 60.5 (C, C-2’), 58.9 (C, C-6’), 57.1 (CH, C-9), 53.3 (CH, C-17), 48.3 
(CH, C-14), 45.9 (C, C-13), 40.8 (CH2, C-3’), 40.5 (CH2, C-5’), 40.1 (CH2, SCH2CH2S), 39.5 (CH2, 
SCH2CH2S), 38.0 (CH2, C-2), 37.0 (C, C-10), 36.8 (CH2, C-1), 34.9 (CH, C-8), 34.1 (2 × CH3, C-7’, 
C-9’), 32.9 (CH2, C-6), 29.4 (CH2, C-7), 25.4 (CH3, C-18), 24.3 (CH2, C-15), 22.2 (CH2, C-16), 21.0 
(2 × CH3, C-8’, C-10’), 19.0 (CH3, C-19), 18.6 (CH3, C-21), 17.4 (CH2, C-4’).  
MS (ESI+) m/z, (%): 530 (100, [M+H]+);  
HRMS (ESI+) m/z: [M+H] + Calcd for C32H52NOS3 530.3485; Found 530.3485; 




Hecogenin (nat-213) (1.00 g, 2.32 mmol) was suspended in 
ethanedithiol (4.0 mL, 47.7 mmol) and the mixture was cooled 
to 0 °C. Trimethylsilyl chloride (0.59 mL, 4.64 mmol) was 
added dropwise and the mixture was stirred in an ice bath for 
2 h. The reaction mixture was poured into 10% aq. NaOH 
(150 mL) and extracted with Et2O (3 × 50 mL). The combined organic layers were washed with 
another portion of 10% aq. NaOH (150 mL), brine (150 mL), dried over MgSO4 and evaporated in 
vacuo to afford 1.13 g (96%) of thioketal nat-214 as a colorless powder, which was crystallized from 
hot EtOAc.  
[α]D20 −43.4 (c 0.304, CHCl3); (Lit.341 [α]D20 −32.0, CHCl3), 
Mp 254-255 °C (Lit.341 Mp 255-257 °C, EtOH), 
IR (CHCl3); ν[cm-1]: 981, 1041, 1054 (C-O-C), 1241, 1371, 1382 (CH3), 1458 (CH2), 2861 (CH2), 
2930 (CH2), 2956 (CH3). 
1H NMR (400 MHz, CDCl3) δ 4.43 (ddd, J = 8.5, 7.8, 6.2 Hz, 1H, CH-16), 3.59 (tt, J = 11.1, 4.6 Hz, 
1H, CH-3), 3.49 (ddd, J = 10.8, 4.1, 1.9 Hz, 1H, CH-26eq), 3.37 (t, J = 10.9 Hz, 1H, CH-26ax), 3.30-
3.10 (m, 4H, SCH2CH2S), 2.61 (dd, J = 8.7, 6.3 Hz, 1H, CH-17), 2.17 (t, J = 13.1 Hz, 1H, CH-11ax), 
2.10-2.01 (m, 2H, CH-11eq, CH-15a), 1.88 (quint, J = 6.9 Hz, 1H, CH-20), 1.08 (d, J = 7.0 Hz, 3H, 
CH3-21), 1.03 (s, 3H, CH3-18), 0.83 (s, 3H, CH3-19), 0.79 (d, J = 6.3 Hz, 3H, CH3-27). 
13C NMR (101 MHz, CDCl3) δ 109.3 (C, C-22), 80.1 (CH, C-16), 79.3 (C, C-12), 71.2 (CH, C-3), 66.8 
(CH2, C-26), 57.2 (CH, C-17), 55.8 (CH, C-14), 52.9 (CH, C-9), 50.4 (C, C-13), 44.6 (CH, C-5), 42.9 
(CH, C-20), 42.0 (CH2, C-11), 39.5 (CH2, CH2-S), 38.2 (CH2, CH2-S), 38.0 (CH2, C-4), 36.7 (CH2, C-
1), 35.4 (C, C-10), 34.8 (CH, C-8), 31.8 (CH2, C-15), 31.63 (CH2), 31.58 (CH2), 31.4 (CH2), 30.3 (CH, 
C-25), 28.8 (CH2), 28.5 (CH2), 17.1 (CH3, C-27), 16.8 (CH3, C-18), 15.0 (CH3, C-21), 12.5 (CH3, C-
19). 
MS (ESI+) m/z, (%): 507 (7, [M+H]+), 529 (100, [M+Na]+), 545 (5, [M+K]+), 1036 (4, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C29H47O3S2 507.2961; Found 507.2961; 
Anal. Calcd for C29H46O3S2: C, 68.73; H, 9.15; S, 12.65; Found: C, 68.77; H, 8.91; S, 12.29. 
 
(25R)-5α-Spirostan-3β-ol or tigogenin (nat-215) and (25R)-5α-spirost-11-en-3β-ol (nat-216) 
Steroid nat-214 (50.0 mg, 99 µmol) was dissolved in a mixture of abs. EtOH (3 mL) and THF (1 mL), 
Raney nickel (500 µL of a settled suspension in EtOH, W-2 quality)342 was suspended in the solution 















vacuo to afford 42.3 mg (99%) of 2:1 mixture of tigogenin (nat-
215) and nat-216 as a colorless powder. 
The 1H and 13C NMR spectra of both compounds were in 
agreement with the literature.294,343 The 1H and 13C NMR 
spectrum of tigogenin was identical to the sample prepared by 
hydrogenation of nonaflate nat-221 (vide infra).  
 
3,12-Bis(ethylenedithio)-pregn-4-ene (nat-217) 
Progesterone (nat-3) (1.05 g, 3.34 mmol) was dissolved in ethanedithiol 
(4.0 mL, 47.7 mmol) and the mixture was cooled to 0 °C. Trimethylsilyl 
chloride (0.61 mL, 4.8 mmol) was added dropwise andthe mixture was 
stirred in ice bath for 1 h. The reaction mixture was poured into 10% aq. 
NaOH (50 mL) and extracted with Et2O (3 × 50 mL). The combined 
organic layers were washed with another portion of 10% aq. NaOH (50 mL), brine (50 mL), dried over 
MgSO4 and evaporated in vacuo to afford crude bis(dithiolane) nat-217 as a colorless powder, which 
was recrystallized from hexane/CH2Cl2 to afford 1.52 g (98%) of colorless crystals. 
Mp 173-175 °C,  
[α]D20 +99.0 (c 0.306, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.48 (s, 1H, CH-4), 3.40-3.33 (m, 4H, CH2-S), 3.29-3.13 (m, 4H, CH2-
S), 1.86 (s, 3H, CH3-21), 1.01 (s, 3H, CH3-19), 0.82 (s, 3H, CH3-18). 
13C NMR (101 MHz, CDCl3) δ 146.5 (C, C-5), 124.0 (CH, C-4), 71.3 (C, C-20), 65.8 (C, C-3), 60.7 
(CH, C-17), 55.9 (CH, C-14), 53.9 (CH, C-9), 44.2 (C, C-13) 41.4 (CH2, CH2-S), 40.0 (CH2, CH2-S), 
39.9 (CH2, C-12), 39.5 (CH2, CH2-S), 38.1 (CH2, C-2), 37.33 (CH2, CH2-S), 37.25 (CH2, C-1), 36.6 
(C, C-10), 35.6 (CH, C-8), 35.4 (CH3, C-21), 32.5 (CH2, C-7), 32.1 (CH2, C-6), 27.0 (CH2, C-16), 24.0 
(CH2, C-15), 21.2 (CH2, C-11), 18.5 (CH3, C-19), 13.2 (CH3, C-18). 
The 1H and 13C NMR spectra are in agreement with the literature.344 
Anal. Calcd for C25H38S4: C, 64.32; H, 8.21; Found: C, 64.58; H, 8.33;  
 
12-(Ethylenedithio)-pregn-4-en-3-one (nat-218) 
Steroid nat-217 (100 mg, 214 µmol) was dissolved in a mixture of 
DMSO (1.8 mL), CH2Cl2 (1.0 mL) and H2O (0.2 mL) and the solution 
was warmed to 50 °C. Acetic acid (12 µL, 210 µmol) was added with 
stirring, followed by IBX (90 mg, 321 µmol). The mixture was stirred at 
50 °C overnight, followed by quenching with saturated aq. NaHCO3 
(12 mL) and 10% aq. Na2S2O3 (12 mL) and extracted with Et2O (3 × 5 mL). The combined organic 
layers were dried with MgSO4 and evaporated in vacuo. The residue was purified by chromatography 
on silica gel (3 g) in 10% EtOAc/hexanes to afford 36.6 mg (44%) of enone nat-218 as colorless 
crystals, which were recrystallized from hexane. 
Mp 220-222 °C (Hexane); 
[α]D20 +70.3 (c 0.182, CHCl3); 
IR (CHCl3); ν[cm-1]: 867 (=C-H), 1231, 1375 (CH3), 1435, 1450 (CH2), 1615 (C=C), 1662 (C=O), 
2857 (CH2), 2874 (CH3), 2942 (CH2), 2968 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.72 (s, 1H, CH-4), 3.38 (dt, J = 10.4, 5.2 Hz, 1H, CH-S), 3.30-3.13 (m, 





















13C NMR (101 MHz, CDCl3) δ 199.5 (C, C-3), 171.3 (C, C-5), 123.8 (CH, C-4), 71.2 (C, C-20), 60.6 
(CH, C-17), 55.7 (CH, C-14), 53.6 (CH, C-9), 44.0 (C, C-13), 41.4 (CH2, CH2-S), 39.7 (CH2, C-12), 
38.5 (C, C-10), 37.4 (CH2, CH2-S), 35.7 (CH2, C-1), 35.6 (CH, C-8), 35.3 (CH3, C-21), 34.0 (CH2, C-
2), 32.8 (CH2, C-6), 31.8 (CH2, C-7), 26.9 (CH2, C-16), 23.9 (CH2, C-15), 20.9 (CH2, C-11), 17.4 
(CH3, C-19), 13.2 (CH3, C-18); 
MS (CI+) m/z, (%): 319 (100, [M+H]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C23H35OS2 391.2129; Found 391.2132; 
Anal. Calcd for C23H34OS2: C, 70.72; H, 8.77; S, 16.41; Found: C, 70.30; H, 8.83; 
 
(25R)-3β-(tert-Butyldimethylsilyloxy)-5α-spirostan-12-one (nat-219) 
Prepared according to literature345 as 1.17 g (93%) of colorless 
plates.  
Mp 287-289 °C (EtOH), sublimes from 230 °C (Lit.345 Mp 187-
189 °C, EtOH); 
[α]D20 +0.3 (c 0.315, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 4.37-4.31 (m, 1H, CH-16), 3.54 (tt, J = 10.8, 4.8 Hz, 1H, CH-3), 3.48 
(dd, J = 10.8, 3.9 Hz, 1H, CH-26eq), 3.35 (t, J = 10.9 Hz, 1H, CH-26ax), 2.51 (dd, J = 8.5, 6.9 Hz, 1H, 
CH-17), 2.39 (t, J = 13.9 Hz, 1H, CH-11β), 2.21 (dd, J = 14.1, 5.0 Hz, 1H, CH-11α), 2.14-2.08 (m, 
1H), 1.90 (qd, J = 11.1, 3.6 Hz, 1H, CH-8), 1.06 (d, J = 7.0 Hz, 3H, CH3-21), 1.04 (s, 3H, CH3-18), 
0.89 (s, 3H, CH3-19), 0.88 (s, 9H, tBu), 0.79 (d, J = 6.3 Hz, 3H, CH3-27), 0.04 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 213.7 (C, C-12), 109.2 (C, C-22), 79.2 (CH, C-16), 71.7 (CH, C-3), 
66.9 (CH2, C-26), 55.8 (CH, C-14), 55.6 (CH, C-9), 55.1 (C, C-13), 53.5 (CH, C-17), 44.8 (CH, C-5), 
42.2 (CH, C-20), 38.4 (CH2, C-4), 37.8 (CH2, C-11), 36.7 (CH2, C-1), 36.1 (C, C-10), 34.4 (CH, C-8), 
31.66 (CH2), 31.61 (CH2), 31.4 (CH2), 31.2 (CH2), 30.2 (CH, C-25), 28.8 (CH2, C-24), 28.4 (CH2), 
25.9 (CH3, tBu), 18.2 (CH3, SiC(CH3)3), 17.1 (CH3, C-27), 16.0 (CH3, C-18), 13.3 (CH3, C-21), 12.0 
(CH3, C-19), −4.6 (CH3, Si(CH3)2). 
Anal. Calcd for C33H56O3Si: C, 72.74; H, 10.36; Si, 5.15; Found: C, 72.69; H, 10.43. 




Diisopropylamine (163 µL, 1.16 mmol) was dissolved in THF 
(3 mL), the solution was cooled to −78 °C, nBuLi (516 µL, 
1.16 mmol, 2.25 M in hexane) was added dropwise and the 
mixture was stirred at −78 °C for 30 min. A solution f steroid 
nat-219 (300 mg, 0.55 mmol) in THF (7 mL) was added 
dropwise and the mixture was stirred at −78 °C for 1 h. N-Phenyl bis(trifluoromethanesulfonimide) 
(393 mg, 1.1 mmol) in THF (2 mL) was added at −78 °C and the mixture was allowed to slowly warm 
to rt overnight. The excess of base was quenched with saturated aq. NH4Cl (50 mL) and the mixture 
was extracted with chloroform (3 × 10 mL). The combined organic layers were washed with saturated 
aq. solution of NaHCO3 (50 mL), dried over MgSO4 and evaporated in vacuo. The residue was 
purified by flash chromatography on silica gel (15 g) in 4% EtOAc/hexanes to afford 281 mg of crude 
triflate nat-220, followed by 104 mg (35%) of recovered nat-219. The crude material was purified by 




















Mp 148-151 °C,  
[α]D20 −36.8 (c 0.261, CHCl3);  
IR (CHCl3); ν[cm-1]: 836 (SiMe), 1009 (C-F, C-OS), 1055, 1067 (C-O-C), 1078 (C-F, C-O-Si), 1141 
(CF3), 1246 (SO2), 1382, 1387 (CH3), 1413 (SO2), 1463 (CH2), 2858 (CH2), 2931 (CH2), 2956 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.56 (d, J = 1.5 Hz, 1H, CH-11), 4.47 (td, J = 7.8, 6.2 Hz, 1H, CH-16), 
3.58 (tt, J = 10.8, 5.2 Hz, 1H, CH-3), 3.47 (dd, J = 10.8, 4.2 Hz, 1H, CH-26eq), 3.34 (t, J = 11.0 Hz, 
1H, CH-26ax), 2.13 (dd, J = 8.2, 6.1 Hz, 1H, CH-17), 2.05 (ddd, J = 11.9, 7.3, 5.8 Hz, 1H, CH-15), 
1.87 (quint, J = 6.7 Hz, 1H, CH-20), 1.02 (s, 3H, CH3-18 ), 1.02 (d, J = 7.0 Hz, 3H, CH3-21), 0.88 (s, 
9H, tBu), 0.80 (s, 3H, CH3-19), 0.79 (d, J = 6.4 Hz, 3H, CH3-27), 0.05 (s, 6H, Si(CH3)2). 
19F NMR (376 MHz, CDCl3) δ −74.30 (s, 3F, CF3). 
13C NMR (101 MHz, CDCl3) δ 156.7 (C, C-12), 114.3 (CH, C-11), 109.3 (C, C-22), 80.4 (CH, C-16), 
71.8 (CH, C-3), 66.9 (CH2, C-26), 57.8 (CH, C-17), 56.4 (CH, C-9), 54.4 (CH, C-14), 45.8 (C, C-13), 
44.7 (CH, C-5), 41.9 (CH, C-20), 38.3 (CH2, C-4), 36.3 (CH2, C-1), 36.2 (C, C-10), 33.0 (CH, C-8), 
31.6 (CH2), 31.4 (CH2), 30.2 (CH2), 30.1 (CH, C-25), 29.7 (CH2), 28.9 (CH2), 28.7 (CH2), 25.9 (CH3, 
tBu), 18.2 (C, SiC(CH3)3), 17.9 (CH3, C-18), 17.1 (CH3, C-27), 13.3 (CH3, C-21), 13.0 (CH3, C-19), 
−4.57 (CH3, SiCH3), −4.60 (CH3, SiCH3). 
MS (ESI+) m/z, (%): 401 (100, [M−TfOH−C8H14O+H]
+), 527 (91, [M−TfOH+H]+), 545 (11, 
[M−TBSOH+H]+), 549 (85, [M−TfOH+Na]+), 567 (73, [M−TBSOH+Na]+), 677 (40, [M+H]+), 699 
(48, [M+Na]+); Fragment C8H14O corresponds to (R)-2-ethylidene-5-methyltetrahydro-2H-pyran. 




Diisopropylamine (163 µL, 1.16 mmol) was dissolved in THF 
(3 mL), the solution was cooled to −78 °C, nBuLi (516 µL, 
1.16 mmol, 2.25 M in hexane) was added dropwise and the 
mixture was stirred at −78 °C for 30 min. A solution f steroid 
nat-219 (300 mg, 0.55 mmol) in THF (7 mL) was added 
dropwise and the solution was stirred at −78 °C for 1 h. Nonaflyl fluoride (198 µL, 1.1 mmol) was 
added neat at −78 °C and the mixture was allowed to slowly warm to rt overnight. The excess of base 
was quenched with saturated aq. NH4Cl (50 mL) and the mixture was extracted with chlorof m (3 × 
10 mL). The combined organic layers were washed with saturated aq. NaHCO3 (50 mL), dried over 
MgSO4 and evaporated in vacuo. The residue was purified by flash chromatography on silica gel 
(15 g) in 5% EtOAc/hexanes to afford 384 mg (84%) of nonaflate nat-221 as colorless solid, followed 
by 47 mg (15%) of recovered nat-219. 
Mp 164-167 °C (hexane),  
[α]D20 −27.6 (c 0.221, CHCl3); 
IR (CHCl3); ν[cm-1]: 588 (SO2), 837 (SiMe), 1010 (C-F, C-OS), 1056, 1067 (C-O-C), 1145 (CF3), 
1242 (SO2), 1352 (C-F), 1382, 1387 (CH3), 1414 (SO2), 2858 (CH2), 2930 (CH2), 2956 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.54 (d, J = 1.4 Hz, 1H, CH-11), 4.47 (td, J = 8.0, 6.0 Hz, 1H, CH-16), 
3.57 (tt, J = 10.8, 4.9 Hz, 1H, CH-3), 3.47 (dd, J = 10.8, 3.9 Hz, 1H, CH-26eq), 3.34 (t, J = 10.9 Hz, 
1H, CH-26ax), 2.13 (dd, J = 8.2, 6.1 Hz, 1H, CH-17), 2.05 (ddd, J = 11.9, 7.3, 5.8 Hz, 1H, CH-15), 
1.91-1.84 (m, 1H, CH-20), 1.03 (s, 3H, CH3-18), 1.02 (d, J = 7.0 Hz, 3H, CH3-21), 0.88 (s, 9H, tBu), 







19F NMR (376 MHz, CDCl3) δ −80.64 (t, J = 9.7 Hz, 3F, CF3), −109.57 (dt, J = 261.2, 13.9 Hz, 1F, 
CFaFbSO2), −110.69 (dt, J = 261.5, 14.1 Hz, 1F, CFa bSO2), −121.02 (m, 2F, CF2CF2CF3), −125.78 
(tdt, J = 14.0, 6.1, 3.1 Hz, 2F, CF2CF2CF3). 
13C NMR (101 MHz, CDCl3) δ 157.0 (C, C-12), 114.6 (CH, C-11), 109.4 (C, C-22), 80.4 (CH, C-16), 
71.8 (CH, C-3), 66.9 (CH2, C-26), 57.8 (CH, C-17), 56.5 (CH, C-9), 54.5 (CH, C-14), 45.9 (C, C-13), 
44.7 (CH, C-5), 41.9 (CH, C-20), 38.3 (CH2, C-4), 36.3 (CH2, C-1), 36.2 (C, C-10), 33.0 (CH, C-8), 
31.6 (CH2), 31.4 (CH2), 30.3 (CH2), 30.16 (CH2), 30.14 (CH, C-25), 28.9 (CH2), 28.7 (CH2), 25.9 
(CH3, tBu), 18.2 (CH3, SiC(CH3)3), 17.9 (CH3, C-18), 17.1 (CH3, C-27), 13.2 (CH3, C-21), 13.0 (CH3, 
C-19), −4.57 (CH3, SiCH3), −4.60 (CH3, SiCH3). 
MS (ESI+) m/z, (%): 401 (41, [M−NfOH−C8H14O+H]
+), 527 (100, [M−NfOH+H]+), 549 (53, 
[M−NfOH+Na]+), 695 (5, [M−TBSOH+H]+), 827 (30, [M+H]+), 849 (28, [M+Na]+); Fragment 
C8H14O corresponds to (R)-2-ethylidene-5-methyltetrahydro-2H-pyran; 
HRMS (ESI+) m/z: [M+H] + Calcd for C37H56F9O6SSi 827.3418; Found 827.3420;  
 
(25R)-3β-(tert-Butyldimethylsilyloxy)-5α-spirost-11-ene (nat-222) 
Steroid nonaflate nat-221 (200 mg, 242 µmol), palladium(II) 
acetate (2.7 mg, 12.1 µmol), triphenylphosphine (6.3 mg, 
24.2 µmol) and tributylamine (57 µL, 242 µmol) were dissolved 
in dry DMF (3 mL) at rt. In a separate flask, formic acid (99%, 
36.6 µL, 0.97 mmol) was slowly added to a solution f 
tributylamine (230 µL, 0.97 mmol) in DMF (2 mL) and the resulting solution was transferred 
dropwise to the warm reaction mixture (60 °C), and stirred at 60 °C for 2 h. The black reaction 
mixture was quenched with saturated aq. NH4Cl (25 mL) and extracted with hexane (3 × 10 mL). The 
combined extracts were washed subsequently with saturated aq. NaHCO3 (25 mL) and brine (25 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography on 
silica gel (5 g) in hexanes to 4% EtOAc/hexanes to aff rd 102 mg (80%) of olefin at-222, followed 
by 10 mg (8%) of recovered ketone at-219. The product crystallized from CH2Cl2/EtOH as colorless 
plates.  
Mp 221-224 °C,  
[α]D20 −33.0 (c 0.203, CHCl3);  
IR (CHCl3); ν[cm-1]: 836 (SiMe), 1052, 1063 (C-O-C), 1093 (C-O-Si), 125  (SiMe), 1376 (CH3), 
1463 (CH2), 2858 (CH2), 2930 (CH2), 2957 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.77 (dd, J = 10.0, 2.8 Hz, 1H, CH-12), 5.45 (br d, J = 9.9 Hz, 1H, CH-
11), 4.42 (q, J = 7.4 Hz, 1H, CH-16), 3.57 (tt, J = 10.5, 4.8 Hz, 1H, CH-3), 3.47 (br dd, J = 10.9, 4.0 
Hz, 1H, CH-26eq), 3.37 (t, J = 10.9 Hz, 1H, CH-26ax), 1.00 (d, J = 6.8 Hz, 3H, CH3-21), 0.88 (s, 9H, 
tBu), 0.81 (s, 3H, CH3-18), 0.79 (d, J = 6.3 Hz, 3H, CH3-27), 0.77 (s, 3H, CH3-19), 0.05 (s, 6H, 
Si(CH3)2).
 
13C NMR (101 MHz, CDCl3) δ 137.4 (CH, C-12), 124.9 (CH, C-11), 109.3 (C, C-22), 80.9 (CH, C-
16), 72.0 (CH, C-3), 66.8 (CH2, C-26), 58.7 (CH, C-17), 56.9 (CH, C-9), 53.0 (CH, C-14), 44.9 (CH, 
C-5), 42.9 (C, C-13), 41.5 (CH, C-20), 38.6 (CH2, C-4), 36.3 (CH2, C-1), 36.0 (C, C-10), 34.0 (CH, C-
8), 31.8 (CH2), 31.4 (CH2), 31.0 (CH2), 30.8 (CH2), 30.3 (CH, C-25), 29.3 (CH2), 28.8 (CH2), 25.9 
(CH3, tBu), 20.5 (CH3, C-18), 18.3(C, SiC(CH3)3), 17.1 (CH3, C-27), 14.5 (CH3, C-21), 12.9 (CH3, C-






MS (ESI+) m/z, (%): 253 (6, [M−H2O−C8H14O−TBSOH+H]
+), 385 (5, [M−H2O−C8H14O+H]
+), 529 
(99, [M+H]+), 551 (100, [M+Na]+); Fragment C8H14O corresponds to (R)-2-ethylidene-5-
methyltetrahydro-2H-pyran; 
HRMS (ESI+) m/z: [M+H] + Calcd for C33H57O3Si1 529.4072; Found 529.4071; 
Anal. Calcd for C33H56O3Si: C, 74.94; H, 10.67; Found: C, 74.79; H, 10.89. 
 
Alternative procedure: Steroid nonaflate nat-221 (30.0 mg, 36 µmol) was dissolved in dry pyridine 
(2 mL) and 10% palladium on carbon (30 mg) was suspended in the solution. The mixture was 
hydrogenated at rt with 10 bar H2 for 5 d, when the starting material was completely consumed. The 
catalyst was filtered off and the solvent was removed in vacuo. The residue was purified by flash 
chromatography on silica gel (1 g) in 5% EtOAc/hexanes to afford 16.3 mg (85%) of olefin nat-222 as 
colorless crystals. 
 
(25R)-5α-Spirostan-3β-ol or tigogenin (nat-215) 
Steroid nat-222 (20.0 mg, 37.8 µmol) was dissolved in a 
mixture of EtOH (1 mL), EtOAc (2.0 mL) and 10% palladium 
on carbon (3.0 mg) was suspended in the solution. The mixture 
was hydrogenated at 50 °C with 10 bar H2 for 8 h, when the 
starting material was completely consumed. The catalyst was 
filtered off and the solvent was removed in vacuo to afford 
15.5 mg (95%) of tigogenin at-215 as colorless crystals. 
Mp 206-208 °C (EtOH), Lit.346 Mp 209-211 °C (EtOH), 
1H NMR (400 MHz, CDCl3) δ 4.39 (ddd, J = 8.6, 7.6, 6.5 Hz, 1H, CH-16), 3.58 (tt, J = 11.1, 4.8 Hz, 
1H, CH-3), 3.47 (ddd, J = 10.8, 4.7, 1.9 Hz, 1H, CH-26eq), 3.37 (t, J = 10.8 Hz, 1H, CH-26ax), 1.98 
(ddd, J = 11.9, 7.5, 5.4 Hz, 1H, CH-15a), 0.96 (d, J = 7.0 Hz, 3H, CH3-21), 0.82 (s, 3H, CH3-19), 0.79 
(d, J = 6.3 Hz, 3H, CH3-27), 0.76 (s, 3H, CH3-18), 0.65 (ddd, J = 12.3, 10.6, 4.2 Hz, 1H, CH-9). 
13C NMR (101 MHz, CDCl3) δ 109.2 (C, C-22), 80.8 (CH, C-16), 71.3 (CH, C-3), 66.8 (CH2, C-26), 
62.2 (CH, C-17), 56.3 (CH, C-14), 54.3 (CH, C-9), 44.8 (CH, C-5), 41.6 (CH, C-20), 40.6 (C, C-13), 
40.1 (CH2, C-12), 38.2 (CH2, C-4), 39.0 (CH2, C-1), 35.6 (C, C-10), 35.1 (CH, C-8), 32.2 (CH2), 31.8 
(CH2), 31.5 (CH2), 31.4 (CH2), 30.3 (CH, C-25), 28.8 (CH2), 28.6 (CH2), 21.1 (CH2, C-11), 17.1 (CH3, 
C-27), 16.5 (CH3, C-18), 14.5 (CH3, C-21), 12.4 (CH3, C-19). 
The 1H and 13C NMR spectra are in agreement with the literature.294 
 
Alternative procedure: Steroid nonaflate nat-221 (70.0 mg, 85 µmol) was dissolved in mixture of 
EtOH (1.75 mL), EtOAc (3.5 mL), Et3N (35 µL, 250 µmol) and 10% palladium on carbon (17.5 mg) 
was suspended in the solution. The mixture was hydrogenated at rt with 10 bar H2 for 33 h, after which 
the starting material was completely consumed. The catalyst was filtered off and the solvent was 
removed in vacuo. The residue was purified by flash chromatography on silica gel (3 g) in 20% 
EtOAc/hexanes to afford 29.7 mg (84%) of steroid nat-215 as a colorless solid. Recrystallization from 
















A suspension of KH (42 mg of KH; 1.05 mmol, ca 35% w/v in mineral oil) was transferred to a pre-
dried Schlenk flask and washed with dry pentane (3 × 2 mL). The remaining solvent was evaporated in 
vacuo and the flask was back-filled with nitrogen. A solution of ketone ent-186A,a (348 mg, 
700 µmol) in THF (3 mL) was added dropwise at rt, which caused immediate foaming of the mixture. 
The suspension was stirred at rt for 1 h, the supernatant was transferred via cannula to a new pre-dried 
Schlenk flask followed by addition of tBuOH (7 µL, 70 µmol). Neat methyl iodide (130 µL, 
2.09 mmol) was added at once, turning the solution cl udy. The reaction mixture was stirred for 
another hour and quenched carefully with saturated q. NH4Cl (5 mL). The mixture was extracted with 
CH2Cl2 (3 × 3 mL) and the combined organic fractions were vaporated in vacuo to afford 360 mg 
(100%) of an inseparable mixture of isomers nt-205 as a white foam. The mixture consisted ca. 50% 
from the major isomers ent-205a,b in a 1:1 ratio, which were assigned based on the consumed material 
for the preparation of nonaflates nt-223 and ent-226 (vide infra). A 3:1 mixture of O-Methylated 
products ent-205d:ent-205e formed ca. 15% of the composition. 
IR (CHCl3); ν[cm-1]: 946, 1087 (ketal), 1132, 1178 (COCOC), 1366, 
1375 (CH3), 1440, 1456 (CH3), 1661 (C=C), 1700 (C=O), 2886 
(CH3), 2936 (CH2), 2974 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.27 (s, 6H, CH-4)a-f, 4.96 (qd, J = 6.6, 
1.6 Hz, 1H, CH-20)a, 4.77-4.67 (m, 1H, CH-20)b, 4.51 (qd, J = 6.4, 
4.1 Hz, 1H, CH-20)c, 4.36 (qd, J = 6.3, 5.0 Hz, 1H, CH-20)d, 4.34 
(qd, J = 6.4, 3.3 Hz, 1H, CH-20)e, 4.09 (qd, J = 6.5, 3.6 Hz, 1H, CH-
20)f, 4.04-3.85 (m, 24H, OCH2CH2O)
a-f, 3.53 (s, 3H, OMe)e, 3.48 (s, 
3H, OMe)d, 3.27-3.18 (m, 1H, CH-17)d, 2.80-2.74 (m, 1H, CH-17)e, 
2.57-0.71 (m, aliphatic region). 
Selected characteristic regions from 13C NMR (101 MHz, CDCl3) δ 
220.1 (C, C-12)b, 219.6 (C, C-12)c/f, 218.2 (C, C-12)c/f, 214.1 (C, C-12)a, 151.6 (C, C-5)e, 151.2 (C, C-
5)d, 150.8 (C, C-5)b, 150.3 (C, C-5)a, 145.2 (C, C-12)d, 143.7 (C, C-12)e, 123.0 (C, C-13)d, 122.9 (C, 
C-13)e, 120.5 (CH, C-4)a, 120.2 (CH, C-4)b, 119.6 (CH, C-4)d, 119.4 (CH, C-4)e, 106.2 (C, C-3)e, 
106.1 (C, C-3)d, 105.93 (C, C-3)b, 105.86 (C, C-3)a, 79.2 (CH, C-20)d, 77.6 (CH, C-20)e, 74.5 (CH, C-
20)a, 74.4 (CH, C-20)b. Signals of isomers ent-205 are marked with the respective letter of alphabet. 
Structure of ent-205c, ent-205f remained undetermined because of low concentration in the sample 
and overlapping signals. 
(ESI+) m/z, (%): 158 (4, [TEMPOH+H]+), 329 (10, [M−TEMPOH−C2H4+H]
+), 357 (4, 
[M−TEMPOH+H]+), 514 (100, [M+H]+), 536 (8, [M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C32H52NO4 514.3891; Found 514.3890; 
Anal. Calcd for C32H51NO4: C, 74.81; H, 10.01; N, 2.73; Found: C, 74.44; H, 10.21; N, 2.49. 
A suspension of KH (77 mg of KH; 1.92 mmol, ca 35% w/v in mineral oil) was transferred to a pre-
dried Schlenk flask and washed with dry pentane (3 × 2 mL). The remaining solvent was evaporated in 
vacuo and the flask was back-filled with nitrogen. A solution of ketone ent-205 (171.5 mg, 334 µmol) 
in THF (7 mL) was added dropwise at rt, followed by dry tBuOH (7 µL, 73 µmol). The reaction 
mixture was stirred at rt for 2 h and nonaflyl fluoride (200 µL, 1.11 mmol) was added at rt. After 
another hour at rt, the mixture was carefully quench d with saturated aq. NaHCO3 (10 mL) and 


















over Na2SO4. The solvent was evaporated in vacuo and the residue was purified by flash column 
chromatography on silica gel (11 g) in 5% EtOAc/hexanes + 1% Et3N to furnish 148.2 mg (56%) of 
1:1.5 mixture of nonaflates ent-223, followed by 27.5 mg (16%) of recovered ketone ent-205, both 
isolated as colorless oils. 
ent-223: IR (CHCl3); ν[cm-1]: 946, 1086, 1132, 1145 (CF3), 1201, 
1228, 1242 (CF3, SO2), 1353 (C-F), 1365, 1375 (CH3), 1411 (SO2), 
1440, 1456 (CH2), 1660, 1689 (C=C), 2874, 2885 (CH3), 2935 (CH2), 
2973 (CH3), 3028 (=CH). 
1H NMR (400 MHz, CDCl3) δ 5.57 (d, J = 1.9 Hz, 1H, CH-11), 5.53 
(d, J = 1.8 Hz, 1H, CH-11)*, 5.32 (t, J = 1.3 Hz, 1H, CH-4), 5.31 (t, J 
= 1.3 Hz, 1H, CH-4)*, 4.31 (qd, J = 6.6, 1.3 Hz, 1H, CH-20), 4.17 (qd, J = 6.5, 4.4 Hz, 1H, CH-20)*, 
4.05-3.85 (m, 8H, OCH2CH2O, OCH2CH2O*), 2.53 (ddd, J = 12.8, 11.5, 7.0 Hz, 1H, CH-14), 2.42-
0.95 (m, aliphatic region), 2.37-2.29 (m, 1H, CH-17)*, 1.99-1.89 (m, 1H, CH-9), 1.91-1.81 (m, 2H, 
CH-9*, CH-17), 1.87-1.77 (m, 1H, CH-14)*, 1.55-1.30 (m, 10H, CH2-3’, CH2-5’, CH2-3’*, CH2-5’*, 
CH-4’a, CH-4’a*), 1.32-1.25 (m, 2H, CH-4’b, CH-4’b*), 1.15 (d, J = 6.5 Hz, 3H, CH3-21), 1.093 (s, 
3H, CH3-18*), 1.087 (d, J = 6.5 Hz, 3H, CH3-21)*, 1.08 (br s, 9H, CH3-7’/CH3-9’, CH3-7’*, CH3-9’*), 
1.07 (br s, 6H, CH3-7’/CH3-9’, CH3-8’/CH3-10’*), 1.06 (s, 3H, CH3-8’/CH3-10’*), 1.05 (s, 3H, CH3-
19), 1.04 (s, 3H, CH3-18), 1.02 (s, 3H, CH3-19)*, 1.01 (s, 3H, CH3-8’/CH3-10’), 0.97 (s, 3H, CH3-
8’/CH3-10’); 
19F NMR (376 MHz, CDCl3) δ −81.59 to −81.69 (m, 6F, CF3, CF3*), −109.94 to −110.74 (m ,1F, 
CFaFbSO2), −110.73 to −111.56 (m ,1F, CFaFbSO2)*, −111.24 to −112.04 (m ,1F, CFaFbSO2), −111.56 
to −112.37 (m ,1F, CFa bSO2)*,−121.88 to −122.02 (m, 4F, CF2CF2CF3, CF2CF2CF3*), −126.78 to 
−126.93 (m, 4F, CF2CF2CF3, CF2CF2CF3*); 
13C NMR (101 MHz, CDCl3) δ 156.6 (C, C-12), 156.2 (C, C-12)*, 149.3 (C, C-5), 148.7 (C, C-5)*, 
122.0 (CH, C-4)*, 121.8 (CH, C-4), 116.2 (CH, C-11), 15.6 (CH, C-11)*, 105.81 (C, C-3)*, 105.78 
(C, C-3), 77.4 (CH, C-20)*, 76.6 (CH, C-20), 64.71 (CH2, OCH2CH2O), 64.66 (CH2, OCH2CH2O)*, 
64.3 (CH2, OCH2CH2O), 64.2 (CH2, OCH2CH2O)*, 60.3 (C, C-2’/C-6’, C-2’/C-6’*), 58.9 (C, C-2’/C-
6’, C-2’/C-6’*), 56.2 (CH, C-9), 56.1 (CH, C-9)*, 52.6 (CH, C-17), 49.95 (CH, C-14)*, 49.50 (CH, C-
17)*, 49.21 (C, C-13), 49.15 (CH, C-14), 47.8 (C, C-13), [40.7, 40.43, 2×40.35 (CH2, C-3’,C-5’, C-
3’*,C-5’*)], 38.1 (C, C-10), 38.0 (C, C-10)*, 34.3 (CH2, C-1), 34.2 (CH2, C-1)*, 33.89 (CH, C-8)*, 
33.85 (CH, C-8), [33.7, 33.6 (CH3, C-7’,C-9’, C-7’*,C-9’*)], 32.5 (CH2, C-6), 32.3 (CH2, C-6)*, 30.7 
(CH2, C-7)*, 30.6 (CH2, C-7), 29.7 (CH2, C-2), 29.6 (CH2, C-2)*, 24.0 (2×CH2, C-15, C-15*), 23.2 
(CH3, C-18)*, 22.5 (CH2, C-16)*, 22.2 (CH3, C-18), [21.4, 21.09 (CH3, C-8’,C-10’, C-8’*,C-10’*)], 
21.07 (CH2, C-16), 18.7 (CH3, C-21), 18.1 (CH3, C-19), 18.0 (CH3, C-19)*, 17.3 (CH2, C-4’, C-4’*), 
16.5 (CH3, C-21)*. Signals of minor diastereomer are marked with an asterisk. 
MS (ESI+) m/z, (%): 796 (100, [M+H]+); 





Alkoxyamine ent-223 (153.8 mg, 193 µmol) was dissolved in a mixture of CH2Cl2 (5 mL) and aq. 
phosphate buffer (pH 7.5, 0.5 M, 10 mL) and the biphasic mixture was cooled to 0 °C. m-CPBA 













45 min and was quenched with 10% aq. Na2S2O3 (5 mL). The mixture was extracted with CH2Cl2 (3 × 
5 mL), the combined organic layers were washed withNaHCO3 (2 × 5 mL), dried over MgSO4 and 
evaporated in vacuo. The residue was purified by flash chromatography on silica gel (5 g) in 5% to 
20% EtOAc/hexanes to afford 19.4 mg (13%) of recovered alkoxyamine ent-223a as a single 
diastereomer, followed by 16.0 mg (13%) of ent-226b and 83.3 mg (66%) of ent-226a, all of them 
isolated as colorless oils.  
ent-223a: 1H NMR (400 MHz, CDCl3) δ 5.57 (d, J = 1.9 Hz, 1H, CH-
11), 5.31 (t, J = 1.3 Hz, 1H, CH-4), 4.31 (qd, J = 6.5, 1.3 Hz, 1H, CH-
20), 4.05-3.85 (m, 4H, OCH2CH2O), 2.53 (ddd, J = 12.8, 11.5, 7.0 
Hz, 1H, CH-14), 2.36-2.27 (m, 1H, CH-6a), 2.19 (br ddd, J = 14.0, 
3.9, 1.8 Hz, 1H, CH-6b), 2.13-2.03 (m, 1H, CH-16a), 1.95 (dd, J = 
10.2, 2.1 Hz, 1H, CH-9), 1.89-1.83 (m, 1H, CH-17), 1.83-1.73 (m, 
1H, CH-16b), 1.82-1.73 (m, 1H, CH-7a), 1.80-1.68 (m, 1H, CH-8), 1.77-1.67 (m, 1H, CH-15a), 1.63-
1.51 (m, 1H, CH-1a), 1.55-1.42 (m, 1H, CH-4’a), 1.53-1.32 (m, 4H, CH2-3’, CH2-5’), 1.45-1.31 (m, 
1H, CH-7b), 1.43-1.33 (m, 1H, CH-15b), 1.30-1.22 (m, 3H, CH2-2, CH-4’b), 1.29-1.15 (m, 1H, CH-
1b), 1.15 (d, J = 6.5 Hz, 3H, CH3-21), 1.08 (s, 3H, CH3-7’/CH3-9’), 1.07 (s, 3H, CH3-7’/CH3-9’), 1.05 
(s, 3H, CH3-19), 1.04 (s, 3H, CH3-18), 1.01 (s, 3H, CH3-8’/CH3-10’), 0.97 (s, 3H, CH3-8’/CH3-10’); 
19F NMR (376 MHz, CDCl3) δ −81.65 (tquint, J = 9.8, 2.0 Hz, 3F, CF3), −111.44 to −111.68 (m, 2F, 
CF2SO2), −121.90 to −122.04 (m, 2F, CF2CF2CF3), −126.78 to −126.93 (m, 2F, CF2CF2CF3); 
MS (ESI+) m/z, (%): 796 (100, [M+H]+); 
13C NMR (101 MHz, CDCl3) δ 156.6 (C, C-12), 149.3 (C, C-5), 121.7 (CH, C-4), 116.2 (CH, C-11), 
105.8 (C, C-3), 76.6 (CH, C-20), 64.7 (CH2, OCH2CH2O), 64.3 (CH2, OCH2CH2O), 60.3 (C, C-2’/C-
6’), 58.9 (C, C-2’/C-6’), 56.2 (CH, C-9), 52.6 (CH, C-17), 49.21 (C, C-13), 49.15 (CH, C-14), 40.7 
(CH2, C-3’/C-5’), 40.4 (CH2, C-3’/C-5’), 38.1 (C, C-10), 34.3 (CH2, C-1), 33.90 (CH3, C-7’/C-9’), 
33.85 (CH, C-8), 33.7 (CH3, C-7’/C-9’), 32.5 (CH2, C-6), 30.6 (CH2, C-7), 29.7 (CH2, C-2), 24.0 
(CH2, C-15), 22.2 (CH3, C-18), 21.4 (CH3, C-8’/C-10’), 21.09 (CH3, C-8’/C-10’), 21.08 (CH2, C-16), 
18.7 (CH3, C-21), 18.1 (CH3, C-19), 17.3 (CH2, C-4’). 
Other spectral characteristics are identical to the mixture of diastereomers ent-223.  
 
ent-226a: IR (CHCl3); ν[cm-1]: 568 (SO2), 907, 946 (COCOC), 1090, 
1125, 1145 (CF3), 1179 (COCOC), 1228, 1242 (CF3, SO2), 1354 (C-F), 
1365 (CH2), 1382 (CH3), 1414 (SO2), 1660 (C=C), 1710 (C=O), 2858 
(CH2), 2883 (CH3), 2936 (CH2), 2973 (CH3). 
1H NMR (400 MHz, CDCl3) δ 5.56 (d, J = 2.2 Hz, 1H, CH-11), 5.31 (br s, 
1H, CH-4), 4.04-3.85 (m, 4H, OCH2CH2O), 2.87 (dd, J = 9.6, 2.7 Hz, 1H, 
CH-17), 2.33-2.22 (m, 1H, CH-6a), 2.31-2.19 (m, 1H, CH-14), 2.21-2.08 (m, 2H, CH-6b, CH-16a), 
2.13 (s, 3H, CH3-21), 2.04-1.97 (m, 1H, CH-9), 1.88-1.77 (m, 2H, CH2-2), 1.86-1.74 (m, 1H, CH-
15a), 1.80-1.68 (m, 4H, CH-1a, CH-7a, CH-8, CH-16b), 1.68-1.55 (m, 1H, CH-1b), 1.52-1.38 (m, 1H, 
CH-15b), 1.25-1.10 (m, 1H, CH-7b), 1.08 (s, 3H, CH3-18), 1.02 (s, 3H, CH3-19).
 
19F NMR (376 MHz, CDCl3) δ −80.66 (m, 3F, CF3,), −109.95 (dtq, J = 262.2, 14.2, 2.3 Hz, 1F, 
CFaFbSO2), −110.98 (dtq, J = 262.3, 14.1, 2.3 Hz, 1F, CFaFbSO2), −121.02 to −121.15 (m, 2F, 
CF2CF2CF3), −125.77 to −125.88 (m, 2F, CF2CF2CF3); 
13C NMR (101 MHz, CDCl3) δ 209.6 (C, C-20), 154.9 (C, C-12), 148.3 (C, C-5), 122.1 (CH, C-4), 
























55.7 (CH, C-9), 49.1 (CH, C-14), 48.8 (C, C-13), 37.9 (C, C-10), 34.0 (CH2, C-1), 33.5 (CH, C-8), 
32.3 (CH2, C-6), 30.48 (CH2, C-7), 30.45 (CH3, C-21), 29.6 (CH2, C-2), 26.2 (CH2, C-16), 24.1 (CH2, 
C-15), 21.5 (CH3, C-18), 18.0 (CH3, C-19).  
MS (ESI+) m/z, (%): 655 (100, [M+H]+), 677 (40, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C27H31F9NaO6S 677.1590; Found 677.1594; 
 
Minor diastereomer ent-226b: 
1H NMR (400 MHz, CDCl3) δ 5.68 (d, J = 1.4 Hz, 1H, CH-11), 5.31 (d, J 
= 1.3 Hz, 1H, CH-4), 4.06-3.83 (m, 4H, OCH2CH2O), 2.93 (dd, J = 8.0, 
4.0 Hz, 1H, CH-17), 2.35-2.08 (m, 2H, CH2-6), 2.17 (s, 3H, CH3-21), 
2.13-1.97 (m, 1H, CH-16a), 1.95-1.85 (m, 1H, CH-8), 1.89-1.82 (m, 2H, 
CH-9, CH-16b), 1.83-1.56 (m, 2H, CH2-1), 1.62-1.54 (m, 1H, CH-14), 
1.26 (s, 3H, CH3-18), 1.07 (s, 3H, CH3-19). Complete assignment of CH2 
groups in positions 2,7 and 15 was not possible due to overlapping signals in the aliphatic region. 
19F NMR (376 MHz, CDCl3) δ −80.66 (m, 3F, CF3), −110.17 (dtq, J = 262.1, 14.2, 2.3 Hz, 1F, 
CFaFbSO2 −111.07 (dtq, J = 262.3, 14.1, 2.3 Hz, 1F, CFaFbSO2), −121.02 to −121.15 (m, 2F, 
CF2CF2CF3*), −125.77 to −125.88 (m, 2F, CF2CF2CF3*); 
13C NMR (101 MHz, CDCl3) δ 209.7 (C, C-20), 154.4 (C, C-12), 149.1 (C, C-5), 121.3 (CH, C-4), 
115.4 (CH, C-11), 105.9 (C, C-3), 64.7 (CH2, OCH2CH2O), 64.2 (CH2, OCH2CH2O), 59.8 (CH, C-17), 
53.8 (CH, C-14), 51.0 (CH, C-9), 48.8 (C, C-13), 37.5 (C, C-10), 36.1 (CH, C-8), 34.1 (CH2, C-1), 
31.7 (CH2, C-6), 31.4 (CH2, C-7), 30.9 (CH3, C-21), 29.5 (CH2, C-2/C-15/C-16), 29.3 (CH3, C-18), 
29.1 (CH2, C-2/C-15/C-16), 28.6 (CH2, C-2/C-15/C-16), 18.0 (CH3, C-19). 
Stereochemistry of C-13 and C-17 was assigned based on the expected anti- stereoselectivity of the 
methylation of minor diastereomer nt-186a. 
 
ent-17α-Pregn-4-ene-3,20-dione or ent-17-isoprogesterone (ent-227a) 
Steroid ent-226a (23 mg, 35 µmol) was dissolved in a mixture of EtOH 
(1 mL), EtOAc (1 mL) and Et3N (35 µL, 0.25 mmol) and the mixture was 
hydrogenated over 10% Pd/C (10 mg, 9.4 µmol) at a slight overpressure of 
hydrogen baloon at rt for a total of 39 h. The catalys  was filtered off and 
solvents were evaporated. The residue was dissolved in a mixture of 
acetone (1 mL) and 1 M aq. HCl (150 µL), stirred at rt for 10 min, diluted with more 1 M aq. HCl 
(3 mL) and extracted with CHCl3 (3 × 1 mL). The combined extracts were washed withsaturated aq. 
NaHCO3 (3 mL), dried over MgSO4 and evaporated in vacuo. The residue was purified by flash 
chromatography on silica gel (1 g) in 20% to 40% EtOAc/hexanes to afford 2.6 mg (24%) of the 19:1 
mixture ent-227a and ent-227b, followed by 3.3 mg (26%) of a 1:1 mixture of alcohols ent-228. 
ent-227a: 
[α]D20 0 (c 0.037, EtOH); Lit. [α]D20 0 (c not given, EtOH) For nat-227a;301 
IR (ATR); ν[cm-1]: 868, 1113, 1168, 1232, 1357, 1383 (CH3), 1454, 1616 (C=C), 1671, 1706 (C=O), 
2861, 2930 (CH2). 
1H NMR (600 MHz, CDCl3) δ 6.01 (dd, J = 10.3, 2.1 Hz, 1H, CH-11*), 5.74 (br s, 1H, CH-4*), 5.72 
(br s, 1H, CH-4), 5.51 (br d, J = 10.2 Hz, 1H, CH-12*), 2.82 (dd, J = 8.3, 2.6 Hz, 1H, CH-17β*), 2.82 
(dd, J = 8.5, 2.7 Hz, 1H, CH-17β), 2.40 (ddd, J = 16.9, 14.4, 5.0 Hz, 1H, CH-2β), 2.37 (m, 1H, CH-

















(m, 1H, CH-16β), 1.86 (m, 1H, CH-7β), 1.83 (m, 1H, CH-15α), 1.78 (m, 1H, CH-12β), 1.75 (m, 1H, 
CH-16α), 1.67 (m, 1H, CH-1α), 1.59 (m, 1H, CH-11α), 1.51 (m, 1H, CH-8β), 1.45 (m, 1H, CH-11β), 
1.29 (m, 1H, CH-14α), 1.27 (m, 1H, CH-15β), 1.18 (m, 1H, CH-12α), 1.17 (s, 3H, CH3-19), 1.11 (m, 
1H, CH-7α), 0.96 (s, 3H, CH3-18), 0.91 (m, 1H, CH-9α). 
13C NMR (150.9 MHz, CDCl3) δ 212.6 (C, C-20), 199.4 (C, C-3), 171.0 (C, C-5), 123.9 (CH, C-4), 
61.0 (CH, C-17), 53.1 (CH, C-9), 49.7 (CH, C-14), 45.5 (C, C-13), 38.5 (C, C-10), 35.8 (CH, C-8), 
35.7 (CH2, C-1), 34.9 (CH2, C-12), 33.9 (CH2, C-2), 32.84 (CH2, C-6), 32.82 (CH3, C-21), 32.1 (CH2, 
C-7), 25.8 (CH2, C-15), 24.4 (CH2, C-16), 21.0 (CH2, C-11), 20.7 (CH3, C-18), 17.4 (CH3, C-19); 
MS (ESI+) m/z, (%): 315 (97, [M+H]+), 337 (100, [M+Na]+), 629 (33, [2M+H]+), 651 (68, [2M+Na]+); 
HRMS (ESI+) m/z: [M+H] + Calcd for C21H31O2 315.2319; Found 315.2322; 
The 1H NMR matched those reported for nat-enantiomer.347 1H NMR signals of minor component ent-
227b are marked by an *. 
 
ent-228: 
1H NMR (400 MHz, CDCl3) δ 3.76-3.67 (m, 4H, CH-2’, CH-2’*), 
3.61-3.55 (m, 4H, CH-1’, CH-1’*), 3.34-3.22 (m, 2H, CH-3, CH-
3*), 2.53-0.68 (m, aliphatic region), 2.14 (s, 3H, CH3-21), 2.12 (s, 
3H, CH3-21*), 0.91 (s, 3H, CH3), 0.89 (s, 3H, CH3), 0.88 (s, 3H, 
CH3), 0.76 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 212.5 (C, C-20*), 211.6 (C, C-20), 79.3 (CH, C-3), 78.9 (CH, C-3*), 
68.8 (CH2, C-1’), 68.7 (CH2, C-1’*), 62.15 (CH2, C-2’), 62.10 (CH2, C-2’*), 61.3 (CH, C-17*), 57.4 
(CH, C-17), 53.2 (CH), 53.0 (CH), 50.3 (CH), 48.5 (C), 45.9 (C), 44.6 (CH), 41.92 (CH), 41.89 (CH), 
39.9 (CH), 37.0 (2 × C, C-10, C-10*), 36.0 (CH), 35.5 (CH2), 35.3 (2 × CH2), 34.83 (CH2), 34.75 
(CH2), 33.0 (CH2), 32.8 (CH3, C-21*), 32.3 (CH2), 30.4 (CH2), 29.6 (CH3, C-21), 28.6 (CH2), 28.5 
(CH2), 28.2 (CH2), 27.2 (CH2), 27.1 (CH2), 26.9 (CH2), 26.6 (CH2), 25.9 (CH2), 25.4 (CH2), 24.3 
(CH2), 23.34 (CH3), 23.27 (CH3), 20.9 (CH3), 12.2 (CH3). Two compounds present in a ca. 1:1 ratio. 
Low amount of the sample did not allow complete assignment. 
MS (ESI+) m/z, (%): 385 (100, [M+Na]+), 748 (34, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C23H38O3Na 385.2714; Found 385.2713; 
 
ent-Pregn-4-ene-3,20-dione or ent-progesterone (ent-3) 
A solution of 9:1 mixture of steroid ent-227a:ent-227b (3.7 mg, 11.7 µmol) 
in EtOH (1.5 mL) and concentrated aq. HCl (35%, 0.3 mL) was refluxed 
for 1.5 h. The solution was diluted with water (1.5 mL) and extracted with 
CH2Cl2 (3 × 1 mL). The organic extracts were washed with saturated aq. 
NaHCO3 (3 mL), dried over MgSO4 and evaporated in vacuo. The residue was purified by flash 
chromatography on silica gel (1 g, impregnated by washing with 3% w/v AgNO3 in MeOH, drying by 
air at rt, then 10 min at 110 °C) in 6:3:1 CH2Cl2/hexane/MTBE to afford 1.7 mg (46%) of ent-
progesterone (ent-3) and ent-17-isoprogesterone nt-227a in 3:1 ratio. 
The 1H, 13C NMR, IR and MS spectra are in agreement with the literature,109 as well as with the 
spectra of commercial nat-progesterone (nat-3). Comparison of 1H and 13C NMR spectra is available 














When the reaction was performed wtihout purification on a 19:1 mixture of steroid ent-227a:ent-227b 
(2.5 mg, 8.0 µmol), the corresponding mixture 3:1 ent-3:ent-227a impure with 5% of ∆11-olefins was 
obtained in quantitative yield. 
5.3. SYNTHESIS OF THE TRUNCATED STEROID ANALOGS 
(2S,4aR,8aS)-4a-Methyldecahydronaphthalen-2-ol (ent-229) and 
(2R,4aS,8aR)-4a-methyldecahydronaphthalen-2-ol (nat-229)  
Benzoate 144 (451 mg, 1.57 mmol) was suspended in hydrazine monohydrate (5 mL) 
and dry ethylene glycol (2 mL) and the solution heated to 150 °C (oil bath) for 2.5 h. 
A part of liquid (5 mL) was distilled off, the remains were transferred into microwave 
vial with the help of dry ethylene glycol (2 × 0.5 mL). Powdered KOH (265 mg, 4.71 mmol) was 
added and the reaction mixture was irradiated in a microwave reactor at 200 °C for 15 min, the 
solution was cooled to rt and the pressure was releas d for safety reasons. The mixture was again 
irradiated in a microwave reactor at 200 °C for 2 h and subsequently poured into water (50 mL). The 
resulting emulsion was extracted with pentane (3 × 15 mL) and the combined organic extracts were 
dried over MgSO4. Evaporation of the solvents afforded 260 mg (98%) of the alcohol 229 as a low-
melting solid. 
Mp 40-42 °C; 
[α]D20 −43.9 (c 0.339, CHCl3) for ent-229; 
[α]D20 +47.5 (c 0.297, CHCl3) for nat-229; 
IR (CHCl3); ν[cm-1]: 1005, 1029, 1054 (C-OH), 1366, 1378 (CH3), 1448, 1467 (CH2), 2865 (CH2), 
2931 (CH2), 2978 (CH3), 3449, 3609 (OH); 
1H NMR (400 MHz, CDCl3) δ 3.60 (tt, J = 10.8, 4.5 Hz, 1H, CH-3), 1.85-1.71 (m, 1H, CH-6a), 1.82-
1.70 (m, 1H, CH-1a), 1.78-1.68 (m, 1H, CH-2a), 1.64 (td, J = 12.6, 10.8 Hz, 1H, CH-4a), 1.59-1.49 
(m, 1H, CH-4b), 1.58-1.45 (m, 2H, CH2-7), 1.51-1.37 (m, 1H, CH-2b), 1.47-1.37 (m, 1H, CH-9a), 
1.46-1.33 (m, 2H, CH2-8), 1.43-1.34 (m, 1H, CH-5), 1.33-1.22 (m, 1H, CH-6b), 1.25 (td, J = 13.7, 3.9 
Hz, 1H, CH-9b), 0.96 (d, J = 0.5 Hz, 3H, CH3-19), 0.88 (br dt, J = 13.3, 3.3 Hz, 1H, CH-1b). 
13C NMR (101 MHz, CDCl3) δ 71.7 (CH, C-3), 39.6 (CH, C-5), 39.4 (CH2, C-9), 36.8 (CH2, C-4), 
31.9 (C, C-10), 31.3 (CH2, C-2), 30.0 (br s, CH2, C-1), 27.7 (CH2, C-6), 27.1 (CH3, C-19), 22.1 (CH2, 
C-7), 20.6 (br s, CH2, C-8). 
MS (CI+) m/z, (%): 149 (30, [M−H2O−H
−]+), 151 (100, [M−H2O+H
+]+), 167 (5, [M−H−]+); 
HRMS (CI+) m/z: [M−H−]+ Calcd for C11H19O 167.1436; Found 167.1439;  
Anal. Calcd for C11H20O: C, 78.51; H, 11.98; Found: C, 78.72; H, 12.05. for ent-229. 
Anal. Calcd for C11H20O: C, 78.51; H, 11.98; Found: C, 78.47; H, 12.17. for nat-229. 
 
Pyridinium (2S,4aR,8aS)-4a-methyldecahydronaphthalen-2-yl sulfate (ent-117) and  
pyridinium (2 R,4aS,8aR)-4a-methyldecahydronaphthalen-2-yl sulfate (nat-117) 
Alcohol 229 (50 mg, 297 µmol) was dissolved in CH2Cl2 (5 mL) and a drop 
of pyridine. The pyridine-sulfur trioxide complex (104 mg, 0.65 mmol) was 
added and the resulting suspension was stirred overnight. The mixture was 
cooled to −18 °C, filtered and the filtrate was evapor ted in vacuo and redissolved in dry CH2Cl2 
(1 mL). The solution was again cooled to −18 °C andthe resulting precipitate filtered off. The filtrae 
is evaporated in vacuo to afford 98.5 mg (99%) sulfate 117 as a colorless solid.  







Mp 96-99 °C for nat-117; 
[α]D20 −38.3 (c 0.175, CHCl3) for ent-117; 
[α]D20 +27.5 (c 0.225, CHCl3) for nat-117; 
IR (CHCl3); ν[cm-1]: 621 (SO3−), 682 (=CH), 821 (COS), 837, 935, 959, 964 (COS), 1042 (SO3−), 
1176, 1262 (SO3
−), 1371 (CH3), 1449, 1469 (CH2), 1490, 1548, 1637 (ring), 2137 (NH
+), 2450-2750 
(NH+), 2866 (CH2), 2936 (CH2), 2978 (CH3), 3072, 3100 (=CH) ; 
1H NMR (400 MHz, CDCl3) δ 12.73 (br s, 1H, NH+), 9.00 (dd, J = 6.6, 1.5 Hz, 2H, CH-2’), 8.47 (tt, J 
= 7.9, 1.6 Hz, 1H, CH-4’), 8.01 (dd, J = 7.9, 6.7 Hz, 2H, CH-3’), 4.48-4.39 (m, 1H, CH-3), 2.01 (dqd, 
J = 12.6, 3.9, 1.7 Hz, 1H, CH-2a), 1.91-1.80 (m, 2H,C 2-4), 1.80-1.70 (m, 2H, CH-9a, CH-6a), 1.65 
(qd, J = 12.6, 3.9 Hz, 1H, CH-2b), 1.56-1.43 (m, 2H, CH2-7), 1.48-1.38 (m, 1H, CH-5), 1.46-1.36 (m, 
1H, CH-1a), 1.43-1.29 (m, 2H, CH2-8), 1.33-1.23 (m, 2H, CH-1b, CH-6b), 0.95 (s, 3H, CH3-19), 0.88 
(dt, J = 13.4, 3.1 Hz, 1H, CH-9b). 
13C NMR (150.9 MHz, CDCl3 at 50 °C) δ 145.4 (CH, C-4’), 142.6 (CH, C-2’), 127.1 (CH, C-3’), 79.3 
(CH, C-3), 39.8 (CH, C-5), 39.0 (br s, CH2, C-1), 33.8 (CH2, C-4), 31.9 (C, C-10), 30.5 (br s, CH2, C-
9), 28.6 (CH2, C-2), 27.7 (CH2, C-6), 27.1 (CH3, C-19), 22.2 (CH2, C-7), 20.8 (br s, CH2, C-8). 
MS (ESI−) m/z, (%): 247 (100, [M−C5H6N
+]−); 
HRMS (ESI−) m/z: [M−C5H6N
+]− Calcd for C11H19O4S 247.1010; Found 247.1007;  
Anal. Calcd for C16H25NO4S: C, 58.69; H, 7.70; N, 4.28; S, 9.79; Found: C, 57.66; H, 7.70; N, 4.28; 
for nat-117; 




Ketone nat-158 (1.73 g, 6.32 mmol), ethylene glycol (2 mL) and hydrazine 
monohydrate (5.0 mL, 103 mmol) were heated to 140 °C for 5 h. Approximately 
3.5 mL of liquid was distilled off and the concentrated residue was transferred to a 
microwave reaction vial. Powdered KOH (1.06 g, 18.9 mmol) was added to the vial 
and the mixture was heated to 180 °C for 30 min. The reaction mixture was poured in water (100 mL) 
and extracted with pentane (3 × 20 mL). The combined organic layers were washed with brine, dried 
over MgSO4 and evaporated in vacuo. Chromatography on silica gel (45 g) in 3% EtOAc/n-pentane 
afforded 333 (26%) of olefins nat-230, followed by 908 mg (55%) of ketal nat-231 as a colorless oil. 
[α]D20 +123.2 (c 0.574, CHCl3) for nat-231; 
IR (CHCl3); ν[cm-1]: 947, 954, 1014, 1086 (C-O-C), 1113, 1170 (ketal), 1233 (COCOC), 1364, 1380 
(CH3), 1451 (CH2), 1659 (C=C), 2855, 2886 (CH3), 2927 (CH2), 2970 (CH3); 
1H NMR (400 MHz, CDCl3) δ 5.24 (d, J = 1.4 Hz, 1H, CH-4), 4.04-3.85 (m, 4H, OCH2CH2O), 2.22 
(tdd, J = 13.7, 4.7, 1.6 Hz, 1H, CH-6a), 2.02 (ddd, J = 13.7, 4.3, 2.4 Hz, 1H, CH-6b), 1.80-1.70 (m, 
4H, CH-1a, CH2-2), 1.75-1.65 (m, 1H), 1.70-1.61 (m, 3H, CH-7a, CH-14a), 1.61-1.52 (m, 1H, CH-
1b), 1.35 (qt, J = 11.2, 3.6 Hz, 1H, CH-8), 1.23-1.12 (m, 2H), 1.15-1.01 (m, 1H, CH-7b), 1.04-0.95 
(m, 1H), 0.99 (s, 3H, CH3-19), 0.97-0.87 (m, 1H, CH-14b), 0.94-0.83 (m, 1H, CH-9); 
13C NMR (101 MHz, CDCl3) δ 151.9 (C, C-5), 119.6 (CH, C-4), 106.3 (C, C-3), 64.5 (CH2, 
OCH2CH2O), 64.2 (CH2, OCH2CH2O), 53.5 (CH, C-9), 37.6 (C, C-10), 37.1 (CH, C-8), 35.2 (CH2, C-
7), 34.7 (CH2, C-14), 34.6 (CH2, C-1), 32.1 (CH2, C-6), 29.9 (CH2, C-2), 26.8 (CH2), 26.3 (CH2), 25.6 
(CH2), 17.9 (CH3, C-19); 






HRMS (ESI+) m/z: [M+Na]+ Calcd for C17H26NaO2 285.1825; Found 285.1824;  
Anal. Calcd for C17H26O2: C, 77.82; H, 9.99; Found: C, 77.94; H, 10.08. for nat-231; 
 
nat-230: 1:1.7:1.6 Mixture of 5α:5β:∆4 isomers as determined by 1H NMR spectrum. 
1H NMR (400 MHz, CDCl3) δ 5.70-5.63 (m, 1H, CH-3)β, 5.57-5.52 (m, 1H, CH-3)α, 
5.36 (dq, J = 10.0, 2.0 Hz, 1H, CH-4)β, 5.31-5.29 (m, 1H, CH-4)*, 5.28 (dq, J = 
10.0, 2.0 Hz, 1H, CH-4)α, 2.27-0.68 (m, aliphatic region), 0.97 (s, 3H, CH3-19)*, 
0.90 (s, 3H, CH3-19)
β, 0.72 (s, 3H, CH3-19)
α. 
13C NMR (101 MHz, CDCl3) δ 145.3 (C, C-5*), 132.3 (CH, C-3β/C-4β), 131.5 (CH, C-4*), 126.9 (CH, 
C-3β/C-4β), 125.5 (CH, C-3α/C-4α), 119.0 (CH, C-3α/C-4α), 54.0 (CH, C-9*), 52.7 (CH, C-9α), 45.9 
(CH, C-5α), 43.6 (CH, C-5β), 40.5 (CH, C-9β), 37.5 (CH2, C-1*), 37.4 (CH, C-8*), 37.3 (CH, C-8
α), 
36.9 (CH, C-8β), 36.1 (CH2), 35.3 (CH2)
α, 35.1, 35.02, 34.98 (CH2)
α, 33.8 (CH2)
α, 33.4 (CH2), 32.7 
(CH2), 30.3 (CH2), 27.6 (CH2), 27.45 (CH2), 27.44 (CH2)
α, 27.1 (CH2)
α, 27.0 (CH2), 26.7 (CH2), 26.6 
(CH2)
α, 26.5 (CH2), 26.02 (CH2), 26.00 (CH2), 25.9 (CH2), 25.5 (CH2)
α, 23.5 (CH2)
α, 23.0 (CH3, C-
19β), 22.5 (CH2), 19.8 (CH3, C-19*), 19.3 (CH2), 11.7 (CH3, C-19
α). Signals of minor 5α-isomer are 
denoted with α, signals of major 5β-isomer with β and signals of ∆4-double bond isomer * where 
possible. Quarternary carbons C-10 were lost in sigal noise. 
 
ent-3-(Ethylenedioxy)-des-D-18-norandrost-4-ene (ent-231) 
Ketone ent-158 (1.00 g, 3.62 mmol) was dissolved in MeOH (25 mL) and tosyl hydrazide (1.01 g, 
5.42 mmol) was added to the stirred solution at rt. Af er 30 min, the conversion to hydrazone was 
complete, as shown by TLC. Solid NaBH4 (2.74 g, 72.4 mmol) was added to the stirred mixture with 
cooling to 25 °C over 1 h. The resulting mixture was stirred overnight, poured in 
water (100 mL) and extracted with pentane (3 × 20 mL). The combined organic 
layers were washed with brine, dried over MgSO4 and evaporated in vacuo. 
Chromatography on silica gel (30 g) in 3% EtOAc/n-pentane afforded 708 mg 
(75%) of ketal ent-231. 
The spectral data were identical to enantiomer nat-231. 
 
Des-D-18-nor-5β-androstan-3-one (nat-233) 
Ketal 231 (380 mg, 1.45 mmol) was dissolved in acetone (10 mL) and water 
(0.5 mL), 3 drops of concentrated aq. HCl (35%) were added and the mixture was 
stirred at rt overnight. The solution was concentrated in vacuo, poured into 5% HCl 
(30 mL) and extracted with pentane (3 × 20 mL). The combined organic extracts 
were washed with saturated aq. NaHCO3, dried over MgSO4 and evaporated in vacuo. The residue was 
dissolved in EtOH (20 mL), a solution of KOH (45 mg) in water (120 µL) was added, followed by 5% 
Pd/CaCO3 catalyst (40 mg). The mixture was hydrogenated using a slight overpressure of hydrogen 
gas for 3 h. The catalyst was filtered off and the solvents partially evaporated. The residue was poured 
into water and extracted with pentane (3 × 20 mL). The combined organic extracts were dried over 
MgSO4 and evaporated in vacuo to afford 291 mg (91%) of ketone 233 as a 1 : 9 mixture of 5α- and 
5β-isomers.  
[α]D20 +27.8 (c 0.431, CHCl3); 
















1H NMR (400 MHz, CDCl3) δ 2.85 (ddd, J = 14.6, 6.0, 1.0 Hz, 1H, CH-4a)*, 2.72 (ddd, 1H, J = 14.9, 
13.3, 0.8 Hz, CH-4a), 2.37 (tdd, J = 14.7, 5.5, 0.9 Hz, 1H, CH-2a), 2.16 (dddd, J = 14.7, 4.3, 3.1, 2.4 
Hz, 1H, CH-2b), 2.06 (ddd, J = 14.5, 5.5, 3.1 Hz, 1H, CH-1a), 2.02 (ddd, J = 14.9, 4.7, 2.4 Hz, 1H, 
CH-4b), 1.96-1.85 (m, 1H, CH-6a), 1.86-1.77 (m, 2H, CH-5), 1.72-1.65 (m, 4H, CH-14a), 1.49-1.42 
(m, 2H, CH-7a, CH-9), 1.41-1.31 (m, 2H, CH-1b, CH-8) 1.27-1.15 (m, 4H, CH-6b, CH-7b, CH-14b), 
1.07-0.98 (m, 1H), 0.97 (s, 3H, CH3-19), 0.96 (s, 3H, CH3-19)*. 
13C NMR (101 MHz, CDCl3) δ 213.4 (C, C-3), 53.2 (CH)*, 46.6 (CH)*, 44.7 (CH2)*, 44.5 (CH, C-5), 
42.3 (CH2, C-4), 40.4 (CH, C-9), 38.2 (CH2)*, 38.1 (CH2)*, 37.3 (CH2, C-2), 36.9 (CH, C-8), 36.8 
(CH)*, 36.5 (CH2, C-1), 35.1 (CH2, C-14), 35.0 (C, C-10), 34.5 (CH2)*, 28.9 (CH2)*, 28.4 (CH2, C-7), 
27.3 (CH2), 27.0 (CH2)*, 26.51 (CH2), 26.49 (CH2)*, 26.45 (CH2), 26.41 (CH2)*, 25.9 (CH2)*, 25.6 
(CH2), 22.7 (CH3, C-19), 11.4 (CH3, C-19)*. 
Signals of minor 5α-isomer are denoted with asterisk. Signal of CH2-14 was assigned by comparison 
with alcohol 234 and sulfate 118. 
MS (EI+) m/z, (%): 149 (100, [M−C4H5O]
+), 220 (66, [M]+•); 
HRMS (EI+) m/z: [M] +• Calcd for C15H24O 220.1822; Found 220.1825;  
Anal. Calcd for C15H24O: C, 81.76; H, 10.98; Found: C, 81.61; H, 11.03. 
 
Des-D-18-nor-5β-androstan-3α-ol (nat-234) and ent-des-D-18-nor-5β-androstan-3α-ol (ent-234) 
Ketone 233 (274 mg, 1.24 mmol) was dissolved in CH2 l2 (5 mL) and dry MeOH 
(5 mL) and the solution was cooled to −78 °C. Dried CeCl3 (337 mg, 1.37 mmol) 
was added to the stirred solution, followed by NaBH4 (52 mg, 1.37 mmol). After 
15 min of stirring at −78 °C, the reaction mixture was warmed slowly to rt and 
quenched with 5% aq. HCl (25 mL). The resulting mixture was extracted with CH2Cl2 (3 × 10 mL) 
and the combined organic extracts were washed with sa urated aq. NaHCO3, dried over MgSO4 and 
evaporated in vacuo. Multiple chromatography on silica gel (10 g) in 10% Et2O/n-pentane afforded 
186.6 mg (78%) of single diastereomer of 3α,5β-alcohol 234 as a colorless amorphous solid. 
[α]D20 +21.8 (c 0.294, CHCl3) for nat-234; 
[α]D20 −34.0 (c 0.209, CHCl3) for ent-234; 
IR (CHCl3); ν[cm-1]: 1015, 1035 (C-OH), 1364, 1380 (CH3), 1450 (CH2), 2858 (CH2), 2927 (CH2), 
2977 (CH2), 3452, 3609 (OH); 
1H NMR (500 MHz, CDCl3) δ 3.62 (tt, J = 11.1, 4.7 Hz, 1H, CH-3), 2.18 (br s, 1H, OH), 1.91-1.84 
(m, 1H, CH-6a), 1.87-1.77 (m, 1H, CH-14a), 1.84-1.72 (m, 1H, CH-4a), 1.80-1.71 (m, 1H, CH-13a), 
1.70-1.62 (m, 1H, CH-2a), 1.70-1.60 (m, 1H, CH-11a), .66-1.58 (m, 2H, CH-1a, CH-7a), 1.50 (dddd, 
J = 12.6, 4.7, 3.8, 2.4 Hz, 1H, CH-4b), 1.46-1.39 (m, 1H, CH-9), 1.44-1.31 (m, 1H, CH-2b), 1.42-1.35 
(m, 1H, CH-5), 1.39-1.32 (m, 1H, CH-12a), 1.33-1.24 (m, 1H, CH-8), 1.29-1.15 (m, 2H, CH-6b, CH-
12b), 1.24-1.14 (m, 2H, CH-13b, CH-11b), 1.04-0.90 (m, 2H, CH-1b, CH-14b), 0.96-0.84 (m, 1H, 
CH-7b), 0.87 (s, 3H, CH3-19). 
13C NMR (150.9 MHz, CDCl3) δ 71.7 (CH, C-3), 42.2 (CH, C-5), 40.0 (CH, C-9), 37.3 (CH, C-8), 
36.2 (CH2, C-4), 35.2 (CH2, C-1), 34.6 (CH2, C-14), 34.5 (C, C-10), 30.5 (CH2, C-2), 29.1 (CH2, C-
12), 27.3 (CH2, C-13), 27.0 (CH2, C-6), 26.5 (CH2, C-11), 25.3 (CH2, C-7), 23.3 (CH3, C-19). 
MS (ESI+) m/z, (%): 245 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C15H26NaO 245.1876; Found 245.1875;  
Anal. Calcd for C15H26O: C, 81.07; H, 11.79; Found: C, 81.11; H, 11.98. for nat-234. 






Pyridinium ent-des-D-18-nor-5β-androstan-3α-yl sulfate (ent-118) and pyridinium des-D-18-nor-
5β-androstan-3α-yl sulfate (nat-118) 
Alcohol 234 (166 mg, 747 µmol) was dissolved in CH2Cl2 (5 mL) and three 
drops of pyridine. The pyridine-sulfur trioxide complex (262 mg, 
1.65 mmol) was added and the resulting suspension was stirred overnight. 
The mixture was cooled to −18 °C and filtered. The filtrate was evaporated 
in vacuo and redissolved in dry CH2Cl2 (3 mL). The solution was again cooled to −18 °C and the 
resulting precipitate filtered off. The filtrate was evaporated in vacuo to afford 248 mg (87%) of 
sulfate 118 as a colorless crystalline solid. 
[α]D20 +22.6 (c 0.230, CHCl3) for nat-118; 
[α]D20 −24.1 (c 0.311, CHCl3) for ent-118; 
IR (CHCl3); ν[cm-1]: 624 (SO3−), 682 (=CH), 828 (COS), 953, 970 (COS), 1047 (SO3−), 1171, 1255 
(SO3
−), 1380 (CH3), 1450 (CH2), 1490 (ring), 2135 (NH
+), 2450-2750 (NH+), 2856 (CH2), 2927 (CH2); 
1H NMR (400 MHz, CDCl3) δ 9.01-8.99 (m, 2H, CH-2’), 8.48 (tt, J = 7.9, 1.6 Hz, 1H, CH-4’), 8.03-
7.99 (m, 2H, CH-3’), 4.47 (tt, J = 11.3, 4.9 Hz, 1H, CH-3), 2.03-1.90 (m, 2H, CH-4a, CH-2a), 1.88-
1.79 (m, 3H, CH-4b, CH-14a, CH-6a), 1.78-1.71 (m, 1H CH-13a), 1.66-1.56 (m, 2H, CH-1a, CH-
11a), 1.63-1.54 (m, 1H, CH-7a), 1.60-1.52 (m, 1H, C-2b), 1.48-1.38 (m, 2H, CH-5, CH-9), 1.38-1.30 
(m, 1H, CH-12a), 1.35-1.22 (m, 1H, CH-8), 1.30-1.20 (m, 2H, CH-12b, CH-6b), 1.20-1.12 (m, 2H, 
CH-13b, CH-11b), 1.04-0.95 (m, 1H, CH-14b), 1.00-0.90 (m, 1H, CH-1b), 0.93-0.83 (m, 1H, CH-7b), 
0.86 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 145.6 (CH, C-4’), 142.4 (CH, C-2’), 127.1 (CH, C-3’), 79.7 (CH, C-3), 
42.3 (CH, C-5), 40.1 (CH, C-9), 37.3 (CH, C-8), 35.3 (CH2, C-1), 34.7 (CH2, C-14), 34.5 (C, C-10), 
33.3 (CH2, C-4), 29.19 (CH2, C-12), 27.9 (CH2, C-2), 27.4 (CH2, C-13), 26.9 (CH2, C-6), 26.6 (CH2, 
C-11), 25.4 (CH2, C-7), 23.3 (CH3, C-19). 
Signals of CH2-6, CH2-7, CH2-11, CH2-12, CH2-13 and CH2-14 were assigned by comparison with 
alcohol 234.  
MS (ESI−) m/z, (%): 301 (100, [M−C5H6N
+]−); 
HRMS (ESI−) m/z: [M−C5H6N
+]− Calcd for C15H25O4S 301.1479; Found 301.1479;  
Anal. Calcd for C20H31NO4S: C, 62.96; H, 8.19; N, 3.67; Found: C, 60.82; H, 8.09; N, 3.61; for nat-
118. 
Anal. Calcd for C20H31NO4S: C, 62.96; H, 8.19; N, 3.67; Found: C, 62.71; H, 8.40; N, 2.81; for ent- 
118. 
 
5.4. SYNTHESIS OF [18,18,18]-D3 PREGNANE STEROIDS 
3α-(Methoxymethoxy)-5β-pregnan-20-one (235) 
To a stirred solution of pregnanolone at-7 (10.00 g, 31.4 mmol) and N,N-
diisopropylethylamine (13.67 mL, 78.5 mmol) in THF (70 mL), 
chloromethylmethylether (4.77 mL, 62.8 mmol) was added dropwise. The 
reaction mixture was refluxed for 2 h. After this time, the conversion was 
complete as indicated by TLC (hexanes:acetone 8:2). The reaction mixture 
was cooled to rt and quenched with saturated aq. NH4Cl (150 mL). The mixture was extracted with 










MgSO4. Evaporation in vacuo afforded 11.15 g (98%) of 235 as an amber oil, which was crystallized 
from EtOAc/heptane. 
Mp 72-73 °C; 
[α]D20 +105.8 (c 0.257, CHCl3); 
IR (CHCl3); ν[cm-1]: 1039, 1047, 1103, 1145 (COCOC), 1359, 1373, 1385 (CH3), 1698 (C=O), 2869, 
2889, 2940 (CH2);  
1H NMR (400 MHz, CDCl3) δ 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 3.54 (tt, J = 11.2, 4.7 Hz, 
1H, CH-3), 3.38 (s, 3H, OCH3), 2.53 (t, J = 9.0 Hz, 1H, CH-17), 2.11 (s, 3H, CH3-21), 0.92 (s, 3H, 
CH3-19), 0.59 (s, 3H, CH3-18);  
13C NMR (101 MHz, CDCl3) δ 209.7, 94.6, 76.8, 63.9, 56.7, 55.2, 44.3, 42.0, 40.3, 39.2, 35.8, 35.3, 
34.7, 33.5, 31.5, 27.7, 27.1, 26.3, 24.4, 23.3, 22.8, 20.8, 13.4; 
MS (ESI+) m/z, (%): 385 (100, [M+Na]+), 748 (7, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C23H38NaO3: 385.2713; Found 385.2713. 
Anal. Calcd for C23H38O3: C, 76.20; H, 10.56; Found: C, 76.12; H, 10.52. 
 
(20R)-3α-(Methoxymethoxy)-5β-pregnan-20-ol (236) and (20S)-3α-(methoxymethoxy)-5β-
pregnan-20-ol (237) 
Ketone 235 (11.15 g, 30.8 mmol) was dissolved in MeOH (250 mL) and the solution was cooled to 
0 °C. Sodium borohydride (1.78 g, 47.05 mmol) was added slowly with stirring. The mixture was kept 
at 0 °C for 2 h, after which it was concentrated in vacuo, poured into 5% aq. citric acid (100 mL) and 
extracted with Et2O (3 × 50 mL). The combined organic layers were washed consecutively with 
saturated aq. NaHCO3 (100 mL), brine (100 mL) and dried with MgSO4. Evaporation in vacuo 
afforded mixture of stereoisomers, which were separated by chromatography on a column of silica gel 
(300 g) in hexanes/EtOAc 9:1 to yield 9.84 g (86%) of compound 236 as a colorless oil and 619 mg 
(7%) of minor S-isomer 237 as colorless crystals. 
236: Mp 95-96 °C (Et2O/hexanes);  
[α]D20 +27.9 (c 0.287, CHCl3); 
IR (CHCl3); ν[cm-1]: 1039, 1046 (C-OH), 1103, 1145 (CH2, OCH2O), 
1235, 1450 (OCH3), 2934 (OCH2O), 3471, 3615 (OH);  
1H NMR (400 MHz, CDCl3) δ 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O), 
3.69 (dq, J = 8.4, 6.2 Hz, 1H, CH-20), 3.53 (tt, J = 11.2, 4.7 Hz, 1H, CH-
3), 3.37 (s, 3H, OCH3), 1.22 (d, J = 6.2 Hz, 3H, CH3-21), 0.92 (s, 3H, CH3-19), 0.64 (s, 3H, CH3-18);  
13C NMR (101 MHz, CDCl3) δ 94.5, 76.8, 70.3, 58.5, 56.3, 55.1, 42.1, 41.9, 40.4, 39.2, 35.4, 35.3, 
34.7, 33.5, 27.7, 27.2, 26.4, 25.7, 24.1, 23.44, 23.36, 20.5, 12.6; 
MS (ESI+) m/z, (%): 387 (100, [M+Na]+), 752 (3, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C23H40NaO3 387.2870; Found 387.2870.  
Anal. Calcd for C23H40O3: C, 75.77; H, 11.06; Found: C, 75.94; H, 11.19. 
 
237:[α]D20 +17.9 (c 0.190, CHCl3); 
IR (CHCl3); ν[cm-1]: 1040 (C-OH), 1102, 1145 (CH2, OCH2O), 1377, 1450 
(CH3), 2869, 2890, 2933, 2942 (CH2), 3611 (OH);  
1H NMR (400 MHz, CDCl3) δ 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O), 








3), 3.37 (s, 3H, OCH3), 1.13 (d, J = 6.1 Hz, 3H, CH3-21), 0.92 (s, 3H, CH3-19), 0.73 (s, 3H, CH3-18);  
13C NMR (101 MHz, CDCl3) δ 94.6, 76.9, 70.6, 58.7, 56.0, 55.1, 42.6, 42.2, 40.5, 40.3, 35.7, 35.4, 
34.8, 33.6, 27.7, 27.2, 26.5, 25.7, 24.5, 23.6, 23.4, 20.7, 12.5; 
MS (ESI+) m/z, (%): 387 (67, [M+Na]+), 752 (100, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C23H40NaO3 387.2870; Found 387.2870.  
Anal. Calcd for C23H40O3: C, 75.77; H, 11.06; Found: C, 75.77; H, 11.08. 
 
(20R)-18-Iodo-3α-(methoxymethoxy)-5β-pregnan-20-ol (238), 
17α-iodo-3α-(methoxymethoxy)-5β-androstane (239) and 17β-iodo-3α-(methoxymethoxy)-5β-
androstane (240) 
In 500 mL jacketed flask, alcohol 236 (9.85 g, 27.0 mmol) together with iodine (6.90 g, 27.2 mmol) 
and bis(acetoxy)iodobenzene (9.95 g, 30.9 mmol) were dissolved in CH2Cl2 (750 mL) and the mixture 
was cooled to 15 °C. The reaction vessel was irradiate  by a halogen floodlight (500 W) for 3 h and 
the reaction was quenched with an aq. solution (200mL) of Na2S2O3 (20 g) and NaHCO3 (10 g). The 
colorless organic layer was washed with brine (200 mL), dried with MgSO4 and concentrated in 
vacuo. The resulting oil was dissolved in a minimal amount of hexanes and crystallized at 5°C to yield 
4.19 g of colorless crystals 238. The mother liquor was concentrated in vacuo, adsorbed on a column 
of Florisil (4 × 30 cm) and eluted with 5% to 15% EtOAc in hexanes to afford 1.54 g (13%) of 17-iodo 
derivatives 239 and 240 as a colorless oil, followed by 3.49 g of 238 (58% overall) as an off-white 
solid.  
238:Mp 124-125.5 °C (Hexanes);  
[α]D20 +9.4 (c 0.233, CHCl3); 
IR (CHCl3); ν[cm-1]: 1045 (C-OH), 1102, 1145 (CH2, OCH2O), 1376 
(CH3), 1423 (CH2I), 2887, 2932, 2944 (CH2), 3600 (OH);  
1H NMR (400 MHz, CDCl3) δ 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-
3), 4.06 (dqd, J = 10.1, 6.1, 4.1 Hz, 1H, CH-20), 3.53 (tt, J = 11.2, 4.6 Hz, 1H, CH-3), 3.37 (s, 3H, 
OCH3), 3.32 (dd, J = 10.6, 1.3 Hz, 1H, CH-18a), 3.13 (dd, J = 10.6, 1.1 Hz, 1H, CH-18b), 2.39 (dt, J = 
13.4, 3.0 Hz, 1H, CH-12β), 2.25 (d, J = 4.2 Hz, 1H, OH), 1.14 (d, J = 6.2 Hz, 3H, CH3-21), 0.92 (s, 
3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 94.6, 76.7, 68.4, 58.8, 56.3, 55.2, 44.5, 41.9, 40.8, 40.3, 36.4, 35.3, 
34.7, 33.6, 27.7, 27.1, 26.3, 25.4, 24.4, 23.3, 22.2, 20.2, 11.2; 
MS (ESI+) m/z, (%): 513 (98, [M+Na]+), 1004 (100, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C23H39INaO3 513.1836; Found 513.1836.  
 
The fraction of 17-iododerivatives was purified by silica gel (45 g) column chromatography in 2% to 
5% EtOAc/hexanes to afford 630 mg (5%) of 239 as a colorless oil, followed by 654 mg (5%) of 240 
as a colorless oil. 
17α-Iodo-3α-(methoxymethoxy)-5β-androstane (239) 
[α]D20 −36.0 (c 0.314, CHCl3); 
IR (CHCl3); ν[cm-1]: 576 (C-I), 911, 1042, 1104, 1145 (COCOC), 1376 
(CH3), 1469 (CH2), 2826, 2887 (CH2). 
1H NMR (400 MHz, CDCl3) δ 4.70 (AB system, J = 6.8 Hz, 2H, OCH2O), 









3.38 (s, 3H, OCH3), 2.77 (dddd, J = 16.0, 11.0, 7.0, 3.7 Hz, 1H, CH-16a), 2.42 (dddd, J = 16.3, 9.6, 
6.0, 1.0 Hz, 1H, CH-16b), 0.94 (s, 3H, CH3-19), 0.81 (s, 3H, CH3-18). 
13C NMR (101 MHz, CDCl3) δ 94.6, 76.8, 55.2, 49.2, 48.2, 45.6, 42.1, 41.0, 40.0, 36.9, 36.6, 35.5, 
34.8, 33.6, 27.7, 27.2, 26.6, 25.1, 23.4, 21.6, 15.7. 
MS (ESI+) m/z, (%): 257 (81, [M+H−HI−CH3OCH2OH]
+), 341 (100, [M+Na−HI]+), 385 (17, [M+H 
−CH3OCH2OH]
+), 469 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H35INaO2 469.1574; Found 469.1574. 
 
17β-Iodo-3α-(methoxymethoxy)-5β-androstane (240) 
[α]D20 +88.5 (c 0.287, CHCl3).  
IR (CHCl3); ν[cm-1]: 606 (C-I), 915 (COCOC), 1036, 1047, 1102, 1145, 
1376 (CH3), 
2869, 2940 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O), 
3.76 (t, J = 9.5 Hz, 1H, CH-17), 3.53 (tt, J = 11.3, 4.8 Hz, 1H, CH-3), 3.37 (s, 3H, OCH3), 2.29 (dtd, J 
= 14.0, 9.3, 5.7 Hz, 1H, CH-16a), 2.08 (dddd, J = 13.9, 11.7, 10.0, 3.7 Hz, 1H, CH-16b), 0.93 (s, 3H
CH3-19), 0.79 (s, 3H, CH3-18).  
13C NMR (101 MHz, CDCl3) δ 94.6, 76.8, 55.2, 50.0, 44.2, 42.2, 42.1, 40.6, 37.3, 37.0, 35.4, 34.8, 
34.3, 33.6, 27.7, 27.1, 26.3, 25.4, 23.4, 20.5, 17.0. 
MS (ESI+) m/z, (%): 469 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H35INaO2 469.1574; Found 469.1574.  
 
(20R)-18-Iodo-3α,20-bis(methoxymethoxy)-5β-pregnane (242) 
To a stirred solution of alcohol 238 (1.808 g, 3.69 mmol) and N,N-
diisopropylethylamine (1.28 mL, 7.35 mmol) in THF (25 mL), 
bromomethyl methyl ether (500 µL, 6.12 mmol) was added dropwise 
at rt and the mixture was warmed to 50 °C for 2 h. T e mixture was 
quenched with water (10 mL) and extracted with CHCl3 (3 × 15 mL). 
The combined extracts were washed with saturated aq. N HCO3 (100 mL) and dried with MgSO4. 
Evaporation in vacuo afforded 1.95 g (99%) compound 242 as a pale yellow oil. 
[α]D20 +57.6 (c 0.264, CHCl3); 
IR (CHCl3); ν[cm-1]: 591 (CH2I), 1041 (C-O), 1103, 1145 (CH2, OCH2O), 1375 (CH3), 1165 (CH2I), 
2886 (CH2);  
1H NMR (400 MHz, CDCl3) δ 4.88 (d, J = 6.6 Hz, 1H, OCHaHbO-20), 4.70 (d, J = 6.6 Hz, 1H, 
OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 3.89 (dq, J = 9.5, 6.0 Hz, 1H, CH-20), 
3.53 (tt, J = 11.2, 4.6 Hz, 1H, CH-3), 3.38 (s, 3H, OCH3), 3.37 (s, 3H, OCH3), 3.32 (dd, J = 10.9, 1.0 
Hz, 1H, CH-18a), 3.13 (dd, J = 10.9, 0.9 Hz, 1H, CH-18b), 2.42 (dt, J = 13.5, 3.11 Hz, 1H, CH-12β), 
1.18 (d, J = 6.1 Hz, 3H, CH3-21), 0.92 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 97.0, 94.6, 76.8, 76.5, 57.1, 56.3, 55.5, 55.1, 43.7, 41.9, 40.43, 40.41, 
36.4, 35.3, 34.7, 33.6, 27.7, 27.1, 26.2, 25.0, 24.0, 23.4, 20.6, 20.4, 9.5; 
MS (ESI+) m/z, (%): 557 (100, [M+Na]+), 1092 (10, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H43INaO4 557.2098; Found 557.2095.  










(20R)-18,20-Epoxy-3α-(methoxymethoxy)-5β-pregnane (241) and (20R)-18,20-epoxy-5β-
pregnan-3α-ol (253b) 
Steroid 242 (175 mg, 327 µmol) and KOH (92 mg, 1.6 mmol) were 
dissolved in anhydrous HMPA (6 mL) and heated to 120 °C for 2 h. The 
reaction mixture was cooled to rt, poured into water (40 mL) and extracted 
with 1:4 CH2Cl2/hexane (3 × 10 mL). The combined organic layers were 
dried over MgSO4 and evaporated in vacuo. Preparative TLC in 20% 
EtOAc/hexanes afforded 101 mg (85%) of 241. 
241: 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O), 3.72 (qd, J = 6.3, 3.0 Hz, 1H, CH-20), 3.68 (d, J = 
9.1 Hz, 1H, CH-18a), 3.53 (tt, J = 11.3, 4.8 Hz, 1H, CH-3), 3.41 (dd, J = 9.0, 1.1 Hz, 1H, CH-18b), 
3.37 (s, 3H, OCH3), 2.05-2.00 (m, 1H, CH-12β), 1.21 (d, J = 6.1 Hz, 3H, CH3-21), 0.87 (s, 3H, CH3-
19). 
Steroid 241 (101 mg, 279 µmol) was dissolved in MeOH (3 mL) andconc. aq. HCl (60 µL, 35% w/v) 
and the homogeneous solution was refluxed for 2 h. The reaction mixture was then poured into 
saturated aq. NaHCO3 (40 mL) and extracted with CHCl3 (3 × 5 mL). The combined extracts were 
dried over MgSO4 and evaporated in vacuo to furnish 89 mg (99%) of 253b. 
253b: Mp 183-184.5 °C (Hexanes); 
[α]D20 +11.0 (c 0.310, CHCl3); 
IR (CHCl3); ν[cm-1]: 1030, 1036 (C-O), 1377 (CH3), 1449, 2868, 2934 (CH2), 
3430, 3610 (OH);  
1H NMR (400 MHz, CDCl3) δ 3.72 (qd, J = 6.3, 3.0 Hz, 1H, CH-20), 3.68 (d, 
J = 9.0 Hz, 1H, CH-18a), 3.68-3.59 (m, 1H, CH-3), 3.41 (dd, J = 9.0, 1.7 Hz, 
1H, CH-18b), 2.00 (ddd, J = 12.4, 4.1, 2.7 Hz, 1H, CH-12β), 1.22 (d, J = 6.3 
Hz, 3H, CH3-21), 0.87 (s, 3H, CH3-19); 
13C NMR (101 MHz, CDCl3) δ 84.5, 71.82, 71.77, 55.9, 55.2, 55.1, 42.0, 40.1, 37.9, 37.1, 36.4, 35.3, 
34.6, 32.1, 30.6, 26.93, 26.91, 26.0, 23.3, 22.8, 21.6; 
MS (ESI+) m/z, (%): 341 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H34NaO2 341.2451; Found 341.2449.  
Anal. Calcd for C21H34O2: C, 79.19; H, 10.76; Found: C, 79.14; H, 10.64. 
 
(20R)-3α,20-Bis(methoxymethoxy)-5β-pregnan-18-ol (243)  
A stirred solution of iodide 242 (4.04 g, 7.56 mmol), N,N-
diisopropylethylamine (1.96 mL, 11.3 mmol), 1,1′-
azobis(cyclohexanecarbonitrile) (380 mg, 1.56 mmol) and 
tris(trimethylsilyl)silane (3.42 mL, 11.08 mmol) in dry toluene 
(50 mL) was heated to 90 °C and continuous stream of oxygen was 
bubbled through the solution with vigorous stirring. After 6 h, the reaction mixture was concentrated 
in vacuo and redissolved in THF (20 mL). A solution of TBAF (1 M in THF, 11 mL) was added 
dropwise while stirring. After 10 minutes, the mixture was poured into water (50 mL), extracted with 
Et2O (3 × 30 mL), washed with saturated aq. NaHCO3 (100 mL) and dried with MgSO4. Evaporation 
in vacuum afforded a crude oil, which was purified by column chromatography on silica gel (150 g) in 
5% acetone/hexanes to yield 2.49 g (78%) of compound 243 as a brownish oil. 
[α]D20 +20.0 (c 0.060, CHCl3); 














1H NMR (400 MHz, CDCl3) δ 4.74 (d, J = 6.5 Hz, 1H, OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.64 (d, J = 6.5 Hz, 1H, OCHaHbO-20), 3.86 (quint, J = 6.5 Hz, 1H, CH-20), 3.60 (d, J 
= 11.3 Hz, 1H, CH-18a), 3.54 (tt, J = 11.2, 4.6 Hz, 1H, CH-3), 3.49 (d, J = 11.3 Hz, 1H, CH-18b), 
3.40 (s, 3H, OCH3), 3.37 (s, 3H, OCH3), 2.42 (dt, J = 12.9, 3.2 Hz, 1H, CH-12β), 1.26 (d, J = 6.3 Hz, 
3H, CH3-21), 0.93 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 94.9, 94.5, 76.8, 76.3, 59.4, 56.2, 56.01, 56.00, 55.1, 47.3, 42.0, 40.6, 
35.8, 35.3, 34.8, 34.7, 33.6, 27.7, 27.1, 26.6, 25.8, 24.1, 23.4, 20.4, 19.6; 
MS (ESI+) m/z, (%): 447 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H44NaO5 447.3081; Found 447.3080;  
Anal. Calcd for C25H44O5: C, 70.72; H, 10.44; Found: C, 70.46; H, 10.03. 
 
Methyl (20R)-3α,20-bis(methoxymethoxy)-5β-pregnan-18-oate (244)  
A stirred solution of alcohol 243 (2.11 g, 4.97 mmol) in acetonitrile 
(12.5 mL), CCl4 (12.5 mL) and water (19 mL) was cooled to 0 °C 
and RuO2·nH2O (60% Ru, 16.8 mg, 2 mol%) was added. NaIO4 
(3.60 g, 16.84 mmol) was added portionwise and the het rogeneous 
reaction mixture was stirred vigorously for 4 h, until the conversion 
was complete. The reaction was quenched by addition of solid 
Na2SO3 (1 g) and after discoloration the solution was poured into 5% aq. citric acid (100 mL). The 
aqueous layer was extracted with Et2O (3 × 40 mL) and the combined organic extracts were dried with 
MgSO4 and evaporated in vacuo. The resulting oil was dissolved in MeOH (30 mL) and a 
diazomethane solution in Et2O was added slowly until the conversion to ester was complete, as 
monitored by TLC in hexanes/acetone 8:2. The solvents were evaporated in vacuo and the crude 
product was purified on a column of silica gel (60 g) in hexanes/EtOAc (8:2) to afford 2.147 g (95%) 
of ester 244 as a colorless oil. 
[α]D20 +59.9 (c 0.157, CHCl3); 
IR (CHCl3); ν[cm-1]: 1038 (C-O), 1103, 1145 (CH2, OCH2O), 1172 (CO-OMe), 1375 (CH3), 1714 
(COOMe), 2884 (CH2);  
1H NMR (400 MHz, CDCl3) δ 4.68 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 4.65 (d, J = 6.9 Hz, 1H, 
OCHaHbO-20), 4.61 (d, J = 6.9 Hz, 1H, OCHaHbO-20), 3.66 (s, 3H, COOMe), 3.54 (tt, J = 11.2, 4.6 
Hz, 1H, CH-3), 3.373 (s, 3H, OCH3), 3.370 (s, 3H, OCH3), 3.86 (dq, J = 8.9, 6.1 Hz, 1H, CH-20), 
2.73-2.68 (m, 1H, CH-12β), 1.15 (d, J = 6.0 Hz, 3H, CH3-21), 0.82 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 175.1, 96.6, 94.6, 77.6, 76.8, 56.89, 56.88, 56.75, 55.6, 55.1, 50.7, 
42.0, 40.4, 37.6, 36.5, 35.3, 34.7, 33.5, 27.7, 27.0, 26.6, 26.2, 24.9, 23.3, 22.6, 20.4;  
MS (ESI+) m/z, (%): 475 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C26H44NaO6 475.3030; Found 475.3027;  
Anal. Calcd for C26H44O6: C, 68.99; H, 9.80; Found: C, 69.50; H, 9.81.  
 
(20R)-3α,20-Bis(methoxymethoxy)-[18,18-2H2]-5β-pregnan-18-ol (245)  
A solution of ester 244 (2.147 g, 4.74 mmol) in THF (10 mL), was 
added dropwise to a refluxing solution of LiAlD4 (610 mg, 
14.53 mmol) in THF (60 mL). After 4 h of reflux, the reaction 
mixture was cooled to rt, quenched with saturated aq. Na2SO4, dried 











vacuo and the oily residue was purified by column chromatography on silica gel (60 g) in 15% 
EtOAc/hexanes to afford 141 mg (7%) of starting materi l 244, followed by 1.453 g (72%) of the 
desired product 245 as a colorless oil. 
[α]D20 +4.7 (c 0.255, CHCl3); 
IR (CHCl3); ν[cm-1]: 1025, 1044 (C-O), 1101, 1145 (CH2, OCH2O), 1377 (CH3), 2109, 2219 (CD2), 
2889 (CH2), 3469 (OH);  
1H NMR (400 MHz, CDCl3) δ 4.74 (d, J = 6.5 Hz, 1H, OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.64 (d, J = 6.5 Hz, 1H, OCHaHbO-20), 3.86 (quint, J = 6.5 Hz, 1H, CH-20), 3.54 (tt, 
J = 11.2, 4.6 Hz, 1H, CH-3), 3.40 (s, 3H, OCH3), 3.37 (s, 3H, OCH3), 3.32 (br s, 1H, OH), 2.52 (dt, J 
= 12.9, 3.4 Hz, 1H, CH-12β), 1.26 (d, J = 6.3 Hz, 3H, CH3-21), 0.93 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 95.0, 94.6, 76.8, 76.3, 56.1, 56.00, 55.96, 55.1, 47.1, 42.0, 40.6, 35.9, 
35.4, 34.8, 34.7, 33.6, 27.7, 27.1, 26.6, 25.8, 24.1, 23.4, 20.4, 19.6; 
MS (ESI+) m/z, (%): 448 (1), 449 (100, [M(D2)+Na]
+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H42D2NaO5 449.3203; Found 449.3207;  
Anal. Calcd for C25H44O5: C, 70.38; H, 10.40; Found: C, 70.35; H, 10.37.  




A solution of alcohol 245 (820 mg, 1.92 mmol) and 1,10-
phenanthroline (1 mg) in THF (10 mL) was cooled in an ice bath 
and a solution of methyllithium (1.6 M in Et2O, 1.20 mL) was added 
dropwise until a persistent red coloration. The soluti n was warmed 
to rt, dry carbon disulfide (355 µL, 5.88 mmol) was added and the 
mixture was stirred overnight. Methyl iodide (180 µL, 2.88 mmol) 
was added to the solution and after 2 h of stirring, the reaction was quenched with saturated aq. 
NaHCO3 (50 mL) and extracted with Et2O (3 × 15 mL). The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated. Chromatography of the residue on silica gel (40 g) in 15% 
EtOAc/hexanes afforded 872 mg (88%) of xanthate 246 as a yellow oil. 
[α]D20 +67.5 (c 0.080, CHCl3);  
IR (CHCl3); ν[cm-1]: 1049 (C-O), 1062 (C=S), 1103 (OCH2O), 1117 (C=S), 1144 (CH2, OCH2O), 
1241 (CSOC), 1374 (CH3), 2241 (CD2), 2884 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.80 (d, J = 6.7 Hz, 1H, OCHaHbO-20), 4.71 (d, 1H, J = 6.7 Hz, 1H, 
OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 3.60-3.49 (m, 2H, CH-20, CH-3), 3.39 
(s, 3H, OCH3), 3.37 (s, 3H, OCH3), 2.59 (s, 3H, SCH3), 2.37 (ddd, J = 12.8, 3.2, 2.5 Hz, 1H, CH-12β), 
1.19 (d, J = 6.0 Hz, 3H, CH3-21), 0.92 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 216.7, 96.9, 94.6, 77.7, 76.8, 56.3, 55.8, 55.7, 55.2, 45.8, 42.0, 40.6, 
36.0, 35.5, 35.3, 34.8, 33.6, 27.7, 27.1, 26.5, 25.8, 24.4, 23.4, 20.8, 20.8, 19.3; 
MS (ESI+) m/z, (%): 539.4 (1.5), 539.4 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C27H44D2NaO5S2 539.2804; Found 539.2803;  
Anal. Calcd for C27H44D2O5S2: C, 62.75; H, 8.97; S, 12.41; Found: C, 63.02; H, 9.12; S, 12.20. 









(20R)-3α,20-Bis(methoxymethoxy)-5β-pregnan-18-yl O-(S-methyl-dithiocarbonate) (246b) 
IR (CHCl3); ν[cm-1]: 1039, 1044 (C-O), 1067 (C=S), 1103, 1144 (CH2, OCH2O), 1374 (CH3), 2870, 
2886 (CH2), 2933; 
1H NMR (400 MHz, CDCl3) δ 4.80 (d, J = 6.7 Hz, 1H, OCHaHbO-20), 4.76 (d, 1H, J = 11.6 Hz, CH-
18a), 4.71 (d, 1H, J = 6.7 Hz, 1H, OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 4.50 
(d, 1H, J = 11.6 Hz, CH-18b), 3.60-3.49 (m, 2H, CH-20, CH-3), .39 (s, 3H, OCH3), 3.37 (s, 3H, 
OCH3), 2.59 (s, 3H, SCH3), 2.36 (ddd, 1H, J = 12.8, 3.2, 2.5 Hz, CH-12β), 1.19 (d, 3H, J = 6.0 Hz, 
CH3-21), 0.92 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 216.7, 96.8, 94.6, 77.6, 76.8, 73.8, 56.4, 55.8, 55.7, 55.2, 46.0, 42.0, 
40.7, 36.0, 35.5, 35.4, 34.8, 33.6, 27.7, 27.1, 26.6, 25.8, 24.5, 23.4, 20.82, 20.77, 19.3. 
MS (ESI+) m/z, (%): 537 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C27H46NaO5S2 537.2679; Found 537.2676.  
 
(20R)-3α,20-Bis(methoxymethoxy)-[18,18,18-2H3]-5β-pregnane (247) 
A stirred solution of xanthate 246 (57 mg, 110 µmol), 1,1′-azobis(2-
methylpropionitrile) (1.8 mg, 11 µmol) and tributyltin deuteride 
(45 µL, 167 µmol) in dry benzene (0.5 mL) was heated to reflux 
under a nitrogen atmosphere. After 2.5 h, the reaction mixture was 
concentrated in vacuo and purified by column chromatography on 
silica gel (2.5 g) in 10% EtOAc/hexanes to afford 16 mg (35%) of compound 247 as a colorless oil.  
[α]D20 +30.0 (c 0.563, CHCl3);  
IR (CHCl3); ν[cm-1]: 913, 1045, 1103, 1144 (COCOC), 1374 (CH3), 1448 (CH2), 2226 (C2H3), 2869 
(CH2), 2887 (CH3), 2932 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.71 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.61 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 3.58 (dq, J = 10.0, 6.1 Hz, 1H, CH-20), 3.53 
(tt, J = 11.2, 4.8 Hz, 1H, CH-3), 3.39 (s, 3H, OCH3), 3.37 (s, 3H, OCH3), 2.06 (dd, J = 9.1, 2.8 Hz, 1H, 
CH-12a), 1.13 (d, J = 6.0 Hz, 3H, CH3-21), 0.92 (s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 95.4, 94.5, 76.9, 76.5, 56.6, 56.02, 56.00, 55.1, 42.3, 42.1, 40.5, 39.7, 
35.8, 35.4, 34.8, 33.6, 29.7, 27.7, 27.2, 26.5, 25.8, 24.3, 23.4, 20.7, 19.8. 
MS (ESI+) m/z, (%): 431 (8, [M(D0)+Na]
+), 432 (4, [M(D1)+Na]
+), 433 (4, [M(D2)+Na]
+), 434 (100, 
[M(D 3)+Na]
+), 846 (22, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H41D3NaO4 434.3320; Found 434.3320.  
Anal. Calcd for C25H41D3O4: C, 72.95; H, 10.77; Found: C, 73.08; H, 10.87.  
Isotopic purity 88%. 
 
(20R)-3α-(Methoxymethoxy)-20-([2H]-methoxymethoxy)-[18,18-2H2]-5β-pregnane (248) and 
(20ξ)-3α-methoxymethoxy-[20,18,18-2H3]-5β-pregnane (249) 
A stirred solution of xanthate 246 (1.33 g, 2.58 mmol), ABCN (63 mg, 0.26 mmol) and 
tris(trimethylsilyl)silyl deuteride (960 µL, 3.09 mmol) in dry toluene (15 mL) was heated to reflux 
under a nitrogen atmosphere. After 5 h, the reaction mixture was concentrated in vacuo and treated 
with a solution of TBAF (3.5 mL, 3.5 mmol, 1 M in THF). The solution was evaporated again and 
purified by column chromatography on silica gel (60 g) in 10% EtOAc/hexanes to afford 654 mg 
(72%) of 249 as a colorless oil, followed by 273 mg (26%) of 248.  






IR (ATR); ν[cm-1]: 841, 918, 1042, 1107, 1148 (COCOC), 1376 
(CH3), 1451 (CH2), 2875, 2939 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.71 (d, J = 6.8 Hz, 1H, OCHaHbO-
20), 4.69 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 4.61 (d, J = 6.8 
Hz, 1H, OCHaHbO-20), 3.58 (dq, J = 10.0, 6.1 Hz, 1H, CH-20), 
3.53 (tt, J = 11.2, 4.8 Hz, 1H, CH-3), 3.39 (s, 2H, 20-OCH2OCH3), 
3.37 (br s, 4H, 3-OCH2OCH3, 20-OCH2OCH2D* ), 2.06 (dd, J = 9.1, 
2.8 Hz, 1H, CH-12a), 1.89-0.91 (m, aliphatic region), 1.13 (d, J = 6.0 Hz, 3H, CH3-21), 0.92 (s, 3H, 
CH3-19), 0.65 (br s, 1H, CH3-18). 
13C NMR (101 MHz, CDCl3) δ 95.4 (CH2, 20-OCH2O), 94.6 (CH2, 3-OCH2O), 76.9 (CH, C-3), 76.4 
(CH, C-20), 56.7 (CH3), 56.04 (CH3), 55.99 (CH), 55.1 (CH), 42.4 (C, C-13), 42.2 (CH, C-5), 40.5 
(CH, C-9), 39.7 (CH2, C-12), 35.8 (CH, C-8), 35.4 (CH2, C-1), 34.8 (C, C-10), 33.6 (CH2, C-4), 27.7 
(CH2, C-2), 27.3 (CH2, C-6), 26.5 (CH2, C-7), 25.8 (CH2, C-15/C-16), 24.3 (CH2, C-15/C-16), 23.4 
(CH3, C-19), 20.7 (CH2, C-11), 19.8 (CH3, C-21), 11.9 (quint, 
2JC-D = 19.1 Hz, CH, C-18). Signals of 
248b are marked with an asterisk, when they are discernable from 248a. 
MS (ESI+) m/z, (%): 432 (3, [M(D1)+Na]
+), 433 (79, [M(D2)+Na]
+), 434 (100, [M(D3)+Na]
+);  
 
249: 1:1 Mixture of [18,18-2H2]-steroid 249a and [20,18,18-
2H3]-steroid 249b. 
IR (CHCl3); ν[cm-1]: 918, 1047, 1106, 1149 (COCOC), 1377 (CH3), 1452 
(CH2), 2874, 2939 (CH2); 
1H NMR (600 MHz, CDCl3) δ 4.69 (d, J = 6.2 Hz, 1H, OCHaHbO), 4.67 
(d, J = 6.2 Hz, 1H, OCHaHbO), 3.52 (tt, J = 11.1, 4.7 Hz, 1H, CH-3), 3.36 
(s, 3H, OCH3), 1.85 (m, 1H, CH-6a), 1.84 (m, 1H, CH-16a), 1.80 (m, 2H, 
CH-1a, CH-4a), 1.72 (m, 2H, CH-2ª, CH-12a), 1.59 (m, 1H, CH-15a), 1.55 (m, 1H, CH-4b), 1.44 (m, 
1H, CH-9), 1.42 (m, 1H, CH-7a), 1.41 (m, 1H, CH-11a), 1.39 (m, 2H, CH2-20), 1.37 (m, 2H, CH-5, 
CH-8), 1.35 (m, 1H, CH-2b), 1.24 (m, 1H, CH-6b), 1.20 (m, 1H, CH-11b), 1.16 (m, 1H, CH-17), 1.15 
(m, 1H, CH-16b), 1.11 (m, 1H, CH-7b), 1.06 (m, 1H, CH-15b), 1.04 (t, J = 19 Hz, 1H, CH-20)*, 1.00 
(m, 1H, CH-14), 0.99 (m, 1H, CH-12b), 0.94 (m, 1H, CH-1b), 0.92 (s, 3H, CH3-19), 0.865 (t, J = 7.3 
Hz, 3H, CH-21), 0.855 (d, J = 7.3 Hz, 3H, CH-21)*, 0.50 (br s, 1H, CH-18). 
13C NMR (150.9 MHz, CDCl3) δ 94.5 (CH2, OCH2O), 76.9 (CH, C-3), 56.0 (CH, C-14), 55.1 (CH3, 
OCH3), 53.1 (CH, C-17), 53.0 (CH, C-17)*, 42.2 (CH, C-5), 42.1 (C, C-13), 40.8 (CH, C-9), 38.2 
(CH2, C-12), 35.9 (CH, C-8), 35.5 (CH2, C-1), 34.8 (C, C-10), 33.6 (CH2, C-4), 28.20 (CH2, C-16), 
28.16 (CH2, C-16)*, 27.7 (CH2, C-2), 27.2 (CH2, C-6), 26.6 (CH2, C-7), 24.6 (CH2, C-15), 23.4 (CH3, 
C-19), 23.1 (CH2, C-20), 22.7 (t, JC-D = 19 Hz, CH, C-20)*, 20.6 (CH2, C-11), 13.3 (CH3, C-21), 13.2 
(CH3, C-21)*, 11.9 (quint, 
2JC-D = 19.1 Hz, CH, C-18). Signals of 249b are marked with an asterisk, 
when they are discernable from 249a. 
 
(20R)-3α,20-Bis(methoxymethoxy)-[18,18-2H2]-5β-pregnan-18-yl p-toluenesulfonate (251) 
 A solution of compound 245 (530 mg, 1.24 mmol), 4-
(dimethylamino)pyridine (15 mg, 0.12 mmol), and pTsCl (1.19 g, 
6.22 mmol) in anhydrous pyridine (3 mL) was stirred at rt overnight. 
The reaction mixture was poured into ice-cold water and extracted 
with Et2O (3 × 20 mL). The combined extracts were washed 















anhydrous Na2SO4. After solvent evaporation, the oily residue was purified by column 
chromatography on silica gel (25 g) in 20% EtOAc/hexanes to give 691 mg (96%) tosylate 251 as a 
white foam: 
[α]D20 +38.4 (c 0.229, CHCl3); 
IR (CHCl3); ν[cm-1]: 961 (COS), 1042 (C-O), 1101, 1144 (CH2, OCH2O), 1178, 1190, 1364 (SO2), 
2246, 2342, 2360 (CD2), 2870, 2885 (CH2), 2933;  
1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 2H, Ar), 7.36 (d, J = 8.0 Hz, 2H, Ar), 4.73 (d, J = 
6.6 Hz, 1H, OCHaHbO-20), 4.67 (AB system, J = 6.8 Hz, 2H, OCH2O-3), 4.61 (d, J = 6.6 Hz, 1H, 
OCHaHbO-20), 3.86 (dq, J = 9.9, 6.0 Hz, 1H, CH-20), 3.49 (tt, J = 11.2, 4.6 Hz, 1H, CH-3), 3.360 (s, 
3H, OCH3), 3.357 (s, 3H, OCH3), 2.45 (s, 3H, Ar-CH3), 2.25 (dt, J = 13.3, 3.1 Hz, 1H, CH-12β), 1.15 
(d, J = 6.0 Hz, 3H, CH3-21), 0.60 (s, 3H, CH3-19);  
13C NMR (101 MHz, CDCl3) δ 144.8, 132.6, 129.8, 128.2, 96.7, 94.6, 77.3, 76.8, 56.2, 55.7, 55.5, 
55.1, 45.5, 41.9, 40.4, 35.8, 35.3, 34.8, 34.6, 33.5, 27.6, 27.0, 26.4, 25.6, 24.3, 23.0, 21.6, 20.8, 20.1; 
MS (ESI+) m/z, (%): 602 (1), 603 (100, [M+Na]+), 604 (36), 605 (7), 606 (3), 1183 (10, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C32H48D2NaO7S 603.3295; Found 603.3294;  
Anal. Calcd for C32H48D2O7S: C, 66.17; H, 8.67; S, 5.52; Found: C, 66.30; H, 8.78; S, 5.62.  
Isotopic purity >99%. 
 
(20R)-[18,18,18-2H3]-5β-Pregnane-3α,20-diol (252)  
Solid LiAlD4 (430 mg, 10.24 mmol) was added to a solution of tosylate 
251 (664 mg, 1.14 mmol) in dry n-heptane (10 mL) and the reaction 
mixture was refluxed for 18 h. The reaction mixture was cooled to rt, 
quenched with saturated aq. Na2SO4, dried with anhydrous Na2SO4 and 
filtered. The filtrate was evaporated in vacuo, the oily residue redissolved 
in MeOH (10 mL), mixed with 6 M HCl (0.10 mL) and refluxed for 4 h. 
The reaction mixture was concentrated in vacuo, poured into saturated aq. NaHCO3 (20 mL) and 
extracted with CHCl3 (3 × 15 mL). The organic layer was dried with anhydrous Na2SO4, filtered and 
evaporated. Chromatography of the residue on silica gel (15 g) in 10% acetone/hexanes yielded 
consecutively 131 mg (36%) of ether 253, 55 mg (15%) of the desired diol 252 and finally 87 mg 
(23%) of triol 254. 
Diol 252: 
Mp 233-235 oC; Lit.348 233.5-234.5 oC for the nondeuterated compound; 
[α]D20 +9.9 (c 0.262, CHCl3), [Lit.348 +12 (c 0.86, EtOH)]; 
IR (CHCl3); ν[cm-1]: 1031 (CO), 1044 (CO), 1378 (CH3), 1449 (CH2), 2227, 2343, 2361 (CD3), 2868, 
2934 (CH2), 3609 (OH);  
1H NMR (400 MHz, CDCl3) δ 3.72 (dq, J = 9.9, 6.1 Hz, 1H, CH-20), 3.63 (tt, J = 11.0, 4.7 Hz, 1H, 
CH-3), 2.03 (dd, J = 8.3, 2.4 Hz, 1H, CH-12β), 1.14 (d, J = 6.0 Hz, 3H, CH3-21), 0.93 (s, 3H, CH3-
19); 
13C NMR (101 MHz, CDCl3) δ 71.9, 70.6, 58.7, 56.0, 42.4, 42.1, 40.5, 40.3, 36.5, 35.8, 35.4, 34.6, 
30.6, 27.2, 26.5, 25.7, 24.5, 23.6, 23.4, 20.7. 
MS (ESI+) m/z, (%): 343 (0, [M(D0)+Na]
+), 344 (0, [M(D1)+Na]
+), 345 (4, [M(D2)+Na]
+), 346 (100, 
[M(D 3)+Na]
+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H33D3NaO2 346.2796; Found 346.2795;  






Mp 183-185 °C (CH2Cl2/hexanes); 
[α]D20 +17.3 (c 0.324, CHCl3); 
IR (ATR); ν[cm-1]: 831, 935, 981, 1047 (CO), 1069, 1095, 1381 (CH3), 1449 
(CH2), 2240 (CD3), 2865, 2933 (CH2), 3351 (OH);  
1H NMR (400 MHz, CDCl3) δ 3.72 (qd, J = 6.3, 3.0 Hz, 1H, CH-20), 3.64 (tt, 
J = 11.0, 4.7 Hz, 1H, CH-3), 2.00 (ddd, J = 12.4, 4.1, 2.7 Hz, 1H, CH-12β), 1.22 (d, J = 6.3 Hz, 3H, 
CH3-21), 0.87 (s, 3H, CH3-19); 
13C NMR (101 MHz, CDCl3) δ 84.5, 71.7, 55.7, 55.2, 55.1, 42.0, 40.1, 37.9, 37.0, 36.4, 35.3, 34.6, 
32.1, 30.6, 26.92, 26.90, 26.0, 23.3, 22.8, 21.6. 
Anal. Calcd for C21H32D2O2: C, 78.70; H, 10.69; Found: C, 78.02; H, 10.53.  
 
(20R)-[18,18-2H2]-5β-Pregnane-3α,18,20-triol (254) 
Mp 214-217 °C (CHCl3); 
[α]D20 +17.4 (c 0.046, CHCl3); 
IR (ATR); ν[cm-1]: 674, 727, 973, 1038 (CO), 1065, 1099, 1116, 1360, 1375 
(CH3), 1453 (CH2), 2218, 2207 (CD2), 2873, 2936, 2953 (CH2), 3341, 3388, 
3445 (OH);  
1H NMR (400 MHz, CD3OD/CDCl3 1:9) δ 3.77 (qd, J = 9.5, 6.3 Hz, 1H, CH-
20), 3.60 (tt, J = 10.9, 4.7 Hz, 1H, CH-3), 2.45 (br d, J = 13.1, 4.1, 2.7 Hz, 1H, CH-12β), 1.17 (d, J = 
5.9 Hz, 3H, CH3-21), 0.94 (s, 3H, CH3-19); 
13C NMR (101 MHz, CDCl3) δ 71.4, 71.3, 57.6, 55.7, 47.0, 41.8, 40.5, 36.0, 35.8, 35.2, 34.8, 34.5, 
30.1, 27.0, 26.6, 26.2, 24.7, 23.2, 21.9, 20.2.  
MS (ESI+) m/z, (%): 359 (0, [M(D0)+Na]
+), 360 (0, [M(D1)+Na]
+), 361 (100, [M(D2)+Na]
+), 700 (7, 
[2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H34D2NaO3 361.2682; Found 361.2681;  
Anal. Calcd for C21H34D2O3: C, 74.51; H, 10.72; Found: C, 73.83; H, 10.54. 
 
[18,18,18-2H3]-5β-Pregnane-3,20-dione (119) 
Steroid 252 (5.0 mg, 15.5 µmol) was dissolved in acetone (3 mL) and CHCl3 
(1.5 mL) and the mixture was cooled in an ice bath. Jones’ reagent327 (100 µL, 
3 M aq. solution, 0.3 mmol) was added dropwise with stirring and the 
suspension was stirred at 0 °C for 30 min. The excess of the reagent was 
quenched with iPrOH (0.1 mL) and the mixture was concentrated in vacuo. 
The mixture was diluted with 2 mL of water and extrac ed with CH2Cl2 (3 × 
2 mL). The combined extracts were washed with saturated aq. NaHCO3 (5 mL), dried with MgSO4 
and evaporated in vacuo. The residue was purified by column chromatography on silica gel (0.5 g) in 
0 % to 10% EtOAc/hexanes to afford 5.0 mg (quant.) of diketone 119 as colorless crystalline solid. 
Mp 114-117 °C, Lit.222 118-119 °C (EtOAc/heptane) for nondeuterated compound; 
[α]D20 +93.8 (c 0.097, CHCl3); 
IR (CHCl3); ν[cm-1]: 1357, 1380 (CH3), 1446, 1453 (CH2), 1703 (C=O), 2220, 2234 (C2H3), 2857, 
2876, 2937 (CH2); 
1H NMR (400 MHz, CDCl3) δ 2.69 (dd, J = 15.0, 13.4 Hz, 1H, CH-4a), 2.55 (t, J = 9.0 Hz, 1H, CH-
















16a), 2.13 (s, 3H, CH3-21), 2.11-2.02 (m, 1H, CH-12a), 2.09-1.99 (m, 2H, CH-1a, CH-4b), 1.96-1.82 
(m, 1H, CH-6a), 1.89-1.78 (m, 1H, CH-5), 1.76-1.66 (m, 1H, CH-15a), 1.72-1.60 (m, 1H, CH-16b), 
1.61-1.51 (m, 1H, CH-11a), 1.58-1.50 (m, 1H, CH-7a), 1.58-1.48 (m, 1H, CH-9), 1.56-1.45 (m, 1H, 
CH-8), 1.51-1.41 (m, 1H, CH-12b), 1.49-1.34 (m, 1H, CH-11b), 1.41 (td, J = 14.4, 4.3 Hz, 1H, CH-
1b), 1.32-1.20 (m, 1H, CH-6b), 1.30-1.20 (m, 2H, CH-14, CH-15b), 1.20-1.07 (m, 1H, CH-7b), 1.03 
(s, 3H, CH3-19). 
13C NMR (101 MHz, CDCl3) δ 213.1 (C, C-3), 209.5 (C, C-20), 63.7 (CH, C-17), 56.6 (CH, C-14), 
44.2 (CH, C-5), 44.1 (br s, C, C-13), 42.3 (CH2, C-4), 40.7 (CH, C-9), 39.0 (CH2, C-12), 37.2 (CH2, C-
2), 36.9 (CH2, C-1), 35.5 (CH, C-8), 34.9 (C, C-10), 31.5 (CH3, C-21), 26.5 (CH2, C-6), 25.8 (CH2, C-
7), 24.4 (CH2, C-15), 22.9 (CH2, C-16), 22.6 (CH3, C-19), 21.2 (CH2, C-11); 
MS (ESI+) m/z, (%): 320 (14, [M(D3)+H]
+), 339 (1, [M(D0)+Na]
+), 340 (0, [M(D1)+Na]
+), 341 (1, 
[M(D 3)+Na]
+), 342 (100, [M(D3)+Na]
+), 661 (4, [2M+Na]+); 
HRMS (CI+) m/z: [M+H] + Calcd for C21H30
2H3O2 320.2669, found 320.2667; 
Anal. Calcd for C21H29D3O2: C, 78.94; H, 10.10; Found: C, 78.43; H, 10.55; 
Isotopic purity 96%. 
 
5.5. SYNTHESIS OF [19,19,19]-D3 PREGNANE STEROIDS 
Methyl (20R)-20-acetoxy-3-oxo-5β-pregnan-19-oate (256) 
A stirred solution of alcohol 255 (564 mg, 1.50 mmol) in acetonitrile 
(3.75 mL), tetrachloromethane (3.75 mL) and water (5.7 mL) was cooled to 
0 °C and RuO2·nH2O (60% Ru, 5.0 mg, 2 mol%) was added. NaIO4 (1.08 g, 
5.05 mmol) was added portionwise and the heterogenous reaction mixture was 
stirred vigorously for 4 h, until the conversion was complete. The reaction was 
quenched by addition of solid Na2SO3 (0.5 g) which caused discoloration of the solution. The solution 
was acidified by addition of concentrated hydrochloric acid to pH 1-2. The steroid was extracted with 
CH2Cl2 (3 × 25 mL). The organic extracts were washed withbrine, dried with MgSO4 and evaporated 
in vacuo. The resulting oil was dissolved in MeOH (5 mL) with Et2O (25 mL) and 
trimethylsilyldiazomethane solution (0.8 mL, 2 M in THF) was added. After 2 h, the esterification was 
complete and the reaction mixture was quenched by addition of acetic acid (0.2 mL). The solvents 
were evaporated in vacuo and the crude product was purified on a column of silica gel (20 g) in 
hexanes/EtOAc (8:2) to afford 507 mg (84%) of ester 256 as a colorless solid. 
Mp 113-116 oC (Et2O);  
[α]D20 +17.1 (c 0.610, CHCl3);  
IR (ATR); ν[cm-1]: 1027 (C-O, acetate), 1205 (C-O, ester), 1251, 1263, 1372 (CH3), 1462 (CH2), 
1721, 1732 (C=O), 2840, 2882 (CH2), 2939; 
1H NMR (400 MHz, CDCl3) δ 4.85 (dq, J = 10.4, 6.1 Hz, 1H, CH-20), 3.70 (s, 3H, OCH3), 2.01 (s, 
3H, OAc), 1.16 (d, J = 6.1 Hz, 3H, CH3-21), 0.79 (s, 3H, CH3-18);  
13C NMR (101 MHz, CDCl3) δ 211.4, 176.0, 170.4, 72.9, 56.1, 54.9, 51.6, 48.3, 42.6, 42.1, 41.4, 39.6, 
39.1, 36.3, 36.1, 31.7, 27.7, 25.9, 25.5, 24.2, 21.7, 21.5, 19.9, 12.5. 
MS (ESI+) m/z, (%): 345 (10, [M–AcOH+H]+), 367 (10, [M–AcOH+Na]+), 427 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C24H36NaO5 427.2455; Found 427.2456.  







Methyl (20R)-20-acetoxy-3α-hydroxy-5β-pregnan-19-oate (257) 
Anhydrous cerium(III) chloride (136 mg, 0.55 mmol) was added to a stirred 
solution of ketone 256 (203 mg, 0.50 mmol) in methanol:tetrahydrofuran (2:1, 
10 mL). The mixture was allowed to stir at room temp rature until 
homogeneous solution resulted. Sodium borohydride (19 mg, 0.50 mmol) was 
added in small portions over 5 min. After 10 min of stirring, acetic acid 
(0.2 mL) was added and the solvent was evaporated in vacuo. The residue 
was partitioned between water (50 mL) and Et2O (50 mL). The aqueous layer was extracted with Et2O 
(2 × 50 mL). The organic layers were collected, washed subsequently with saturated aq. KHCO3 
(50 mL) and water (50 mL), dried, and the solvent was evaporated. Preparative TLC of the residue in a 
mixture of benzene/EtOAc (8:2) afforded 191 mg (94%) of 257 as a colorless solid.  
Mp 94-96 oC (acetone/hexane);  
[α]D20 +13.8 (c 0.650, CHCl3);  
IR (ATR); ν[cm-1]: 1042 (C-O, acetate), 1088, 1117, 1140, 1217 (C-O, ester), 1244, 1372 (CH3), 1460 
(CH2), 1735 (C=O), 2880, 2955 (CH2), 3278 (O-H); 
1H NMR (400 MHz, CDCl3) δ 4.83 (dq, J = 10.4, 6.1 Hz, 1H, CH-20), 3.72 (tt, J = 10.8, 4.8 Hz, 1H, 
CH-3), 3.66 (s, 3H, OCH3), 2.01 (s, 3H, OAc), 1.15 (d, J = 6.1 Hz, 1H, CH3-21), 0.71 (s, 3H, CH3-18); 
13C NMR (101 MHz, CDCl3) δ 177.2, 170.4, 72.9, 70.4, 56.1, 54.8, 51.2, 48.7, 42.4, 39.5, 39.1, 37.7, 
36.5, 35.8, 30.4, 29.4, 28.3, 26.5, 25.4, 24.2, 21.4, 20.9, 19.8, 12.3. 
MS (ESI+) m/z, (%): 269 (26, [M–AcOH–HCOOMe–H2O+H]
+), 287 (26, [M–AcOH–HCOOMe+H]+) 
329 (11, [M–AcOH–H2O+H]
+), 347 (36, [M–AcOH+H]+), 407 (10, [M+H]+), 429 (100, [M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C24H38NaO5 429.2612; Found: 429.2612;  
Anal. Calcd for C24H38O5: 70.90 C, 9.42 H; Found: 70.84 C, 9.45 H. 
 
Methyl (20R)-3α,20-dihydroxy-5β-pregnan-19-oate (258) 
Aq. sulfuric acid (3 M, 3 mL) was added to a solution of acetate 257 (271 mg, 
0.67 mmol) in methanol (30 mL) and the reaction mixture was stirred at room 
temperature. After 7 days, methanol was evaporated in vacuo. The residue 
was partitioned between Et2O (250 mL) and water (50 mL) and the aqueous 
phase was extracted with Et2O (2 × 50 mL). The organic layers were 
collected, washed subsequently with saturated aq. KHCO3 (2 × 100 mL) and 
water (100 mL), dried, and the solvent was evaporated. Preparative TLC of the residue in a mixture of 
benzene/EtOAc (1:1) afforded 206 mg (84%) of  258as a colorless solid,  
Mp 235-238 oC (acetone/hexane); 
[α]D20 +7.2 (c 0.570, CHCl3); 
IR (ATR); ν[cm-1]: 1044 (C-OH), 1099, 1117, 1139, 1223, 1278, 1373 (CH3), 1460 (CH2), 1727 
(C=O), 2878 (CH2), 2940, 3299, 3356 (O-H); 
1H NMR (400 MHz, CDCl3) δ 3.77-3.70 (m, 2H, CH-20, CH-3), 3.67 (s, 3H, OCH3), 1.14 (d, J = 6.1 
Hz, 3H, CH3-21), 0.84 (s, 3H, CH3-18); 
13C NMR (101 MHz, CDCl3) δ 177.3, 70.7, 70.6, 58.4, 56.3, 51.3, 48.9, 42.7, 40.4, 39.3, 37.8, 36.6, 
36.0, 30.5, 29.7, 28.5, 26.6, 25.7, 24.6, 23.6, 21.0, 12.5. 
MS (ESI+) m/z, (%): 365 (6, [M+H]+), 387 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C22H36NaO4 387.2506; Found: 387.2506;  










Methyl (20R)-3α,20-bis(methoxymethoxy)-5β-pregnan-19-oate (259) 
Diol 258 (255 mg, 0.70 mmol) was dissolved in dry dichloromethane 
(12 mL), the resulting solution was cooled in an ice bath, and N,N-
diisopropylethylamine (1.46 mL, 8.4 mmol) and bromomethyl methyl 
ether (90%, 0.38 mL, 4.2 mmol) were added. The mixture was stirred at 
room temperature for 12 h, poured into ice water (100 mL) and extracted 
with Et2O (2 × 100 mL). The collected extracts were washed sequentially 
with 5% aq. citric acid (2 × 100 mL), water (100 mL), saturated aq. KHCO3 (100 mL) and water 
(100 mL), dried and the solvent was evaporated. Preparative TLC of the residue in a mixture of 
benzene/Et2O (4:1) afforded 266 mg (84%) of derivative 259 as a colorless oil,  
[α]D20 +4.6 (c 0.550, CHCl3); 
IR (CHCl3); ν[cm-1]: 913 (C-OCH2OCH3), 1036, 1103, 1142, 1193 (C-O, ester), 1718 (C=O), 2826, 
2889 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.72 (d, J = 6.9 Hz, 1H, OCHaHbO-20), 4.70 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.62 (d, J = 6.9 Hz, 1H, OCHaHbO-20), 3.66 (s, 3H, COOCH3), 3.64-3.56 (m, 1H, 
CH-3), 3.60 (dq, J = 9.8, 6.0 Hz, 1H, CH-20), 3.40 (s, 3H, CH2OCH3), 3.38 (s, 3H, CH2OCH3), 1.13 
(d, J = 6.0 Hz, 3H, CH3-21), 0.73 (s, 3H, CH3-18);  
13C NMR (101 MHz, CDCl3) δ 177.3, 95.4, 94.7, 76.4, 75.8, 56.5, 56.4, 56.1, 55.2, 51.3, 49.0, 42.6, 
39.9, 39.3, 37.8, 36.7, 33.3, 30.5, 28.6, 27.0, 26.6, 25.8, 24.4, 21.0, 19.8, 12.4. 
MS (ESI+) m/z, (%): 391 (23, [M–CH3OCH2OH+H]
+), 475 (100%, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C26H44NaO6 475.3030; Found 475.3031. 
Anal. Calcd for C26H44O6: 68.99 C, 9.80 H; Found: 68.74 C, 9.78 H. 
 
(20R)-3α,20-Bis(methoxymethoxy)-[19,19-2H2]-5β-pregnan-19-ol (260) 
Protected ester 259 (500 mg, 1.11 mmol) in THF (15 mL) was refluxed with LiAlD 4 (140 mg, 
3.33 mmol) under argon for 4 h. The reaction mixture was chilled in an ice bath, the remaining 
deuteride was destroyed with saturated aq. Na2SO4, and the mixture was diluted with Et2O (15 mL). 
The solids were filtered off on a celite column (3 cm), which was washed 
with Et2O (50 mL). The resulting solution was washed sequentially with 
cold 5% aq. citric acid, water, saturated aq. KHCO3 (2×50 mL), and water. 
After drying, the solvents were evaporated, leaving 435 mg (92%) of 260 
as a colorless oil. 
[α]D20 +39.5 (c 0.299, CHCl3); 
IR (CHCl3); ν[cm-1]: 912 (COCOC, methoxymethoxy), 1038, 1056 (C-OH), 1102, 1144, 1376 (C-
CH3), 2120, 2243 (CD2), 2826, 2889 (CH2), 3479, 3624 (OH); 
1H NMR (400 MHz, CDCl3) δ 4.71 (d, J = 7.0 Hz, 1H, OCHaHbO-20), 4.70 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.60 (d, J = 6.9 Hz, 1H, OCHaHbO-20), 3.61-3.51 (m, 2H, CH-3, CH-20), 3.39 (s, 3H, 
CH2OCH3), 3.38 (s, 3H, CH2OCH3), 1.12 (d, J = 6.1 Hz, 3H, CH3-21), 0.67 (s, 3H, CH3-18); 
13C NMR (101 MHz, CDCl3) δ 95.4, 94.7, 76.5, 76.4, 56.7, 56.5, 56.0, 55.2, 42.5, 40.1, 40.0, 38.8, 
35.7, 34.2, 33.4, 28.4, 27.3, 26.8, 26.0, 25.8, 24.2, 20.8, 19.8, 12.5; 
MS (ESI+) m/z, (%): 449 (100, [M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H42
2H2NaO5 449.3206, found 449.3205.  














Hydroxy derivative 260 (400 mg, 0.94 mmol) in THF (10 mL) was cooled 
to 0 oC under argon and n-BuLi in THF (1.6 M, 0.88 mL, 1.55 mmol) was 
added dropwise. The reaction mixture was stirred for 7 h at room 
temperature followed by addition of carbon disulfide (228 mg, 3.00 mmol) 
and the stirring was continued for 15 h. Iodomethane (254 mg, 1.79 mmol) 
was added in a single portion and the reaction mixture was stirred for 
another 3 h. The red solution was quenched with water, the product was extracted with Et2O (3 × 
10 mL), washed sequentially with cold 5% aq. citric acid (25 mL), water, saturated aq. KHCO3 (2 × 
25 mL), and water (25 mL). After drying over MgSO4, the solvents were evaporated. The residue was 
purified by preparative TLC on silica gel in toluene/EtOAc 7:3, to afford 394 mg (81%) of 261 as a 
yellow oil. 
[α]D20 +30.6 (c 0.346, CHCl3);  
IR (CHCl3); ν[cm-1]: 912, 1038, 1057 (C=S), 1102, 1144, 1242 (COC, xanth te), 1376 (CH3), 1412 (S-
CH3), 2120, 2243 (CD2), 2826, 2889 (CH2); 
1H NMR (400 MHz, CDCl3) δ 4.71 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 4.70 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.61 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 3.62-3.54 (m, 2H, CH-3, CH-20), 3.393 (s, 
3H, CH3O), 3.385 (s, 3H, CH3O), 2.57 (s, 3H, CH3S), 1.12 (d, J = 6.0 Hz, 3H, H-21), 0.70 (s, 3H, H-
18);  
13C NMR (101 MHz, CDCl3) δ 216.2, 95.5, 94.7, 76.4, 76.1, 56.7, 56.5, 56.0, 55.2, 42.5, 40.04, 39.95, 
38.6, 35.9, 35.6, 33.4, 29.2, 27.2, 26.9, 25.9, 25.8, 24.2, 21.0, 19.8, 18.9, 12.6. 
MS (ESI+) m/z, (%): 539 (42, [M+Na]+), 1055 (100, [2M+Na]+);  
HRMS (ESI+) m/z: [M+Na]+ Calcd for C27H44
2H2NaO5S2 539.2804, found 539.2793.  
Isotopic purity >99%. 
 
(20R)-3α,20-Bis(methoxymethoxy)-[19,19,19-2H3]-5β-pregnane (262) 
A reaction mixture of tributyltin deuteride (312 µL, 1.16 mmol), 2,2'-
azobis(2-methylpropionitrile) (12.5 mg, 77.4 µmol), xanthate 261 (400 mg, 
0.774 mmol) in dry benzene (20 mL) was refluxed under argon for 4 h. 
After cooling to room temperature, the solvent was evaporated, and the 
oily residue was purified by chromatography on silica gel (25 g) in 15% 
EtOAc/hexanes to afford 312 mg (98%) of steroid 262as a colorless oil.  
[α]D20 +28.6 (c 0.342, CHCl3);  
IR (CHCl3); ν[cm-1]: 1038, 1102 (COCOC), 1144, 1376 (CH3), 2126, 2211, 2225 (CD3), 2826, 2889 
(CH2); 
1H NMR (400 MHz, CDCl3) δ 4.71 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 4.69 (AB system, J = 6.8 Hz, 
2H, OCH2O-3), 4.61 (d, J = 6.8 Hz, 1H, OCHaHbO-20), 3.58 (dq, J = 9.9, 6.0 Hz, 1H, CH-20), 3.53 
(tt, J = 11.1, 4.7 Hz, 1H, CH-3), 3.39 (s, 3H, CH3O), 3.37 (s, 3H, CH3O), 1.12 (d, J = 6.0 Hz, 3H, 
CH3-21), 0.68 (s, 3H, CH3-18). 
13C NMR (101 MHz, CDCl3) δ 95.4, 94.5, 76.8, 76.4, 56.7, 56.02, 55.99, 55.1, 42.5, 42.1, 40.4, 39.7, 
35.8, 35.3, 34.5, 33.5, 27.6, 27.2, 26.4, 25.8, 24.3, 20.7, 19.8, 12.4. 
MS (ESI+) m/z, (%): 431 (0, [M(D0)+Na]
+), 432 (0.6, [M(D1)+Na]
+), 433 (1.3, [M(D2)+Na]
+), 434 
(100, [M(D3)+Na]













HRMS (ESI+) m/z: [M+Na]+ Calcd for C25H41
2H3NaO4 434.3320, found 434.3319; 
Anal. Calcd for C25H41D3O4: C, 72.95; H, 10.77; Found: C, 73.23; H, 11.40; 
Isotopic purity: 98%. 
 
(20R)-[19,19,19-2H3]-5β-Pregnane-3α,20-diol (263) 
Steroid 262 (324 mg, 788 µmol) was dissolved in MeOH (10 mL) and conc. 
aq. HCl (100 µL, 35% w/v) was added dropwise with stirring. The reaction 
mixture was refluxed for 3 h, followed by quenching with saturated aq. 
NaHCO3 (50 mL). The suspension was extracted with CHCl3/nBuOH (20:1, 3 
× 10 mL), dried with MgSO4 and evaporated in vacuo to afford 245 mg (96%) 
of diol 263 as colorless crystals. 
Mp 232-234 oC (EtOH); Lit.348 233.5-234.5 oC for the nondeuterated compound; 
[α]D20 +2.8 (c 0.216, EtOH); Lit.348 +12 (c 0.86 in EtOH); 
IR (CHCl3); ν[cm-1]: 1033 (C-OH), 1378 (CH3), 1452 (CH2), 2203, 2221, 2225 (CD3), 2867 (CH2), 
2887 (CH3), 2930 (CH2), 3279, 3342, 3609 (OH); 
1H NMR (400 MHz, CDCl3) δ 3.72 (dd, J = 9.8, 6.1 Hz, 1H, CH-20), 3.63 (tt, J = 11.0, 4.7 Hz, 1H, 
CH-3), 2.08-2.00 (m, 1H, CH-12a), 1.14 (d, J = 6.1 Hz, 3H, CH3-21), 0.74 (s, 3H, CH3-18); 
13C NMR (101 MHz, CDCl3) δ 71.9, 70.6, 58.7, 56.0, 42.6, 42.1, 40.5, 40.3, 36.4, 35.7, 35.4, 34.6, 
30.6, 27.2, 26.5, 25.7, 24.5, 23.6, 20.7, 12.5. 
MS (ESI+) m/z, (%): 339 (0), 340 (0), 341 (5), 346 (100, [M(D3)+Na]
+), 668 (54, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H33
2H3NaO2 346.2796, found 346.2796; 
Anal. Calcd for C21H33D3O2: C, 77.96; H, 11.21;Found: C, 78.92; H, 11.54;  
Isotopic purity: 95%. 
 
[19,19,19-2H3]-5β-Pregnane-3,20-dione (120) 
Steroid 263 (285 mg, 881 µmol) was suspended in acetone (60 mL) and the 
mixture was cooled in an ice bath. Jones’ reagent (0.9 mL, 3 M aq. solution, 
2.7 mmol) was added dropwise with stirring and the suspension was stirred at 
0 °C for 2 h. The excess of the reagent was quenched with iPrOH and the 
mixture was concentrated in vacuo. The mixture was diluted with 30 mL of 5% 
aq. HCl and extracted with CHCl3 (3 × 10 mL). The combined organic layers 
were washed with saturated aq. NaHCO3 (25 mL), dried with MgSO4 and evaporated in vacuo. The 
residue was purified by column chromatography on silica gel (10 g) in 10% EtOAc/hexanes to afford 
271 mg (96%) of diketone 120 as colorless crystals. 
Mp 116-119 °C, Lit.222 118-119 °C (EtOAc/heptane) for the nondeuterated compound; 
[α]D20 +105.7 (c 0.280, CHCl3); 
IR (ATR); ν[cm-1]: 1186, 1204, 1356, 1392 (CH3), 1461 (CH2), 1703, 1724 (C=O), 2211, 2230 (C2H3), 
2860, 2935 (CH2); 
1H NMR (400 MHz, CDCl3) δ 2.69 (dd, J = 15.0, 13.4 Hz, 1H, CH-4a), 2.56 (t, J = 9.0 Hz, 1H, CH-
17), 2.34 (tdd, J = 14.6, 5.3, 0.7 Hz, 1H, CH-2a), 2.23-2.14 (m, 1H,CH-2b), 2.23-2.11 (m, 1H, CH-
16a), 2.13 (s, 3H, CH3-21), 2.11-2.02 (m, 1H, CH-12a), 2.09-1.99 (m, 2H, CH-1a, CH-4b), 1.96-1.82 
(m, 1H, CH-6a), 1.89-1.78 (m, 1H, CH-5), 1.76-1.66 (m, 1H, CH-15a), 1.72-1.60 (m, 1H, CH-16b), 
1.61-1.51 (m, 1H, CH-11a), 1.58-1.50 (m, 1H, CH-7a), 1.58-1.48 (m, 1H, CH-9), 1.56-1.45 (m, 1H, 










1b), 1.32-1.20 (m, 1H, CH-6b), 1.30-1.20 (m, 2H, CH-14, CH-15b), 1.20-1.07 (m, 1H, CH-7b), 0.64 
(s, 3H, CH3-18).
 
13C NMR (101 MHz, CDCl3) δ 213.0 (C, C-3), 209.4 (C, C-20), 63.8 (CH, C-17), 56.6 (CH, C-14), 
44.3 (C, C-13), 44.1 (CH, C-5), 42.3 (CH2, C-4), 40.7 (CH, C-9), 39.1 (CH2, C-12), 37.1 (CH2, C-2), 
36.9 (CH2, C-1), 35.5 (CH, C-8), 34.7 (C, C-10), 31.5 (CH3, C-21), 26.5 (CH2, C-6), 25.8 (CH2, C-7), 
24.4 (CH2, C-15), 22.9 (CH2, C-16), 21.2 (CH2, C-11), 13.4 (CH3, C-18). 
MS (ESI+) m/z, (%): 320 (3, [M(D3)+H]
+), 339 (0), 340 (0), 341 (5), 342 (100, [M(D3)+Na]
+), 661 
(35, [2M+Na]+); 
HRMS (ESI+) m/z: [M+Na]+ Calcd for C21H29
2H3NaO2 342.2483, found 342.2483; 
Anal. Calcd for C21H29D3O2: C, 78.94; H, 10.10; Found: C, 78.72; H, 10.34; 
Isotopic purity: 95%. 
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6. APPENDIX A:  K INETIC DATA OF THE HAJOS-PARRISH-EDER-SAUER-
WIECHERT REACTION  
Reaction catalyzed by 5 mol% of prolinanilides 60 and 0.5 mol% of benzoic acid 
Methodology: 
Prolinanilide 60 (0.10 mmol, 5 mol%) was weighted in a conical 2 mL reaction vial, followed by 
addition of benzoic acid (1.2 mg, 10 µmol, 0.5 mol%), triketone 50 (392.5 mg, 2.00 mmol) and a V-
shaped stir bar. The mixture was stirred at 700 rpm at rt in the closed vessel. At time given in the table, 
ca 3 mg aliquots were taken from the homogeneous mixture. The samples were immediately diluted 
with 10% iPrOH/hexane (1.5 mL, HPLC grade). Ca. 15 µL of the diluted sample was analyzed by 
HPLC (isocratic 50% EtOAc/hexane on Hibar® RT 250-4 LiChrospher® Si 100 Column (Merck 
Millipore, 5 µm particle size, L × I.D. 25 cm × 4 mm) t = 25 °C, 1.0 mL·min-1). Detection was 
performed by a light scattering detector (1.60 SLM of nitrogen, evaporator T = 40 °C and nebuliser T 
= 40 °C). Retention times were: t21 = 6.93 min, t50 = 7.40 min, t21i = 10.59 min. 
Analysis of the final product 21 was performed on a Chiralcel® OD column (Daicel, 250 × 4.6 mm, 
10µm particle size, isocratic hexane/iPrOH 90:10, 1.0 mL·min-1, detection at 254 nm) and gave 
retention times tS = 16.0 min, tR = 16.7 min. 
 
Table 11: HPESW reaction co-catalyzed by 0.5 mol% of benzoic ac d 
 
 Composition (%) 
 Catalyst: (R)-60a Catalyst: (S)-60d 
Time (h) 50 21i 21 50 21i 21 
0.00 100 0.0 0.0 100 0.0 0.0 
0.33 83.5 16.5 0.0 90.7 9.3 0.0 
0.67 73.4 26.6 0.0 85.9 14.1 0.0 
1.00 69.6 30.2 0.2 74.9 24.9 0.2 
2.00 51.5 46.5 2.1 63.5 35.5 1.0 
3.00 37.0 55.8 7.2 47.7 49.3 3.0 
4.00 18.9 68.2 12.8 35.8 56.1 8.2 
5.00 15.5 54.2 30.3 28.3 54.2 17.5 
6.00 7.2 49.8 43.0 19.1 49.8 31.1 
8.00 1.6 21.7 76.7 4.3 37.3 58.5 
10.00 0.3 7.1 92.6 0.8 12.7 86.5 
20.00 0.0 0.0 100a 0.0 0.0 100b 
Linear proportionality was assumed between the amount f compounds 50, 21i, 21 and the detector response. 
The composition of the reaction mixture was calculated as percentual ratio of these 3 compounds. The princi al 
retention times were obtained by analysis of pure compounds. a Final product ent-21 had ee = 93.4%. b Final 
product nat-21 had ee = 92.8%.  
 146 



































Reaction catalyzed by 5 mol% of prolinanilide 60a and 0.5 mol% of benzoic acid 
Methodology: Identical to the previous case, but higher amount of benzoic acid (12.2 mg, 
100 µmol, 5.0 mol%) was used. 
 
Table 12: HPESW reaction co-catalyzed with 5.0 mol% of benzoic acid 
 
 Composition (%) 
Time (min) 50 21i 21 
0 100 0.0 0.0 
10 81.3 18.5 0.2 
25 61.2 36.4 2.4 
40 39.6 49.4 10.9 
60 22.5 42.8 34.6 
85 3.9 21.8 74.3 
110 0.4 8.0 91.6 
130 0.0 2.3 97.7 
165 0.0 0.0 100a 
Linear proportionality was assumed between the amount f compounds 50, 21i, 21 and the detector response. 
Composition of the reaction mixture was calculated as percentual ratio of the 3 compounds. The principal 
retention times were obtained by analysis of pure compounds. a Final product ent-21 had ee = 93.6%. 


















7. APPENDIX B: BIOLOGICAL ACTIVITIES  
7.1. NMDA  RECEPTOR ACTIVITY  
The in vitro activity of 117 and 118 at NMDA receptors was tested by Mgr. Barbora Krausová in 
the laboratory of Dr. Ladislav Vyklický, Jr. at the Institute of Physiology of Academy of Sciences of 
the Czech Republic. The currents triggered by 100 µM glutamate were recorded from HEK293 cells, 
voltage-clamped at a holding potential of −60 mV, which expressed recombinant GluN1/GluN2 
receptors. All compounds were tested at single concentrations (50-200 µM). The inhibition of 
responses to fast application of glutamate was measur d and the IC50 was determined using the 
formula IC50 = c × [(1 − I ) / I ]
1 / h, where c is the concentration of a steroid analog, I is the relative 
degree of inhibition and h = 1.2 or 1.0 is the apparent Hill coefficient.50,58 Full experimental details are 
provided elsewhere.58  
Table 13: Inhibitory activity of selected compounds at NMDA receptora 
Compound Relative Inhibition b SD
c c (µM)d IC50 (µM ) SD
c h ne 
nat-2 84% ± 3% 100 25 ± 5 1.2 5 
nat-117 56% ± 6% 200 160 ± 36 1.0 4 
ent-117 40% ± 6% 200 308 ± 78 1.0 7 
nat-118 78% ± 6% 50 28 ± 9 1.0 5 
ent-118 58% ± 2% 100 36 ± 3 1.0 7 
a The data are courtesy of Ms. B. Krausová from Dr. L. Vyklický’s group at Physiological Institute AS CR. b 
Change of current induced by 100 µM glutamate. c Standard deviation. d Concentration of applied steroid analog. 
e Number of cells studied. 
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7.2. ANTIVIRAL ACTIVITY  
All compounds synthesized during the total synthesis of ent-progesterone, including the bicyclic 
and tricyclic steroid analogs (Chapters 3.1, 3.2), were tested for potential antiviral activity. A high-
throughput screening for hepatitis-C virus (HCV) replicons 1A, 1B and 2A was performed at Gilead 
Sciences (California, USA), the results of most active compounds are summarized in Table 14. Some 
low micromolar activities were detected, yet the gap between EC50 and CC50 was very narrow in all 
active compounds. These compounds were also tested in human immunodeficiency virus (HIV) and 
human rhinovirus assays at Gilead Sciences, but none of the compounds showed any appreciable 
activity. An identical set of compounds was tested for activity against the dengue virus in Vero cells, 
by Dr. Jan Weber’s group (IOCB AS CR, Praha). Two genotypes were included in the assay – DENV-
1 and DENV-2. Only compound ent-150c exhibited detectable activity, but also considerable 
cytotoxicity.  
























(µM ) EC50 (µM ) 
CC50 
(µM ) 
ent-172 3.7 33.0 31.5 18.4 n/a n/a > 50 > 50 > 50 
nat-150b 4.7 23.2 14.2 8.4 n/a n/a < 50 < 50 < 50 
ent-186A,a 7.3 19.9 21.8 16.0 n/a n/a > 50 > 50 > 50 
ent-184b 8.2 36.1 21.2 39.4 n/a n/a > 50 > 50 > 50 
nat-161 8.6 26.8 29.0 26.2 n/a n/a > 50 > 50 > 50 
ent-186B,b 9.2 15.2 27.4 ≥ 44 n/a n/a n/a n/a n/a 
ent-161 10.8 ≥ 44 31.0 28.8 n/a n/a n/a n/a n/a 
ent-150c 3.5 ≥ 44 29.2 ≥ 44 3.4 28.0 3 7 26 
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8. APPENDIX C: X-RAY DATA SHEETS 
Single-crystal X-ray diffraction data for all compounds were obtained on a Bruker Apex II CCD 
diffractometer applying monochromatic Mo Kα radiation (λ = 0.71073 Å) at 150 K. The structures 
were solved by direct methods and refined by full-matrix least squares based on F2.349 The hydrogen 
atoms were fixed into idealized positions (riding model) and assigned temperature factors Hiso( ) = 
1.2 Ueq(pivot atom). The crystallographic data are summarized in Tables S1-S3. Crystallographic data 
(excluding structure factors) for structures nt-161 (CCDC 1048883), nat-184a (CCDC 1048884), 
ent-193 (CCDC 1048885), ent-206 (CCDC 1048886), ent-195 (CCDC 1048887) and ent-207 
(CCDC 1048888) have been deposited at the Cambridge Crystallographic Data Centre with their 
respective CCDC numbers given in parentheses. Copies f the data can be obtained, free of charge by 
application to the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, 
UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). 








Empirical formula C17H22O3 C31H46NO4 C20H26O3 
Mr 274.35 496.69 314.41 
Crystal habit Prism, colorless Prism, colorless Prism, colorless 
Crystal size [mm] 0.54 × 0.48 × 0.33 0.71 × 0.64 × 0.61 0.47 × 0.42 × 0.41 
Crystal system Orthorhombic Monoclinic Orthorhombic 
Space group P212121 P21 P212121 





11.0475 (4)  











Volume [Å3] 1441.77 (8)  1402.00 (6) 1698.17 (7) 
Z  4 2 4 
Dx [Mg m
−3] 1.264 1.177 1.230 
µ [mm−1] 0.09 0.08 0.08 
θmax [°] 27.5 27.5 27.5 
Reflections measured 10226 20924 11011 
Unique reflections/observed 
reflections 
3314/3074 [I > 2σ(I)] 6417/6185 [I > 2σ(I)] 3907/3672 [I > 2σ(I)] 
Rint
a 0.022 0.019 0.017 
Parameters refined 182 330 210 
R (F)b, [F2 > 2σ(F2)] 0.033 0.044 0.037 
wR (F2)c 0.081 0.123 0.097 
Sd 1.06 1.03 1.06 
∆ρmax; ∆ρmin [e Å–3] 0.20; −0.17 0.83; −0.23 0.26; −0.19 
a Rint = Σ│Fo
2 − Fo,mean
2│/ Σ Fo





2)2)]½, weighting scheme: w = [σ2(Fo
2) + (w1P)
2 + w2P]
-1, where P = [max(Fo
2,0) + 2Fc















Empirical formula C30H47NO3 C20H26O3 C21H28O3 
Mr 469.69 314.41 328.43 
Crystal habit Plate, colorless Prism, colorless Prism, colorless 
Crystal size [mm] 0.65 × 0.38 × 0.12 0.48 × 0.36 × 0.20 0.46 × 0.32 × 0.32 
Crystal system Orthorhombic Monoclinic Orthorhombic 
Space group P212121 P21 P212121 

















Volume [Å3] 2651.56 (15) 831.15 (3) 1730.53 (9) 
Z  4 2 4 
Dx [Mg m
−3] 1.177 1.256 1.261 
µ [mm−1] 0.07 0.08 0.08 
θmax [°] 27.5 27.5 27.5 
Reflections measured 23544 12879 14978 
Unique reflections/observed 
reflections 
6093/5083 [I > 2σ(I)] 3829/3627 [I > 2σ(I)] 3970/3725 [I > 2σ(I)] 
Rint
a 0.034 0.021 0.023 
Parameters refined 314 210 220 
R (F)b, [F2 > 2σ(F2)] 0.041 0.032 0.034 
wR (F2)c 0.090 0.083 0.088 
Sd 1.02 1.04 1.02 
∆ρmax; ∆ρmin [e Å–3] 0.20; −0.19 0.22; −0.17 0.26; −0.15 
 
a Rint = Σ│Fo
2 − Fo,mean
2│/ Σ Fo





2)2)]½, weighting scheme: w = [σ2(Fo
2) + (w1P)
2 + w2P]
-1, where P = [max(Fo
2,0) + 2Fc











(1)  In The ACS Style Guide; Garson, L. R., Coghill, A. M., Eds.; The ACS Style Guide; American 
Chemical Society: Washington, DC, 2006; pp 135–202. 
(2)  Gross, C. G. In Encyclopedia of Neuroscience; Adelman, G., Ed.; Birkhäuser Verlag AG: 
Boston, 1987; pp 843–847. 
(3)  Loewi, O. Pflügers Arch. Gesamte Physiol. Menschen Tiere 1924, 204, 629–640. 
(4)  Dale, H. H.; Feldberg, W.; Vogt, M. J Physiol. 1936, 86, 353–380. 
(5)  Dale, H. H. J. Pharmacol. Exp. Ther. 1914, 6, 147–190. 
(6)  Holz, R. W.; Fisher, S. K. In Basic Neurochemistry (Eighth Edition); Brady, S. T., Siegel, G. J., 
Albers, W. R., Price, D. J., Eds.; Academic Press: New York, 2012; pp 235–257. 
(7)  Davenport, H. W. Physiologist 1991, 34, 129–190. 
(8)  Tata, J. R. EMBO reports 2005, 6, 490–496. 
(9)  Butenandt, A. Naturwissenschaften 1929, 17, 879–879. 
(10)  Butenandt, A. Angew. Chem. 1931, 44, 905–908. 
(11)  Butenandt, A.; Hanisch, G. Hoppe-Seyler’s Z. Physiol. Chem. 1935, 237, 89–97. 
(12)  David, K.; Dingemanse, E.; Freud, J.; Laqueur, E. Hoppe-Seyler’s Z. Physiol. Chem. 1935, 233, 
281–283. 
(13)  Butenandt, A.; Westphal, U. Ber. dtsch. Chem. Ges. A/B 1934, 67, 1440–1442. 
(14)  Slotta, K. H.; Ruschig, H.; Fels, E. Ber. dtsch. Chem. Ges. A/B 1934, 67, 1270–1273. 
(15)  Hartmann, M.; Wettstein, A. Helv. Chim. Acta 1934, 17, 878–882. 
(16)  Allen, W. M. Science 1935, 82, 89–93. 
(17)  Mason, H. L.; Myers, C. S.; Kendall, E. C. J. Biol. Chem. 1936, 114, 613–631. 
(18)  Reichstein, T. Helv. Chim. Acta 1936, 19, 1107–1126. 
(19)  Simpson, S. A.; Tait, J. F.; Wettstein, A.; Neher, R.; von Euw, J.; Reichstein, T. Experientia 
1953, 9, 333–335. 
(20)  Selye, H. Proc. Soc. Exp. Biol. Med. 1941, 46, 116–121. 
(21)  Paul, S. M.; Purdy, R. H. FASEB J. 1992, 6, 2311–2322. 
(22)  Neurosteroids: a new regulatory function in the nervous system; Baulieu, E.-E., Robel, P., 
Schumacher, M., Eds.; Contemporary endocrinology; Humana Press: Totowa, N.J, 1999. 
(23)  Baulieu, E. E.; Robel, P.; Schumacher, M. In International Review of Neurobiology; Giovanni 
Biggio, R. H. P., Ed.; Neurosteroids and Brain Function; Academic Press: San Diego, CA, 
2001; Vol. 46, pp 1–32. 
(24)  Scholfield, C. Pflügers Arch. 1980, 383, 249–255. 
(25)  Lodge, D.; Anis, N. A. Br. J. Anaesth. 1984, 56, 1143–1152. 
(26)  Harrison, N. L.; Simmonds, M. A. Brain Res. 1984, 323, 287–292. 
(27)  Corpéchot, C.; Young, J.; Calvel, M.; Wehrey, C.; Veltz, J.; Touyer, G.; Mouren, M.; Prasad, 
V.; Banner, C.; Sjövall, J. Endocrinology 1993, 133, 1003–1009. 
(28)  Corpéchot, C.; Synguelakis, M.; Talha, S.; Axelson, M.; Sjövall, J.; Vihko, R.; Baulieu, E.-E.; 
Robel, P. Brain Res. 1983, 270, 119–125. 
(29)  Corpéchot, C.; Robel, P.; Axelson, M.; Sjövall, J.; Baulieu, E. E. Proc. Natl. Acad. Sci. U. S. A.
1981, 78, 4704–4707. 
(30)  Baulieu, E. E. In Steroid hormone regulation of the brain; Fuxe, K., Gustafsson, J.-Å., 
Wetterberg, L., Eds.; Wenner-Gren Center internatiol symposium series; Pergamon Press: 
Oxford; New York, 1981; pp 3–14. 
(31)  Giatti, S.; Romano, S.; Pesaresi, M.; Cermenati, G.; Mitro, N.; Caruso, D.; Tetel, M. J.; Garcia-
Segura, L. M.; Melcangi, R. C. Steroids 2015, DOI: 10.1016/j.steroids.2015.03.014, In press. 
(32)  Melcangi, R. C.; Panzica, G. C. J. Neuroendocrinol. 2013, 25, 957–963. 
(33)  Panzica, G. C.; Balthazart, J.; Frye, C. A.; Garcia-Segura, L. M.; Herbison, A. E.; Mensah-
Nyagan, A. G.; McCarthy, M. M.; Melcangi, R. C. J. Neuroendocrinol. 2012, 24, 1–15. 
(34)  Melcangi, R. C.; Panzica, G.; Garcia-Segura, L. M. Neuroscience 2011, 191, 1–5. 
(35)  Korinek, M.; Kapras, V.; Vyklicky, V.; Adamusova, E.; Borovska, J.; Vales, K.; Stuchlik, A.; 
Horak, M.; Chodounska, H.; Vyklicky, L. Steroids 2011, 76, 1409–1418. 
(36)  Todorovic, S.; Covey, D.; Zorumski, C.; Jevtovic-Todorovic, V. Curr. Med. Chem. 2005, 5, 
157–164. 
 154 
(37)  Birzniece, V.; Bäckström, T.; Johansson, I.-M.; Lindblad, C.; Lundgren, P.; Löfgren, M.; 
Olsson, T.; Ragagnin, G.; Taube, M.; Turkmen, S.; Wahlström, G.; Wang, M.-D.; Wihlbäck, 
A.-C.; Zhu, D. Brain Res. Rev. 2006, 51, 212–239. 
(38)  Hassel, B.; Dingledine, R. In Basic Neurochemistry: Principles of Molecular, Cellular, and 
Medical Neurobiology; Brady, S. T., Siegel, G. J., Albers, R. W., Price, D. L., Benjamins, J., 
Eds.; Elsevier/Academic Press: Oxford, 2012; pp 342– 66. 
(39)  Traynelis, S. F.; Wollmuth, L. P.; McBain, C.J.; Menniti, F. S.; Vance, K. M.; Ogden, K. K.; 
Hansen, K. B.; Yuan, H.; Myers, S. J.; Dingledine, R. Pharmacol. Rev. 2010, 62, 405–496. 
(40)  Karakas, E.; Furukawa, H. Science 2014, 344, 992–997. 
(41)  Lee, C.-H.; Lü, W.; Michel, J. C.; Goehring, A.; Du, J.; Song, X.; Gouaux, E. Nature 2014, 
511, 191–197. 
(42)  Vyklicky, V.; Korinek, M.; Smejkalova, T.; Balik, A.; Krausova, B.; Kaniakova, M.; 
Lichnerova, K.; Cerny, J.; Krusek, J.; Dittert, I.; Horak, M.; Vyklicky, L. Physiol. Res. 2014, 63 
Suppl 1, S191–S203. 
(43)  Malayev, A.; Gibbs, T. T.; Farb, D. H. Br. J. Pharmacol. 2002, 135, 901–909. 
(44)  Horak, M.; Vlcek, K.; Chodounska, H.; Vyklicky Jr, L. Neuroscience 2006, 137, 93–102. 
(45)  Jang, M.-K.; Mierke, D. F.; Russek, S. J.; Farb, D. H. Proc. Natl. Acad. Sci. U. S. A.2004, 101, 
8198–8203. 
(46)  Park-Chung, M.; Wu, F. S.; Farb, D. H. Mol. Pharmacol. 1994, 46, 146–150. 
(47)  Park-Chung, M.; Wu, F.-S.; Purdy, R. H.; Malayev, A. A.; Gibbs, T. T.; Farb, D. H. Mol. 
Pharmacol. 1997, 52, 1113–1123. 
(48)  Weaver, C. E.; Land, M. B.; Purdy, R. H.; Richards, K. G.; Gibbs, T. T.; Farb, D. H. J. 
Pharmacol. Exp. Ther. 2000, 293, 747–754. 
(49)  Yaghoubi, N.; Malayev, A.; Russek, S. J.; Gibbs, T. T.; Farb, D. H. Brain Res. 1998, 803, 153–
160. 
(50)  Petrovic, M.; Sedlacek, M.; Horak, M.; Chodounska, H.; Vyklický, L. J. Neurosci. 2005, 25, 
8439–8450. 
(51)  Vyklicky, V.; Krausova, B.; Cerny, J.; Balik, A.; Zapotocky, M.; Novotny, M.; Lichnerova, K.; 
Smejkalova, T.; Kaniakova, M.; Korinek, M.; Petrovic, M.; Kacer, P.; Horak, M.; Chodounska, 
H.; Vyklicky, L. Sci. Rep. 2015, 5, Article number: 10935, DOI:10.1038/srep10935. 
(52)  Cao, X.; Cui, Z.; Feng, R.; Tang, Y.-P.; Qin, Z.; Mei, B.; Tsien, J. Z. Eur. J. Neurosci. 2007, 
25, 1815–1822. 
(53)  Tang, Y.-P.; Wang, H.; Feng, R.; Kyin, M.; Tsien, J. Z. Neuropharmacology 2001, 41, 779–
790. 
(54)  Tang, Y.-P.; Shimizu, E.; Dube, G. R.; Rampon, C.; Kerchner, G. A.; Zhuo, M.; Liu, G.; Tsien, 
J. Z. Nature 1999, 401, 63–69. 
(55)  Roberts, E. In Neurosteroids; Baulieu, E.-E., Robel, P., Schumacher, M., Eds.; Contemporary 
Endocrinology; Humana Press: Totowa, NJ, 1999; pp 337– 47. 
(56)  Flood, J. F.; Morley, J. E.; Roberts, E. Proc. Natl. Acad. Sci. U. S. A.1992, 89, 1567–1571. 
(57)  Vallée, M.; Shen, W.; Heinrichs, S. C.; Zorumski, C. F.; Covey, D. F.; Koob, G. F.; Purdy, R. 
H. Eur. J. Neurosci. 2001, 14, 2003–2010. 
(58)  Borovska, J.; Vyklicky, V.; Stastna, E.; Kaprs, V.; Slavikova, B.; Horak, M.; Chodounska, H.; 
Vyklicky, L. Br. J. Pharmacol. 2012, 166, 1069–1083. 
(59)  Chodounska, H.; Kapras, V.; Vyklicky, L.; Borovska, J.; Vyklicky, V.; Vales, K.; Stuchlik, A.; 
Rambousek, L. Pregnanolone Derivatives Substituted in 3alpha-Position with the Cationic 
Group, Method of Their Production, Usage and Pharmaceutical Preparation Involving Them. 
WO2012110010 (A1), August 23, 2012. 
(60)  Stastna, E.; Chodounska, H.; Pouzar, V.; Kapras, V.; Borovska, J.; Cais, O.; Vyklicky, L. 
Steroids 2009, 74, 256–263. 
(61)  Stastna, E.; Chodounska, H.; Pouzar, V.; Kapras, V.; Cais, O.; Vyklicky, L.; Kohout, L. 
Anionic Pregnane Compounds, Method for Their Producing and Use of Them. 
WO2010003391 (A2), January 14, 2010. 
(62)  Kudová, E.; Chodounská, H.; Kapras, V.; Vyklic ý, L.; Valeš, K.; Jahn, U. Amfifilní 
sloučeniny s neuroprotektivními účinky. CZ Pat. Appl. PV 2014-575, 2014. 
 155 
(63)  Vales, K.; Rambousek, L.; Holubova, K.; Svoboda, J.; Bubenikova-Valesova, V.; Chodounska, 
H.; Vyklicky, L.; Stuchlik, A. Behav. Brain. Res. 2012, 235, 82–88. 
(64)  Holubova, K.; Nekovarova, T.; Pistovcakova, J.; Sulcova, A.; Stuchlík, A.; Vales, K. Front. 
Behav. Neurosci. 2014, 8, DOI: 10.3389/fnbeh.2014.00130. 
(65)  Rambousek, L.; Bubenikova-Valesova, V.; Kacer, P.; Syslova, K.; Kenney, J.; Holubova, K.; 
Najmanova, V.; Zach, P.; Svoboda, J.; Stuchlik, A.; Chodounska, H.; Kapras, V.; Adamusova, 
E.; Borovska, J.; Vyklicky, L.; Vales, K. Neuropharmacology 2011, 61, 61–68. 
(66)  Kleteckova, L.; Tsenov, G.; Kubova, H.; Stuchlik, A.; Vales, K. Neurosci. Lett. 2014, 564, 11–
15. 
(67)  Vidrna, L.; Černý, I.; Pouzar, V.; Borovská, J.; Vyklický, V.; Vyklický, L.; Chodounská, H. 
Steroids 2011, 76, 1043–1050. 
(68)  Chodounská, H.; Vyklický Jr., L. Personal communication. 
(69)  Moss, G. P. Pure Appl. Chem. 1989, 61, 1783–1822. 
(70)  Favre, H. A.; Powell, W. H. In Nomenclature of Organic Chemistry; Royal Society of 
Chemistry: Cambridge, 2013; pp 1293–1438. 
(71)  Favre, H. A.; Powell, W. H. In Nomenclature of Organic Chemistry; Royal Society of 
Chemistry: Cambridge, 2013; pp 1515–1542. 
(72)  Akk, G.; Covey, D. F.; Evers, A. S.; Steinbach, J. H.; Zorumski, C. F.; Mennerick, S. 
Psychoneuroendocrinology 2009, 34S1, S59–S66. 
(73)  Chen, Z.-W.; Manion, B.; Townsend, R. R.; Reich rt, D. E.; Covey, D. F.; Steinbach, J. H.; 
Sieghart, W.; Fuchs, K.; Evers, A. S. Mol. Pharmacol. 2012, 82, 408–419. 
(74)  Covey, D. F. Steroids 2009, 74, 577–585. 
(75)  Casy, A. F. The Steric Factor in Medicinal Chemistry: Dissymmetric Probes of 
Pharmacological Receptors; Springer Science & Business Media: New York, 1993. 
(76)  Pfeiffer, C. C. Science 1956, 124, 29–31. 
(77)  Biellmann, J.-F. Chem. Rev. 2003, 103, 2019–2034. 
(78)  Wittmer, L. L.; Hu, Y.; Kalkbrenner, M.; Evers, A. S.; Zorumski, C. F.; Covey, D. F. Mol. 
Pharmacol. 1996, 50, 1581–1586. 
(79)  Zorumski, C. F.; Wittmer, L. L.; Isenberg, K.E ; Yuefei, H.; Covey, D. F. Neuropharmacology 
1996, 35, 1161–1168. 
(80)  Zorumski, C. F.; Mennerick, S. J.; Covey, D. F. Synapse 1998, 29, 162–171. 
(81)  Covey, D. F.; Nathan, D.; Kalkbrenner, M.; Nilsson, K. R.; Hu, Y.; Zorumski, C. F.; Evers, A. 
S. J. Pharmacol. Exp. Ther. 2000, 293, 1009–1016. 
(82)  Katona, B. W.; Krishnan, K.; Cai, Z. Y.; Manio , B. D.; Benz, A.; Taylor, A.; Evers, A. S.; 
Zorumski, C. F.; Mennerick, S.; Covey, D. F. Eur. J. Med. Chem. 2008, 43, 107–113. 
(83)  Nilsson, K. R.; Zorumski, C. F.; Covey, D. F. J. Med. Chem. 1998, 41, 2604–2613. 
(84)  Akwa, Y.; Ladurelle, N.; Covey, D. F.; Baulieu, E.-E. Proc. Natl. Acad. Sci. U. S. A.2001, 98, 
14033–14037. 
(85)  Djebaili, M.; Hoffman, S. W.; Stein, D. G. Neuroscience 2004, 123, 349–359. 
(86)  VanLandingham, J. W.; Cutler, S. M.; Virmani, S.; Hoffman, S. W.; Covey, D. F.; Krishnan, 
K.; Hammes, S. R.; Jamnongjit, M.; Stein, D. G. Neuropharmacology 2006, 51, 1078–1085. 
(87)  Akhrem, A. A.; Titov, Y. A. Total Synthesis of Steroids; Plenum Press: New York, 1970. 
(88)  Blickenstaff, R. T.; Ghosh, A. C.; Wolf, G. CTotal Synthesis of Steroids; Organic Chemistry: 
A Series of Monographs; Academic Press: New York, 1974; Vol. 30. 
(89)  Chapelon, A.-S.; Moraléda, D.; Rodriguez, R.; Ollivier, C.; Santelli, M. Tetrahedron 2007, 63, 
11511–11616. 
(90)  Kotora, M.; Hessler, F.; Eignerová, B. Eur. J. Org. Chem. 2012, 29–42. 
(91)  Mackay, E.; Sherburn, M. Synthesis 2014, 47, 1–21. 
(92)  Mulheirn, G. Endeavour 2000, 24, 107–110. 
(93)  Woodward, R. B.; Sondheimer, F.; Taub, D.; Heusl r, K.; McLamore, W. M. J. Am. Chem. 
Soc. 1952, 74, 4223–4251. 
(94)  Cardwell, H.; Cornforth, J.; Duff, S.; Holtermann, H.; Robinson, R. Chem. Ind. 1951, 389–390. 
(95)  Cardwell, H. M. E.; Cornforth, J. W.; Duff, S. R.; Holtermann, H.; Robinson, R. J. Chem. Soc. 
1953, 361–384. 
(96)  Stork, G.; McMurry, J. E. J. Am. Chem. Soc. 1967, 89, 5464–5465. 
 156 
(97)  Johnson, W. S.; Semmelhack, M. F.; Sultanbawa, M. U. S.; Dolak, L. A. J. Am. Chem. Soc. 
1968, 90, 2994–2996. 
(98)  Johnson, W. S.; Gravestock, M. B.; McCarry, B. E. J. Am. Chem. Soc. 1971, 93, 4332–4334. 
(99)  Cran, J.; Han, Y.; Zhang, F. Synthesis of Ent-Progesterone and Intermediates Thereof. 
WO2014145302 (A2), September 18, 2014. 
(100)  van Tamelen, E. E.; Faler, D. L. Proc. Natl. Acad. Sci. U. S. A.1985, 82, 1879–1880. 
(101)  Yoder, R. A.; Johnston, J. N. Chem. Rev. 2005, 105, 4730–4756. 
(102)  Micheli, R. A.; Hajos, Z. G.; Cohen, N.; Parrish, D. R.; Portland, L. A.; Sciamanna, W.; Scott, 
M. A.; Wehrli, P. A. J. Org. Chem. 1975, 40, 675–681. 
(103)  Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1973, 38, 3244–3249. 
(104)  Hajos, Z. G.; Parrish, D. R. United States Patent: 3975440 - Asymmetric synthesis of organic 
compounds. 3975440, August 17, 1976. 
(105)  Hajos, Z. G.; Parrish, D. R. Asymmetrische Synthese polycyclischer organischer 
Verbindungen. DE2102623 (A1), July 29, 1971. 
(106)  Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615–1621. 
(107)  Rychnovsky, S. D.; Mickus, D. E. J. Org. Chem. 1992, 57, 2732–2736. 
(108)  Ohloff, G.; Maurer, B.; Winter, B.; Giersch, W. Helv. Chim. Acta 1983, 66, 192–217. 
(109)  Auchus, R. J.; Sampath Kumar, A.; Andrew Boswell, C.; Gupta, M. K.; Bruce, K.; Rath, N. P.; 
Covey, D. F. Arch. Biochem. Biophys. 2003, 409, 134–144. 
(110)  Hu, Y.; Wittmer, L. L.; Kalkbrenner, M.; Evers, A. S.; Zorumski, C. F.; Covey, D. F. J. Chem. 
Soc., Perkin Trans. 1997, 3665–3672. 
(111)  Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem. Int. Ed. 1971, 10, 496–497. 
(112)  Bradshaw, B.; Bonjoch, J. Synlett 2012, 23, 337–356. 
(113)  Zlotin, S. G.; Kucherenko, A. S.; Beletskaya, I. P. Russ. Chem. Rev. 2009, 78, 737–784. 
(114)  Buchschacher, P.; Fürst, A.; Gutzwiller, J. Org. Synth. 1985, 63, 37–41. 
(115)  Bui, T.; Barbas III, C. F. Tetrahedron Lett. 2000, 41, 6951–6954. 
(116)  Davies, S. G.; Russell, A. J.; Sheppard, R. L.; Smith, A. D.; Thomson, J. E. Org. Biomol. 
Chem. 2007, 5, 3190–3200. 
(117)  Inomata, K.; Akahane, Y.; Inage, N.; Nagamine, T.; Endo, Y. Heterocycles 2007, 74, 637–648. 
(118)  Inomata, K.; Akahane, Y.; Endo, Y. Heterocycles 2009, 77, 1065–1078. 
(119)  Kanger, T.; Kriis, K.; Laars, M.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. J. Org. 
Chem. 2007, 72, 5168–5173. 
(120)  Zhou, P.; Zhang, L.; Luo, S.; Cheng, J.-P. J. Org. Chem. 2012, 77, 2526–2530. 
(121)  Xu, C.; Zhang, L.; Zhou, P.; Luo, S.; Cheng, J.-P. Synthesis 2013, 45, 1939–1945. 
(122)  Fuentes de Arriba, Á. L.; Seisdedos, D. G.; Simón, L.; Alcázar, V.; Raposo, C.; Morán, J. R. J. 
Org. Chem. 2010, 75, 8303–8306. 
(123)  Zhang, X.-M.; Wang, M.; Tu, Y.-Q.; Fan, C.-A; Jiang, Y.-J.; Zhang, S.-Y.; Zhang, F.-M. 
Synlett 2008, 2831–2835. 
(124)  D’Elia, V.; Zwicknagl, H.; Reiser, O. J Org. Chem. 2008, 73, 3262–3265. 
(125)  de Arriba, Á. L. F.; Simón, L.; Raposo, C.; Alcázar, V.; Morán, J. R. Tetrahedron 2009, 65, 
4841–4845. 
(126)  Bradshaw, B.; Etxebarría-Jardi, G.; Bonjoch, J.; Viózquez, S. F.; Guillena, G.; Nájera, C. Adv. 
Synth. Catal. 2009, 351, 2482–2490. 
(127)  Guillena, G.; Nájera, C.; Viózquez, S. Synlett 2008, 3031–3035. 
(128)  Bradshaw, B.; Extebarria-Jardi, G.; Bonjoch, J.; Viózquez, S. F.; Guillena, G.; Nájera, C. Org. 
Synth. 2011, 88, 330–341. 
(129)  Bañón-Caballero, A.; Guillena, G.; Nájera, C.; Faggi, E.; Sebastián, R. M.; Vallribera, A. 
Tetrahedron 2013, 69, 1307–1315. 
(130)  Mori, K.; Katoh, T.; Suzuki, T.; Noji, T.; Yamanaka, M.; Akiyama, T. Angew. Chem. Int. Ed. 
2009, 48, 9652–9654. 
(131)  Harada, N.; Sugioka, T.; Uda, H.; Kuriki, T. Synthesis 1990, 53–56. 
(132)  Copper-catalyzed asymmetric synthesis; Alexakis, A., Krause, N., Woodward, S., Eds.; Wiley-
VCH: Weinheim, Germany, 2014. 
(133)  Berthon, G.; Hayashi, T. In Catalytic Asymmetric Conjugate Reactions; Córdova, A., Ed.; 
Wiley-VCH: Weinheim, Germany, 2010; pp 1–70. 
 157 
(134)  Hayashi, T.; Yamasaki, K. Chem. Rev. 2003, 103, 2829–2844. 
(135)  Edwards, H. J.; Hargrave, J. D.; Penrose, S. D.; Frost, C. G. Chem. Soc. Rev. 2010, 39, 2093. 
(136)  Jean, M.; Casanova, B.; Gnoatto, S.; van de Weghe, P. Org. Biomol. Chem. 2015, 13, 9168–
9175. 
(137)  Gutnov, A. Eur. J. Org. Chem. 2008, 4547–4554. 
(138)  Shockley, S. E.; Holder, J. C.; Stoltz, B. M. Org. Process Res. Dev. 2015, 19, 974–981. 
(139)  Pellissier, H. Adv. Synth. Catal. 2015, 357, 2745–2780. 
(140)  Kotora, M.; Betík, R. In Catalytic Asymmetric Conjugate Reactions; Córdova, A., Ed.; Wiley-
VCH: Weinheim, Germany, 2010; pp 71–144. 
(141)  Reich, R. J. Compt. Rend. 1923, 177, 322–324. 
(142)  Gilman, H.; Straley, J. M. Recl. Trav. Chim. Pays-Bas 1936, 55, 821–834. 
(143)  Kharasch, M. S.; Tawney, P. O. J. Am. Chem. Soc. 1941, 63, 2308–2316. 
(144)  Gilman, H.; Jones, R. G.; Woods, L. A. J. Org. Chem. 1952, 17, 1630–1634. 
(145)  Whitesides, G. M.; Fischer, W. F.; San Filippo, J.; Bashe, R. W.; House, H. O. J. Am. Chem. 
Soc. 1969, 91, 4871–4882. 
(146)  House, H. O.; Respess, W. L.; Whitesides, G. M. J. Org. Chem. 1966, 31, 3128–3141. 
(147)  Corey, E. J.; Posner, G. H. J. Am. Chem. Soc. 1967, 89, 3911–3912. 
(148)  The chemistry of organocopper compounds; Rappoport, Z., Marek, I., Eds.; Patai series; Wiley: 
Chichester, U.K., 2009. 
(149)  Jastrzebski, J. T. B. H.; van Koten, G. In Modern Organocopper Chemistry; Krause, N., Ed.; 
Wiley-VCH: Weinheim, Germany, 2002; pp 1–44. 
(150)  Breit, B.; Demel, P. In Modern Organocopper Chemistry; Krause, N., Ed.; Wiley-VCH: 
Weinheim,Germany, 2002; pp 188–223. 
(151)  Alexakis, A.; Bäckvall, J. E.; Krause, N.; Pàmies, O.; Diéguez, M. Chem. Rev. 2008, 108, 
2796–2823. 
(152)  Harutyunyan, S. R.; den Hartog, T.; Geurts, K.; Minnaard, A. J.; Feringa, B. L. Chem. Rev. 
2008, 108, 2824–2852. 
(153)  Mori, S.; Nakamura, E. In Modern Organocopper Chemistry; Krause, N., Ed.; Wiley-VCH: 
Weinheim, Germany, 2002; pp 315–346. 
(154)  Harutyunyan, S. R.; López, F.; Browne, W. R.; Correa, A.; Peña, D.; Badorrey, R.; Meetsma, 
A.; Minnaard, A. J.; Feringa, B. L. J. Am. Chem. Soc. 2006, 128, 9103–9118. 
(155)  Kitamura, M.; Miki, T.; Nakano, K.; Noyori, R. Bull. Chem. Soc. Jpn. 2000, 73, 999–1014. 
(156)  House, H. O.; Umen, M. J. J. Am. Chem. Soc. 1972, 94, 5495–5497. 
(157)  House, H. O. Acc. Chem. Res. 1976, 9, 59–67. 
(158)  Casey, C. P.; Cesa, M. C. J. Am. Chem. Soc. 1979, 101, 4236–4244. 
(159)  Reetz, M. T.; Kindler, A. J. Chem. Soc., Chem. Commun. 1994, 2509–2510. 
(160)  Reetz, M. T.; Kindler, A. J. Organomet. Chem. 1995, 502, C5–C7. 
(161)  Krause, N.; Gerold, A. Angew. Chem. Int. Ed. 1997, 36, 186–204. 
(162)  Yamamoto, Y. In Houben-Weyl Methods of Organic Chemistry Vol. E 21b, 4th Edition 
Supplement: Stereoselective Synthesis: C-C Bond Formation by Addition to C=O, C=N and 
Reactions Involving Olefinic Double Bonds; Helmchen, G., Ahlbrecht, H., Eds.; Houben-Weyl; 
Georg Thieme Verlag: Stuttgart, 1995; pp 2041–2067. 
(163)  Smith III, A. B.; Dunlap, N. K.; Sulikowski, G. A. Tetrahedron Lett. 1988, 29, 439–442. 
(164)  Luong-Thi, N.-T.; Rivière, H. Tetrahedron Lett. 1970, 11, 1579–1582. 
(165)  House, H. O.; Fischer, W. F. J. Org. Chem. 1968, 33, 949–956. 
(166)  Asami, M.; Sato, S.; Honda, K.; Inoue, S. Heterocycles 2000, 52, 1029–1032. 
(167)  Barton, D. H. R.; Boivin, J.; Gastiger, M.; orzycki, J.; Hay-Motherwell, R. S.; Motherwell, 
W. B.; Ozbalik, N.; Schwartzentruber, K. M. J. Chem. Soc., Perkin Trans. 1 1986, 947–955. 
(168)  Marshall, J. A.; Andersen, N. H. J. Org. Chem. 1966, 31, 667–673. 
(169)  Lovely, C. J.; Brueggemeier, R. W. Bioorg. Med. Chem. Lett. 1995, 5, 2513–2516. 
(170)  Yajima, A.; Mori, K. Eur. J. Org. Chem. 2000, 4079–4091. 
(171)  Zard, S. Z. In Radical Reactions in Organic Synthesis; Oxford University Press: New York, 
2003; pp 193–244. 
(172)  Wille, U. In Comprehensive Organic Synthesis II (Second Edition); K ochel, P., Ed.; Elsevier: 
Amsterdam, 2014; pp 300–316. 
 158 
(173)  Murphy, J. A. J. Org. Chem. 2014, 79, 3731–3746. 
(174)  Guo, F.; Clift, M. D.; Thomson, R. J. Eur. J. Org. Chem. 2012, 2012, 4881–4896. 
(175)  Nair, V.; Deepthi, A. Tetrahedron 2009, 65, 10745–10755. 
(176)  Nair, V.; Deepthi, A. Chem. Rev. 2007, 107, 1862–1891. 
(177)  Burton, J. W. In Encyclopedia of Radicals in Chemistry, Biology and Materials; Chatgilialoglu, 
C., Studer, A., Eds.; John Wiley & Sons, Ltd: Chichester, U.K., 2012; Vol. 2, pp 901–942. 
(178)  Snider, B. B. Tetrahedron 2009, 65, 10738–10744. 
(179)  Snider, B. B. Chem. Rev. 1996, 96, 339–364. 
(180)  Demir, A. S.; Emrullahoglu, M. Curr. Org. Synth. 2007, 4, 321–350. 
(181)  Linker, T. J. Organomet. Chem. 2002, 661, 159–167. 
(182)  Zabicky, J. In The Chemistry of Metal Enolates; Patai series; John Wiley & Sons, Chichester, 
U.K. 2009; pp 461–550. 
(183)  Schmittel, M.; Lal, M.; Lal, R.; Röck, M.; Langels, A.; Rappoport, Z.; Basheer, A.; Schlirf, J.; 
Deiseroth, H.-J.; Flörke, U.; Gescheidt, G. Tetrahedron 2009, 65, 10842–10855. 
(184)  Baran, P. S.; Ambhaikar, N. B.; Guerrero, C. A.; Hafensteiner, B. D.; Lin, D. W.; Richter, J. M. 
ARKIVOC 2006, 7, 310–325. 
(185)  DeMartino, M. P.; Chen, K.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 11546–11560. 
(186)  Toma, Š.; Šebesta, R. Synthesis 2015, 47, 1683–1695. 
(187)  Hyster, T. K. In e-EROS Encyclopedia of Reagents for Organic Synthesis; Crich, D., Fuchs, P., 
Charette, A. B., Rovis, T., Eds.; John Wiley & Sons, Ltd: Chichester, U.K., 2012; p doi: 
10.1002/047084289X.rn01460. 
(188)  Connelly, N. G.; Geiger, W. E. Chem. Rev. 1996, 96, 877–910. 
(189)  Jahn, U. J. Org. Chem. 1998, 63, 7130–7131. 
(190)  Jahn, U.; Hartmann, P. Chem. Commun. 1998, 209–210. 
(191)  Khobragade, D. A.; Mahamulkar, S. G.; Pospíšil, L.; Císařová, I.; Rulíšek, L.; Jahn, U. Chem. 
Eur. J. 2012, 18, 12267–12277. 
(192)  Duhović, S.; Diaconescu, P. L. Polyhedron 2013, 52, 377–388. 
(193)  Kafka, F.; Holan, M.; Hidasová, D.; Pohl, R.; Císařová, I.; Klepetářová, B.; Jahn, U. Angew. 
Chem. Int. Ed. 2014, 53, 9944–9948. 
(194)  Jahn, U.; Kafka, F.; Pohl, R.; Jones, P. G. Tetrahedron 2009, 65, 10917–10929. 
(195)  Holan, M.; Pohl, R.; Císařová, I.; Jahn, U. Eur. J. Org. Chem. 2012, 2012, 3459–3475. 
(196)  Jagtap, P. R.; Ford, L.; Deister, E.; Pohl, R.; Císařová, I.; Hodek, J.; Weber, J.; Mackman, R.; 
Bahador, G.; Jahn, U. Chem. Eur. J. 2014, 20, 10298–10304. 
(197)  Jahn, U.; Rudakov, D.; Jones, P. G. Tetrahedron 2012, 68, 1521–1539. 
(198)  Goddard, J.-P.; Gomez, C.; Brebion, F.; Beauvière, S.; Fensterbank, L.; Malacria, M. Chem. 
Commun. 2007, 2929–2931. 
(199)  Dinca, E.; Hartmann, P.; Smrček, J.; Dix, I.; Jones, P. G.; Jahn, U. Eur. J. Org. Chem. 2012, 
4461–4482. 
(200)  Jahn, U.; Rudakov, D. Org. Lett. 2006, 8, 4481–4484. 
(201)  Nguyen, P. Q.; Schäfer, H. J. Org. Lett. 2001, 3, 2993–2995. 
(202)  Jahn, U.; Hartmann, P.; Kaasalainen, E. Org. Lett. 2004, 6, 257–260. 
(203)  Jahn, U.; Dinca, E. Chem. Eur. J. 2009, 15, 58–62. 
(204)  Jahn, U.; Dinca, E. J Org. Chem. 2010, 75, 4480–4491. 
(205)  Xu, J.; Caro-Diaz, E. J. E.; Trzoss, L.; Theodorakis, E. A. J. Am. Chem. Soc. 2012, 134, 5072–
5075. 
(206)  Lee, H. G.; Ahn, J. Y.; Lee, A. S.; Shair, M. D. Chem. Eur. J. 2010, 16, 13058–13062. 
(207)  Krygowski, E. S.; Murphy-Benenato, K.; Shair, M. D. Angew. Chem. Int. Ed. 2008, 47, 1680–
1684. 
(208)  Chen, P.; Cao, L.; Tian, W.; Wang, X.; Li, C. Chem. Commun. 2010, 46, 8436–8438. 
(209)  Baran, P. S.; Richter, J. M.; Lin, D. W. Angew. Chem. Int. Ed. 2005, 44, 609–612. 
(210)  Fischer, H. Chem. Rev. 2001, 101, 3581–3610. 
(211)  Bachmann, W. E.; Wiselogle, F. Y. J. Org. Chem. 1936, 01, 354–382. 
(212)  Fischer, H. J. Am. Chem. Soc. 1986, 108, 3925–3927. 
(213)  Studer, A. Chem. Soc. Rev. 2004, 33, 267–273. 
(214)  Daikh, B. E.; Finke, R. G. J Am. Chem. Soc. 1992, 114, 2938–2943. 
 159 
(215)  Studer, A. Angew. Chem. Int. Ed. 2000, 39, 1108–1111. 
(216)  Uenoyama, Y.; Tsukida, M.; Doi, T.; Ryu, I.; Studer, A. Org. Lett. 2005, 7, 2985–2988. 
(217)  Ciccimaro, E.; Blair, I. A. Bioanalysis 2010, 2, 311–341. 
(218)  Fan, T. W.-M.; Lorkiewicz, P. K.; Sellers, K.; Moseley, H. N. B.; Higashi, R. M.; Lane, A. N. 
Pharmacol. Ther. 2012, 133, 366–391. 
(219)  Schellekens, R. C. A.; Stellaard, F.; Woerdenbag, H. J.; Frijlink, H. W.; Kosterink, J. G. W. Br. 
J. Clin. Pharm. 2011, 72, 879–897. 
(220)  Furuta, T.; Eguchi, N.; Yokokawa, A.; Shibasaki, H.; Kasuya, Y. Steroids 2000, 65, 180–189. 
(221)  Joubert, C.; Beney, C.; Marsura, A.; Luu-Duc, C. J. Labelled Compd. Radiopharm. 1995, 36, 
745–754. 
(222)  Kapras, V.; Slavickova, A.; Stastna, E.; Vyklicky, L.; Vales, K.; Chodounska, H. Steroids 
2012, 77, 282–287. 
(223)  Barton, D. H. R.; Beaton, J. M.; Geller, L. E.; Pechet, M. M. J. Am. Chem. Soc. 1960, 82, 
2640–2641. 
(224)  Barton, D. H. R.; Beaton, J. M.; Geller, L. E.; Pechet, M. M. J. Am. Chem. Soc. 1961, 83, 
4076–4083. 
(225)  Barton, D. H. R.; Beaton, J. M. J. Am. Chem. Soc. 1960, 82, 2641–2641. 
(226)  Čeković, Ž. Tetrahedron 2003, 59, 8073–8090. 
(227)  Reese, P. B. Steroids 2001, 66, 481–497. 
(228)  Majetich, G.; Wheless, K. Tetrahedron 1995, 51, 7095–7129. 
(229)  Kirk, D. N.; Rajagopalan, M. S.; Varley, M. J. J. Chem. Soc., Perkin Trans. 1 1983, 2225–
2227. 
(230)  Arunachalam, T.; Santaniello, E.; Patel, K.; Caspi, E. J. Chem. Soc., Perkin Trans. 1 1987, 61–
69. 
(231)  Tureček, F.; Vereš, K.; Kočovský, P.; Pouzar, V.; Fajkoš, J. J. Org. Chem. 1983, 48, 2233–
2237. 
(232)  Kirk, D. N.; Smith, C. Z.; Varley, M. J.; Hon ur, J. W. J. Chem. Soc., Perkin Trans. 1 1990, 
2745–2748. 
(233)  Černý, I.; Pouzar, V.; Buděšínský, M.; Bičíková, M.; Hill, M.; Hampl, R. Steroids 2004, 69, 
161–171. 
(234)  Baba, S.; Shinohara, Y.; Kasuya, Y. J. Labelled Compd. Radiopharm. 1978, 14, 783–791. 
(235)  Holland, H. L.; Taylor, G. J. Can. J. Chem. 1981, 59, 2809–2819. 
(236)  Komarapuri, S.; Krishnan, K.; Covey, D. F. J. Labelled Compd. Radiopharm. 2008, 51, 430–
434. 
(237)  Fischer, E. Ber. Dtsch. Chem. Ges. 1905, 38, 2914–2934. 
(238)  Sato, K.; Kuriyama, M.; Shimazawa, R.; Morimoto, T.; Kakiuchi, K.; Shirai, R. Tetrahedron 
Lett. 2008, 49, 2402–2406. 
(239)  Ramachandran, S.; Newman, M. S. Org. Synth. 1973, Coll. Vol. V, 486–488. 
(240)  Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Chem. Rev. 2007, 107, 5471–5569. 
(241)  Hoang, L.; Bahmanyar, S.; Houk, K. N.; List, B. J. Am. Chem. Soc. 2003, 125, 16–17. 
(242)  Dawson, R. M. C.; Elliott, D. C.; Elliott, W. H.; Jones, K. M. Data for Biochemical Research, 
3rd Edition.; Oxford University Press: Oxford, 1986. 
(243)  Gershkovich, I. M.; Myakisheva, E. A.; Grudtsyn, Y. D.; Kaminskii, A. Y. Russ. J. Org. Chem. 
1984, 20, 623–629. 
(244)  Nyberg, A. I.; Usano, A.; Pihko, P. M. Synlett 2004, 1891–1896. 
(245)  Fuentes de Arriba, Á. L.; Simón, L.; Raposo, C.; Alcázar, V.; Sanz, F.; Muñiz, F. M.; Morán, J. 
R. Org. Biomol. Chem. 2010, 8, 2979. 
(246)  Park, K.; Scott, W. J.; Wiemer, D. F. J. Org. Chem. 1994, 59, 6313–6317. 
(247)  Kametani, T.; Suzuki, K.; Nemoto, H. J. Org. Chem. 1982, 47, 2331–2342. 
(248)  Karimi, S. J. Nat. Prod. 2001, 64, 406–410. 
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